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Abstract 
Human respiratory syncytial viruses (hRSV) are a major cause of lower respiratory tract 
disease on primary infection of infants and children.  There is no effective vaccine 
against the virus, but high risk infants can be protected by administration of 
palivizumab (PZ), a humanised anti-fusion glycoprotein.  In previous studies, hRSV 
isolated from the naso-pharyngeal secretions of infected infants were found to be 
dominated by slow growing variants which were largely refractory to neutralization by 
PZ.  On further passage in tissue culture, the slow growing variants were replaced by 
fast growing, neutralization susceptible variants.   
 
The aim of this study was to investigate the mechanism of neutralization phenotype 
shift between slow-growing neutralization resistant and fast-growing neutralization 
susceptible clones.  Neutralization resistance was found to be cell-line dependent with 
cell lines varying in their permissiveness to antibody treated virus.  Antibody resistant 
and susceptible viruses showed no differences in the amount of the membrane 
expressed F glycoprotein or post-translational processing of the F polypeptide.  They 
were also equally susceptible to inhibition by clathrin endocytosis inhibitors 
(monodansylcadaverine and chlorpromazine) suggesting that endocytosis was required 
for entry of both.  They were further tested for susceptibility to anti-fusion inhibitors.  
These included a peptide derived from the F glycoprotein heptad repeat 2 and two small 
molecular weight compouds BMS-433771 and BTA9881.  It was found that all three 
compounds failed to inhibit slow growing PZ resistant virus clones in parallel with PZ, 
but efficiently blocked fast growing PZ susceptible virus clones.  These studies suggest 
that differences in antibody susceptibility stem from differences in the mechanism of 
fusion for the two virus clones.  
  
The full genomes of virus clones with resistant and susceptible phenotypes were 
sequenced to identify mutations which correlate with the difference in antibody 
susceptibility.  The two clones differed at four sites in the SH, G, F and L genes.  These 
mutations were sought in a number of virus clones expressing a range of susceptibility 
to antibody neutralization.  No single mutation was associated with the shift from 
neutralization resistant to susceptible phenotype in all clones.   However, a mutation at 
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nucleotide 6162 in the L gene was associated with the shift from resistance to 
susceptibility in one virus lineage.   
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Chapter 1: Literature review 
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1.1 Discovery 
Human respiratory syncytial virus (hRSV) was first discovered in chimpanzees with 
mild upper respiratory illness and initially named chimpanzee coryza agent (CCA 
virus).  Antibody to the CCA virus was found in a person who had a respiratory 
infection and worked with infected chimpanzees.  An increase of antibody was observed 
during convalescence (Morris et al., 1956).  Thereafter, two strains of a similar virus 
were recovered from the throat swabs of infants with bronchopneumonia (Long virus) 
and with laryngotracheobronchitis (Snyder virus).  In cell cultures, both isolates 
produced a cytopathic effect forming a multinucleated mass of cytoplasm, a syncytium, 
similar to that observed with CCA virus.  The antigenic properties of the two human 
isolates were also indistinguishable from CCA virus and not related to other syncytium 
– producing viruses or the adenoviruses (Chanock et al., 1957).  The three viruses were 
categorized together and renamed respiratory syncytial virus (Chanock and Finberg, 
1957).  
1.2 Classification and Morphology 
hRSV is a member of the Paramyxoviridae family in the Mononegavirales order which 
also includes the Bornaviridae, Filoviridae and Rhabdoviridae (Figure 1.1).  All 
members of the Mononegavirales contain linear, non-segmented, negative-strand RNA 
genomes. The family of Paramyxoviridae is divided into two subfamilies: 
Paramyxovirinae and Pneumovirinae.  The subfamily Pneumovirinae is further 
classified into two genera, Metapneumovirus and Pneumovirus.  The Metapneumovirus 
genus comprises avian metapneumovirus (AMPV) and human metapneumovirus 
(hMPV).  Pneumonia virus of mice (PVM), bovine respiratory syncytial virus (bRSV) 
and hRSV are grouped together in the Pneumovirus genus.  The type species of hRSV is 
the A2 strain (Collins and Crowe, 2007).  
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Figure 1.1 Taxonomy of the Mononegavirales order 
[Modified from original by  International Committee on Taxonomy of Viruses (2011)] 
hRSV particles are pleomorphic in form varying from kidney-shaped or round (100-300 
nm in diameter) to filamentous forms 60-100 nm in diameter and up to 10 µm in length.  
All forms contain a helical nucleocapsid (11-15 nm in diameter) and have peripheral 
spikes on the viral envelope (10-12 nm in length).  The filamentous morphology is 
predominant (Norrby et al., 1970; Bachi and Howe, 1973; Roberts et al., 1995).  The 
helical nucleocapsid or ribonucleoprotein (RNP) complex of hRSV consists of the large 
polymerase protein (L), the phosphoprotein (P), the nucleocapsid protein (N), and the 
RNA genome (Figure 1.2).  The M2-1 protein is also found to associate with 
nucleocapsids (Collins and Crowe, 2007).  All proteins of RNP complex are present in 
cytoplasmic inclusions and are involved in viral replication and transcription (Garcia et 
al., 1993; Carromeu et al., 2007).    
 
The nucleocapsid is covered with a lipid envelope derived from the plasma membrane 
of host cell.  The matrix protein (M) forms a layer between the nucleocapsid and the 
envelope.  The envelope carries three viral transmembrane glycoproteins which 
individually project from the surface as virion spikes.  These glycoproteins are the 
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attachment glycoprotein (G), the fusion glycoprotein (F) and the small hydrophobic 
protein (SH) (Collins and Crowe, 2007) as shown in Figure 1.2.  The G and F 
glycoproteins are the major neutralization and protective antigens (Taylor et al., 1984; 
Connors et al., 1991).  
 
 
Figure 1.2: The structure of hRSV 
[Modified from original by  Ghildyal et al. (2006)] 
1.3 The hRSV Genome  
hRSV genome is a single-strand of non-segmented, negative – sense RNA and its size is 
approximately 15,200 nucleotides.  It begins with a 3’leader region (44 nucleotides), 
followed by 10 viral genes and ends with a 5’trailer region (155 nucleotides) without 
capping and polyadenylation.  Each gene contains a highly conserved gene start (GS) 
sequence and a semi-conserved gene end (GE) sequence as shown in Figure 1.3 which 
control the process of transcription (Kuo et al., 1997).  In the prototype strain A2, 3′-
CCCCGUUUA-5’ is the GS sequence for all genes, except the L gene which starts with 
3′-CCCUGUUU-5’.  The GE sequence of each gene varies between 12 and 13 
nucleotides and contains three regions, an upstream conserved sequence 
3’...UCAAU...5’, a non-conserved central region and a tract of U residues at the end 
varying from U4 to U7 (Collins and Crowe, 2007).  In between the GS and GE 
sequences, the genes are separated by non-conserved intergenic regions of 1 to 52 
nucleotides except M2/L, which overlap by 68 nucleotides.  Therefore, the GE of the 
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M2 gene is in the coding region of the L gene, whereas the GS of the L gene is in the 
M2 gene as shown in Figure 1.3 (Collins and Crowe, 2007).  
 
In transcription, mRNA synthesis is started from the 3’ end of the genome, which has 
only one promoter, and ten separate mRNAs are sequentially produced.  Transcription 
of each subgenomic mRNA is started at its GS sequence and terminated at its GE 
sequence.  A cap structure and poly(A) tails are added at 5’end and at 3’end of each 
mRNA, respectively.  A different amount of mRNA is produced for each gene.  The 
transcription frequency of the gene at the 3’ end is higher than that at the 5’ end because  
a proportion of polymerase molecule “falls off” the genome at each gene end 
sequentially reducing the efficiency of translation at each succeeding gene (Collins and 
Wertz, 1983; Krempl et al., 2002).  The mRNAs generated are the templates for 
translating 11 proteins.  Each mRNA contains a single open reading frames (ORF) 
coding for a unique protein, except for the M2 mRNA which contains 2 ORFs (Collins 
and Crowe, 2007).  The first ORF, encoding the M2-1 protein, is upstream and overlaps 
with the second ORF, encoding the M2-2 protein, by 32 nucleotides.  Translation of the 
M2-2 ORF initiates after the translation of the M2-1 ORF has terminated (Ahmadian et 
al., 2000).   
 
 
Figure 1.3: Diagram of hRSV genome 
[Modified from original by  Collins and Melero (2011)] 
Viral genes are depicted as rectangles (not to scale) which have the gene start (white boxes) and gene end 
(red boxes). The genome has a 3’leader (le) and 5’trailer (tr) regions with 10 viral genes between the two 
ends arranged as follows: non-structural protein 1 gene (NS1), non-structural protein 2 gene (NS2), 
nucleocapsid protein gene (N), phosphoprotien gene (P), matrix protein gene (M), small hydrophobic 
protein gene (SH), attachment glycoprotein gene (G), fusion glycoprotein gene (F), M2 gene containing 
two ORF for encoding M2-1 and M2-2 proteins and large polymerase protein gene (L).  The genes 
encoding the non-structural protein, the matrix proteins, the viral glycoproteins and the RNA-dependent 
RNA polymerase complex are shown as pink, blue, yellow and green, respectively.   
 
1.4 The hRSV Proteome 
1.4.1 The nonstructural proteins 1 and 2  
The hRSV non-structural protein 1 (NS1) and non-structural protein 2 (NS2) (formerly 
known as 1C and 1B, respectively) are 139 and 124 amino acids in length, respectively. 
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They have molecular weights of approximately 14,000 for the NS1 protein and 11,000 
for the NS2 protein measured by gel electrophoresis (Collins and Wertz, 1985).  There 
are four identical amino acids (DLNP) in the carboxyl-terminus of both proteins, but 
other sequences are not similar.  This feature may account for the cross-reaction when 
both proteins have been investigated by a rabbit antibody against a synthetic peptide 
containing 12 amino acids of the C-terminus of the NS2 protein (Collins and Wertz, 
1985; Johnson and Collins, 1989).  
 
NS1 and NS2 proteins are expected to be expressed in infected cells at high levels 
because of their promoter-proximal location, but only a low amount of NS1 and NS2 
proteins is detectable using monoclonal antibodies.  Connors et al. (1991) demonstrated 
that mice immunized with recombinant vaccinia virus expressing NS1 and NS2 proteins 
were not resistant to hRSV challenge.  These results suggested that neither NS1 nor 
NS2 proteins are the protective antigens.  
 
The NS1 protein was shown to be co-precipitated by a murine monoclonal antibody 
against the M protein, suggesting that the NS1 protein is associated with the M protein 
in infected cells.  Whereas no viral structural protein is associated with the NS2 protein 
(Evans et al., 1996), it has been suggested that there is an interaction between the NS2 
protein and host cell cytoskeletal intermediate filaments (Weber et al., 1995).  Recently, 
recombinant NS1 and NS2 proteins have been reported to form homomers and 
heteromers (NS1-NS2).  When recombinant NS1 or NS2 proteins were expressed alone, 
high amounts of the NS1 protein appeared in the nucleus and of the NS2 protein in the 
mitochondria.  However, when the NS1 protein was co-expressed with the NS2 protein, 
the NS1 was also observed in the mitochondria, indicating that the localization of the 
NS1-NS2 heteromer was in the mitochondria (Swedan et al., 2011).   
 
Neither NS1 nor NS2 proteins are essential for viral replication; therefore, they are 
defined as accessory proteins (Teng and Collins, 1998).  However, virus growth can be 
attenuated in vitro and in vivo by gene deletion of NS1 or NS2 genes from recombinant 
hRSV (Teng and Collins, 1999; Whitehead et al., 1999a; Teng et al., 2000).  The NS1 
protein has been found to have a negative regulatory effect on transcription and RNA 
replication in a minigenome replication system (Atreya et al., 1998).  Also, NS proteins 
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are capable of suppressing premature apoptosis via an IFN- and NF-κB dependent 
pathway, thereby facilitating viral growth (Bitko et al., 2007).   
 
NS proteins are vital inhibitors of the innate immune response through the inhibition of 
one or multiple signalling factors of the type I IFN induction and/or response pathway.  
Recent studies have shown that NS proteins suppress IFN induction by reducing levels 
of TNF receptor-associated factor 3 (TRAF3).  TRAF3 acts as an integrator of IFN-
inducing signals from both the retinoic acid – inducible gene I (RIG-I) and Toll – like 
receptor (TLR) pathways.  Swedan et al. (2009) showed the TRAF3 levels were sharply 
decreased by recombinant NS1 and NS2 proteins together, by the NS1 protein alone, 
but weakly by the NS2 protein alone.  Levels of TRAF3 – downstream IκB kinase ε 
(IKKε), which plays a role in activation of the IFN regulatory factors (IRF), was also 
reduced by the recombinant NS1 protein, but increased by the NS2 protein.  The N-
terminal of the NS1 protein is found to be necessary for the reduction of IKKε (Swedan 
et al., 2011).  NS2 protein can bind to the N-terminal caspase activation and recruitment 
domain (CARD) sequence of RIG-I and inhibit the interaction between RIG-I and the 
downstream of mitochondrial antiviral-signalling proteins (MAVs) blocking the 
activation of the IFN promoter (Ling et al., 2009).  NS1 protein was not able to interact 
with RIG-I.  
 
NS1 and NS2 proteins have also been shown to suppress the activation of interferon 
regulatory factor 3 (IRF3) which is one of the transcription factors for IFN-β and IFN–
α1 genes.  In wild-type hRSV infected cells containing substantial amounts of NS1 and 
NS2 proteins, the activation and nuclear translocation of IRF3 was suppressed.  
Correspondingly, recombinant hRSV lacking NS1 and NS2 genes increased the level of 
IRF3 activation (Spann et al., 2005).  Although the NS1 protein is unable to associate 
with RIG-I, a recent study has shown that the NS1 protein can directly interact with 
IRF-3 and its coactivator CBP (CREB – binding protein).  Consequently, the formation 
of IRF-3 associated with CBP is inhibited preventing binding of IRF-3 with the IFN 
promoter (Ren et al., 2011).   
 
Lo et al. (2005) has demonstrated that recombinant NS1 plus NS2 proteins and NS2 
expressed alone in human pulmonary epithelial cells (A549) also suppress the IFN 
response pathway by decreasing the level of signal transducer and activator of 
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transcription 2 (STAT2).  Ramaswamy et al. (2004) has reported that the loss of STAT2 
expression likely occurs due to the proteasome-mediated degradation of STAT2.  
STAT2 levels are restored after adding a proteasome inhibitor in hRSV infected cells. 
Whilst recombinant hRSV lacking NS1 and NS2 genes increased the STAT2 level in 
A549 and monocyte derived macrophage (Spann et al., 2004; Lo et al., 2005), 
recombinant NS1 protein alone had little effect on the STAT2 suppression and NS2 
protein alone and the combination of NS1 and NS2 proteins produced a significant 
reduction (Lo et al., 2005).  Although these results suggest that reduction of the STAT2 
level is predominantly caused by NS2 function, the C-terminal DLNP tetrapeptide, the 
four amino acids identical in both NS1 and NS2, is reported to be important for the 
reduction of STAT2 levels by binding with the cellular microtubule-associated protein 
1B (MAP1B) (Swedan et al., 2011).  Also, the NS1 protein has been shown to form 
Elongin-Cullin E3 ligase complexes leading to proteasome-mediated STAT2 
degradation (Elliott et al., 2007). 
1.4.2 The nucleocapsid protein  
The hRSV nucleocapsid protein (N) contains 391 amino acids which is smaller than that 
of other paramyxoviruses (489 – 553 amino acids) (Collins et al., 1985).  However, the 
structure and function of the N protein are likely to be similar to those of other 
mononegaviruses.  
 
Evidence from deletion mutation, yeast two-hybrid experiments and recent three-
dimensional (3D) modelling of recombinant hRSV N/RNA complexes indicate that the 
N protein contains two functional domains which are N- and C- terminal domains.  The 
N-terminus is essential for binding to the L polymerase, whilst the C-terminus contains 
the P binding region (Krishnamurthy and Samal, 1998; Tawar et al., 2009).  The C-
terminus of the P protein is reported to bind this region of the N protein (Garcia-Barreno 
et al., 1996; Mallipeddi et al., 1996).  In the 3D crystal structure of a recombinant hRSV 
N protein, it has been shown that each N monomer associates with seven nucleotides of 
bound RNA.  The RNA binding is in the groove between the C- and N-terminus of the 
N protein (Tawar et al., 2009).   
 
The encapsidation of viral RNA with the N protein is necessary for viral replication and 
transcription because the viral polymerase only recognizes the N-RNA complex and 
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also the N-RNA complex is resistant to nuclease treatment (Murphy et al., 2003).  The 
N-terminus of the N protein is demonstrated to be required for nucleocapsid formation 
and RNA synthesis using a minigenome system (Khattar et al., 2000).  Therefore, the N 
protein can be an important target for producing an effective antiviral compound.  One 
such is RSV604, an anti-hRSV compound, exhibiting potent antiviral activity against 
hRSV isolates of both subgroup A and B.  The resistant mutations of RSV604 have 
been mapped to the conserved N-terminus of the N protein (residues 105 – 139) 
(Chapman et al., 2007).   
1.4.3 The phosphoprotein  
The hRSV phosphoprotein (P), which is 241 amino acids in length, is shorter than that 
of other paramyxoviruses (391 – 602 amino acids), but its activities are similar.  The P 
protein associates with N, L and M2-1 proteins for RNA synthesis (Garcia-Barreno et 
al., 1996; Khattar et al., 2000).  The C-terminal of the P protein binds to the C-terminal 
of the N protein opening the ribonucleoprotein structure.  Subsequently, the L protein 
can interact with the N-RNA template.  In addition, the P protein interacts with newly 
synthesized soluble N (N
0
) to prevent illegitimate polymerization before the latter binds 
to the nascent RNA chain during viral replication (Curran et al., 1995).   
 
The P protein is able to form a homotetramer oligomerizing via a coiled-coil motif 
which contains a repeated pattern of hydrophobic and hydrophilic amino acids.  The P 
oligomerization domain is located between residues 120 – 150 in the central region of 
the P protein (Asenjo and Villanueva, 2000; Castagne et al., 2004).  
 
The phophorylation of the P protein occurs at several serines (S) and threonines (T) 
residues by cellular casine kinase II (Mazumder and Barik, 1994; Dupuy et al., 1999).  
The S232 is the major phosphorylation site, but other minor phosphorylation sites are 
S116, S117, S119, S237 and T108 (Barik et al., 1995; Sanchez-Seco et al., 1995; 
Asenjo et al., 2006).  Site-directed mutagenesis studies have indicated that 
phosphorylation of S232 and S237 is essential for the transcriptional activity of the P 
protein (Mazumder and Barik, 1994; Barik et al., 1995).  The former is also important 
for the elongation activity of the P-L complex during RNA transcription (Dupuy et al., 
1999).  Moreover, the phosphorylation at T108 is involved in the control of the P-M2-1 
interaction and facilitates the incorporation of the M2-1 protein into a viral polymerase 
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complex during viral transcription (Asenjo et al., 2006).  However, it has been shown 
that the phosphorylation of the P protein is not compulsory for the interaction of the P-
P, P-N (Castagne et al., 2004) and P-M2-1 complexes (Mason et al., 2003), but it is 
necessary for efficient virus budding and replication in vitro and in vivo (Lu et al., 
2002). 
1.4.4 The large polymerase protein  
The hRSV large polymerase protein (L) is a component of the viral RNA dependent 
RNA polymerase complex which also includes P, N and M2 proteins.  It is 2,165 amino 
acids in length which is similar to the L protein of other paramyxoviruses.  The 
localization of the L protein in infected cells appears to be near the viral membrane 
associated with N and P proteins (Carromeu et al., 2007).  The L protein plays a major 
role in all enzymatic activities during viral replication and transcription, including 
capping, methylation and polyadenylation. After alignment analysis of the 
Mononegavirales L proteins, six discrete segments (region I to VI) containing highly 
conserved residues have been revealed (Poch et al., 1990).  The central region of the L 
protein (II to V) contains the most highly conserved amino acid sequences and has an 
area of highly positive charged protein residues in region II.  This area is likely to be 
involved in the recognition of template.   
 
Furthermore, it has been found that mutation of the GDNQ motif, lying in region III of 
all the Mononegavirales L proteins and at residues 810-813 of the hRSV Long strain L 
protein, inactivated the polymerase activity (Jin and Elliott, 1992; Sleat and Banerjee, 
1993; Schnell and Conzelmann, 1995; Fix et al., 2011).  Therefore, the GDNQ motif 
has been proposed as the polymerase active site.  In addition, a single amino acid 
change in  region IV of the hRSV L protein caused the production of high levels of 
polycistronic readthrough RNAs due to a lower ability to terminate at gene end 
sequence (Cartee et al., 2003).  The guanylation and methlylation activity involved in a 
cap structure synthesis have been located in the regions V and VI respectively of the 
Mononegavirales L protein (Ferron et al., 2002; Liuzzi et al., 2005; Ogino et al., 2005).   
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1.4.5 The M2-1 protein 
The M2-1 protein, or 22kDa protein, is encoded by the 5’-proximal ORF of the M2 
gene (Collins et al., 1990).  The M2 gene is only found in the subfamily Pneumovirinae, 
while the subfamily Paramyxovirinae lacks this gene.  The M2-1 protein is 194 amino 
acids in length and forms a homotetramer (Tran et al., 2009).  The M2-1 protein is 
located in cytoplasmic inclusions (Garcia et al., 1993) and also in the nucleus of 
infected cells (Reimers et al., 2005).  It has been thought that the M2-1 protein may be 
translocated into the nucleus following interaction with the Rel A protein leading the 
induction of NF- κB activation. 
 
The M2-1 protein is involved in elongation or anti-termination activity during RNA 
transcription.  High amounts of incomplete mRNAs were produced in a minigenome 
system lacking the M2-1 ORF plasmid due to the premature termination of 
transcription, whilst there was a substantial change to the efficient full-length mRNAs 
synthesis when an M2-1 ORF plasmid was added.  However, this activity of the M2-1 
protein depends on the position of the target gene.  The synthesis of full-length NS1 and 
NS2 mRNAs is not associated with M2-1 protein expression. In contrast, the M2-1 
protein is very important in producing complete mRNAs from the other, downstream 
genes.  In addition, it was found that there was no difference in genome synthesis in the 
presence or absence of the M2-1 protein suggesting that the M2-1 protein is not 
involved in RNA replication (Collins et al., 1996; Fearns and Collins, 1999b).     
 
Besides intragenic anti-termination, the M2-1 protein also acts as a transcriptional anti-
terminator at gene end sequences (GE-anti-termination activity).  It has been reported 
the synthesis of polycistronic mRNAs increased when whole M2 plasmid containing 
M2-1 and M2-2 ORF and M2-1 ORF alone were expressed. (Hardy and Wertz, 1998; 
Fearns and Collins, 1999b; Hardy et al., 1999). 
 
The M2-1 protein carries a conserved C3-H1 motif (C-X7-C-X5-C-X3-H) at the N-
terminus.  This motif in other proteins has been reported to bind zinc ions (Worthington 
et al., 1996).  When the predicted zinc-coordinating residues in this motif were mutated, 
the ability of both transcriptional readthrough and the interaction with the N protein 
were inhibited.  However, a mutation in a non-coordinating residue increased 
readthrough transcription, but still blocked the association with the N protein (Hardy 
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and Wertz, 2000).  These findings suggest that the anti-termination activity of the M2-1 
protein requires the zinc binding motif, but not the interaction between the M2-1 protein 
and the N protein.    
 
Two forms of the M2-1 protein are present in infected cells and can be demonstrated in 
reducing sodium dodecyl sulphate-polyacrylamide gels (SDS-PAGE).  It has been 
shown that the slower migrating form is phosphorylated, whereas the faster form is 
unphosphorylated.  The mutation in the predicted zinc-coordinating residues caused a 
shift from the slower migrating form to the faster form, suggesting that this motif is also 
important for phosphorylation.  Together these results indicate that the predicted zinc 
coordinating residues of the C3-H1 motif in the M2-1 protein are necessary for the 
maintenance of protein integrity, efficient transcriptional readthrough at gene junctions 
and efficient phosphorylation (Hardy and Wertz, 2000).  The serine residues 58 and 61 
of the M2-1 protein have been found to be the sites of phosphorylation (Cartee and 
Wertz, 2001) instead of threonine 56 and serine 58 as previously reported by Cuesta et 
al. (2000).  Mutation of S58 and S61 resulted in the reduction of antitermination 
activity, indicating that the phosphorylation of the M2-1 protein is important for hRSV 
transcription, but had no effect on the association with N protein (Cartee and Wertz, 
2001).  It has been reported that the M2-1 protein has RNA binding capacity and the 
M2-1/N interaction is mediated by viral RNA (Cuesta et al., 2000; Cartee and Wertz, 
2001).   
 
1.4.6 The M2-2 protein 
An 11kDa M2-2 protein (90 amino acids) is encoded by the 3’-proximal ORF of the M2 
mRNA that is located slightly upstream of the M2-1 gene end (Collins et al., 1990).  A 
low level of the M2-2 protein is expressed and found to be localized in cytoplasmic 
inclusion bodies (Ahmadian et al., 2000).  It has been reported that the removal of the 
M2-2 protein does not affect the replication in cell culture; therefore, the M2-2 protein 
is defined as an accessory protein.  However, recombinant hRSV with an M2-2 deletion 
can be attenuated in vivo (Jin et al., 2000a).   
 
The amount of genomic RNA and antigenomic RNA in hRSV lacking the M2-2 protein 
is less than hRSV wild-type, whereas the level of mRNA is significantly increased.  It 
has thus been suggested that the M2-2 protein is a regulator of the switch from viral 
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transcription to RNA replication (Bermingham and Collins, 1999; Jin et al., 2000a). 
Overexpression of the M2-2 protein blocks viral replication (Cheng et al., 2005). 
1.4.7 The matrix protein 
The hRSV matrix protein (M) is a non-glycosylated protein of 256 amino acids in 
length that has no homologous sequence with the M protein of other paramyxoviruses 
and is smaller than them (335 – 375 amino acids).  The hRSV M protein comprises two 
domains connected by a linker region (Money et al., 2009).  The C and N-terminal 
domains have high and low hydrophobicity, respectively.  The C-terminal domain of the 
M protein is thought to interact with the plasma membrane (Ghildyal et al., 2006).  In 
addition, positively-charged patches are found on the surface of both domains and the 
linker, suggesting an ability of the M protein to interact with negatively-charged host 
membrane or viral nucleocapsid (Money et al., 2009).   
 
The function of the M protein in other mononegaviruses is to inhibit viral transcription 
prior to assembly and to bring the envelope complex together with the nucleocapsid in 
the formation of viral particles (Kaptur et al., 1991; Lenard, 1996; Coronel et al., 2001).  
The hRSV M protein has been shown to be an essential structural protein for viral 
replication and passage (Teng and Collins, 1998).  It can be associated with the RNP, an 
association mediated by the M2-1 protein, and is localised in cytoplasmic inclusions in 
the late phase of infection.  The M protein has viral transcription inhibition activity 
(Ghildyal et al., 2002; Li et al., 2008).  Also, in the early infection, the M protein is 
detected in the nucleus of the infected cells and inhibits transcription of host cell which 
may conceivably facilitate viral replication (Ghildyal et al., 2003).  
 
The M protein is associated with the cytoplasmic side of the plasma membrane co-
ordinating all components of virus in the step of budding (Marty et al., 2004).  It is able 
to bind with the plasma membrane without viral glycoprotein expression.  However, its 
co-expression with the F glycoprotein results in M protein sorting into lipid rafts 
(Henderson et al., 2002).  It has been reported that lipid rafts are used for packaging and 
budding of hRSV and that the M, G and N proteins are all present in them (Marty et al., 
2004).  The M protein has also been shown to interact with the amino terminus of the G 
protein (Ghildyal et al., 2005).  Furthermore, the M protein has a capacity for RNA 
binding which is not sequence specific.  The function of M protein-RNA interaction is 
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unknown, but it may relate to transcription inhibition of the host cell during early 
infection (Rodriguez et al., 2004).  
1.4.8 The small hydrophobic protein  
The small hydrophobic protein of hRSV (SH) is a surface, type II transmembrane 
protein (Collins and Mottet, 1993).  The integral membrane proteins are divided into 4 
topological classes: types I, II and III have single, membrane – spanning, hydrophobic 
segments and type IV have multiple transmembrane segments.  Type I transmembrane 
proteins contain a signal sequence and an extracellular region at the N-terminus and 
have a transmembrane anchor domain at the C-terminus.  Type III proteins have the 
same oriention as type I proteins, but do not have a signal sequence.  Type II proteins, 
including, the hRSV SH, also lack a signal sequence but are anchored into the 
membrane via a hydrophobic, N-terminal anchor with an extracellular C-terminal region 
(Harvey, 2007). 
 
The length of the polypeptide chain in the SH protein is slightly different between 
subgroups A and B being composed of 64 and 65 amino acids, respectively.  It has been 
shown that the amino acid sequence of the SH protein among hRSV clinical isolates is 
relatively highly conserved within the subgroups (Chen et al., 2000).   
 
During infection, SH protein is produced in several forms comprising two non-
glycosylated and two glycosylated forms.  All four forms are integral membrane 
proteins which are produced and processed on intracellular membranes.  SHo (full- 
length 7.5kDa, most abundant species) and SHt (4.5kDa, N-terminally truncated form) 
are non-glycosylated species.  SHt is possibly synthesized by translational initiation at 
the second start codon (AUG), while SHo is originated from the first AUG.   SHg (13-
15kDa) is an N-linked glycosylated form modified from SHo.  SHp (21 - 30kDa) is a 
modified species synthesized by adding polylactosaminogylcan to the N-linked 
carbohydrate of SHg.   The SHo, SHg and SHp forms are transported to the cell surface; 
however, only SHo and SHp are incorporated into virions. 
 
The function of the SH protein is still unclear. It has been observed that it induces a 
permeability change in the Escherichia coli membrane when it is expressed in the 
bacterial cell, suggesting that it has an ion-channel function (Perez et al., 1997).   
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Recently, the transmembrane domain of the SH protein has been found to form α-helical 
pentamers which have cation-selective ion channel activity (Gan et al., 2008). 
Furthermore, SH protein may be essential for infectivity in vivo as the recombinant 
hRSV lacking the SH gene is attenuated in mice and chimpanzees; however, deletion of 
the SH gene from recombinant hRSV does not affect viral replication in tissue culture 
(Bukreyev et al., 1997; Whitehead et al., 1999a).   
 
Expression of a recombinant parainfluenza virus 5 (PIV5) in which the PIV5 SH is 
replaced with hRSV SH (PIV5ΔSH-RSV-SH) and study of hRSV with a deleted SH 
gene (RSVΔSH) suggest that the SH protein of hRSV is able to inhibit TNF-α mediated 
NF-κB activation and is similar in this respect to the SH protein in PIV5.  hRSV SH 
protein can also inhibit apoptosis (Wilson et al., 2006; Fuentes et al., 2007).  
1.4.9 The attachment glycoprotein 
The hRSV attachment glycoprotein (G) is a type II glycoprotein which contributes to 
virus binding (Levine et al., 1987), but for which the full role in virus replication 
remains uncertain.  The amino acid sequence and structural features of the hRSV G 
glycoprotein are significantly different from those of other paramyxovirus attachment 
proteins (HN or HA proteins) (Wertz et al., 1985; Johnson et al., 1987).  There are two 
different forms of the G glycoprotein observed in the infected cell.  One is a membrane-
bound form (Gm) which is full-length containing 289 to 319 amino acids depending on 
the virus strain (Collins and Crowe, 2007).  The other is a soluble form (Gs) that is 
secreted into the culture medium before virus release (Hendricks et al., 1987; Hendricks 
et al., 1988).  The Gs protein is produced from an alternative translation initiation at the 
third AUG (residue 48) located in the middle of the G ORF and further trimmed by N-
terminal proteolytic cleavage following residue 65.  Therefore, the soluble G 
glycoprotein lacks 65 amino acids including the entire signal and the hydrophobic 
transmembrane region (Roberts et al., 1994).  
 
The Gm glycoprotein is synthesized as a 32kDa precursor by transcriptional initiation at 
the second AUG of the mRNA.   Only a short peptide of 15 amino acids residues is 
encoded from the first AUG.  The Gm precursor is then modified by the addition of 
high-mannose N-linked sugars to asparagine residues leading to an increase in the mass 
of the protein to 45 - 50kDa (Wertz et al., 1989; Collins and Mottet, 1992).  These 
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intermediate proteins form homo-oligomers (trimers or tetramers) probably in the 
endoplasmic reticulum and O-linked sugars are added to serines (S) and threonines (T) 
on the surface of the oligomers.  The mature form of the G glycoprotein is produced in 
the trans-Golgi compartment with a monomeric molecular weight of approximately 80 – 
90kDa as estimated by SDS-PAGE (Collins and Mottet, 1992) and then transported into 
the cell surface. 
 
The Gm glycoprotein consists of three major parts - the N-terminal cytoplasmic domain 
(residues 1 – 37), the hydrophobic transmembrane domain (residues 38 – 63) and the C-
terminal ectodomain (residues 64 – 298 based on strain A2) as shown in Figure 1.4 
(Satake et al., 1985; Wertz et al., 1985).  The ectodomain consists of a central region 
which is largely conserved among different virus isolates flanked by two mucin-like 
variable regions, resembling the structure of the 55kDa tumor necrosis factor receptor 
(Langedijk et al., 1998).  The mucin-like regions have a high amount of potential 
acceptor sites for O-linked sugar (S/T) and N-linked sugar and also have a high proline 
(P) and serine content (Melero et al., 1997).  The amino acid compositions of these 
regions are similar to the mucins produced by many epithelial tissues (Apostolopoulos 
and McKenzie, 1994). 
 
As shown in Figure 1.4, the central region segment lacks potential glycosylation sites 
and contains a 13-amino acid completely conserved segment (residue 164 – 176 based 
on strain A2) which overlaps a sequence  with four cysteine  (C) residues (position 173, 
176, 182 and 186) which form a cystine noose by two disulfide bridges occurring 
between C173 and C186, and between C176 and C182 (Gorman et al., 1997).  The 
C182 to C186 segment is a CX3C motif similar to that of the CX3C chemokine 
fractalkine (Fkn) which binds to cells via CX3CR1 and glycosaminoglycans (GAGs) 
(Tripp et al., 2001).  It has been reported that GAGs are required for hRSV infection 
(Feldman et al., 1999; Hallak et al., 2000a; Hallak et al., 2000b) and a major heparin 
binding domain (HBD) maps to amino acid position 184-198 of the G protein (Feldman 
et al., 1999).   
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Figure 1.4: Scheme of the primary structure of the G glycoprotein based on hRSV A2 strain. 
[Modified from original by Polack et al. (2005) and Wertz and Moudy (2004)] 
Areas of mucin-like variable region, conserved region, the 13-amino acid (aa) segment and the CX3C 
chemokine fractalkine are denoted.  Positions of N- and O-linked carbohydrate are depicted as triangles 
( ) and rods ( ), respectively.  Cysteine residues are shown with filled ovals and the disulfide bridges 
with dotted lines. NH2: N-terminal domain; COOH: C-terminal domain; CT: cytoplasmic domain; TM: 
transmembrane domain; C: conserved cysteine; GCRR: cysteine rich region. 
 
Melero et al. (1997) described the 3D structure of the Gm molecule (homotrimer).  The 
cytoplasmic tail at the N-terminus, followed by the transmembrane region and then the 
first hypervariable region form a rod-like feature (Figure 1.5).  The cysteine noose 
containing conserved and group specific epitopes sits at the loop of the rod-like shape.  
The second carboxyl-terminal hypervariable region which follows the cluster of 
cysteine at the end of molecule and carries strain-specific epitopes loops back on itself 
to sit at the top of the rod giving the whole structure of the appearance of a lollipop.   
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Figure 1.5: Model of the 3-D structure of the hRSV G protein. 
[Modified from original by  Melero (2007) and Melero et al. (1997)] 
A proposed homotrimer is modified from the model of Langedijk et al. (1996). Hatched and shaded 
rectangles are depicted as the transmembrane domains and the mucin-like variable regions, respectively. 
Areas of several structural motifs are indicated. Disulphide bonds (S-S) and the N- and C-terminal 
domain are denoted. 
 
A cold-passaged candidate hRSV vaccine (cp-52) lacking the G and SH genes (Karron 
et al., 1997) or recombinant virus lacking the G gene alone (Teng et al., 2001) replicate 
as well as wild type in vitro depending on cell types.  However, both viruses exhibit 
reduced efficiency of the viral replication in mice suggesting that the G glycoprotein is 
necessary for viral replication in vivo.  In addition, the Gs protein is found to be 
sufficient for the virus growth both in vivo and in vitro, indicating that both cyoplasmic 
and transmembrane forms are not required for the viral replication (Teng et al., 2001).   
 
The conserved regions in the ectodomain of Gm are believed to be the putative receptor 
binding site for attachment activity (Johnson et al., 1987).  Nevertheless, the deletion of 
this conserved region including the cysteine noose and  part or all of the 13- amino acid 
conserved segment from the G protein has no effect on hRSV replication either in vivo 
or in vitro (Teng and Collins, 2002).  The removal of the heparin-binding domain in the 
recombinant hRSV also does not decrease the efficiency of viral growth in vitro, 
although there is a slight reduction in vivo (Teng et al., 2001).  
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Polack et al. (2005) have demonstrated that the cysteine noose or G cysteine-rich region 
(GCRR) is involved in modulating the innate inflammatory response.  Recombinant 
hRSV lacking the GCRR or with the disulfide bridges in the GCRR disrupted have 
enhanced production of IL-6 in human monocytes and inhibited nuclear translocation of 
the NF-κB transcription factor.  Moreover, the GCRR can block the production of 
proinflammatory cytokines elicited via TLR2, 4 and 9 agonists.  The expression of the 
full-length G protein or the CX3C motif of the G protein in CX3CR1
+
 cytotoxic T cells 
also decreases the pulmonary influx of immune cells associated with innate and 
adaptive immune response (Harcourt et al., 2006).   Therefore, the GCRR and CX3C 
motifs appear to inhibit inflammatory responses. 
 
It has been found that the recombinant hRSV producing only the Gm protein has higher 
susceptible to neutralizing antibodies than wild-type hRSV in tissue culture cells and 
mice suggesting that the Gs protein serves as an antigen decoy to escape antibody 
neutralization (Bukreyev et al., 2008).  Infection of human lung epithelial cells (A549) 
by a spontaneous hRSV mutant which cannot produce the Gs protein (RSV-ΔsG) 
resulted in the enhancement of the host cell inflammatory response when compared to 
wild type virus infection (Arnold et al., 2004).  Similarly, RSV-ΔsG infection in mice 
stimulated a high amount of eosinophils and macrophages and a high concentration of 
IFN-γ and IL-10 (Schwarze and Schauer, 2004).  The Gs protein appears to be 
important in blocking chemokine release.  It seems likely that Gs protein acts as a 
soluble factor inhibiting inflammatory responses.  
1.4.10 The fusion glycoprotein  
Primary structure of the fusion protein 
The hRSV fusion glycoprotein (F) is a type I membrane protein which is initially 
synthesized as an inactive pre-F0 precursor protein (574 amino acids).  This precursor 
contains a hydrophobic signal peptide at the N-terminus and a hydrophobic 
transmembrane anchor domain at the C-terminus.  The signal peptide is thought to 
initiate transport of the nascent pre-F0 protein across the plasma membrane and into the 
lumen of the endoplasmic reticulum.  F0 (~ 70kDa) is synthesized by removal of  the 
signal peptide using a signal peptidase (Collins et al., 1984), followed by N-
glycosylation and homo-oligomerization (into trimers) in the endoplasmic reticulum 
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(Collins and Mottet, 1991; Anderson et al., 1992).  The F0 is then cleaved twice at 
residue 109 and 136 as shown in Figure 1.6 (Gonzalez-Reyes et al., 2001) by furin-like 
proteases in the trans-Golgi to generate the F2 (~ 20kDa) and F1 (~ 50kDa) subunits, 
respectively.  The two subunits are held together by a disulfide bond between conserved 
cysteines (Collins and Mottet, 1991; Bolt et al., 2000).   
 
The primary structure of the F glycoprotein in all paramyxoviruses comprises an F1 
subunit with hydrophobic domains at both ends which are the trans-membrane anchor 
(TM) at the C-terminus and a fusion peptide (FP) at the N- terminus  as shown in Figure 
1.6.  The fusion peptide is believed to have the same function as other fusion peptides 
that penetrate into the target membrane during the membrane fusion process (Durrer et 
al., 1996).  Each hydrophobic domain is adjacent to a heptad-repeat (HR), HR1 for the 
fusion peptide and HR2 for the transmembrane domain (Chambers et al., 1990).  A HR3 
has been identified within the F2 protein by a computer search strategy, but its function 
has not yet been established (Matthews et al., 2000).  The F1 subunit contains one site 
for N-linked glycosylation, while two N-linked glycosylation sites are found in the F2 
subunit (Rixon et al., 2002).  The cytoplasmic tail (CT) extends from transmembrane 
anchoring domain of F1 at the C-terminus (Colman and Lawrence, 2003).   
 
The orientation of the F0 precursor is NH2–F2–FP–HR1–F1–HR2–TM–CT–COOH 
(Collins et al., 1984).  Cleavage at both residues 109 and 136 upstream of the fusion 
peptide is necessary for the formation of syncytia in the hRSV infection.  The cleavage 
site I is RARR at residues 106-109 and the cleavage site II is KKRKRR at residues 131-
136 (Gonzalez-Reyes et al., 2001; Zimmer et al., 2001).  Cleavage site II is conserved 
in all hRSV and bRSV isolates, but differs from the cleavage sites of all other 
paramyxovirus F glycoproteins which usually contain one site only of three or four 
basic amino acids (Klenk and Garten, 1994).  A short peptide of 27 amino acids (p27) is 
released after the endoproteolytic cleavage at both sites of F0.   The hRSV p27 peptide 
contains two to three N-glycosylation sites depending of the hRSV subtype, whereas the 
p27 peptide of the bRSV contains only one N-glycosylation motif.   
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Figure 1.6: Scheme of the primary structure of F glycoprotein based on hRSV long strain. 
[Modified from original by Yunus et al. (2010)] 
The F glycoprotein contains two subunits, F1 and F2.  The F1 subunit has two heptad-repeat (HR) 
domains, HR1 and HR2 depicted as unfilled rectangles, and two hydrophobic regions, the fusion peptide 
(FP) and the transmembrane domain (TM) shown as filled rectangles.  In the F2 subunit, the location of 
an additional predicted HR3 is shown.  The N-terminal (NH2) domain, furin cleavage site I (RARR), site 
II (KKRKRR), the disulfide (-S-S-) bond, C-terminal domain (COOH) and the cytoplasmic tail (CT) are 
also denoted.  The conserved N-glycosylation sites are represented as the lollipop-shaped structure in the 
F1 and F2 subunits. The numbering of amino acids is based on the F0 precursor. 
 
Secondary and tertiary structure of the fusion protein 
Virus membrane-fusion proteins are divided into two classes based on structural 
features; class I and class II.  Class I viral fusion proteins are synthesized as inactive 
single-chain precursors assembling into trimers.  They are proteolytically cleaved by 
host proteases to generate two subunits and fold to a pre-fusion form with a metastable 
conformation (Chen et al., 1998).  Their structures are trimeric spikes perpendicularly 
projecting from the viral membrane and have primarily secondary structures of α-helix. 
After exposure to low pH or binding to the cell receptor, the fusion protein is activated 
to form an extended structure (pre-hairpin intermediate form) and the N-terminal fusion 
peptide is inserted into the target membrane.  A trimer of hairpins containing a central 
α-helical coiled-coil (six-helix bundles, 6HB) is then formed, the post-fusion structure. 
In this 6HB motif, three N-terminal regions of the fusion protein (HR1) form an inner 
trimeric coiled-coil core and three C-terminal regions (HR2) pack against the coiled-coil 
in an antiparallel orientation (Carr and Kim, 1993; Bullough et al., 1994).  The 
examples of class I fusion proteins are the influenza virus hemagglutinin protein (HA),  
HIV-1 gp41 protein, parainfluenza virus 5 (PIV5; formerly known as Simian virus 5, 
SV5) F glycoprotein and hRSV F glycoprotein.   
 
The structures of class II fusion proteins found in flavivirus and alphavirus are different 
from class I proteins.  These fusion proteins are synthesized by proteolytic processing of 
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an accessory protein and β-sheet is the predominant secondary structure of the fusion 
subunit.  They orientate in parallel to the viral membrane.  Their internal hydrophobic 
loops are thought to be inserted into the target membrane during fusion and a trimer of 
hairpins containing a β structure (non-coiled-coil) is the post-fusion form (Earp et al., 
2005; Kielian, 2006; Kielian and Rey, 2006). 
 
The hRSV F glycoprotein is not triggered by low pH and not by the attachment of the G 
glycoprotein to the host cell receptor (see details in section 1.5.3).  It is still unclear 
what triggers this F glycoprotein.  However, the structure of hRSV F glycoprotein is 
similar to other class I fusion proteins.  In pre-fusion form, the hRSV F glycoprotein is a 
trimer of heterodimers containing three N-terminal F2 proteins linked to three F1 
transmembrane proteins by disulphide bonds.  After activation, the fusion peptide 
inserts into the host cytoplasmic membrane, followed by subsequent conformational 
changes and the formation of a 6HB structure which is the interaction of the HR1 and 
HR2 domains.  In this structure, an inner trimeric coiled-coil core containing highly α-
helical contents formed by three HR1 peptides organizes along the central axis of the F 
glycoprotein and three HR2 peptides interact along the grooves of  the HR1 trimer in an 
antiparallel arrangement to construct the 6HB (Lawless-Delmedico et al., 2000; 
Matthews et al., 2000; Zhao et al., 2000).  Peptides derived from the HR2 region can 
block the viral infection likely due to the inhibition of the 6HB formation (Lambert et 
al., 1996).  This hexameric form of the F glycoprotein probably brings the viral 
membrane and the host cell membrane into close apposition (Zhao et al., 2000).  The 
HR3 located in the F2 polypeptide has not been shown to associate with HR1, HR2 or 
the 6HB motif (Matthews et al., 2000).   
 
The 3D structure of the hRSV F glycoprotein has been modelled from its homology 
with the F glycoprotein of Newcastle disease virus (NDV-F) as shown in Figure 1.7. 
Although the percentage of sequence homology between both viruses is low, several 
features are the same in the hRSV-F and NDV-F glycoprotein such as the morphology, 
the function and key sequences in identical positions (Smith et al., 2002).  As shown in 
NDV-F (Chen et al., 2001), the trimeric F molecule is divided into three parts that are 
head, neck and stalk (core).  There is a large channel in the head region running through 
the axis and three symmetrical radial channels intersecting the axial channel between 
the head and neck regions.  The F1 and F2 polypeptides form the head and neck, whilst 
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the stalk region contains HR1 and HR2 of the F1 polypeptides forming a six-membered 
antiparallel helical coiled-coil as mentioned above.  The three fusion peptides and three 
viral transmembrane domains are present at the base of the stalk, indicating that this 
model represents the post-fusion form of the hRSV-F glycoprotein (Morton et al., 
2003).  
                       
 
Figure 1.7: Model of the 3-D structure of the hRSV F glycoprotein (A) and a full-length F rosette 
(B).  
[Modified from original by Calder et al. (2000), Morton et al. (2003) and McLellan et al. (2011)] 
(A) The trimeric F glycoprotein, depicted as polypeptide ribbons with each F2/F1 monomer in a different 
color, is divided into head, neck and stalk (core) regions.  The base of the stalk contains the three 
transmembrane domains and three fusion peptides.  Antigenic site II and antigenic sites IV, V, VI are 
colored in red and blue, respectively.  Antigenic site I is at the top of the head. (B) The full-length F 
rosette consists of three lollipop-shaped rods and three cone-shaped.  The locations of all antigenic sites 
are shown. 
Morphology of the hRSV fusion glycoprotein 
The morphology of the full-length F glycoproteins of hRSV (FWT) has been studied by 
the electron microscope (EM).  FWT was purified from recombinant vaccinia viruses 
infected cells expressing FWT by immunoaffinity chromatography, followed by sucrose 
gradient centrifugation.  The EM studies of FWT revealed rosettes of rods which contain 
both inverted cone-shaped and lollipop-shaped rods (Figure 1.7B).  However, the rods 
are mainly cone-shaped (70%) with only a minority lollipop-shaped.  The wider ends of 
A B 
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both rod types project from the centre of the rosette, suggesting that the inner ends are 
hydrophobic membrane anchors which facilitate aggregation.  The size of both rods is 
19 nm in length and 6 nm in width.  The length of the stem is 10 nm for the lollipop-
shaped rods.  The end views of both types is triangular which is consistent with the full-
length F glycoprotein which usually forms a trimer (Calder et al., 2000).  
 
Conversely, preparations of a mutated F glycoprotein lacking the transmembrane region 
and cytoplasmic tail or a mutant anchorless F glycoprotein (FTM-) mainly contained 
unaggregated cone-shaped rods the end views of which were the same as the FWT 
molecules (triangular), suggesting that aggregation of the cones is dependent on the 
membrane anchor.  The anchorless F glycoprotein was sometimes found in rosettes 
which contained predominantly lollipop-shaped rods in contrast to the full-length F 
glycoprotein rosettes which were mostly cone-shaped rods (Calder et al., 2000).  The 
anchorless F glycoprotein completely cleaved with trypsin at both site I and II also 
formed rosettes with a high amount of lollipop-shaped rods.  A high proportion of 
unaggregated cone-shaped rods observed in the untreated anchorless F glycoprotein was 
predominantly uncleaved F0 and FΔ1-109, an intermediate cleaved only at cleavage site I 
(after residue 109).   Trypsin treatment resulted in the formation of rosettes and it was 
suggested that this was due to exposure of the fusion peptides in the anchorless F 
glycoprotein.  In line with this, the removal of the first portion of the fusion peptide 
leads to inhibition of the anchorless F molecule aggregation (Ruiz-Arguello et al., 
2004). 
 
Inhibition of cleavage at site I, by two amino acids substitution (R108N/R109N), results 
in a low proportion of aggregated molecules and an increase of unaggregated 
(uncleaved) F0 molecule.  Inhibition of cleavage at site II, by the deletion of four amino 
acids (residues 131-134), results in the appearance of individual cone-shaped rods, 
indicating that the site II is necessary to aggregate the anchorless F molecules (Ruiz-
Arguello et al., 2002).     
 
From these finding, it is suggested that the cone-shaped molecule represent the pre-
activated (uncleaved) F glycoprotein which, in the full length form, aggregate into 
rosettes via their hydrophobic transmembrane anchors.  Cone-shaped forms of 
molecules lacking the transmembrane region are thus found only as monomers.  
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Lollipop shaped molecules are the post-activated (cleaved) structures in which the 
hydrophobic fusion peptide is exposed.  Lollipop shaped forms of anchorless F may 
form rosettes aggregated via the fusion peptide (Gonzalez-Reyes et al., 2001; Ruiz-
Arguello et al., 2002).   
 
Taken together, these observations suggest that the activation of the F glycoprotein by 
cleavage at both sites might be important in exposure of the fusion peptide which plays 
a particular role in fusion process.  The inhibition of cleavage at either site I or II of the 
F glycoprotein has been found to block the formation of syncytia, suggesting that 
membrane fusion has to be promoted by cleavage at both sites (Gonzalez-Reyes et al., 
2001). 
Epitope mapping of the fusion protein 
Several anti-F monoclonal antibodies (MAbs) have been used in identifying and 
mapping epitopes on the F molecule.  There are three types of the epitopes identified 
according to their biological activity: neutralizing and fusion-inhibiting epitopes,  
neutralizing epitopes and non-neutralizing epitopes (Walsh et al., 1986).  Using 
competitive binding assays with 15 MAbs, four antigenic domains (A, B, C, and D) 
were identified.  Antigenic site A and B are recognized by MAbs with potent 
neutralizing and fusion activities.  MAbs with only neutralizing activity is bound to 
antigenic site C, whilst antigenic site D is recognized by MAbs without neutralizing and 
fusion-inhibiting activity (Trudel et al., 1987b).   
 
Similar studies by Beeler and van Wyke Coelingh (1989) were largely in agreement 
with that of Walsh et al. (1986) and Trudel et al. (1987b) recognizing antigenic domains 
(A, B and C) and a potential bridge site (AB).  Garcia-Barreno et al. (1989) reported 
five non-overlapping antigenic areas (Ia, Ib, II, III and IV) from 14 anti-F MAbs.  The 
antigenic site II and IV correspond with site A (Trudel et al., 1987b) and C (Arbiza et 
al., 1992), respectively.  Lopez et al. (1998) identified further antigenic sites V and VI 
from 12 neutralizing anti-F Mabs.  
 
The location of each antigenic site is mapped on the primary structure of the F molecule 
by 
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 (i) Testing the reactivity of monoclonal antibodies (Trudel et al., 1987a; Bourgeois 
et al., 1991; Arbiza et al., 1992) or polyclonal antibodies (Scopes et al., 1990) with 
synthetic peptides or with protein fragments expressed in bacteria (Martin-Gallardo et 
al., 1991; Naval et al., 1997). This first method has the limitation of mapping only 
linear epitopes.  
(ii) Identifying amino acid residues which are important for epitope integrity from 
virus mutants which escape neutralization selected by growing and passaging viruses in 
the presence of individual  anti-F MAbs (Lopez et al., 1990; Arbiza et al., 1992; Lopez 
et al., 1998).   
(iii) The two complementary procedures have been combined identifying epitopes 
initially by sequencing escape mutants selected by anti-F MAbs and confirming the 
position of the antigenic sites by binding to synthetic peptides which contain the same 
mutation as the resistant viruses (Arbiza et al., 1992).  
 
Using identification of escape mutants, epitopes in antigenic site I are located in the 
centre of the cysteine rich-region (Lopez et al., 1998).  Epitopes in antigenic site II 
involve residues 255 – 275 which contain a helix-loop-helix structure (Arbiza et al., 
1992; Lopez et al., 1993; Toiron et al., 1996).  In mapping of antigenic site II by 
synthetic peptides, it was found that antibody reactivities were dependent on the length 
of peptide.   The antigenicity of a 61 residue peptide (aa 215-275) of the F1 subunit was 
higher than a shorter 41 (aa 235-275) and 21 (aa 255-275) residue peptides.  F215-275 
peptide contains a high content of ordered structures with two predicted α-helices and a 
high resistance to trypsin digestion compared to peptides F235-275 and F255-275.  
Taken together, these observations suggest that a particular folded conformation was 
required for efficient antibody binding in this region (Arbiza et al., 1992; Lopez et al., 
1993).  Antigenic sites IV, V and VI clustered near the carboxy-terminal end of the 
cysteine rich-region (Arbiza et al., 1992; Lopez et al., 1998).   
 
These antigenic regions were not only mapped to the primary structure of F molecule, 
but they were also located on the 3D structure of F glycoprotein by two methods.  
Firstly, the binding of antibodies to the anchorless F glycoprotein (soluble rod) and full-
length F glycoprotein (rosettes) was studied by the EM.  The binding of antibody in the 
rosettes showed the same position as in the cone-shaped soluble rods (Calder et al., 
2000)  Secondly, the antigenic sites were located by sequence on the RSV-F model 
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(Smith et al., 2002; Morton et al., 2003).  The data from both methods agreed (Figure 
1.7).  Antigenic site I is at the top of the head in the 3D structure or at the distal end of 
the rods in the rosettes.  Antigenic site II is at the base of the head in the F model or the 
base of the head region of rods under the EM.  Antigenic sites IV, V and VI are located 
on the side of the head in the model or the side of the rods in the aggregated of lollipop- 
and cone-shaped rods.  
Function of the F glycoprotein 
The hRSV F glycoprotein is thought to play a major role in allowing the penetration of 
the virus nucleocapsid into the host cell by membrane fusion.  This conclusion is 
supported by similarities of  the sequences and structures of hRSV F glycoprotein 
related to the fusion proteins of other paramyxoviruses (Collins et al., 1984; Spriggs et 
al., 1986), the ability of monoclonal antibodies against the hRSV F glycoprotein to 
neutralize infectively and block the cell-cell fusion in tissue culture (Walsh and Hruska, 
1983) and the ability of HR2 peptides and small molecular weight inhibitors of fusion to 
block infectivity (Lambert et al., 1996; Cianci et al., 2004a; Cianci et al., 2004c; 
Douglas et al., 2005; Bond et al., 2007; Luttick et al., 2007; Bonfanti et al., 2008).  
 
The F glycoprotein is not only responsible for the viral entry into a host cell by fusion, 
but it also mediates the syncytial formation which is the major characteristic of hRSV 
cytopathic effect (CPE) and is a route for viral spread (Merz et al., 1980).   The hRSV F 
glycoprotein is able to form syncytia without other proteins (Kahn et al., 1999), whereas 
most paramyxoviruses require both F glycoprotein and the attachment of the HN for 
fusion.  However, studies have shown that there is an increase of syncytial formation 
efficiency when G and SH proteins are coexpressed with the F glycoprotein (Heminway 
et al., 1994). 
 
Besides fusion and the syncytium formation, it has been suggested that F glycoprotein is 
able to facilitate viral attachment.   hRSV subgroup B strain (hRSV B1/cp-52) lacking 
both G and SH proteins due to a large deletion is able to infect tissue culture cells and 
attach to cells via cell surface glycosaminoglycan (GAG) (Feldman et al., 2000).  In 
addition, soluble heparin has been shown to block the attachment of the bRSV- F 
glycoprotein as well as the G glycoprotein (Karger et al., 2001).  These studies indicate 
that the F glycoprotein could be a mediator of both attachment and infectivity. 
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1.5 The hRSV replicative cycle 
1.5.1 hRSV binding  
The G and F glycoproteins have been shown to be involved in the binding of virus to 
the host cells; however, the cellular receptor (s) involved has not been characterized.  
Several methods (Dimmock et al., 2007) have been used to identify proposed receptors 
for the hRSV attachment as follows. 
(i) Competition by soluble candidate receptors incubated with hRSV before inoculation, 
leading to inhibition of the viral infection.  
(ii) Inhibition of viral growth by antibodies against candidate receptors applied to cells 
before viral exposure. 
(iii) Silencing of candidate receptor expression by RNA interference (RNAi).  
(iv) Expression of candidate receptors in nonpermissive cells, leading to susceptibility 
to hRSV infection.  
 
Glycosaminoglycans (GAGs)   have been identified as receptors for binding of G and F 
glycoproteins (Hallak et al., 2000b; Techaarpornkul et al., 2001).  GAGs are 
unbranched polysaccharide chains consisting of repeating disaccharide units of 
hexuronic acid and hexosamine with different post-synthetic modifications such as 
sulphation.  Hexuronic acid may be either glucuronic acid or iduronic acid and 
hexosamine may be either glucosamine or galactosamine depending on the GAG types 
(Hallak et al., 2000a; Hallak et al., 2000b).   
 
There are seven types of GAGs, five of which are present on the surface of most cells. 
These are heparan sulphate (HS), hyaluronic acid (HA) and chondroitin sulphate A, B 
and C (CS-A, B, and C).  The other two types are heparin and keratan sulphate present 
only on mast cells and keratinocytes, respectively (Hallak et al., 2000a).  All of GAGs 
are connected to transmembrane core proteins, except HA which is secreted and may be 
bound to the cell surface mediated by CD44 (Knudson and Knudson, 1993).  The 
functions of CD44 are involved in cell – cell interaction, adhesion and migration 
(Pasonen-Seppanen et al., 2012). 
 
The composition of HS is glucoronic acid or iduronic acid connected to N-
acetylglucosamine resembling heparin, although heparin contains a higher degree of 
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sulphation than HS (Powell et al., 2004).  CS-B also contains iduronic acid, but is 
linked to N-acetylgalactosamine and modified by sulphation at carbon 4.  CS-A and CS-
C consist of glucoronic acid linked to N-acetylgalactosamine.  The sulphation of CS-A 
and CS-C occur on carbon 4 and carbon 6, respectively. 
 
Several studies have reported that preincubation of hRSV with heparin inhibits viral 
infection in vitro (Krusat and Streckert, 1997; Bourgeois et al., 1998; Martinez and 
Melero, 2000).  In addition, HS and CS-B also block hRSV infection, indicating that 
GAGs containing iduronic acid are required for hRSV infection (Hallak et al., 2000a).  
Apart from the composition of iduronic acid, N-sulphate and a minimum length of 10 
saccharides in the structure are necessary for the interaction between hRSV and GAGs 
(Hallak et al., 2000b).  Although interaction of hRSV with GAGs has been shown to be 
important for the viral infection, hRSV replication in GAG-deficient cells is not 
completely inhibited, being reduced by only 80%.  This suggests that not only GAGs 
are involved in virus binding and that other cellular receptors may play a role (Hallak et 
al., 2000a). 
 
CX3CR1, a receptor of the CX3C chemokine fractalkine Fkn, has also been found to 
facilitate hRSV infection via the G glycoprotein.  Both the G and Fkn proteins contain 
heparin-binding domains and a CX3C motif and both are large glycoproteins consisting 
of an intracellular, transmembrane and extracellular domain.  The G glycoprotein binds 
to CX3CR1 via its CX3C motif and to heparin through heparin-binding domains.  
hRSV infection in cells expressing  CX3CR1 has been reported to be inhibited by the 
addition of heparin or antibodies to CX3CR1 or peptide containing a CX3C motif, 
suggesting that the CX3CR1 and GAGs are receptors for hRSV infection (Tripp et al., 
2001). 
 
Surfactant protein A (SP-A) present in the epithelial lining of the lung has been shown 
to attach G glycoprotein.  SP-A is a member of the C-type lectin family called collectins 
which are multimeric glycoproteins with carbohydrate recognition domains connected 
to collagen stalks.  Collectins function as immune system molecules that bind to surface 
carbohydrates of inhaled pathogens (Haagsman, 1998).  The carbohydrate recognition 
region of the SP-A has been shown to bind to a carbohydrate moiety of the G 
glycoprotein.  Enhanced hRSV replication correlates with increased concentration of the 
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SP-A in Hep-2C cells, indicating that binding of hRSV may be augmented by SP-A 
(Hickling et al., 2000).  However, the SP-A has also been found to be involved in viral 
clearance (see details in 1.9.1). 
 
In addition to the candidate receptors bound by the G glycoprotein, the F glycoprotein 
can bind to RhoA (a small GTP binding protein), which is important for the formation 
of syncytia (Gower et al., 2001), and also attaches to intercellular adhesion molecule-1 
(ICAM-1) which is found on the surface of epithelial cells (Behera et al., 2001). 
Likewise, nucleolin expressed on the surface of many cell types has been recently 
shown to be a receptor for hRSV binding via the F glycoprotein (Tayyari et al., 2011).    
The significance of these multiple receptors in entry and infection of hRSV remains to 
be determined. 
1.5.2 hRSV entry by endocytosis 
There are several different mechanisms of internalization by endocytosis involved in 
virus entry as shown in Figure 1.8.  Phagocytosis is involved in the uptake of large 
particles and is used by specialized cells such as macrophages and amoeba.    
Pinocytosis, the internalization of fluid and solutes, is further categorised into 2 
subgroups: dynamin-independent and dynamin-dependent entry.  Macropinocytosis, 
lipid raft-mediated endocytosis, non-clathrin/non-caveolar-mediated endocytosis are 
dynamin-independent.  Caveolar endocytosis and clathrin-mediated endocytosis require 
dynamins (Mercer and Helenius, 2009). 
 
Once inside the cell, material internalized within endocytic vesicles progresses through 
the endosome network.  Early endosomes are located in the periphery of the cytoplasm.  
These firstly develop into maturing endosomes and then into late endosomes, which 
fuse with lysosomes to generate endolysosomes in which degradation processes occur.  
Dense core lysosomes form the end point of degradation and await fusion with further 
incoming late endosomes.   Incoming membrane components are recycled back to the 
plasma membrane (Mercer et al., 2010). 
 
Endocytosis is a process which depends on energy; therefore, it can be interrupted by 
the inhibition of energy production, for instance, exposure to metabolic inhibitors (e.g. 
sodium azide) or to low temperatures (Punnonen et al., 1998; Atkinson et al., 2002).   
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Sodium azide has been reported to interfere with the entry of adenovirus (Svensson and 
Persson, 1984) and influenza A virus (Nussbaum and Loyter, 1987) into cultured cells, 
but there is not any effect on that of hRSV (Srinivasakumar et al., 1991).  These early 
findings suggested that endocytosis is not involved in the entry of hRSV, whereas both 
adenovirus and influenza require endocytosis for penetration through the plasma 
membrane.   However, more recently, caveolar (Werling et al., 1999) and clathrin-
mediated endocytosis (Kolokoltsov et al., 2007; Gutierrez-Ortega et al., 2008) has been 
found to be involved in the entry of hRSV in dendritic cells and HeLa cells, 
respectively.   
   
Figure 1.8 Diagram of endocytic pathways used by viruses  
[Taken from Mercer and Helenius (2009)] 
Viruses shown in this diagram are semliki forest virus (SFV); vesicular stomatis virus (VSV); human 
immunodeficiency virus 1(HIV‑1); flaviviruses (Flavi); bunyaviruses (Bunya); influenza virus 
(Influenza); adenovirus 2/5 (Ad2/5); simian virus 40 (SV40); BK virus (BK); human papilloma virus 
16(HPV16); lymphocytic choriomeningitis virus (LCMV); polyomavirus (PVD); vaccinia virus mature 
virion (VV MV); adenovirus 3 (Ad3); coxsackievirus B (CVB); herpes simplex virus 1 (HSV1); 
echovirus 1(EV1) and Acanthamoeba polyphaga mimivirus (AMPV).  Dynamins are indicated as small 
blue circles at the neck of forming endocytic vesicles.  The blue lines represent actin.  
 
Caveolar endocytosis (Caveolae) 
Caveolae contain oligomerized caveolin molecules associated with cholesterol and 
sphingolipids.  These form spherical or flask-shaped vesicles of approximately 70 nm in 
diameter by invagination of the plasma membrane with a neck region composed of 
dynamin (Stan, 2002; Nichols, 2003).   Dynamin is a GTPase responsible for scission of 
newly formed vesicles from the membrane (Henley et al., 1999).  Hence, budding of 
caveolae into the cytoplasm is believed to occur at the plasma membrane.   
32 
 
Caveolae are found on the surface of many mammalian cell types, but are highly 
abundant in specific cell types such as adipocytes, endothelial cells, fibroblasts and 
smooth muscle cells (Parton and Simons, 2007).  Their composition, appearance, and 
function depend on cell type.  For example, caveolae appear as grape-like structures or 
single indentations in epithelial cells, but form clusters or linear rows of multiple units 
in muscle cells (Parton et al., 1997; Pelkmans and Helenius, 2002). 
  
The involvement of caveolae in the uptake of hRSV in dendritic cells has been reported.  
The inhibition of caveolae using phorbol myristate acetate and filipin has been shown to 
block the presentation of the hRSV antigen by dendritic cells, indicating that the uptake 
of hRSV is mediated by caveolae in these cells.   These finding has been confirmed in 
the same cells by investigating the co-localization of hRSV and caveolae using mAbs 
against hRSV F glycoprotein and caveolin-1, respectively.  Both hRSV and caveolae 
co-localized at the cellular surface 5 minutes after infection and in the cytoplasm after 
30 minutes.  The additions of inhibitors involved in blocking other mechanisms of 
endosome formation such as the mannose receptor (mannan), macropinocytosis 
(cytochalasin D) and clathrin-mediated endocytosis (amiloride) had no effect in the 
hRSV uptake of dendritic cells, suggesting that dendritic cells require caveolae in 
uptake of hRSV (Werling et al., 1999). 
Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis is a process involving the formation of clathrin-coated 
pits and vesicles on the cytoplasmic side of the plasma membrane which are found in all 
eukaryotic cells.  This process mainly mediates the internalization of extracellular fluid, 
receptors and ligands (Mellman, 1996).   
 
Clathrin occurs in the cytoplasm and is divided into two types, clathrin heavy and light 
chains.  It forms a soluble clathrin triskelion which consists of three clathrin heavy and 
three clathrin light chains.  The structure of the triskelion contains three bent limbs 
radiating from a centre.  Triskelia do not directly interact with cargo receptors or with 
membrane.  They bind to adaptor proteins (e.g. AP2) and cargo adaptors (e.g. epsin) 
which are produced in the cytoplasm and recruited to clathrin-coated vesicle formation 
sites.  The process of this formation consists of five stages (McMahon and Boucrot, 
2011).  
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(1) Initiation is the formation of a membrane invagination called a clathrin-coated 
pit.  FCH domain only proteins (FCHO) bind to phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2)-rich zones of the plasma membrane, EGFR pathway substrate 15 
(EPS15) and intersectins to initiate the pit formation.  
(2) Cargo selection is the recruitment of adaptor protein 2 (AP2), transmembrane 
receptors and cargo-specific adaptor proteins.  The AP2 is an heterotetrameric complex 
which contains α, β2, µ2 and s2 subunits and plays a role in binding to PtdIns(4,5)P2, 
receptors, cargo, cargo-specific adaptor proteins and clathrin (Collins et al., 2002; Kelly 
et al., 2008).  Different cargo-specific adaptor proteins are recruited by different 
receptors. 
(3) Clathrin coat assembly is the recruitment of clathrin triskelia by the AP2 and by 
cargo-specific adaptor proteins to polymerize in hexagons and pentagons and form a 
clathrin coat around the pit (a clathrin-coated vesicle).  
(4) Vesicle scission is budding of vesicles mediated by the GTPase dynamin 
recruited at the vesicle neck.  The GTP hydrolysis induces membrane scission.   
(5) Uncoating and clathrin component recycling is the disassembly of the clathrin 
coat. The uncoated vesicles fuse with their target endosome and components of the 
clathrin machinery are released back into the cytoplasm for recycling. 
 
Clathrin-mediated endocytosis has been implicated in the entry of hRSV into HeLa cells 
by RNA silencing techniques (siRNA).  The inhibition of genes related to clathrin-
mediated endocytosis, such as the light chain subunit of clathrin and the alpha subunit 
of the AP2, significantly blocks hRSV infection.  These results have been confirmed by 
expression of dominant-negative mutants for EPS15 and treatment with 
chlorpromazine, both of which result in the inhibition of the hRSV infection 
(Kolokoltsov et al., 2007).  Chlorpromazine has been reported to cause the loss of 
clathrin and the AP2 at the cell surface and their reappearance on endosomal 
membranes (Wang et al., 1993). 
 
Monodansylcadaverine (MDC) inhibits the polymerization of clathrin (Nandi et al., 
1981).  In human epithelial cells, localization of hRSV antigens in the presence of MDC 
was observed on the surface of infected cells after incubation with anti-RSV antibodies 
for 0, 30 and 60 min using indirect immunofluorescence and confocal laser scanning 
microscopy.  In contrast, hRSV antigens were located inside the cells after incubation 
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for 30 and 60 min when infected cells were treated with caveolae inhibitor (methyl-
beta-cyclodextrin, MBCD).  These results suggest that caveolae are not involved in 
hRSV uptake in non-dendritic cells, whereas clathrin-mediated endocytosis is.   
1.5.3 hRSV membrane fusion  
In line with other members of the Paramyxoviridae, hRSV membrane fusion has been 
found to occur through a pH-independent mechanism being resistant to treatment with 
lysosomotropic agents ammonium chloride and chloroquine which increase pH in the 
endosome (Srinivasakumar et al., 1991; Kolokoltsov et al., 2007).  In contrast, the 
fusion of Vesicular Stomatitis Virus was fully inhibited by both drugs (Kolokoltsov et 
al., 2007).  Ammonium chloride also significantly reduced infection of Influenza A 
virus (Nussbaum and Loyter, 1987) and adenovirus (Svensson and Persson, 1984).  
These findings suggest that, unlike the paramyxoviruses, these three viruses enter host 
cells via a pH-dependent process.   
 
F glycoproteins of most paramyxoviruses expressed on the cell surface at neutral pH 
induce cell-cell fusion and syncytium formation (Smith et al., 2009).  Triggering of 
membrane fusion, however, requires a homotypic attachment protein.  This is so for 
measles virus, Newcastle disease virus and Hendra (Stone-Hulslander and Morrison, 
1997; Bishop et al., 2008; Corey and Iorio, 2009).  For hRSV, membrane fusion, both 
virus-cell and cell-cell, is mediated by the F glycoprotein without the G glycoprotein.   
Several studies have reported that recombinant hRSV lacking SH and G genes retain 
infectivity and syncytium formation in certain cell lines (Karron et al., 1997; 
Techaarpornkul et al., 2002).   
 
Despite differences in triggering, the process of hRSV fusion is thought to be similar to 
that of other paramyxoviruses.  The activation of the F glycoprotein involves a shift 
from the pre-fusion form to the post-fusion form.  This process has been proposed to 
occur in proximity to the cell membrane starting with the exposure of the hydrophobic 
fusion peptide at the N-terminus of the F1 polypeptide and resulting in its insertion into 
the host cell membrane and the formation of a prehairpin intermediate.  This forms a 
protein bridge between the two membranes, the C-terminus being embedded in the viral 
membrane.  Then, a conformational change occurs by refolding of the pre-fusion F 
glycoprotein to form the 6HB structure as described in section 1.4.10 (Lawless-
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Delmedico et al., 2000; Matthews et al., 2000).  As a result, the viral membrane and the 
host cell membrane are brought close to each other.  The two membranes eventually 
fuse by mixing of lipid components and the nucleocapsid is released into the cytoplasm 
(Melero, 2007).              
1.5.4 hRSV transcription 
The template for hRSV transcription is the RNA genome encapsidated with N protein. 
There is a single promoter located at the 3’ terminus which is 44 nucleotides in length 
and includes the leader region (Dickens et al., 1984; Collins et al., 1991).  The RNA-
dependent RNA polymerase complex composed of N, P, L and M2-1 proteins mediate  
viral transcription and replication both of which occur in the cytoplasm of infected cells.   
Three proteins (N, P and L) are required for sequential transcription of the genes on the 
monopartite genomic RNA guided by the GS and GE sequences (Kuo et al., 1996b; 
Kuo et al., 1997).  The M2-1 is involved in the elongation and antitermination activity 
(Collins et al., 1995; Collins et al., 1996; Hardy and Wertz, 1998; Fearns and Collins, 
1999b; Hardy et al., 1999).   
 
The polymerase is thought to comprise the large protein (L) and phosphoprotein (P) in a 
minimal complex.  The functions of this complex are promoter recognition, RNA 
synthesis and mRNA processing (Mazumder and Barik, 1994).   The L-P complex has 
been shown to be sufficient for the activity of RNA synthesis in vitro; nevertheless, 
within host cells actin and profilin are also important in viral RNA transcription (Burke 
et al., 1998; Burke et al., 2000).  Actin binds to the RNA template via its divalent-
cation-binding domain and recruits profilin which acts as a transcriptional cofactor 
(Harpen et al., 2009). 
 
Initiation of hRSV transcription requires 11-nt at the 3’terminus of the leader 
(polymerase binding site), a U-rich region at the end of the leader and the gene start 
sequence (GS) (Cowton et al., 2006).  The correct spacing among the three regions has 
been reported to be important in viral transcription (Fearns et al., 2000; McGivern et al., 
2005).  After initiation, the mRNA is capped and methylated at the 5‘end (Liuzzi et al., 
2005) and the polymerase continues to transcribe along the genome, elongates to the 
end of the gene and polyadenylates the 3’end of mRNA when its active site is 
positioned on the U tract of GE sequence.  Then, the nascent mRNA is released. 
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After termination of transcription at the GE sequence, the polymerase is believed to 
scan the intergenic region to locate the next GS sequence.  Extending the length of the 
intergenic regions located between the GS and GE sequences has been shown to have 
no effect on the efficient scanning activity of polymerase (Bukreyev et al., 2000).   For 
the overlapping region of the M2 and L genes, the polymerase has been reported to 
transcribe to the GE sequence of the M2 gene and then scan backwards to reinitiate at 
the GS sequence of the L gene (Fearns and Collins, 1999a).   
 
Differences in the intergenic junctions have been reported to regulate the termination of 
hRSV transcription.  It has been shown that the gene junctions of the NS1/NS2, NS2/N, 
M2/L and L/trailer inefficiently terminate transcription, whereas the intergenic region of 
the N/P, P/M, M/SH, SH/G and G/F effectively terminate.  The most efficient 
termination was at the SH/G gene junction. Terminations at gene junctions are 
independent of the absence or presence of the M2 protein, except for the F/M2 gene 
junction.  In the absence of the M2 protein, efficient termination occurs at F/M2; 
however, the levels of readthrough transcripts are higher in the presence of the M2 
protein.  As only F glycoprotein will be translated from the readthrough.  This indicates 
that the M2 protein may be responsible for  negative feedback regulation of its own 
expression (Hardy et al., 1999). 
 
The polymerase tends to dissociate from the template at intergenic regions and can only 
re-initiate transcription at the 3’end of genome due to the location of promoter.  
Consequently, there is a 3’ to 5’ gradient of gene expression with the number of 
transcripts from 3’end of genome being higher than that of genes located towards the 
5’end (Kuo et al., 1996a; Hardy and Wertz, 1998; Krempl et al., 2002).  When 
complete, hRSV transcription results in ten mono-cistronic mRNAs with 5’cap 
structures and 3’poly (A) tails which are then translated by the machinery of host cell.   
1.5.5 hRSV replication 
RNA replication involves the synthesis of a full-length positive-sense RNA (anti-
genome) which is complementary to the genome.  The anti-genome serves as the 
template for the production of progeny genomes.  hRSV RNA replication is controlled 
by the M2-2 protein which is responsible for the transition from transcription to 
replication (Bermingham and Collins, 1999; Jin et al., 2000a).   
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During replication, the anti-genome is synthesized without guiding by the GS and GE 
sequences.  However, it contains the trailer-complement (TrC) promoter of 155 
nucleotides in length at its 3’end and acts as a promoter for synthesis of new full-length 
negative-sense genomes.  The replication level from the TrC promoter is higher than 
that from the genomic leader, resulting in an imbalance between antigenome and 
genome in infected cells (Mink et al., 1991; Fearns et al., 2000).   
 
It has been recently shown that the complete trailer increases promoter activity, 
facilitates virus growth by enabling optimal genome production and subverts stress 
granule formation when comparing with mutant recombinant viruses containing 
truncated trailer sequences or with leader-complement sequence substituted for the 
trailer region (Hanley et al., 2010).   
 
Both the anti-genome and genome are encapsidated with N proteins during synthesis.  It 
is thought that the encapsidation reduces the activation of host anti-viral defense and 
also protects these RNAs, which lack stabilization by 5’cap and 3’ poly (A) tails, from 
degradation (Collins and Melero, 2011).   
1.5.6 hRSV assembly and release 
Following production of viral proteins and genomic RNA, assembly of new virions 
occurs in the cytoplasm of target cell without the involvement of the nucleus.  The M 
protein facilitates viral assembly by interacting at the plasma membrane with both the 
nucleocapsids in cytoplasm (Ghildyal et al., 2002; Marty et al., 2004; Li et al., 2008) 
and the envelope glycoproteins on plasma membrane (Henderson et al., 2002; Ghildyal 
et al., 2005).  In polarized cells, assembly and budding of hRSV occurs at the apical 
surface (Roberts et al., 1995; Zhang et al., 2002).   
 
It has been reported that G, F and SH glycoproteins are not involved in viral release 
(Batonick et al., 2008).  There is no any effect on the release of hRSV from polarized 
epithelial cells when individual G, F, SH glycoproteins or pairs of these genes are 
deleted.  However, recombinant hRSV lacking the F glycoprotein has recently been 
shown to reduce the co-localization between the G and N proteins and between the SH 
and N proteins at the plasma membrane.  Furthermore, the G glycoprotein is not 
localized at the surface of cells infected with recombinant hRSV lacking the F 
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glycoprotein gene.  These findings fit with those of Oomens et al. (2006) who found no 
the G glycoprotein localized to viral filaments at the plasma membrane in cells infected 
with recombinant hRSV lacking the cytoplasmic tail of the F glycoprotein (FCT), 
whereas it was present in wildtype hRSV.  Filamentous structures were rarely present in 
the cells infected with FCT.  Deletion of the F glycoprotein gene also resulted in a 
decrease in the incorporation of the G and SH proteins into budded virions and the 
removal of the G glycoprotein gene reduced the amount of SH protein incorporated into 
released virions (Batonick and Wertz, 2011).  Taken together, these results suggest that 
the F glycoprotein may be involved in protein sorting at the plasma membrane and that 
hRSV assembly requires expression of both the F and G genes. 
 
Several studies have shown that host cell cytoskeletal elements are involved in hRSV 
assembly and egress (Kallewaard et al., 2005).  Knockdown of profilin and vasodilator-
stimulated phosphoprotein (a regulator of profilin and actin) with siRNAs inhibited 
hRSV release (Bitko et al., 2003; Musiyenko et al., 2007).   
1.6 Transmission and pathogenesis of hRSV infection 
Transmission of hRSV mainly occurs through close contact with infected patients or by 
contact with environment surfaces contaminated with respiratory secretions (fomites). 
Small aerosol particles are not a major route for the spread of hRSV infection.  Families 
are thought to be the major cause of nosocomial hRSV infections.  It has been reported 
hRSV can survive on skin for up to 20 minutes, on rubber gloves for 90 minutes and on 
countertops for 6 hours and can entry to the body by nose or eye (Hall et al., 1975; Hall 
and Douglas, 1981).   
 
Strict compliance with gown and glove precautions significantly reduces the spread of 
viral infections in hospital (Leclair et al., 1987).  Furthermore, careful hand washing 
and contact precautions may also limit the transmission of hRSV infection, especially 
during the seasonal epidemic.  Hand washing agents reported to effective kill hRSV are 
70% isopropanol and chlorhexidine-detergent solutions (Platt and Bucknall, 1985).   
 
Infection of hRSV in humans has an incubation period of 4 – 5 days (Collins and 
Crowe, 2007). After entry, hRSV initially replicates in the nasopharyngeal epithelium 
and can spread to the lower respiratory tract within 1 – 3 days.  Spread from upper to 
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lower respiratory tract is believed to occur by aspiration of secretion or cell-cell fusion 
along the respiratory epithelium lining the airways (Hoffman et al., 2004; Johnson et 
al., 2007).  Besides airways and lung tissues, hRSV has been found to spread in 
circulating inflammatory cells and cells from blood (Domurat et al., 1985; Krilov et al., 
1987; Panuska et al., 1992).  
 
After viral replication in the human respiratory epithelium, viral cytotoxicity and the 
immune response lead to manifestations of bronchiolitis and pneumonia.  For 
bronchiolitis, there is obstruction of the bronchioles and alveoli caused by a 
combination of mucus, cell debris and inflammatory cells leading to air trapping. 
During pneumonia, the interalveolar walls thicken, resulting in infiltrating mononuclear 
cells and fluid into the alveolar spaces (Aherne et al., 1970; Neilson and Yunis, 1990).  
 
hRSV shedding in children with primary infection has been found to be longer than that 
in children experiencing secondary infection (Okiro et al., 2010).   hRSV was shed in 
children less than 2 years for an average of 9 days compared to 3.9 days in children 
aged 2-16 years (Hall et al., 1976).  In addition, viral shedding has been shown to be 
prolonged in immunocompromised individuals for weeks and even several months (Hall 
et al., 1986; Cheng et al., 2008). 
1.7 Clinical features of hRSV infection 
The clinical manifestations of hRSV infection range from mild to serious illness based 
on age.  Mild illness or upper respiratory tract infection is a frequent presentation in 
healthy adults and older children with rhinorrhea, nasal congestion, pharyngitis, cough, 
low grade fever and acute otitis media.  Chest X ray of this stage is normal.  Severe 
symptoms usually occur only in primary hRSV infection among infants younger than 24 
months, elderly patients, immunocompromised patients, or patients with chronic 
underlying diseases.  The most serious lower respiratory tract diseases are life-
threatening bronchiolitis and pneumonia (Ogra, 2004; O'Donnell, 2009).   
 
Children with bronchiolitis firstly have mild symptoms followed by lower respiratory 
symptoms such as wheezing, dyspnea, tachypnea and poor feeding (Ruuskanen and 
Ogra, 1993; Hall, 2001). Radiographic manifestations of bronchiolitis are 
hyperexpansion with diffuse interstitial shadow and peribronchial thickening.  Fine 
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crackles and a chest X ray of alveolar, segmental, or lobar consolidation occur in 
pneumonia patients (Simoes, 1999).   
 
Late preterm infants (born between 34 – 36 weeks gestation) have been shown to be at 
greater risk of severe lower respiratory symptoms than full term babies due to 
immaturity of both humoral and cell-mediated immunity and also to incomplete lung 
development such as reduced expiratory air flow and diminished gas exchange 
(Friedrich et al., 2006; Friedrich et al., 2007).  Both morbidity and mortality are 
substantially increased in late preterm infants compared with full term infants (Resch 
and Paes, 2011). 
1.8 Epidemiology 
hRSV is a major cause of respiratory tract infection in infants and children under 2 
years of age with worldwide distribution.  The highest incidence of serious illness 
(bronchiolitis or pneumonia) occurs between 6 weeks and 9 months of age (Simoes, 
1999).  Children with underlying risk factors are in a high-risk group of hRSV infection, 
for example, children with bronchopulmonary dysplasia (BPD) (Groothuis et al., 1988), 
cardiac abnormalities (MacDonald et al., 1982), and premature birth (Navas et al., 
1992).  There are other risk factors which also may be involved in more severe illness 
including low socioeconomic status, crowding, exposure to smoking and family history 
of atopy and asthma (Simoes, 1999).  
 
The prevalence of hRSV infection varies with season and region.  In temperate zones 
outbreaks appear annually in the cold season, peaking in February – March (Kim et al., 
1973; Mufson et al., 1973).  In tropical and subtropical regions, hRSV epidemics occur 
year round, but peak during the rainy season (Spence and Barratt, 1968; Huq et al., 
1990; Vardas et al., 1999).  Recently, a systematic review and meta-analysis (1995 – 
2009) has reported the incidence of hRSV infection caused acute lower respiratory 
infection (ALRI) in children younger than 5 years commonly occurs worldwide, but the 
incidence in developing countries is more than twice that of industrialised countries.  
Furthermore, hRSV is a major cause of mortality associated with ALRI after hospital 
admission (66,000 – 199,000 deaths in children in 2005), especially in developing 
countries (Nair et al., 2010).  
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Reinfection with hRSV is common not only in children younger than 24 months, but 
also in healthy older children and adults.  Studies have shown that healthy adults with 
recent natural hRSV infection can be re-infected by intranasal challenging repeatedly 
(Hall et al., 1991).  Nevertheless, the symptoms of reinfection are usually less severe 
than the previous infection.  hRSV is also a cause of morbidity in elderly people 
(Fleming and Cross, 1993; Han et al., 1999) and immunocompromised patients such as 
patients undergoing chemotherapy with underlying disorders of cellular immunity or 
following a bone-marrow or solid-organ transplantation (Englund et al., 1988; 
Whimbey et al., 1995).    
1.8.1 hRSV subgroups 
hRSV is comprised of two major subgroups (A and B) based on antigenic and genetic 
differences.   Initially, hRSV was divided into three groups identified by monoclonal 
antibodies (MAbs) against the F, G and N proteins.  They were group 1 (Long strain), 
group 2 (18537 strain) and group 3 (A2 strain) (Anderson et al., 1985).  Subsequently, 
group 1 and 3 were found to be similar and group 2 viruses were distinct (Anderson et 
al., 1985).  Based on neutralization studies and reactivity with anti-P, N, M, G and F 
MAbs, isolates similar to Long and A2 strains formed the A subgroup.  Isolates similar 
to the 18537 strain formed the B subgroup (Gimenez et al., 1984; Mufson et al., 1985; 
Gimenez et al., 1986; Morgan et al., 1987).  Using MAbs recognizing different viral 
proteins, several studies found the greatest variation between subgroups A and B was 
found in the G glycoprotein.  
 
Subsequently, the nucleotide sequences of individual proteins in both subgroups were 
analysed confirming the split of isolates into two distinct subgroups.  The hRSV Long 
and A2 strains are regarded as the prototype subgroup A viruses, whereas the hRSV 
18537 and 8/60 strain are regarded as subgroup B prototypes (Sullender, 2000).  The 
amino acid sequences of the NS1, NS2, N and F glycoproteins are highly conserved 
between subgroup A (A2 strain) and B (18537 strain) with 87 – 96% identity.  The 
sequences of the G glycoprotein in Long strain share 94% identity with the A2 strain.  
Likewise, the sequence comparisons of the G glycoprotein within subgroup B (8/60 and 
18537) showed only 2% amino acid differences (Sullender et al., 1990). 
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In contrast, the ectodomain of the G glycoprotein shared only 53% amino acid identity 
between subgroups (A2 = subgroup A and 18537 = subgroup B) (Johnson et al., 1987).  
Nonetheless, all isolates share a single highly conserved region in the G ectodomain 
(residues 164 - 174) which is proposed to be a functional domain for the attachment 
activity of the G glycoprotein (Johnson et al., 1987; Johnson and Collins, 1988; Johnson 
and Collins, 1989).    Similarly, A2 (A) and 8/60 (B) were divergent by 44% amino acid 
differences (Sullender et al., 1990).   
1.8.2 hRSV genotypes 
Besides the major variation between subgroups A and B, antigenic and genetic variation 
has been reported to exist within each sub-group.  Among a large panel of isolates of 
subgroup A viruses, Cane et al. (1994) observed 20% genetic diversity in the G gene 
with a high level of coding changes.  The variability of the G gene has also been 
reported among subgroup B viruses with 9% amino acid differences occurring in the 
domains of the G glycoproteins flanking either side of the conserved region.  The types 
of mutations were single amino acid substitutions, frameshifts and alterations of 
termination codons, resulting in different protein lengths (Sullender et al., 1991).  It has 
been thought that the genetic variability of the G glycoprotein may be caused by 
immunologic pressure likely from the host response.  Genetic diversity of the G 
glycoproteins may contribute to the ease of hRSV reinfection (Sullender et al., 1991).  
Prevalence studies of hRSV in several countries have shown fluctuation of the 
predominant strain between subgroup A and B.  However, hRSV subgroup A was found 
to be more frequently predominant in most countries than subgroup B (Cane, 2001).  
Multiple genotypes, generally with representatives from both subgroups have been 
found to co-circulate in a single epidemic and different genotypes are predominant in 
each hRSV season (Cane et al., 1994).  In addition, a displacement of the predominant 
circulating genotypes (lineages) has been observed in consecutive hRSV epidemics, 
suggesting that this may help the viruses to escape from pre-existing immunity (Peret et 
al., 2000).   
 
In North America, the distribution of hRSV genotypes was evaluated during a single 
epidemic in 5 different communities from 1994 – 1995 (Peret et al., 2000) using 
nucleotide sequencing of the G glycoprotein gene in both subgroups A and B viruses.  
Six genotypes of subgroup A (GA1 – GA3 and GA5 – GA7) and two genotypes of 
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subgroup B (GB3 and GB4) were detected.  Subgroup A strains was predominant in 
four of five communities. Within each community, there were different predominant 
genotypes circulating.  Genotypes GA5 and GA7 predominated in Winnipeg, GA1 and 
GB4 in Rochester, GA5 in Houston and GA1 in St. Louis. 
 
In South Africa, the variability of the G glycoprotein gene was determined in 4 
successive seasons from 1997 – 2000 (Venter et al., 2001).  Subgroup A strains was 
predominant in two epidemics, whereas subgroups A and B were equally co-circulated 
in other epidemics.  There were four genotypes of subgroup A (GA5, GA7, GA2 and 
SAA1) and five genotypes of subgroup B (GB3, GB4, SAB1, SAB2 and SAB3) 
identified from isolates.  One new subgroup A (SAA1 or South Africa A1) and three 
new subgroup B viruses (SAB1 – SAB3) were detected.  Co-circulating with different 
genotypes was identified in each epidemic.  Genotypes GA5, GB3 and SAB3 were 
detected over 4 seasons.  In addition, a shift of genotypes and more variability were 
determined in subgroup A strains, whilst subgroup B strains was more stable. 
 
Recently, the most prevalent genotypes in subgroup A are the genotypes GA2 and GA5 
identified in most European countries and other geographic areas (Frabasile et al., 2003; 
Sato et al., 2005; Parveen et al., 2006; Ostlund et al., 2008; Reiche and Schweiger, 
2009).   
1.9 Immunology 
The host immunological response to hRSV infection consists of innate and adaptive 
immunity.  These responses may ameliorate or exacerbate the severity of infections.  
1.9.1 Innate immunity 
Innate immunity is a non - pathogen specific rapid host response which is initiated by 
recognition of pathogens via pattern recognition receptors (PRRs), including Toll-like 
receptors (TLRs), and other molecules such as surfactant protein (SP) in the lung.  Up to 
15 TLRs have been identified in mammals and recognize various pathogen molecules. 
For example, TLR3 and 7 recognize dsRNA and ssRNA, respectively (Alexopoulou et 
al., 2001; Lund et al., 2004).  Some TLRs are present on the cell surface of monocytes 
(TLR4 and 5), whilst some of them are found in endosomes (TLR3, 7, 8 and 9).  
However, all TLRs can activate IFN induction leading to production of type I 
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interferons (IFN-α/β).  IFN stimulates of the Jak-Stat signalling cascade, resulting in the 
expression of many different genes which are necessary for biological effects.  
Furthermore, type I IFNs induce the production of proinflammatory cytokines such as 
TNF-α, IL-1 and IL-6.  In the lung airways, these cytokines stimulate alveolar 
macrophages and dendritic cells (DCs) to produce chemokines, leading to a recruitment 
of neutrophils and NK cells from the circulation to the site of infection.  The release of 
cytokines and the influx of innate immune cells limit virus replication.  Stimulation of 
dendritic cells facilitates the initiation of antigen specific T cell and B cell responses 
(Kohlmeier and Woodland, 2009).   
 
For hRSV, the F glycoprotein has been found to be recognized by TLR4 and CD14 in 
human monocytes resulting in the production of proinflammatory cytokines including 
TNF-α, IL-6 and IL-12.  Deficiency of TLR4 in mice is associated with persistence of 
hRSV infection when compared to controls (Kurt-Jones et al., 2000).  Both G and F 
glycoproteins of hRSV are also recognized by human surfactant proteins-A (SP-A) and 
only G glycoproteins by human SP-D (Ghildyal et al., 1999; Hickling et al., 1999).  
These surfactant proteins can be produced from the respiratory epithelium.  Binding 
between the SP and viral proteins increases the uptake of hRSV by human peripheral 
blood mononuclear cells (PBMC) and human macrophages cell lines expressing SP-A 
receptors (Barr et al., 2000). 
 
Despite this, poor induction of type I interferons in human has been reported in the 
infection of hRSV compared to those of other respiratory viruses (Hall et al., 1978; 
Roberts et al., 1992).  The NS1 and NS2 proteins have been shown to be involved in 
suppression of the IFN production (see details in section 1.4.1).  The efficacy of IFN-
α/β in hRSV infection remains uncertain.  hRSV has been shown to be variably resistant 
to the effect of IFN-α/β in cell culture (Atreya and Kulkarni, 1999) and in mice (Merolla 
et al., 1995; Guerrero-Plata et al., 2005).  There have also been conflicting reports of 
treatment with IFN-α in humans.  For instance, Chipps et al. (1993) reported no 
differences of bronchiolitis symptoms or the duration of oxygen requirement between 
IFN- α treated children and untreated control groups.  Whereas, Sung et al. (1993) 
found that IFN-α treatment improved the clinical course.   
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Secreted cytokines and chemokines are the important signals in activation of alveolar 
macrophages, NK cells and maturation of dendritic cells.  Human alveolar macrophages 
have been reported to stimulate the production of TNF- α, IL-1β, IL-6, IL-8, IL-10 and 
IL-12 following hRSV infection (Becker et al., 1991; Panuska et al., 1995).  These 
cytokines subsequently modulate the activation and recruitment of other inflammatory 
cells such as neutrophils, natural killer (NK) cells and lymphocytes (McNamara and 
Smyth, 2002).  The depletion of macrophages in mice has inhibited the stimulation and 
recruitment of NK cells and increased viral loads (Pribul et al., 2008). 
 
In the mouse model, NK cells activated by alveolar macrophages have been found to be 
primary sources for production of IFN-γ (Hussell and Openshaw, 1998).  Natural killer 
T (NKT) cells, which are a subset of CD1d-restricted T cells co-expressing semi-
invariant T-cell receptor and NK-cell markers (Brutkiewicz et al., 2003), have been 
implicated in viral clearance, IFN-γ production and effective expansion of CD8+ T cells 
during hRSV infection (Johnson et al., 2002).   
 
DCs, the major antigen presenting cells, are present in the respiratory epithelium.  They 
are activated by cytokines and migrate to the draining lymph nodes preceding the 
adaptive immune response.  They are divided into two subsets, conventional DCs and 
plasmacytoid DCs (pDCs).  The balance between the two DCs is essential for 
determining the outcome of hRSV infection.  In mice, increased amounts of pDC have 
been shown to increase the levels of IFN-α and Th1 cytokines and also reduce 
pathophysiology of hRSV infection with a decrease of airway inflammation and mucus 
overexpression.  In contrast, depletion of pDC has resulted in an increase of viral loads, 
Th2 cytokines production, airway inflammation and hyperresponsiveness (Smit et al., 
2006; Wang et al., 2006; Smit et al., 2008).   
 
Innate immune response can be significant determinants of hRSV severity.  In the 
nasopharyngeal aspirate of human infants, levels of IL-8, a potent neutrophil 
chemoattractant, has been associated with the severity of bronchiolitis (Smyth et al., 
2002).  High levels of neutrophils have been found in brochoalveolar lavage (BAL) 
fluids from hRSV infected infants with bronchiolitis (Everard et al., 1994).  A genetic 
polymorphism close to the IL-8 gene and associated with increased production of IL-8 
is also correlated with disease severity (Hull et al., 2000).  In several studies, 
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polymorphisms involved in the recognition stage including TLR4, SP-A and SP-D 
genes have also been linked to susceptibility to severe hRSV infection (Lahti et al., 
2002; Lofgren et al., 2002; Tal et al., 2004; Mandelberg et al., 2006; Lofgren et al., 
2010).   Severe hRSV disease was found in mice lacking SP-A when compared to those 
with normal levels, suggesting SP-A is necessary for hRSV clearance (LeVine et al., 
1999). 
1.9.2 Adaptive immunity 
The adaptive immunological responses develop after primary infection requiring several 
days for production of immune effectors including antiviral cytokines, cytotoxic T cells 
and specific antibodies.  Furthermore, immunological memory is also formed for rapid 
immune response when reinfections occur.  Adaptive immunity can be divided into 
humoral and cell-mediated immunity (Welliver, 2008).  The cell-mediated response 
predominantly functions in the clearance of viral infection, whereas the humoral 
response is principally associated with protective immunity in hRSV infection 
(McNamara and Smyth, 2002). 
Cell-mediated immunity 
Prolonged hRSV shedding for weeks to several months occurs in patients with defective 
cell mediated immune responses suggesting that cell-mediated immunity functions in 
the clearance of hRSV.   There are two types of T lymphocytes involved in the cellular 
immune response, CD8
+
 cytotoxic T cells (CTL) and CD4
+
 T helper cells, and both play 
a role in both the protective and the immunopathogenic responses after hRSV infection.  
The CD4
+
 T helper cells can be categorised into two types based on functions, CD4
+
 
regulatory T cells (Treg) and CD4
+ 
T effector cells.  Treg cells are necessary for 
controlling immune response to hRSV infection.   In both humans and mice, Treg cells 
have been found to be increased in peripheral blood or lung after hRSV infection.  The 
reduction of Treg cells resulted in enhanced disease severity in mice, suggesting that 
Treg cells play a role in modulating inflammation (Cusi et al., 2010; Fulton et al., 2010; 
Lee et al., 2010).  The CD4
+ 
T effector cells consist of type 1 CD4
+ 
T effector cells (Th1 
cells) secreting IFN-γ, TNF-α and IL-2 which promote vigorous cytotoxic T cell 
responses.   Type 2 CD4
+ 
T effector cells (Th2 cells), characterized by secretion of IL-4, 
IL-5, IL-10 and IL-13, induce the production of IgE and eosinophilia (Romagnani, 
1992; McNamara and Smyth, 2002).  In addition to the Th1/Th2 paradigm, Th17 cells 
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are novel CD4
+
 T effector cells that secrete the IL-17 family cytokine involved in 
activating granulocytes and macrophages (Kurts, 2008).  Increased numbers of Th17 
cells were found in peripheral blood from human infants with hRSV bronchiolitis (Li et 
al., 2012).  CD4
+
 T cell responses to formalin-inactivated hRSV vaccine (FI-RSV) have 
been extensively studied, see details in section 1.10.2.   
 
A number of studies have sought to establish the relative role of CD4
+
 and CD8
+
 cells in 
the mouse model of hRSV infection.  In immunodeficient mice with persistent hRSV 
infections, the transfer of hRSV specific CTLs has been shown to clear viruses in the 
lung (Cannon et al., 1987).  Passive transfer of hRSV specific CD8
+
 or CD4
+
 
lymphocytes into normal mice infected with hRSV has also been shown to reduce the 
shedding of hRSV, but pulmonary damage was exacerbated.  Both antiviral and 
immunopathogenic effects were more pronounced with CD4
+
 compared to CD8
+
 cells 
(Cannon et al., 1988; Munoz et al., 1991; Alwan et al., 1992).    Depletion of both CD8
+ 
and CD4
+
 lymphocytes in mice has prolonged hRSV replication, but with no evidence 
of illness.  Together these studies suggest that, at least in mice, the host immune 
response is the main determinant of disease rather than viral cytocidal effect (Graham et 
al., 1991).   
 
Immunization of mice with the recombinant virus expressing only the F glycoprotein 
activates a Th1 type response, whilst a Th2 type response is promoted by the 
immunization with recombinant G protein, suggesting that the G epitope may be 
responsible for vaccine-augmented disease (see section 1.10.2) (Alwan et al., 1994; 
Hancock et al., 1996).  Moreover, the secreted form of the G protein has been found to 
be much more capable of promoting eosinophila compared to the membrane-bound G 
protein, increasing IL-5, IL-13 (Johnson and Graham, 1999).  The secreted F 
glycoprotein can also induce an intermediate Th2-like phenotype resulting in the release 
of IL-4 and IL-5; however, in this case the development of pulmonary eosinophilia is 
less than that in mice induced by secreted G proteins and is accompanied by high levels 
of IFN-γ and the production of hRSV F specific CTL (Bembridge et al., 1999). 
 
In man, blood CTL responses vary between 7 days and 3 months after hRSV infection 
depending on the age of the patients.  They are detectable in 65% of older infants (6-24 
months) compared to 35-38% in infants less than 5 month old after 5 - 6 days of 
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infection (Chiba et al., 1989).  Poor responses in younger infants may be because of the 
immunological immaturity or suppression by maternal antibody.  In patients with severe 
hRSV infections, blood CTL peaked between days 9 and 12 after the onset of symptoms 
(Heidema et al., 2007).  However, in nasal aspirates and BAL, the viral load has been 
reported to usually decrease during 3 – 6 days after the onset of symptom (Malley et al., 
2000; Buckingham et al., 2002; Perkins et al., 2005; Campanini et al., 2007).  The 
severity of disease has not been correlated with the amounts of hRSV specific CTLs 
(Heidema et al., 2007).  Human CTLs have been shown to significantly recognize the 
NS2, N, M, SH, F and M2-1 proteins of hRSV.  However, the G, P and NS1 proteins 
were not recognized (Cherrie et al., 1992).  In a post mortem study, low amounts of 
lymphocytes were found in lung tissue of children with severe hRSV diseases (Welliver 
et al., 2007).  However, hRSV specific CTLs have been detected in BAL of infants with 
severe hRSV disease (Heidema et al., 2007).  Taken together, these finding suggest that 
CTL responses do not correlate well with recovery. 
 
It has been reported that there was no difference between Th-1 and Th-2 cytokines 
detected in plasma samples from patients with severe hRSV disease and Th-1 type 
immune responses was predominant in stimulated T-cell cultures based on high levels 
of IFN-γ and low levels of IL-4 and IL-10 (Brandenburg et al., 2000; Tripp et al., 
2002).  However, a body of evidence suggests that Th-2 type responses are associated 
with severe hRSV infection.  Blood CD4
+
 cells were detected at high levels in infected 
infants with severe disease compared to control groups, whereas CD8
+
 cells were 
decreased (Roman et al., 1997).  Levels of IL-4, IL-4/IFN-γ and IL-10/IL-12 detected in 
infected patients with hRSV bronchiolitis were significantly higher than those in the 
control infants (Roman et al., 1997; Legg et al., 2003; Hassan et al., 2008).  Likewise, 
low levels of IFN-γ mRNA in the acute phase were observed in PBMC from infants 
with severe disease, whilst there were higher levels in infants with moderate illness 
(Aberle et al., 1999; Legg et al., 2003).  
Humoral immunity 
Several studies have demonstrated that antibodies can protect against hRSV infection.  
The F and G glycoproteins are the major protective antigens (Elango et al., 1986; 
Olmsted et al., 1986) and provide a relatively long-term protection (Connors et al., 
1991).  Mice immunized with recombinant vaccinia viruses (rVV) encoding only the F 
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or G protein were fully resistant to hRSV challenge on both day 9 and 28 compared to 
mice immunized with rVV expressing the M2 and N proteins which exhibited 
incomplete resistance on day 9.  Resistance in mice immunized with other viral proteins 
(P, SH, M, NS1 and NS2) was undetectable (Connors et al., 1991).  Similarly, rVV 
encoding the bRSV F, G or N proteins induced resistance to hRSV challenge in calves 
(Taylor et al., 1997).  MAbs directed against F or G were able to protect both mice and 
cotton rats against hRSV challenge (Taylor et al., 1984; Walsh et al., 1984). 
 
Human infants receive antibodies from their mothers, transplacentally and in breast 
milk, and also make their own humoral responses to infection.  Any of these may 
contribute to protection against hRSV.  Higher levels of maternally derived antibodies 
are associated with a lower incidence of hRSV infection in young infants (Roca et al., 
2002; Stensballe et al., 2009).  Furthermore, levels of antibody from infants hospitalized 
with hRSV were lower than those from randomly selected infants born during the same 
period, indicating that the level of maternal antibody is related to prevention of hRSV 
infection in infants less than 6 months of age (Glezen et al., 1981).  However, no 
difference between maternal antibody levels to either F or G glycoproteins has been 
found in infants hospitalized with severe hRSV infection (Toms et al., 1989).   Breast-
fed infants have been reported to receive maternal antibody in the form colostrum in 
which hRSV specific IgA and IgG antibodies and neutralizing activity can be detected 
(Downham et al., 1976; Scott et al., 1981) and it may be for this reason that breast 
feeding is significantly correlated with protection of lower respiratory tract illness from 
hRSV infection (Holberg et al., 1991).   
 
Serum antibodies of IgM, IgG and IgA isotypes can be produced in infants and children 
after primary hRSV infection.   The serum IgM specific antibody normally presents a 
few days after infection and antibodies persist for 2 – 10 weeks (Welliver et al., 1980).  
The virus-specific IgG response occurs in the second week, peaks in the fourth week 
beginning to decline after 1 – 2 months (Hall, 1998).  All three immunoglobulin can be 
boosted and detected within 5 – 7 days after reinfection (Welliver et al., 1980). 
 
Older infants and children tend to produce greater hRSV-specific IgG, IgM, and IgA 
antibody responses than young infants (Welliver et al., 1980; Meurman et al., 1984).  
Poor responses in infants are attributed both to immunological immaturity and the 
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suppressive effect of pre-existing maternal antibody in infant sera (Murphy et al., 1986).  
Passively acquired hRSV antibodies in cotton rats and mice have been shown to reduce 
antibody responses (Murphy et al., 1988). 
 
Besides serum antibodies, specific anti-hRSV antibodies of IgM, IgG and IgA isotypes 
in both free and cell-bound forms are detectable in the secretions of infants (McIntosh et 
al., 1978; Kaul et al., 1981; Wright et al., 2002).  It has been shown the higher levels of 
nasal neutralizing antibodies correlate with reduced hRSV replication; however, patients 
possessing secretory IgA anti-hRSV antibodies may still  be infected with the virus 
(Mills et al., 1971; Hall et al., 1991).  
 
Increasing levels of hRSV specific IgE and histamine have been detected in the 
nasopharyngeal secretions of infants with acute bronchiolitis, suggesting that secretion 
IgE antibody might play a role in the pathogenesis of hRSV infection (Welliver et al., 
1981; Bui et al., 1987).  Leukotriene C4, a potent mediator of obstructive airway 
disease, has been shown to be directly related with the levels of specific IgE in infected 
infants (Volovitz et al., 1988).  Therefore, it has been postulated that IgE-mediated 
hypersensitivity may be the cause of severe illness.  However, another study failed to 
demonstrate secretory or serum IgE antibodies in either acute or convalescent samples 
from infants with hRSV infection (Toms et al., 1996). 
Anti-hRSV neutralizing antibodies 
Antibody responses induced by hRSV infection can recognize several viral proteins; 
nevertheless, only the F and G protein induce neutralizing antibodies (Groothuis, 1994).  
Neutralizing antibodies against the F glycoprotein tend to be cross-reactive among 
subgroup A, subgroup B, and bRSV (Taylor et al., 1992).  In contrast, antibodies 
recognizing the G glycoprotein are either subgroup specific or strain specific. 
Antibodies reacting with the cysteine noose of the hRSV or bRSV are cross-reactive or 
subgroup specific, but individually do not neutralize efficiently.  However, pooling 
MAbs recognizing strain specific, group specific and conserved epitope increases the 
level of neutralization (Langedijk et al., 1997; Martinez et al., 1997; Martinez and 
Melero, 1998).  
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MAbs against the fusion glycoprotein with both neutralizing and fusion inhibiting 
activity have been shown to be highly protective in mice.  These recognize antigenic 
site B (Taylor et al., 1992) or site A (site II)  (Trudel et al., 1987b), whereas MAbs with 
only neutralizing activity recognize antigenic site C (site IV) (Trudel et al., 1987b).   
Limited studies suggest that neutralizing antibodies may be important in protection 
against severe disease in human infants.  Glezen et al. (1981) have demonstrated that 
titres of neutralizing antibodies in infants with severe illness are lower than those from 
randomly selected healthy infants born in the same period of time.  Similarly, infants 
with high neutralizing maternal antibodies were protected from hRSV infection, 
whereas infants with low levels of antibodies became infected (Ogilvie et al., 1981).   
 
The mechanism of viral neutralization by antibodies has been suggested to involve 
interference at different stages of viral infection including:  
(i) Aggregation of virions by antibodies to reduce the number of available 
infectious units (Dimmock, 1993).  This has been demonstrated by an electron 
microscope study of influenza virus with influenza-specific IgM, IgG and IgA.  
Aggregation did not occur at high antibody:virus ratios due to lack of free epitopes 
(Armstrong et al., 1990; Outlaw and Dimmock, 1990; Armstrong and Dimmock, 1992).  
(ii) Inhibition of viral attachment to cells by binding to glycoproteins mediating 
attachment such as antibodies to the hemagglutinin (HA) protein of influenza virus.  
(iii) Inhibition of endocytosis for some viruses entering to the cells via endocytosis.   
For example, IgM has been reported to neutralize influenza virus by interfering the 
ability of virus to bind a sufficient number of cell receptors involving in initiation of 
endocytosis (Taylor and Dimmock, 1985; Outlaw and Dimmock, 1990). 
(iv) Inhibition of fusion between virus and host cell membranes by interrupting 
fusion process at cellular  membranes at neutral pH such as antibodies against the F 
glycoproteins of PIV3 or in endosomal vesicles at low pH.  Antibodies may affect 
conformational changes in the fusion process or block the contact between viral and 
cellular membranes (Klasse and Sattentau, 2002). 
(v) Post-entry mechanisms where interference with further replicative steps occur 
after the viral capsid enters into the cytoplasm of the host cell.  Antibody to the HA of 
influenza virus has been shown to block virion transcriptase activity (Possee et al., 
1982). 
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A body of evidence suggests that viruses are inactivated by multi-hit events rather than 
by a single-hit.   In a multi-hit model, more than one antibody molecule is required to 
neutralize one virion, whereas in a single-hit model the binding of one antibody 
molecule to a virus particle is sufficient (Burton et al., 2001).   Each virus needs a 
different amount of antibody molecule in order to neutralize.  For instance, 10-20 
antibody molecules per virion are required to neutralize rhinovirus by 90% (Smith et al., 
1993), whilst influenza virus requires over 100 antibody molecules per virion for 90% 
neutralization (Taylor et al., 1987). 
 
The degree of neutralization may relate to antibody occupancy on the virion.  Increasing 
occupancy of antibody on HIV-1 results in increased neutralization level, irrespective of 
epitope recognized.  In these occupancy theories of neutralization, viruses has been 
proposed to be neutralized when they are bound with antibody and rendered incapable 
of attachment or fusion to the host cell membrane (Burton et al., 2000).  Factors 
influencing antibody occupancy are the number of antigens on the virus surface, the 
proximity of the viral antigens to each other on the surface of the virion, the number of 
antibody binding sites on the virion and the size of the virion (Klasse and Sattentau, 
2002).   
 
Conversely, viral neutralization may occur by steric or direct inhibition of a proportion 
of the virion surface, resulting in prevention of necessary interactions between virus 
particle and target cell membrane.  This is termed the coating theory of virus 
neutralization.  This theory can explain the neutralization by antibodies to antigens on 
the particle surface which do not participate in viral entry.  For example, antibodies 
against influenza NA proteins, which function at virus release rather than entry, would 
become neutralizing when a high level of NA proteins are present on the surface (Klasse 
and Sattentau, 2002).   
1.10 Treatment and prevention 
1.10.1 Treatment 
The management of hRSV infection depends on the severity of disease.  Most cases of 
mild lower respiratory tract disease are usually self-limiting conditions and may not 
require hospital admission. There are no specific drug treatments; therefore, patients 
with severe illness are managed by the supportive care such as secretion removal, 
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oxygen administration and mechanical ventilation.  The use of anti-inflammatory agents 
has been studied in treatment of severe disease because the effects of immune response 
on severity are greater than those of viral replication.  However, there is no evidence 
that anti-inflammatory agents alone are of benefit for hRSV patients (Simoes, 1999; 
Patel et al., 2004). 
Small molecule anti-hRSV compounds 
Several small molecule anti-hRSV compounds have been discovered. Many compounds 
pass through animal testing and a few are in the early-phase of clinical trials.  Most of 
them belong to a series of benzimidazole derivatives and are synthesized to inhibit the 
formation of the six helix bundle in the F molecule during the fusion process which is a 
crucial stage in the life cycle of hRSV (Collins and Melero, 2011). 
Ribavirin 
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-caroboxamide) is a guanosine analog 
which functions on incorporation into the viral genome.  It has been evaluated for hRSV 
treatment since the 1980s (Hall et al., 1983).  Its use, however, remains controversial.  
Some studies have demonstrated that ribavirin administration is able to decrease the 
duration of mechanical ventilation and the length of hospital stay (Ventre and Randolph, 
2004).  In contrast, other studies have shown that the mortality rate of hRSV infected 
patients does not differ between treatment with and without ribavirin (Moler et al., 
1996; Randolph and Wang, 1996).  
 
The use of ribavirin in hRSV infected patients “may be considered” according to the 
recommendation of the American Academy of Pediatrics (AAP) (Committee on 
infectious disease, 1996).  Patients with hRSV infection have to be given a small-
particle aerosol of ribavirin (Hall et al., 1983).  At present, ribavirin is not 
recommended for use in the routine for treatment of hRSV infection; however, it can be 
considered in high risk patients for severe disease such as those who are 
immunocompromised or who have haemodynamically significant cardiopulmonary 
disease (Subcommittee on diagnosis and management of bronchiolitis, 2006).    
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BTA9881 
BTA9881 (Biota, AstraZeneca, London, UK) is a derivative of imidazoisoindolone 
which has antiviral activity by inhibiting the F glycoprotein (Bond et al., 2007).  It has 
been successfully tested in rodents with promising oral bioavailability and efficacy 
(Luttick et al., 2007).  In 2007, it completed phase I clinical trials having been evaluated 
in 72 healthy adult volunteers (Biota Scientific Management Pty Ltd, 2007) and the 
results showed this drug was a long-lasting in plasma of humans and also displayed 
approximately 100% oral bioavailability.  However, its safety profile was 
unsatisfactory; therefore, the development of this drug has been discontinued (Biota 
Holdings Limited, 2009). 
BMS-433771  
BMS-433771 (Bristol-Myers Squibb, Wallingford, USA) is a radiolabelled analogue of 
benzimidazole and is an oral fusion inhibitor containing a photoreactive diazirine group.  
Studies using photoactivated affinity probes have shown that BMS-433771 binds within 
the hydrophobic pocket of the HR1 associated with the HR2 in a trimer-of-hairpins 
structure (Cianci et al., 2004b).   
 
The binding site of BMS-433771 was also mapped by generating the resistant viruses in 
the presence of several analogs of BMS-43771 and analysing their sequences.  Although 
the compounds used for isolating the escape mutants were either the early synthetic 
analogs (BMS-233675 and BMS-243458) or structurally related compound (BABIM), 
all selected mutants were cross-resistant to BMS-433771, indicating that there was a 
common or overlapping site of action among these compounds.  The molecular targets 
of BMS-433771 analysed from the escape mutants were located within the F1 domain 
of the F glycoprotein, including the fusion peptide (F140I, V144A), the cysteine-rich 
region (D392G, K394R) and the HR2 (D489Y).  Furthermore, it was found that a 
rescued transfectant virus with a mutation at K394R produced by reverse genetics was 
resistant to BMS-433771, showing that a single-residue substitution in the F1 subunit 
alone can generate resistance to BMS-433771 (Cianci et al., 2004c). 
 
In in vitro studies, BMS-433771 was found to protect Hep-2 cell from the hRSV clinical 
isolates of both subgroup A and B induced CPE with a 50% effective concentration of 
20 nM (12 nM obtained from testing with Long strain) and did not have cell protection 
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for infection with other viruses (Cianci et al., 2004c).  The compound blocked virus-cell 
fusion early in infection during viral entry and cell-cell fusion mediated by the F 
glycoprotein, but had no effect upon the viral attachment (Cianci et al., 2004c; Magro et 
al., 2010). 
 
In animal models, lungs of BALB/c mice given with BMS-433771 orally before 
inoculation of hRSV had reduced virus titres compared to control groups (Cianci et al., 
2004c).  BMS-433771, given in either single or multiple doses, was able to reduce virus 
titres in both BALB/c mice and cotton rats, although effects were greater in mice than in 
cotton rats.  These results were confirmed by a pharmacodynamic analysis that showed 
the EAUC50 (a value that determines the potency of compounds in vivo achieving 50% 
of the maximum response) of mice was higher than that of cotton rats.  Moreover, the 
escape mutant (K394R) was resistant to BMS-433771 in mice, confirming the in vitro 
studies (Cianci et al., 2004a).  The development of this compound has recently been 
discontinued by Bristol-Myers Squibb (Olszewska and Openshaw, 2009).  
TMC353121  
TMC353121 (Tibotec Pharmaceuticals, Mechelen, Belgium) is a benzimidazole 
derivative which has been reported to block both virus-cell and cell-cell fusion.  The 
binding site was mapped by generating resistant mutants and located in the cysteine-rich 
region (K394R and S398L) and the HR2 region (D486N) of the F1 polypeptide.  
However, it has been reported that this inhibitor binds both HR1 (Y198) and HR2 
(D486) within a hydrophobic pocket of the six helix bundle complex (Roymans et al., 
2010).  TMC353121 exhibited antiviral activity in vitro for viruses of both subgroups A 
and B.  In cotton rats, this inhibitor produced a high reduction of hRSV titre when   
administered shortly before virus challenge, suggesting that it has to be present before 
fusion (Bonfanti et al., 2008).  TMC353121 is currently in preclinical evaluation by 
Tibotec (Olszewska and Openshaw, 2009). 
JNJ-2408068 
JNJ-2408068 is a benzimidazole derivative which has been shown to inhibit hRSV 
infection in both subgroup A and B in in vitro studies and which does not have antiviral 
activity to other paramyxoviruses such as HPIV2, Mumps virus or hPIV3.  Its 
mechanism of action is similar to that of TMC35321 and it binds both the HR1 and 
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HR2 within a hydrophobic pocket of the six helix bundle in the F glycoprotein.  In 
addition, JNJ-2408068 is able to block both virus-cell fusion (early stage) and also cell-
cell fusion at the end of the infection cycle (Douglas et al., 2005).  Two resistant 
mutants have been characterised with changes in the F gene, S398L and D486N.  JNJ-
2408068 has been reported to block the release of proinflammatory cytokines from 
infected cells (IL-6, IL-8 and RANTES) (Andries et al., 2003).  This compound remains 
to be completely evaluated in humans. 
YM-53403 
YM-53403 (Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan) is a benzazepine 
derivative which is able to inhibit hRSV replication in both subgroup A and B (EC50 = 
0.2-0.4 µM) and there is no antiviral activity to measles virus, influenza A virus or 
HSV-1.   Unlike BMS-433771, it has been shown to reduce the virus titre when added 
up to 8 hours post-infection similar to ribavirin which blocks RNA synthesis during the 
viral replication.  The mapping of YM-53403 by sequencing mutant viruses has 
revealed changes in the L protein (Y1631H) (Sudo et al., 2005).  This compound has 
not yet been fully tested in human.  
RSV-604 
RSV-604 (Novartis, Basel, Switzerland) is a benzodiazepine derivative which has been 
reported to have submicromolar antiviral activity (EC50 = 0.5-0.9 µM) against several 
isolates of both subgroup A and B in in vitro studies.  This inhibitor is active up to 6 
hour after hRSV inoculation, like YM-53403, suggesting that RSV604 functions at late 
stage of the replication cycle.  Resistant mutations of RSV604 have been shown to have 
changes in the highly conserved N protein.  Currently, RSV604 is testing in phase II 
clinical trials (Chapman et al., 2007). 
Heptad-repeat peptide 
In HIV-1, it has been reported that synthetic peptides based on the sequences of the 
highly conserved regions in the transmembrane (TM) protein gp41 (fusion protein) have 
potent antiviral activity (Wild et al., 1992; Wild et al., 1993).  Those regions are the 
leucine zipper region at residue 558-595 (peptide DP-107) and an extended amphipathic 
α-helix region at residue 643-678 (peptide DP-178) which were predicted to form a 
helical structure in fusogenic viral proteins (Gallaher et al., 1989; Delwart et al., 1990).  
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From sequence analysis, the hRSV F1 protein motifs HR1 and HR2 presented a high 
level of homology to DP-107 and DP-178 in gp41 (Gallaher, 1987).   
 
Therefore, it is seemed likely that peptides synthesized from the sequences of HR1 and 
HR2 would inhibit hRSV induced membrane fusion.  The location of the HR1 (residues 
149-206) and HR2 (residues 474-523) domains was identified in the F glycoprotein of 
the Long strain hRSV and sequential overlapping peptides of 35 amino acids in length 
shifting by 1 amino acid from the N-terminus were synthesized to scan across the entire 
HR1 and HR2 domains.  The abilities of these peptides in protecting cell monolayers 
from hRSV infection were analysed.  It was found that overlapping peptides scanned 
across the HR2 domains presented substantially more potent antiviral activity than those 
of the HR1 domains, especially peptide based on residues 488 – 522, namely T-118.  Its 
sequence is FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST (Lambert et al., 
1996).  T-118 was acetylated at the N-terminal region and amidated at the C-terminal 
region to enhance the biological half-life (Powell, 1993).  It had the submicromolar 
antiviral activity (EC50 = 0.05 µM) against hRSV induced fusion. Similarly, in a 
separate study, a 39-amino acid HR2 peptide based on residue 478 – 516 of the F1 
protein, namely F478-516, also inhibited the viral antigen production and neutralized 
hRSV when present during the active process of viral entry (Magro et al., 2010).   
 
The inhibiting mechanism of hRSV fusion by HR2 peptides is likely to be similar to 
that of DP178 inhibition of HIV-1 gp41-mediated membrane fusion (Figure 1.9) (Zhao 
et al., 2000).  After activation of the gp41, a prehairpin intermediate is formed by the 
projection of the fusion peptide (red lines) into the host cell membrane, forming a 
trimeric coiled coil of the HR1 domain (grey).  At this stage, the HR2 region has not yet 
associated with the HR1 coiled coil.  Therefore, HR2 peptides (orange box) can bind to 
the HR1 region of the fusion protein, resulting in the inhibition of 6HB formation 
(hairpin) and the blocking of membrane fusion.   
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Figure 1.9  Model of membrane fusion  process based on the HIV-1 gp41 protein 
[Modified from original by  Zhao et al. (2000) and  Chan and Kim (1998)]. 
1.10.2 Vaccines 
The development of effective RSV vaccines presents many difficulties.  As severe RSV 
disease usually occurs in young infants (2-6 months), a vaccine would need to be 
administered during the first weeks of life for efficient protection (Collins and Crowe, 
2007).  Infants of this age have low immune responses compared to older children and 
adults due to their immaturity and the immunosuppressive effect of maternal antibodies 
(Crowe, 1999; Crowe et al., 2001).  It has been difficult to achieve sufficient attenuation 
of potential live virus vaccines, especially for seronegative infants (Wright et al., 2000) 
and formalin-inactivated vaccines have been found to augment rather than ameliorate 
disease severity. 
Formalin-inactivated RSV vaccines  
Formalin-inactivated RSV vaccines (FI-RSV) were first developed using a similar 
process to that for other, successful, vaccines for polio and influenza.  After 
propagation, hRSV was formalin – inactivated, ultracentrifuged and alum-precipitated 
(FI-RSV).  FI-RSV vaccines were tested by intramuscular administration to infants and 
young children in four separate trials during 1965 – 1966 (Chin et al., 1969; Fulginiti et 
al., 1969; Kapikian et al., 1969; Kim et al., 1969).   In these clinical trials, FI-RSV was 
poorly protective and was associated with severe disease after subsequent natural 
infection with hRSV.  In epidemics, the hospitalization rate of infants immunized with 
FI-RSV vaccines (80%) was higher than that of children vaccinated with FI-
parainfluenza virus vaccine (5%) and two infants died due to FI-RSV vaccine.   
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The induction of severe disease in mice induced by the inoculation of  anti-RSV CD4
+
 
and CD8
+
 T cells suggested the hypothesis is that FI-RSV stimulates a CD4
+
 response 
in the absence of neutralizing antibody which leads to inflammation, but not protection. 
More recently however, it has been proposed that enhancement of severe illness by FI-
RSV may involve an imbalance between the Th1 and Th2 CD4
+
 T cell response and this 
has been studied in both animal models and using specimens from hRSV infected 
patients, nasopharyngeal secretions and peripheral blood mononuclear cells.  Together, 
these studies suggest that Th2 responses induce eosinophilic infiltrates in lung and an 
increasing ratio of IL-4/IFN-γ as compared with the Th1 responses which promote a 
strong CTL response with undetectable IL-4 (Graham et al., 1993; Roman et al., 1997; 
Bont et al., 2001; Legg et al., 2003; Semple et al., 2007; Byeon et al., 2009).   
Live attenuated vaccine 
Several live, attenuated hRSV vaccines have been developed since the 1960s.  It has 
been reported that these vaccines do not result in augmented disease in animal models 
and in clinical trials (Wright et al., 2007).  Furthermore, intranasal administration of 
these vaccines induces both local and systemic immune responses and also escapes 
from immunosuppressive effect of maternal antibodies (Crowe et al., 1995).   
Live attenuated vaccines by conventional methods 
Initially, hRSV was attenuated by 52 serial passages at the suboptimal temperature of 
26°C (cold-passage, cp-RSV) in bovine tissue culture (Friedewald et al., 1968).  This 
virus was completely attenuated in hRSV-seropositive children and adults, but still 
remained of unacceptable virulence in young infants (Kim et al., 1971).   
 
The chemical mutagen (5-fluorouracil, 5-FU) was used to generate temperature-
sensitive (ts) mutants of the virus unable to replicate at 37-39°C.  These mutants are 
presumed incapable of infecting the lower respiratory tract which has a temperature of 
37°C (Gharpure et al., 1969).  The infectivity of RSV ts mutants (ts-1 and ts-2) has been 
shown to be poor in adults and children, but they are still not satisfactory when 
intranasally administered to hRSV-seronegative children (Wright et al., 1976; Wright et 
al., 1982).   
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Therefore, these approaches were continued by mutagenizing a cp-RSV mutant with 5-
FU, screening for either small plaque (sp) or temperature sensitive (ts) phenotypes by 
plaque titration at 32°C or 38°C, respectively.  Two ts mutants, cpts-248 and cpts-530, 
were the most of restricted in replication in mice when compared to wild-type virus.  
Both the cpts-248 and cpts-530 had a more stable ts phenotype than the ts-1 virus.  In 
addition, the cpts-248 was highly immunogenic and attenuated in seronegative 
chimpanzees (Crowe et al., 1994b).   
 
The cpts-248 was additionally attenuated by a second round of mutagenesis with 5-FU, 
selecting progeny for either ts or sp phenotypes.  The resultant cpts-248/404 mutant has 
been reported to be fully restricted in replication in chimpanzees and to have a stable ts 
phenotype.  Moreover, chimpanzees immunized with the cpts-248/404 mutant produced 
a high level of antibody and were completely protected against wild-type virus 
challenge, indicating that this vaccine has a favourable balance between attenuation and 
immunogenicity (Crowe et al., 1994a).   The cpts-248/404 vaccine was tested in phase I 
clinical trials in children and infants less than 2 months of age.  It was highly attenuated 
in these infants; however, it caused mild nasal congestion (Wright et al., 2000).  
Therefore, this vaccine was unacceptable for immunization in very young infants.  
Additional attenuating mutations are required and may be introduced in the cpts-
248/404 vaccine using reverse genetics.   
Live attenuated vaccines by reverse genetics 
The production of live attenuated vaccines by conventional methods has subsequently 
been replaced by reverse genetics which is able to produce viruses containing a 
combination of desirable attenuating mutations and has led to the generation of 
“designer” vaccines (Collins and Murphy, 2005).  In this method, infectious RSV is 
constructed in tissue cultures in which five viral components involved in transcription 
and replication are co-expressed.   These are cDNAs encoding the full length RSV 
antigenome with a ribozyme at the downstream end which generates a correct 3’end 
after cleavage and four cDNAs encoding the proteins of the polymerase complex (N, P, 
L and M2-1 proteins).  All cDNAs are expressed from a T7 RNA polymerase promoter 
and transfected into Vero cells which are safe for human use (Collins et al., 1995).  
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Identification of the mutations involved in RSV attenuation is required to develop live 
attenuated vaccines using reverse genetics.  Deletion of accessory hRSV proteins has 
been found to be associated with attenuation.  Recombinant hRSV mutants lacking 
either the NS2 or SH gene were attenuated in chimpanzees (Whitehead et al., 1999a).  
Using reverse genetics, a recombinant vaccine candidate has been generated by deletion 
of the SH gene of cpts-248/404 resulting in the production of rA2cp248/404ΔSH.   On 
examination of the levels of attenuation of this vaccine in adults, seropositive- and 
seronegative- children, it was found there was no difference between 
rA2cp248/404ΔSH and cpts-248/404.  The development of rA2cp248/404ΔSH virus 
was continued by adding the 1030 mutation, generating rA2cp248/404/1030ΔSH virus 
or MEDI-559.  rA2cp248/404/1030 was reported to be more temperature sensitive in 
vitro and more attenuated in vivo than cpts-248/404 (Whitehead et al., 1999b).   
rA2cp248/404/1030ΔSH virus was more attenuated in seronegative children and 
produced more protective immunity compared to rA2cp248/404ΔSH virus (Karron et 
al., 2005).  At present, MEDI-559 is in phase I/IIa clinical trials which are recruiting 
healthy children between 1 and 24 months old to test its viral shedding, 
immunogenicity, tolerability and safety (MedImmune LLC, 2008a). 
 
Mutants with NS1, NS2, SH and M2-2 genes removed individually or in different 
combination from the genome also showed a reduction in replication in the lungs of 
cotton rats compared to the wild-type A2 strain (Jin et al., 2000b).  Moreover, the 
deletions of the NS1 or NS2 increased the immnunogenicity due to the loss of their 
functions involved in blocking the IFNα/β system which led to enhanced induction of 
both innate and adaptive immunity (Valarcher et al., 2003).  Immunogenicity could also 
be enhanced by the removal of M2-2 gene.  This gene correlated with shifts between 
transcription and replication.  The absence of M2-2 gene results in an increase in viral 
gene expression, including that of the F and G glycoproteins (Bermingham and Collins, 
1999).  It has been reported that recombinant hRSV viruses lacking either NS1 
(rA2ΔNS1) or M2-2 (rA2ΔM2-2) administered to seronegative chimpanzees were 
limited in replication in both the upper and lower respiratory tract, but that the level of 
neutralizing antibody induced by these mutant viruses was only slightly less than that 
induced by wild-type hRSV.  Chimpanzees immunized with either rA2ΔNS1 or 
rA2ΔM2-2 were protected from challenge with wild-type hRSV (Teng et al., 2000).  
These constructs remain to be completely evaluated in humans.  
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A number of alternative mechanisms for attenuation of hRSV have been tried, but have 
yet to be fully explored.   The replacement of charged amino acids in the L protein with 
alanine, a non-charged amino acid, has been found to facilitate attenuation producing 
recombinant hRSV virus which is more temperature sensitive and is capable of only 
limited replication in the lung of cotton rats (Tang et al., 2002).   Another strategy is the 
modification at the cleavage sites of the F glycoprotein at the two positions digested by 
cellular protease. These sites have been reported to be important in activation of 
membrane fusion (Gonzalez-Reyes et al., 2001).  Therefore, it is possible to attenuate 
hRSV by changing the sequences at these sites; however, this method has yet to be fully 
evaluated (Collins and Murphy, 2005).  Alteration of the gene order also may lead to 
increase in immunogenicity.   Changing the position of the F and G gene so that they 
are in a more promoter proximal position in recombinant hRSV virus enhances the 
expression of both genes, resulting in an increase in the level of serum F glycoprotein 
specific IgG antibody, but not IgG antibody specific to G glycoprotein (Krempl et al., 
2002).    
Recombinant animal viruses 
Recombinant animal viruses engineered to express genes encoding hRSV proteins using 
reverse genetics are also promising anti-hRSV candidate vaccines.  The advantage of 
this strategy that is efficient restriction of replication in humans is not dependent upon a 
temperature sensitive phenotype.  One such candidate is a chimeric bRSV/hRSV 
expressing the hRSV F and G protein.  However, this construct has been found to be 
over-attenuated in chimpanzees and did not induce resistance to wild-type hRSV 
challenge.   It may be that replacing more bRSV genes with hRSV genes may increase 
the immunogenicity in primates (Buchholz et al., 2000). 
 
Bovine parainfluenza virus type 3 (bPIV3) has also been widely studied as a potential 
vaccine vector for hRSV genes.  A chimeric bPIV3 in which the wild type fusion (F) 
and hemagglutinin-neuraminidase (HN) genes were replaced with genes from human 
parainfluenza virus type 3 (hPIV3) was found to be attenuated in the lungs of hamsters 
and fully protected them against hPIV3 challenge (Haller et al., 2000).  In addition, this 
virus has been shown to be immunogenic and safe for administration to young infants 
and children (Karron et al., 1996; Lee et al., 2001).    
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Chimeric b/h PIV3 has been further modified by the insertion of the hRSV F or G 
proteins.  Hamsters immunized with either chimeric virus were protected from 
challenge with both hRSV and hPIV3 (Tang et al., 2003).   Furthermore, African green 
monkeys immunized with the b/h PIV3/RSV (MEDI-534) harbouring either the native 
or soluble hRSV F glycoprotein were resistant to wild-type hRSV challenge and 
released neutralizing F-protein specific IgG antibody (Tang et al., 2004).  MEDI-534 is 
currently in phase I/IIa clinical trials testing in infants and children between 1 and 24 
months of age who are seronegative to both hPIV3 and hRSV (MedImmune LLC, 
2008b).  
Subunit vaccines 
Subunit vaccines are an alternative strategy for immunization against hRSV consisting 
of viral glycoproteins either purified from infected cell culture or produced by 
recombinant vectors.  F glycoprotein has been developed as a candidate vaccine 
following purification by affinity chromatography, PFP-1, (90% F and 5% G proteins) 
or by ion exchange chromatography, PFP-2 (>99.9% F and <0.1% G proteins).  Both 
PFP-1 and PFP-2 were adsorbed to alum and evaluated in hRSV-seropositive children, 
children with cystic fibrosis, healthy elderly people and pregnant women.  It was found 
that these vaccines did not enhance disease severity on subsequent natural infection and 
induced the production of neutralizing antibodies (Tristram et al., 1993; Paradiso et al., 
1994; Piedra et al., 1995; Falsey and Walsh, 1996; Piedra et al., 1996; Groothuis et al., 
1998; Munoz et al., 2003).  However, PFP-1 did not protect against recurrent hRSV 
infection (Belshe et al., 1993).  PFP-3 vaccine was subsequently developed from highly 
purified cold passaged and temperature sensitive mutant strains.  In a phase II trial 
performed in children with cystic fibrosis, anti-F neutralizing and binding antibodies 
were maintained for 28 days post-vaccination (Piedra et al., 2003).   
 
Using recombinant technology it has been possible to link the hRSV glycoproteins to 
molecules which may enhance the immune response.  A G protein fragment (residue 
130 – 230, designated G2Na) has been fused to an albumin binding region (BB) of 
streptococcocal protein G, generating BBG2Na vaccine (Power et al., 1997).  BB 
domain was selected to be a fusion partner because it can increase the half-life of fused 
peptides, resulting in extended exposure of the immunogens to the immune responses 
(Makrides et al., 1996).  BB domain also has carrier-related properties which facilitate 
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antibody response to weak immunogens (peptides) (Sjolander et al., 1997).  Moreover, 
the BB domain can be effectively purified by affinity chromatography on albumin-
Sepharose (Nygren et al., 1988).  
 
Seropositive adults given BBG2Na vaccine produced high neutralizing antibodies and 
did not present enhanced disease after hRSV infection (Power et al., 2001).  
Nevertheless, infant macaques immunized with BBG2Na and challenged with hRSV 
were found to produce IL-13 which is involved in Th2 responses similar to the effect of 
FI-RSV vaccine.  Low levels of eosinophilia were also present in the lungs of animals 
on subsequent hRSV challenge (de Waal et al., 2004).  BBG2Na reached clinical phase 
III, but it was terminated due to evidence of adverse reactions in vaccinees (Nguyen et 
al., 2012). 
 
By recombinant expression of the F glycoprotein, it has been possibly develop to a 
subunit vaccine that is composed of the post-fusion form of the F glycoprotein (trimer) 
lacking the fusion peptide, transmembrane and cytoplasmic region, resulting in no 
aggregation.  This vaccine has been reported to protect cotton rat from hRSV challenge 
and induce the high levels of neutralizing antibody.  It was found that the post-fusion 
form presents the neutralizing binding site recognized by several antibodies such as 
palivizumab (PZ), motavizumab and 101F (McLellan et al., 2011; Swanson et al., 
2011). 
 
The immunogenicity of viral proteins may be enhanced by presentation within virus-
like particle (VLP) (Noad and Roy, 2003).  VLPs resemble viral particles containing 
structural proteins and lipid with no genetic materials which are incapable of 
replication.  Hence, the VLP vaccine is safe and also highly immunogenic because 
antigens on its surface and core can potentially stimulate both humoral and cell-
mediated immune response. (Sedlik et al., 1999; Lechmann et al., 2001; Liu et al., 
2002; Swenson et al., 2005).   
 
The VLP vaccines which are allowed for human use have been successfully developed 
against papillomavirus and hepatitis B viruses.  hRSV VLPs have been generated by 
connecting the ectodomain of hRSV G protein to the cytoplasmic tail and 
transmembrane domain of the NDV HN (VLP-H/G).  This chimeric protein is 
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incorporated into the VLP containing NDV N and M proteins.  It was found that the ND 
VLP with hRSV G protein (ND VLP-H/G) protected mice from hRSV challenge and 
did not cause enhanced disease in lungs on subsequent hRSV challenge (Murawski et 
al., 2010).  ND VLP-H/G assembled with a chimeric RSV F/NDV F glycoprotein (F/F) 
has been subsequently generated (ND VLP-H/G+F/F).  Anti-hRSV F and G protein 
antibody responses and neutralizing antibodies were stimulated in mice immunized with 
ND VLP-H/G+F/F.  On subsequent hRSV challenge, no enhanced lung pathology was 
detected in ND VLP-H/G+F/F - immunized mice, suggesting that these VLP vaccines 
can efficiently protect mice against hRSV infection  (McGinnes et al., 2011).  However, 
this vaccine remains to be completely evaluated in humans. 
1.10.3 Passive immunization 
RSV intravenous immunoglobulin  
RSV intravenous immunoglobulin licensed in 1996 (RS-IVIG, RespiGam
TM
, 
MedImmune, Inc, Gaithersburg, MD) is purified human polyclonal IgG containing high 
hRSV-neutralizing activity.   Cotton rats treated with the RS-IVIG were resistant to 
wild-type hRSV challenge by 99% (Siber et al., 1994).  Two doses of the RS-IVIG (750 
and 150 mg/kg) was evaluated in high risk children with chronic lung disease of 
prematurity (CLD) and congenital heart disease (CHD).  There were significantly fewer 
lower respiratory tract infections and lower levels of hospitalization in the high-dose 
group compared to those in the low-dose group.   
 
The evaluation of the RS-IVIG with a high dose was confirmed in children with CLD 
compared to placebo controls with a reduction of hospitalization related to hRSV.  
However, there was a problem in some children caused by infusion of a large volume of 
fluid (The PREVENT Study Group, 1997).  Children with CHD receiving the RS-IVIG 
suffered a higher frequency of unanticipated cyanotic episodes with an unsatisfactory 
outcome after surgery for children with cyanotic CHD.   Therefore, the RS-IVIG has not 
been further developed because of low efficiency and safety concerns (Simoes et al., 
1998).  RS-IVIG may also interfere with subsequent vaccination with other viruses such 
as measles, mumps and rubella (Wu et al., 2008). 
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Anti-F monoclonal antibodies 
Palivizumab 
Palivizumab (MEDI-493, Synagis
TM
, MedImmune, Inc, Gaithersburg, MD) or PZ is a 
humanized monoclonal antibody against a conserved region of hRSV F glycoprotein 
which binds antigenic site II (or site A) in the N-terminal region of F1 in both pre- and 
post-fusion forms of the glycoprotein (Swanson et al., 2011; Magro et al., 2012).  It has 
been shown that PZ is 20-30 fold more effective than RS-IVIG.  PZ was synthesized by 
transplanting six complementarity determining regions (CDRs) of anti-hRSV F 
glycoprotein MAb 1129 (3 CDRs of light chain and 3 CDRs of heavy chain) into a 
human IgG1/κ antibody in the corresponding light and heavy chain regions (Johnson et 
al., 1997).  The MAb 1129 was secreted from the 1129 hybridoma constructed by 
fusion of murine myeloma cell lines with mouse splenic lymphocytes.  These 
lymphocytes were derived from mice intravenously injected with hRSV A2 strain and 
subsequently intranasally inoculated with recombinant F glycoprotein (Beeler and van 
Wyke Coelingh, 1989).  Hence, PZ consists of immunoglobulin sequences of both 
human (95%) and murine (5%) origin (Johnson et al., 1997). 
 
The antigenic site of PZ was mapped by the production of escape mutants in the 
presence of PZ.  These were MP4, MS412 and F212.   The MP4 and MS412 mutants 
were fully resistant to PZ both in vitro and in vivo and had point mutations in the region 
encoding the F1 chain at nucleotide 828 (AT, K272M) and 827 (AC, K272Q), 
respectively.   Mutant F212 was partially neutralized by PZ in vitro, but was completely 
susceptible to PZ in vivo.  The mutation of the F212 was also found in the region 
encoding the F1 subunit at nucleotide 816 (AT, N268I).  The locations of all escape 
mutants were in antigenic site II, suggesting that this site was specific for the binding of 
PZ (Zhao et al., 2004a; Zhao et al., 2004b).    
 
Mutation of hRSV isolates collected from NPS of infants receiving a high dose of PZ 
also occurred at residue 272 which changed from lysine (K) to glutamate (E) (Boivin et 
al., 2008).  Similarly, in a separate study, mutations in the F gene of isolates derived 
from patients given PZ were found at residues 272 (K272E and K272Q) and 275 
(S275F and S275L).  However, there were only a low frequency of variants with amino 
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acid changes in antigenic site II and the resistant phenotype disappeared after passaging 
mixtures of wild-type and mutant variants (Zhu et al., 2011).   
 
In in vitro studies, PZ was able to neutralize all hRSV from clinical isolates of both 
subgroups A and B tested (Johnson et al., 1997).  The neutralization to hRSV by PZ has 
been studied and it has been found that PZ does not inhibit viral attachment or budding, 
but blocks viral transcription.  It was suggested that PZ is active at the stage of fusion.  
This study also showed PZ inhibited cell-to-cell fusion mediated by the F glycoproteins. 
It has been suggested that this antibody acts by preventing the conformational change of 
the F glycoprotein involved in the fusion process (Huang et al., 2010). 
 
In in vivo studies, a 99% reduction of hRSV titres in the lungs of cotton rats was found 
with serum levels of PZ of 40 µg/ml.  There was no enhancement of pathology or viral 
infection after hRSV challenge (Johnson et al., 1997).  In 1,502 high-risk children, 
intramuscular injection of PZ at 15 mg/kg decreased hRSV hospitalizations by 55%.  
Premature children with and without brochopulmonary dysplasia (BPD) injected with 
PZ had a reduction in hRSV hospitalization of 39% and 78%, respectively. 
Furthermore, PZ was revealed to be safe in all studies and patients given PZ had the 
same side effects as the placebo groups (The IMpact-RSV Study Group, 1998).  After 
this trial, PZ was approved by the Food and Drug Administration (FDA) in 1998.  
 
PZ was also evaluated for protective effect in young children with hemodynamically 
significant congenital heart disease and showed a 45% reduction in the length of hRSV 
hospitalization.  Moreover, patients who required supplemental oxygen had a 73% 
reduction in hRSV hospitalization.  At present, according to the recommendation of the 
American Academy of Pediatrics (AAP) (Committee on infectious disease, 2009) PZ is 
recommended for use in young children (≤ 2 years of age) with hemodynamically 
significant congenital heart disease, chronic lung disease of prematurity, premature 
infants (≤ 32 weeks’gestation) and high-risk infants (32 - 35 weeks’gestation).  The 
latter group is limited to infants born within 3 months before the start of hRSV season 
or at any time during the hRSV season.  
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Motavizumab 
Motavizumab (MEDI-524, MedImmune, Inc, Gaithersburg, MD) has been developed 
from PZ by mutagenization of the PZ immunoglobulin gene.  There were only 13 amino 
acids of motavizumab that differ from PZ.  The modifications improve binding affinity 
and in vitro neutralization which are reported to be approximately 70-fold and 20-fold 
greater than those for PZ, respectively.  The mechanism of neutralization has been 
reported to be the same as PZ.  Motavizumab was not associated with the stage of viral 
attachment and budding; however, it inhibited both the virus-cell and cell-cell fusion 
(Huang et al., 2010).  In addition, it has been confirmed that motavizumab can bind to 
antigenic site II of the F glycoprotein in the pre-fusion, intermediate and post-fusion 
states (McLellan et al., 2011).   
 
Motavizumab can reduce virus titres in cotton rats 10 – 100 fold more than PZ at the 
same concentration and block viral growth in the upper respiratory tract (Wu et al., 
2005; Wu et al., 2007).   In phase III clinical trials, motavizumab decreased the 
percentage of hospitalization (26%) compared to PZ; however, antidrug antibodies were 
detected by 1.8% of patients receiving motavizumab and the incidence of 
hypersensitivity reactions in motavizumab recipients (0.4%) was slightly increased from 
patients treated with PZ (0.1%) (Carbonell-Estrany et al., 2010).  Recently, it has been 
reported that the US FDA Antiviral Drugs Advisory Committee has not approved the 
license application for motavizumab due to concern about the increase of 
hypersensitivity reactions and have requested additional clinical data about frequency 
and severity of these reactions (The antiviral drug advisory committee of the Food and 
Drug Administration, 2010).   Subsequently, MedImmune has decided to discontinue 
further development of motavizumab (MedImmune, 2010).  
Numax-YTE 
Numax-YTE (MEDI-557, MedImmune, Inc, Gaithersburg, MD) was developed from 
motavizumab by improving its circulation half-life.  The neonatal Fc receptor (FcRn) is 
responsible for maintaining the levels of serum IgG.   The IgG pathway is initiated by 
the uptake of circulating IgGs into cells by pinocytosis and IgGs then bind to FcRn 
located in the wall of the acidic endosomes.  This binding depends on the pH with a 
tight binding occurring at pH 6.0, but no binding at pH 7.4.  After binding in the 
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endosome, bound IgGs are recycled back to the cell surface and easily released into 
circulation  (Junghans, 1997). 
 
The Fc region of motavizumab was modified for higher affinity binding to FcRn, 
resulting in a better recycling step and thus longer circulation half-life.  The Fc domain 
of Motavizumab was engineered by three substitution mutations, M252Y/S254T/T256E 
(YTE), and this antibody was named NuMax-YTE.  This modification resulted in an 
increased (10-fold) binding affinity of NuMax-YTE for cynomolgus monkey and 
human FcRn at pH 6.0 and also effective dissociation from FcRn at pH 7.4.  NuMax-
YTE has been shown to have a 4-fold increased circulation half-life compared to the 
original motavizumab, but still maintains its activities in binding to antigen and 
blocking hRSV replication (Dall'Acqua et al., 2006).  This product is currently in 
clinical testing for human. 
  
 
  
Chapter 2: Background of project
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2.1 Introduction 
hRSV is the major cause of severe respiratory disease in infants and young children 
leading to hospitalization and death worldwide.  It has been reported that there are 
approximately 64 million cases and 160,000 deaths caused by hRSV disease every year 
(WHO, 2009).  Prevention of this disease in high risk infants has only been 
accomplished by the administration of palivizumab (PZ) which is a humanized 
monoclonal antibody (MAb) directed against the F glycoprotein.  However, PZ has only 
reduced hRSV hospitalization by 55% (Fenton et al., 2004).   
 
Previous studies have reported that all hRSV isolates are susceptible to neutralization by 
PZ (Johnson et al., 1997; DeVincenzo et al., 2004).  hRSV resistant to PZ have been 
isolated from nasopharyngeal secretions of infants receiving PZ, suggesting that PZ 
exerts selective pressure for resistance to develop.  Their sequence analysis revealed the 
mutation at residue 272, 275 and 276 (K272E/Q, S275F/L and N276S) which are in the 
PZ epitope (Boivin et al., 2008; Adams et al., 2010; Zhu et al., 2011).  None of these 
studies have ever shown resistant hRSV in infants without PZ treatment. 
 
Against this background it was surprising that Marsh et al. (2007) reported that the 
predominant hRSV variants isolated from untreated infants are slow growing and 
resistant to neutralization by anti-F glycoprotein MAbs.  These isolates did not carry 
mutations in known anti-F MAb epitopes.  Similar isolates were subsequently found to 
be additionally resistant to neutralization by PZ and to hRSV immune human serum 
(Gias, 2006; Welsh, 2010).  However, on further passage in culture these isolates 
rapidly lost their resistance and fast growing, neutralization susceptible variants came to 
predominate in the cultures (Gias, 2006; Marsh et al., 2007; Welsh, 2010). 
 
This may indicate that virus present in the respiratory tract is less susceptible to 
neutralization by anti-F antibodies than had been thought hitherto.  However, it is 
unclear whether it is the early resistance in the Newcastle studies or the susceptibility 
found by others which represents the true state of virus in the respiratory tract.  
Whichever, this phenomenon is worth elucidating as it presents a complicating factor in 
assessing the results of neutralization studies on clinical isolates. 
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In order to locate the genetic changes responsible for this loss of resistance on passage, 
one such isolate, hRSV R17532, was passaged repeatedly in culture.  The virus retained 
resistance to neutralization up to passage 9, but thereafter resistance was variably lost 
after a further one or two passages.  Sequence comparison of R17532 virus stocks 
comprising two neutralization resistant cultures at passage 1 and 10 (10a) and one 
susceptible culture also at passage 10 (10b) revealed no nucleotide changes in the M, 
SH genes or associated intergenic regions (Gias, 2006; Marsh et al., 2007).  A single 
nucleotide change (T  C) was observed in the G gene between resistant passage 1 and 
susceptible 10b at position 884, resulting in change from isoleucine to threonine in the 
residue 295.  Both T and C were detected in chromatogram of the resistant passage 10a.  
For the F gene, four changes occurred between passage 1 and 10b.  Two changes 
occurred (C  T) at nucleotide positions 1802 and 1833 in the 5’untranslated region 
and two changes were detected in the F coding region shifting residue 20 from 
phenylalanine to leucine in the signal peptide region and residue 152 from isoleucine to 
methionine in the HR1 region.  However, these changes in the susceptible 10b virus 
were shared with the still resistant 10a virus (Marsh et al., 2007).   
 
In similar studies by Gias (2006), resistant and susceptible variants of two virus isolates, 
N5843 and R17532, were cloned and their F genes sequenced.  For R17532, 
neutralization resistant clone R3 and susceptible clone R11 differed with a change from 
isoleucine to methionine at amino acid 152, the same change as that observed by Marsh 
et al. (2007) in uncloned cultures.  They further differed at amino acid 386 in the 
cysteine-rich domain, with a leucine in the resistant and an isoleucine in the susceptible 
clone.  Neither of these residues varied between resistant and susceptible N5843 clones.  
Resistant N5843 clone N1 and susceptible clone N10a differed only by a single 
nucleotide change from proline in clones N1 to serine in clone N10a at amino acid 101 
in the F2 subunit.   
 
These studies, therefore, whilst demonstrating that point mutations tend to accumulate 
in F and G glycoprotein genes on passage found that none were correlated 
unequivocally with changes in neutralization phenotype.  Whilst it is possible that the 
observed phenotype changes are the result of different, possibly multiple mutations in 
different cultures and clones, it is also possible that mutations in regions of the genome 
encoding the non-membrane associated proteins and controlling replication and 
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transcription may be responsible.  In an attempt to investigate the possibility that 
differences in susceptibility to neutralization result from differences in the efficiency of 
transcription of the F gene with consequent differences in the concentration of F 
glycoprotein in the virion, Gias (2006) assessed the F glycoprotein content of virus 
cultures and purified virions from resistant and susceptible clones.  Resistant clones R3 
and N1 had higher amount of the F glycoprotein per infectious particle than the 
susceptible clones R11 and N10a.  However, the F glycoprotein per genome copy of 
purified virions was significantly higher in only clone R3 compared to clone R11.  The 
amount of the F glycoprotein genome in purified clone N1 was similar to that in 
purified clone N10a (Gias, 2006).  
 
Welsh (2010) initiated studies of the early stages of virus binding and entry of resistant 
and susceptible clones in the hope of determining differences which might account for 
changes in the efficacy of antibody neutralization.  PZ was found to bind equally to the 
F glycoprotein of either purified resistant or susceptible hRSV clones.  Resistant clones 
were independent on cell surface heparan sulphate (HS) in binding, whereas susceptible 
clones required HS.  In addition, resistant clones bound to the cells faster than 
susceptible clones.  These results suggested that the neutralization susceptibility to PZ 
of low and high passage viruses may be affected by differences in receptor usage for 
cell binding.  
 
In previous studies, Huang et al. (2010) found that PZ did not inhibit viral attachment 
and suggested that neutralization by PZ occurs after the attachment step.  In agreement 
with this Welsh (2010) demonstrated that PZ did not block viral attachment of either 
neutralization resistant or susceptible R17532 virus clones.  It therefore seems that 
differences between the two clones in susceptibility to neutralization by PZ most likely 
occur at post-attachment steps. 
2.2 Aims  
This study seeks to further investigate the genetic and phenotypic differences between 
slow growing, neutralization resistant and fast growing, neutralization susceptible 
clones of hRSV with the aim of elucidating the mechanism of resistance and its possible 
significance in the pathogenesis of human hRSV infection.  
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The specific aims of this project are: 
1. To reclone and verify the neutralization susceptibilities of multiple independent 
R17532 clones.  
2. To compare neutralization resistant and susceptible clones at post-attachment 
stages of entry. 
3. To compare F protein expression levels on the surface of cells infected with 
resistant and susceptible R17532 clone. 
4. To test the conclusion of previous studies that the genetic changes in the 
membrane associated protein genes are not correlated with neutralization 
phenotype conversion.  
5. To identify the mutations in the full genome of virus clones with resistant and 
susceptible phenotypes that are associated with the differences in replication rate 
and antibody susceptibility. 
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Chapter 3: Materials and methods 
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3.1 General Reagents 
All chemicals were obtained from Sigma-Aldrich (Poole, UK) or Fisher Scientific 
(Leicestershire, UK) unless stated otherwise.  Sterilisation of reagents was carried out 
by autoclaving at 15 lbs for 15 minutes at 121°C.  Distilled water was produced by the 
Aquatron A4S distillation system (J, Bibby Science Products Ltd., UK) and this water 
was treated with diethyl pyrocarbonate (DEPC) for use in molecular biology.  The 
DEPC-treated water was prepared by incubating with 0.1% (v/v) DEPC at 37°C 
overnight before autoclaving.  
3.2 Immunoreagents 
Table 3.1: Sources and specificities of immunoreagents 
 
Immunoreagents Specificity Source 
Palivizumab (PZ) hRSV F glycoprotein 
Abbott Laboratories Ltd., Kent, 
UK (The IMpact-RSV Study 
Group, 1998) 
MAb 1E3 hRSV F glycoprotein 
Kindly supplied by Prof. 
G.L.Toms (West et al., 1994) 
Mouse anti-hRSV MAb pool hRSV N, P, F and  M2 proteins 
Novocastra Leica, Leica 
Biosystems Newcastle Ltd., 
Newcastle upon Tyne, UK. 
Polyclonal rabbit anti-mouse 
fluorescein isothiocyanate 
(FITC) conjugated 
immunoglobulin 
Mouse immunoglobulin 
DakoCytomation Glostrup, 
Denmark 
Polyclonal goat anti-mouse 
peroxidase conjugated 
immunoglobulin (NCL-GAMP) 
Mouse immunoglobulin 
Novocastra Leica, Leica 
Biosystems Newcastle Ltd., 
Newcastle upon Tyne, UK. 
 
3.3 Cell cultures 
3.3.1 Materials 
Cell lines 
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Table 3.2: Sources of cell lines. 
 
Cell line Source Reference 
HeLa NCL Human cervical carcinoma 
Kindly supplied by F. Fenwick 
(University of Newcastle upon Tyne). 
HeLa NCL79†  Human cervical carcinoma 
Kindly supplied by Prof G. L. Toms 
(University of Newcastle upon Tyne). 
HeLa Lucy Human cervical carcinoma 
Kindly supplied by Dr J. Hiscox 
(University of Leeds). 
HeLa JSF Human cervical carcinoma 
Kindly supplied by Prof G. E. Blair 
(University of Leeds). 
HeLa CPV Human cervical carcinoma 
Kindly supplied by Prof D. Rowlands 
(University of Leeds). 
16HBE140 Human bronchial epithelial cell 
Kindly supplied by Dr D. Grunert 
(University of Vermont, Burlington, 
VT; (Cozens et al., 1994)). 
Vero African green monkey kidney 
Clinical Virology unit, Royal Victoria 
Infirmary, Newcastle upon Tyne. 
†The HeLa cell, HeLa NCL79, was selected from available lines circulating in the virus diagnostic 
community in the 1970s following screening for its ability to isolate hRSV from clinical specimens (R. 
McGuckin personal communication) and was preserved in liquid nitrogen until resuscitated for this study. 
Phosphate Buffered Saline (PBS) 
Two PBS A tablets (Oxoid, Basingstoke, Hampshire, UK) were dissolved in 200 ml of 
distilled water, autoclaved and stored at room temperature. 
Heat-inactivated foetal calf serum (FCS) 
FCS (Biosera, Biosera Ltd, East Sussex, UK) was heat-inactivated in a water bath at 
56°C for 30 minutes, then aliquoted in 20 ml volumes and stored at -20°C. 
0.4% (w/v) Phenol red indicator solution  
Phenol red was diluted in PBS to a final concentration of 0.4% and the pH was adjusted 
with 1 M NaOH until the solution turned red in colour. 
Gassed sodium bicarbonate buffer 
44 g of NaHCO3 and 2.5 ml of 0.4% (w/v) phenol red solution were dissolved in 1 litre 
of distilled water.  The solution was gassed by bubbling 5% CO2 through it until a peach 
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coloured solution was produced.  It was then aliquoted in 5 ml volumes, autoclaved and 
stored at room temperature. 
Growth Medium (GM) 
GM was prepared in 500 ml volumes containing Eagle’s Minimum Essential Medium 
(EMEM) (BioWhittaker, Cambrex BioScience Verviers, Belgium), 10% (v/v) of heat-
inactivated FCS, 1% (v/v) of 10 mg/ml Penicillin-Streptomycin (PAA Laboratories, 
Austria), 1% (v/v) of 200 mM L-glutamine (PAA Laboratories, Austria) and 5% (v/v) 
of gassed sodium bicarbonate buffer.  Media for 16HBE140 cell had the addition of 
non-essential amino acids (PAA Laboratories, Austria). 
Maintenance Medium (MM) 
MM was prepared in 500 ml volumes containing Eagle’s Minimum Essential Medium 
(EMEM), 2% (v/v) of heat-inactivated FCS, 1% (v/v) of 10 mg/ml Penicillin-
Streptomycin, 1% (v/v) of 200 mM L-glutamine and 5% (v/v) of gassed sodium 
bicarbonate buffer.  Media for 16HBE140 cell had the addition of non-essential amino 
acids (PAA Laboratories, Austria).  
Versene/Trypsin solution 
0.25 g of ethylene-diamine-tetra-acetic acid (EDTA) were dissolved in 1 litre of PBS, 
aliquoted in 100 ml volumes, autoclaved and stored at 4°C.  Versene (EDTA) solution 
had the addition of 2.5% of sterile trypsin solution (PAA Laboratories, Austria) to a 
final concentration of 0.025% (v/v) prior to use. 
3.3.2 Routine cell cultures 
Cells were either cultured in 4 oz flat glass bottles or plastic tissue culture flasks.  When 
the cells were confluent, the monolayers were routinely subcultured as follows.  The 
GM was removed and the cells were gently washed with 5 ml of PBS followed by 5 ml 
of versene/trypsin solution.  After discarding versene/trypsin, the cells were then 
incubated at 37°C in 5% CO2 for 5 – 10 minutes until the cells were dissociated.  The 
cells were re-suspended in 3 ml of GM and split into three sterile bottles or flasks.  The 
GM was added to each bottle or flasks and incubated at 37°C in 5% CO2.  The cells 
were routinely passaged every 3 days. 
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3.4 Virological methods 
3.4.1 Virus stocks 
hRSV strain R17532 (subgroup A) stocks at passage level 2 (P2-GLT_24/09/98) and 
level 5 (P5-AC_10/04/98 and P5-RM_23/05/09) and R17532 clones at passage level 3 
(R3.2_7/05/04 and R3.7.8_7/05/04) and level 11 (R11.2_5/04/04 and 
R11.1.1_20/11/09) and strain A2 were kindly provided by Prof G.L. Toms.  
3.4.2 Growth of hRSV in 4 oz flat glass bottles or 75 cm3 culture flasks 
After rapidly thawing in a 37°C water bath, virus stock was diluted 1/10 in cold MM 
and then held on ice.  The GM was discarded from 80 – 90% confluent HeLa cells in 4 
oz flat glass bottle or plastic tissue culture flasks (section 3.3.2) and 300 µl of virus 
suspension were inoculated onto a monolayer of cells.  An equal volume of MM was 
added to another HeLa cell bottle or flask as a negative control.  The HeLa cells were 
incubated for an hour at 37°C in 5% CO2 with rocking every 15 minutes before 12 ml of 
MM were added and then re-incubated at 37°C in 5% CO2.  The media were replaced 
after 24 hours and every 48 hours.  The cultures were examined daily for cytopathic 
effect and scored on a subjective four counting scoring system 1 – 4+, where 1+ 
represents just discernible CPE and 4+ complete involvement of the whole monolayer. 
When 3+ to 4+ cytopathic effect (CPE) developed, hRSV was harvested by scraping the 
remaining cells into the media using a cell scraper. Virus cultures were aliquoted into 2 
ml vials, snap frozen in liquid nitrogen and stored at -80 °C.  Infected cells used in RNA 
extraction were aliquoted into 1.5 ml centrifuge tubes and centrifuged at 500 x g for 5 
minutes.  The supernatants were aspirated and cell pellets were stored at -80 °C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
3.4.3 Growth of hRSV in 225 cm3 culture flasks 
Confluent HeLa cells were stripped with versene/trypsin as described in section 3.3.2. 
Cell lysate was re-suspended in 10 ml of GM, transferred to 225 cm
3
 culture flask and 
40 ml of GM were added.  The flask was incubated at 37°C in 5% CO2 for 3 days until 
the monolayer displayed approximately 80 – 90% confluence.   Virus stock was rapidly 
thawed in a 37°C water bath and diluted 1/10 in cold MM.  The GM was discarded from 
HeLa culture flask and 5 ml of virus suspension were inoculated onto the monolayer. 
Five millilitres of MM were added to another HeLa cell flask as a negative control. 
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Both flasks were incubated for an hour at 37°C in 5% CO2 with rocking every 15 
minutes.  Following incubation, 45 ml of MM were added and the monolayers were 
treated  thereafter as described in section 3.4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
3.4.4 Biological cloning of hRSV isolates by plaque purification  
The procedure for plaque purification of hRSV was modified from a protocol based on 
that of Herlocher et al (1999).  
Materials 
Neutral red solution 
Neutral red solution (3 g/L) was diluted 1/3 in PBS. 
Overlay media 
3.2 g of low gelling temperature Agarose Type VII (Sigma, St Louis, MO, USA) were 
melted in 200 ml of distilled water in a boiling water bath.  The 1.6% (w/v) agarose 
solution was aliquoted in 12 ml volumes, autoclaved and stored at room temperature.  
For the nutrient first overlay, 1.6% (w/v) agarose was melted at 100C and cooled to 
37C before mixing with an equal volume of double strength growth medium pre-
warmed to 37C.  For the second overlay, an aliquot of 1.6% (w/v) agaorose was 
melted, cooled to 37C and 1.5 ml of 1 g/L neutral red were added. 
Method 
Confluent Vero cells were stripped from 4 oz flat glass bottle or plastic tissue culture 
flasks as described in section 3.3.2 and re-suspended in 20 ml of GM.  Cell suspension 
was then seeded into 6-wells plates at 3 ml per well and the plates were incubated at 
37C under 5% CO2 in a moist box (a plastic lunchbox containing a wad of moisture 
paper towel to ensure high humidity) overnight.  When the cells reached 80 – 90% 
confluence, the GM was discarded from each well and the cells were washed once with 
4 ml of PBS per well.  Virus stocks were rapidly thawed and ten-fold serial dilutions 
from 10
-1
 to 10
-5
 were prepared in cold MM.  500 µl of each viral dilution were 
inoculated onto a cell culture well and 500 μl of MM were added to a further well as a 
negative control.  The virus was allowed to adsorb for 1 hour at 37C under 5% CO2 in 
a moist box with rocking every 15 minutes.  The inocula were then removed and the 
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monolayers were washed 3 times with PBS.  Three millilitres of the first nutirient 
overlay medium were gently added to each well and the agarose was allowed to 
solidify.  The plate was then incubated at 37C with 5% CO2 in a moist box until early 
CPE had developed as determined by examination under the microscope.  
 
When virus plaques were visible and ready to be picked, 2 ml of the second overlay 
containing 0.01% neutral red solution were gently added to each well.  The agarose was 
allowed to solidify as above and the plate was then incubated at 37C with 5% CO2 in a 
moist box overnight.  On the same day, HeLa cell culture tubes were prepared as 
follows.  Confluent HeLa cells were stripped from 4 oz flat glass bottle or culture flasks 
as described in section 3.3.2 and re-suspended in 30 ml of GM.  Cell suspension was 
then seeded into 30 glass tissue culture tubes with 1 ml per tube and the tubes were 
incubated overnight at 37C under 5% CO2 at a 25° angle.  The following day, the 
monolayers in tubes displayed 80 - 90% confluence.  
 
The plaques were visible as light areas against a dark background.  Plaques were 
carefully marked on the base of the plates under the stereomicroscope.  Isolated plaques 
were then picked with sterile 200 μl pipette tips and emulsified in 200 μl of cold MM by 
pipetting up and down.  Two hundred microlitres of each emulsified plaque were 
inoculated into a HeLa cell culture tube after discarding the media.  A similar volume of 
MM was added additional tubes to act as negative controls.  The tubes were then 
incubated in a roller drum at 37 C for 1 hour.  After incubation, 800 µl of MM were 
added to each tube and tubes were re-incubated as above.  The CPE in each tube was 
observed every day and the media were replaced after 24 hours and every 48 hours until 
4+ CPE was observed.  Virus clones were harvested by scraping the remaining cells into 
the media using a Pasteur pipette and aliquoted into 2 ml vials.  The vials were snap 
frozen in liquid nitrogen and stored at -80 °C.   
3.4.5 Quantitation of hRSV titres using the fluorescent focus assay           
Materials 
75% (v/v) Acetone/PBS 
25 ml of PBS were added to 75 ml of acetone and allowed to equilibrate overnight at 
4C. 
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0.0033% (w/v) Naphthalene black  
0.2 g of naphthalene black were dissolved in 6 L of PBS, aliquoted into volumes of 500 
ml, autoclaved and stored at room temperature. 
Methods 
Plate preparation and infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Confluent monolayers of cells were dissociated and re-suspended in GM to obtain 3 × 
10
5
 cells/ml.  96-well plates were seeded with 200 µl per well of cell suspension and 
incubated at 37 °C under 5% CO2 overnight in a moist box.  The following day, the 
cells were 80 – 90% confluent.  Ten- fold dilutions of virus samples were prepared in 
cold MM from 10
-1 
to 10
-6
.   The GM was discarded from the cell culture plate and then 
25 µl of each virus dilution were inoculated onto triplicate wells. Twenty-five 
microlitres of MM were added a further well as a negative control and the plate was 
incubated at 37°C under 5% CO2 for 1 hour in a moist box.  After incubation, the 
inocula were discarded and the wells were washed with 200 µl of Hanks’ balance salt 
solution (HBSS).  Two hundred microlitres of MM were added to each well and the 
culture plate was incubated at 37°C in 5% CO2 for 18 hours in a moist box.  
Fixing and immunofluorescent staining 
After 18 hours, the MM was discarded and the cells were fixed in 200 µl of cold 75% 
(v/v) acetone in PBS for 10 minutes at 4°C.  After fixation, the acetone was discarded 
and then 25 µl of mouse anti-hRSV MAb pool diluted to 1/5 in PBS were added to each 
well.  The plate was incubated at 37°C for 30 minutes in a moist box and then washed 
twice with 200 µl of PBS.  Twenty-five microlitres of polyclonal rabbit anti-mouse 
fluorescein isothiocyanate (FITC) conjugated immunoglobulin diluted to 1/20 in PBS 
were added into each well and the plate was re-incubated as above.  After incubation, 
the plate was washed twice with 200 µl of PBS and 200 µl of 0.0033% (v/v) 
naphthalene black were added in each well and left at room temperature for 10 minutes.  
Then, the plate was washed once with 200 µl of PBS for 5 minutes and followed by 
distilled water for 1 minute.  The plate was air dried at room temperature and examined 
under a fluorescence microscope (Nikon Eclipse E400, Tokyo, Japan) using a 10x 
objective lenses.  The number of fluorescent foci per well were counted in wells 
containing between 20 and 60 foci and the virus titre (focus forming units per ml or 
FFU/ml) was calculated using the following formula:  
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Virus titre = Average number of fluorescent foci per well × dilution factor × 40 
3.4.6 Quantitation of hRSV titres using immunoperoxidase focus assay    
Materials 
0.4% Nutrient agarose overlay medium 
1.6 g of low gelling temperature Agarose Type VII (Sigma, St Louis, MO, USA) were 
melted in 200 ml of distilled water in a boiling water bath.  The 0.8% (w/v) agarose 
solution was aliquoted in 12 ml volumes, autoclaved and stored at room temperature.  
For the 0.4% nutrient agarose overlay medium, 0.8% (w/v) agarose was melted at 
100C and cooled to 37C before mixing with an equal volume of double strength 
growth medium pre-warmed to 37C.   
0.025% (v/v) Eosin solution 
0.5% (v/v) Eosin solution was diluted 1/20 in distilled water. 
10 x PBS/T 
80 g of NaCl, 2 g of KH2PO4, 29 g of Na2HPO4 and 2 g of KCl were dissolved in 800 
ml of distilled water.  5 ml of Tween 20 were added and followed by distilled water to a 
final volume of 1 litre.  The solution was aliquoted in 500 ml volumes, autoclaved and 
stored at room temperature. 
PTF buffer 
10 ml of  heat-inactivated FCS were added to 90 ml 1xPBS/T and stored at -20°C. 
NT buffer 
8.76 g of NaCl and 6.06 g of Trizma base were dissolved in 800 ml of distilled water 
and adjusted to pH 7.5 with concentrated HCl.  The solution was made up to 1 litre with 
distilled water, autoclaved and stored at 4°C.  
4-chloronapthol substrate 
4-chloronapthol substrate was freshly prepared by adding 30 μl of 30% (v/v) H2O2 to 50 
ml of NT buffer for the solution 1.  The solution 2 contained 30 mg of 4-chloronapthol 
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dissolved in 10 ml of cold methanol and two solutions were then mixed immediately 
prior to use. 
Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
This assay was performed as the quantitation of hRSV using fluorescent focus assay in 
section 3.4.5, except the addition of media after washing with HBSS.  Two hundred 
microlitres of 0.4% nutrient agarose overlay medium were added to each well and the 
culture plate was incubated at 37°C in 5% CO2 for 10 minutes at 4°C for gel 
solidification.  The plate was re-incubated at 37C with 5% CO2 in a moist box for 72 
hours.  After incubation, the media was discarded and the cells were fixed in 200 µl of 
cold 75% (v/v) acetone in PBS for 10 minutes at 4°C.  After fixation, the acetone was 
discarded and then 25 µl of mouse anti-hRSV MAb pool diluted to 1/5 in PTF buffer 
were added to each well.  The plate was incubated at 37°C for 1 hour in a moist box and 
then washed three times with 200 µl of 1x PBS/T. 
 
Twenty-five microlitres of polyclonal goat anti-mouse peroxidase conjugated 
immunoglobulin (NCL-GAMP) diluted to 1/1000 in PTF buffer were added into each 
well.  The plate was incubated at 37°C for 1 hour in a moist box and then washed with 
1x PBS/T as above.  One hundred microlitres of 4-chloronapthol substrate were added 
to each well and the plate was incubated at 37°C for 1 hour.  After incubation, the 
substrate was discarded and the plate was rinsed with tap water.  Forty microlitres of 
0.025% eosin were added to each well and left for approximately one minute.  The plate 
was then rinsed with distilled water, air dried at room temperature and the multicellular 
foci of infection were counted under the stereomicroscope.  The virus titre was 
calculated using the same formula as section 3.4.5.         
3.4.7 Enzyme Linked Immunosorbent Assay (ELISA) 
Materials 
Substrate buffer 
5.1 g of citric acid and 18.4 g of anhydrous Na2HPO4 were dissolved in 1 litre of 
distilled water and adjusted to pH 5.0.  The solution was aliquoted in 200 ml volumes, 
autoclaved and stored at room temperature.  
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62.5 mg/ml O-phenylendiamine dihydrochloride (OPD) stock solution 
1.25 g OPD were dissolved in 20 ml of substrate buffer, aliquoted of 0.4 ml volumes 
and stored at -20C. 
OPD substrate solution 
Immediately before use, 0.4 ml of OPD were thawed and mixed with 24.6 ml of 
substrate buffer and 10 μl of 30% (v/v) H2O2 solution. 
3 M H2SO4  
420 ml of distilled water were placed on ice and 80 ml of concentrated H2SO4 was 
slowly added to the water and mixed.  
Washing buffer (10x PBS containing 0.5% (v/v) Tween 20) 
160 g of NaCl, 4 g of KH2PO4, 23 g of anhydrous Na2HPO4 and 4 g of KCl were 
dissolved in 2 litres of distilled water and 10 ml of Tween 20 were added in the 
solution.  The pH was adjusted to 7.4 and the solution was autoclaved. 
Method 
A 96-well plate was seeded with HeLa cells as described in section 3.4.5.  Virus stocks 
were adjusted in cold MM to a final titre of 5 x 10
5
 FFU/ml and held on ice.   The GM 
was discarded from the cell culture plate and then 25 µl of each virus were inoculated 
onto HeLa monolayer.  Twenty-five microlitres of MM were added as negative controls.  
The plate was incubated at 37 °C under 5% CO2 for 1 hour in a moist box.  After 
incubation, the inocula were discarded and the wells were washed with 200 µl of 
Hanks’ balance salt solution (HBSS).  Two hundred microlitres of MM were added to 
each well and the culture plate was incubated at 37 °C in 5% CO2 for 18 hours in a 
moist box.   
 
After 18 hours, the MM was discarded and the cells were fixed with acetone/PBS as 
described in section 3.4.5.  Anti-F MAb 1E3 was serially four-fold diluted from 1/100 
to 1/102400 in PTF buffer and then 50 µl of each dilution were added to duplicate wells 
of each viral dilution and control.  The plate was incubated at 37C for 90 minutes in a 
moist box and then washed three times with 1x PBS/T at 3 minute interval.  Fifty five 
microlitres of polyclonal goat anti-mouse peroxidase conjugated immunoglobulin 
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(NCL-GAMP) diluted to 1/1000 in PTF buffer were added into each well.  The plate 
was incubated at 37°C for 1 hour in a moist box and then washed with 1x PBS/T as 
above.  After washing, 50 µl of OPD substrate solution was added to each well and 
incubated as above for 20 minutes.  The reaction was stopped by adding 50 µl of 3M 
H2SO4 in each well and the plate was read at an optical density of 492 nm using an 
MRX II Microplate reader (Dynex Technologies, UK). 
3.4.8 Quantitation of hRSV by the dilution end point method 
HeLa cell culture tubes were prepared as described in section 3.4.4 and ten-fold 
dilutions of virus samples, up to 10
-6
, were made in cold MM and held on ice.  The GM 
was discarded from 80 – 90% confluent tissue culture tubes.  Two hundred microlitres 
of each virus dilution were inoculated into triplicate cell culture tubes and 100 µl of 
MM were added to an additional tube as a negative control.  The tubes were then 
incubated in a roller drum at 37C for 1 hour.  After incubation, 800 µl of MM were 
added to each tube and tubes were incubated at 37C in a roller drum.  The cytopathic 
effect (CPE) was observed in each tube every day.  Using separate pipettes for each tube 
to ensure no cross-contamination, the media were replaced after 24 hours and every 48 
hours until all positive tubes exhibited 4+CPE.  Observation was terminated at 15 days 
postinoculation.  The endpoint dilution was calculated by the Reed-Muench method and 
expressed as TCID50/ml (Reed and Muench, 1938).  
3.4.9 Dilution endpoint neutralization assay 
Material 
1 mg/ml PZ stock 
PZ (Abbott Laboratories Ltd., Kent, UK) was prepared to a final concentration of 50 
mg/ml in distilled water according to the manufacturer’s instructions and then diluted 
1/50 with MM. 
Method 
HeLa cell culture tubes were prepared (section 3.4.4) and monolayers incubated until 
approximately 80% confluent.  PZ stock was serially four-fold diluted from 1/16 to 
1/4096 in cold MM.  The diluted PZ solutions were added to an equal volume of MM 
containing approximately 100 TCID50 (50% tissue culture infective dose) of the virus 
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under test in a clean 96-well round bottom plate.  The plate was incubated at 37°C under 
5% CO2 for 1 hour in a moist box.  After incubation, 240 µl of the virus/PZ mixture was 
inoculated onto triplicate cell culture tubes and the MM was added to an additional tube 
as a negative control.  The tubes were then incubated in a roller drum at 37C.  After 1 
hour, 800 µl of MM was added to each tube and tubes were then re-incubated at 37C in 
a roller drum.  The CPE in each tube was observed every day and the media were 
replaced after 24 hours and every 48 hours until 15 days.  This assay was performed 
three times for each virus and the neutralization titres were calculated by the Reed-
Muench method (Reed and Muench, 1938). 
3.4.10 Focus reduction neutralization assay  
Mock neutralization assay  
For each virus under test, a mock neutralization assay was performed to establish a viral 
working dilution for use in a focus neutralization assay.  A 96-well plate was seeded 
with Vero or HeLa cells as described in section 3.4.5.  Five-fold dilutions of virus stock 
were prepared in cold MM from 1/5 to 1/625.   In a clean 96-well round bottom plate, 
50 µl of MM were added to each well to mimic antibody and 50 µl of each virus 
dilution were added.  100 µl of MM were added to a further well as a negative control.  
The plate was incubated at 37 °C under 5% CO2 for 1 hour in a moist box.  After 
incubation, the GM was discarded from the 96-well tissue culture plate containing 
confluent cells.  25 µl of virus/MM mixtures were inoculated onto triplicate wells of 
tissue culture plate and the culture plate was incubated at 37 °C under 5% CO2 for 1 
hour in a moist box.  The inocula were removed and the cells were washed with 200 µl 
of HBSS.  For assays to be read at 18 hours, two hundred microlitres of MM were 
added in each well.  For the plates to be read at 24 to 72 hours, 200 µl of 0.4% nutrient 
agarose overlay medium (section 3.4.6) was added to each well and the plate was 
incubated for 10 minutes at 4°C for gel solidification.  The plate was re-incubated at 
37C with 5% CO2 in a moist box for the requisite time (24 to 72 hours), then fixed and  
stained either for immunofluorescent foci (section 3.4.5) or immunoperoxidase foci 
(section 3.4.6).  The number of foci determined as described in section 3.4.5.  Virus 
dilutions, which gave a focus number between 40 and 160 FFU per well, were used in 
the focus neutralization assay. 
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Neutralization assay  
A 96-well plate was seeded with HeLa or Vero cells as described in section 3.4.5.  
Serial four-fold dilutions of PZ were prepared in cold MM from 1/4 to 1/4096 and held 
on ice.  Virus stock was diluted in cold MM to contain 40 – 160 FFU/25 μl as 
determined by the mock neutralization test (see above).  Fifty microlitres of virus 
dilution were then mixed with 50 μl of each PZ dilution in a clean 96-well round bottom 
plate.  For a virus control, 50 μl of virus dilution were mixed with 50 μl of MM and 100 
μl of MM were added to a further well as a negative control.  The plate was incubated at 
37 °C under 5% CO2 for 1 hour in a moist box.  After incubation, the GM was discarded 
from the 96-well plate tissue culture plate containing confluent cells prepared as 
described in section 3.4.5.  Twenty-five microlitres of each virus/PZ mixture and 
controls in the 96-well round bottom plate were inoculated onto the triplicate wells of 
tissue culture plate.  Thereafter, the plate was cultured and stained as described for the 
mock neutralization test above.  The 50% effective concentration (EC50) of PZ for each 
virus was that antibody concentration reducing the virus focus count by 50% compared 
to the virus control and was calculated using a nonlinear regression equation with the 
Prism
TM
 Graphpad programme.  Comparison of neutralization among virus clones was 
compared by two-way ANOVA. 
3.4.11 Focus inhibition assay for the endocytosis inhibitors 
Trypan blue exclusion test of cell viability for endocytosis inhibitors  
Materials 
0.4% (v/v) trypan blue 
Trypan blue stock (10%) was diluted in sterile PBS to a final concentration of 0.4%. 
Monodansylcadaverine (MDC) stock 
Monodansylcadaverine stock was freshly prepared by dissolving 600 µg MDC in 50 µl 
DMSO and adding MM to a final concentration of 1 mM.  
Chlorpromazine (CP) stock 
Chlorpromazine stock was freshly prepared by dissolving 800 µg CP in 50µl DMSO 
and adding MM to a final concentration of 40 µg/ml. 
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Method 
A 96-well plate was seeded with HeLa cells as describe in section 3.4.5.  For the MDC 
test, the MDC stock was diluted to 150, 100, 75, 50 and 25 µM with MM.  The GM was 
removed from the plate and 100 µl of the diluted MDC solutions were added into each 
well.  In a control well, 100 µl of MM were added and the plate was incubated at 37 °C 
under 5% CO2 in a moist box for 2 hours.  After incubation, the MDC solutions were 
discarded and the wells were washed with 200 µl of Hanks’ balance salt solution 
(BioWhittaker, Cambrex BioScience Verviers, Belgium).  Then, 150 µl of 0.4% nutrient 
agarose (section 3.4.6) containing the MDC solutions at concentrations corresponding 
to those above were added into each well.  The plate was incubated for 10 minutes at 
4°C for gel solidification and then re-incubated at 37C with 5% CO2 in a moist box for 
72 hours.  For the CP test, the CP stock was diluted with MM to 20, 15, 10, 5 and 2.5 
µg/ml.  After discarding the GM, 100 µl of the diluted CP solutions were each added in 
a well and 100 µl of MM were added to a control well.  The plate was incubated at 37C 
with 5% CO2 in a moist box for 6 hours and washed as above.  After washing, 200 µl of 
MM was added to each well and the plate was then re-incubated at 37C with 5% CO2 
in a moist box for up to 72 hours. 
 
After 72 hours, the media in both tests were discarded from the plate and washed twice 
with PBS.  Twenty five microlitres of versene solution were added into each well and 
incubated at 37C for 5-10 minutes until the cells were dissociated.  The cells were re-
suspended in 25 µl of PBS and 10 µl of cell suspension were mixed with 10 µl of 0.4% 
trypan blue.  Cell/trypan blue mixture was incubated for 3 minutes at room temperature. 
One drop of mixture was applied to an improved Neubauer hemocytometer and the 
unstained (viable cell) and stained (nonviable) cells were separately counted.  The 
percentage of viable cell was calculated using the following formula:  
% cell viability = (the number of viable cells/ total number of cells) x 100 
The 50% cytotoxic concentration (CC50) of endocytosis inhibitors was that the 
concentration reducing the cell viability by 50% and was calculated using a nonlinear 
regression equation with the Prism
TM
 Graphpad programme. 
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Focus inhibition assay using the endocytosis inhibitors 
A 96-well plate was seeded with HeLa cells (section 3.4.5) and the endocytosis 
inhibitors (MDC and CP) were diluted at concentrations which were found to be non-
toxic for the cells (see above).  The cells were treated with each inhibitor (100 µl/well) 
in triplicate wells for 1 hour at 37°C under 5% CO2 in a moist box.   The virus stock was 
diluted in MM to contain 40 – 160 FFU/25 μl as determined by a mock neutralization 
assay (see section 3.4.10).  After 1 hour treatment, 50 µl of each inhibitor was mixed 
with 50 µl of diluted virus in a clean 96-well round bottom plate.  For a virus control, 50 
μl of each virus dilution was  mixed with 50 μl of MM and 100 μl of MM were added to 
a further well as a negative control.  Twenty-five microlitres of each virus/inhibitor 
mixture and controls in the 96-well round bottom plate were inoculated onto the 
triplicate wells of tissue culture plate in the same concentration of inhibitors treated.  
 
After inoculation, the plate for MDC test was incubated at 37°C under 5% CO2 for 1 
hour and the inocula were removed from tissue culture plate after incubation.  The cells 
were washed with 200 µl of HBSS and 200 µl of 0.4% nutrient agarose overlay medium 
(section 3.4.6) containing the MDC at concentrations corresponding to those in the 
inoculum were added to each well.  The plate was incubated for 10 minutes at 4°C for 
gel solidification and then incubated at 37C with 5% CO2 in a moist box for 72 hours.  
For the CP test, the plate was incubated for 5 hours at 37 °C under 5% CO2 after 
inoculation.  The inocula were discarded and the wells were washed with 200 µl of 
HBSS.  Two hundred microlitres of 0.4% nutrient agarose overlay medium (section 
3.4.6) without the CP were added to each well and the culture plate was incubated at 37 
°C in 5% CO2 for 72 hours.  Following incubation, all plates were fixed, stained and the 
number of foci in each well was determined as described in section 3.4.6.  The 50% 
effective concentration (EC50) for each drug, that concentration which reduced the focus 
count by 50% when compared to the virus controls, was determined by nonlinear 
regression equation using the Prism
TM
 Graphpad programme.  Comparison of inhibition 
among virus clones was compared by two-way ANOVA. 
3.4.12 Focus inhibition assay for the antiviral agents directed against the F 
glycoprotein 
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Materials 
R17532-Heptad repeat 2 (HR2) peptide 
- Peptide formulation  
The hRSV inhibitory HR2 peptide was formulated based upon the study of Lambert et 
al. (1996) (see section 1.10.1) in which the HR2 domain was identified in the F 
glycoprotein of the hRSV Long strain with a computer search strategy recognizing 
sequences predicted to form helical structures in fusogenic viral proteins.  The amino 
acid sequence of the R17532 strain F glycoprotein was identical to that of the Long 
strain in this region, except at residue 518 which was A in the Long strain, but V in  
both R17532 clones R11 and R3 (Gias, 2006).  Therefore, the sequence of the peptide 
used in this study, R17532-HR2, was  
“FDASISQVNEKINQSLAFIRKSDELLHNVNVGKST”. 
- Peptide synthesis 
The R17532-HR2 peptide was manufactured as lyophilized crude peptides by 
GenScript, New Jersey, USA.  It was modified with acetylation at N-terminus and 
amidation at C-terminus to enhance biological half-life (Powell, 1993).  
- Peptide preparation  
4 mg of the peptide were dissolved in 100 µl DMSO and diluted with distilled water to a 
final concentration of 1 mM.  Diluted solution was aliquoted in 100 µl volumes and 
stored at -80 °C. 
The BTA9881 and BMS-433771 stocks 
The BTA9881 was kindly supplied by Laura Wood (Biota Holdings Limited, Notting 
Hill, Australia) and BMS-433771 was kindly provided by Mark Krystal (Bristol-Myers 
Squibb, Wallingford, USA).  The BTA9881 and BMS-433771 were prepared by 
dissolving in 100 µl DMSO and diluted with distilled water to a final concentration of 2 
mM.  Stock solutions were aliquoted in 100 µl volumes and stored at -80 °C. 
Methods 
The HR2 peptide and BTA9881 were diluted to 80, 20, 5, 1.25, 0.312 and 0.078 µM in 
MM and the BMS-433771 was diluted to 20, 5, 1.25, 0.312, 0.078 and 0.0195 µM.  The 
assay was carried out as for the focus reduction neutralization assay and read at 72 
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hours as described in section 3.4.10, except that virus/PZ mixture was immediately 
added to HeLa cell monolayers without a 1 hour pre-incubation and the antiviral agents 
at concentrations corresponding to those in the inocula were incorporated in the nutrient 
agarose overlay medium.  The immunoperoxidase method was used to stain the plate as 
described in section 3.4.6.  The 50% effective concentration (EC50) was calculated as 
described in section 3.4.10. 
3.4.13 Virus purification methods by iodixanol density gradients ultracentrifugation 
This protocol for purification of hRSV by ultracentrifugation in iodixanol density 
gradient was performed as described by Gias et al. (2008). 
Materials 
500 mM Tris-HCL  
30.29 g of Tris base (Melford, Suffolk, UK) were dissolved in distilled water and the 
pH was adjusted to 7.5 with concentrated HCl.  The buffer was made up to a final 
volume of 500 ml with distilled water, autoclaved and stored at 4C. 
1 M MgSO4 solution  
24.65 g of MgSO4.7H2O were dissolved in 100 ml distilled water, autoclaved and stored 
at 4C. 
0.25 M Sucrose solution  
8.56 g of sucrose were dissolved in 100 ml distilled water, sterilized by filtering through 
0.22 µm filter (Corning Incorporated, USA) and stored at 4C. 
50% (w/v) PEG 6000  
250 g of PEG 6000 were dissolved in 40 ml of NT buffer (prepared in section 3.4.6) in a 
56C water bath, brought to a final volume of 500 ml, sterilized by filtering through 
0.22 µm filter and stored at 4C. 
OptiPrep
TM
 iodixanol solution  
Iodixanol solution was supplied as a 60% (w/v) solution by Axis-Shield PoC AS, Oslo, 
Norway and was wrapped in aluminium foil and stored at 4C. 
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0.5 M EDTA 
93.06 g of EDTA and 10 g NaOH were dissolved in 350 ml distilled water and the pH 
was adjusted to 8.0 with NaOH.  The solution was made up to a final volume of 500 ml, 
autoclaved and stored at room temperature. 
Methods 
Clarification of virus clone stocks 
Virus cell lysate was harvested at 4+ CPE from 225 cm
3
 flasks (see section 3.4.3) and 
aliquoted in 25 ml volumes.  Lysate were then sonicated on ice using a SANYO MSE 
Soniprep sonicator at amplitude of 5 microns for 1 minute repeated three times with a 1 
minute rest between each.  Sonicated virus material was then pooled together and 
centrifuged in sterile 50 ml centrifuge tubes in a MSE Coolspin centrifuge at 3,250 g 
(4,000 rpm) for 20 minutes at 4C.  The clarified viral supernatants were transferred to a 
sterile 250 ml Schott bottle and 500 µl of supernatant were taken for subsequent 
infectious focus and neutralization assays.  The clarified viral supernatant was then 
adjusted to 0.1 M MgSO4 and 50 mM Tris-HCl (pH 7.5) (Fernie and Gerin, 1980). 
PEG precipitation 
50% (w/v) PEG 6000 was added to the clarified viral supernatant to a final 
concentration of 10% (v/v) and allowed to precipitate overnight at 4C with moderate 
stirring.  After overnight precipitation, the PEG solution was centrifuged at 3,250 g  
(4,000 rpm) for 20 minutes at 4C in a MSE Coolspin centrifuge.  The supernatant was 
carefully removed and the pellet was re-centrifuged as above.  The pellet was then re-
suspended in 1 ml of cold NT and held on ice.  1 M MgSO4 was added to the PEG viral 
suspension to a final concentration of 100 mM MgSO4.  The suspension was collected 
in 10 µl volumes and combined with EDTA to a final concentration of 1 mM EDTA 
and infectivity was quantified by the immunoperoxidase focus assay (section 3.4.6).  
Rate zonal ultracentrifugation: discontinuous iodixanol density gradient 
Gradient medium containing 20%, 36% and 52% (v/v) of iodixanol, 10 mM Tris-HCl 
pH 7.5, 100 mM MgSO4 and 0.25 M sucrose added up to 10 ml were individually 
prepared as described in Table 3.3.  
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Table 3.3: Preparation of gradient medium for discontinuous iodixanol density gradient 
 
Solution 
Gradient medium with Iodixanol 
20% 36% 52% 
60% iodixanol 3.30 ml 6.00 ml 8.70 ml 
500 mM Tris-HCl pH 7.5 0.20 ml 0.20 ml 0.20 ml 
1 M MgSO4 1.00 ml 1.00 ml 1.00 ml 
0.25 M sucrose 5.50 ml 2.80 ml 0.10 ml 
Total volume 10.00 ml 10.00 ml 10.00 ml 
 
Two discontinuous gradients were immediately prepared in 14 ml Ultraclear centrifuge 
tubes (Beckman, USA) before use by sequentially adding 4 ml of 52%, 36% and 20% 
iodixanol medium.  The PEG-concentrated virus sample was then added on the top of 
each gradient in equal volumes (approximately 0.5 ml each).  The gradients were 
centrifuged in a SW-40 rotor for 90 minutes at 154,693 g (35,000 rpm) at 4C.  After 
centrifugation, visible virus bands locating the interface between the 20% and 36% 
iodixanol medium were collected from each gradient using pipette tips and held on ice.  
The fraction samples containing 1mM EDTA were carried out the immunoperoxidase 
focus assay as described in section 3.4.6. 
Buoyant density ultracentrifugation: continuous iodixanol density gradient 
Gradient medium containing 20%, 32%, 42% and 52% (v/v) of iodixanol, 10 mM Tris-
HCl pH 7.5, 100 mM MgSO4 and 0.25 M sucrose added up to 9 ml were individually 
prepared as described in Table 3.4.  
 
Table 3.4: Preparation of gradient medium for continuous iodixanol density gradient 
 
Solution 
Gradient medium with Iodixanol 
20% 32% 42% 52% 
60% iodixanol 3.00 ml 4.80 ml 6.30 ml 7.80 ml 
500 mM Tris-HCl pH 7.5 0.18 ml 0.18 ml 0.18 ml 0.18 ml 
1 M MgSO4 0.90 ml 0.90 ml 0.90 ml 0.90 ml 
0.25 M sucrose 4.92 ml 3.12 ml 1.62 ml 0.12 ml 
Total volume 9.00 ml 9.00 ml 9.00 ml 9.00 ml 
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Two continuous gradients were prepared in 14 ml Ultraclear centrifuge tubes (Beckman, 
USA) by sequentially layering 4 ml of 52%, 42%, 32% and 20% iodixanol medium.  
The tubes were wrapped in aluminium foil and stored overnight at 4C to allow the 
gradient to diffuse.  The virus bands collected from each discontinuous gradient were 
diluted 1/2 in cold NT buffer containing 100 mM MgSO4 and layered on the top of each 
continuous gradient.  The gradients were centrifuged in a SW-40 rotor for 18 hours at 
154,693 g (35,000 rpm) at 4C.  After 18 hours, the gradient fractions were harvested in 
approximately 700 μl volumes and the density was measured using a refractometer 
(ATACO, USA).  Each fraction was aliquoted in 200 µl volumes for RNA extraction 
and the rest aliquoted for virus assay.  All fractions were snap-frozen in liquid nitrogen 
and stored at -80 C.  The fraction samples with 1 mM EDTA were subsequently used 
in immunoperoxidase focus assay and neutralization assay.  
3.5 DNA analysis methods 
3.5.1  RNA extraction   
Total RNA extraction from hRSV virus stock 
Total RNA was extracted from infected cells using the RNeasy Mini Kit (QIAGEN, 
Crawley, W. Sussex, UK) according to the manufacturer’s instructions.  The RNA was 
eluted in the DEPC treated water and stored at -20C or used immediately.  The amount 
of RNA was determined using a ND-1000 Nanodrop spectrophotometer (NanoDrop 
products, Wilmington).   
RNA extraction from purified hRSV virus 
Two hundred microlitres of iodixanol gradient fractions containing purified virus 
(section 3.4.13) were thawed rapidly at 37C.  RNA extraction was carried out using 
QIAamp
® 
MinElute Virus Spin Kit (QIAGEN, Crawley, W. Sussex, UK) according to 
manufacturer’s instruction. Carrier RNA in the kit reagent precluded direct 
determination of the concentration of hRSV RNA recovered. 
3.5.2  Reverse transcription (RT) 
Reverse transcription was carried out in 20 μl volumes containing 0.5 – 1 μg RNA (or 
10 µl of RNA from purified virus), 1 mM dNTPs (Thermo Scientific Fermentas, UK), 
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20 pmol RT primer (Table 3.5 and 3.6), 20 units RNasin ribonuclease inhibitor 
(Promega, Madison, UK), 1x RevertAid
TM
 H Minus M-MuLV reverse transcription 
buffer, 200 units RevertAid
TM
 H Minus M-MuLV Reverse transcriptase (Thermo 
Scientific Fermentas, UK) and DEPC-treated water.  Synthesis of cDNA was carried 
out in a PTC-200 Thermal Cycler (MJ Research, now Bio-Rad, Hemel Hempstead, UK) 
at 42°C for 60 minutes and 70°C for 10 minutes.  The reaction was then cooled at 4°C 
and either used immediately or stored at -20°C.  
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Table 3.5: Sequences and sources of primers. 
 
Name Sequence (5’3’) Nucleotide Source† 
NS1 CGCGAAAAAATGCGTACAAC 2-20 In house 
NS1.1 ATTTTTTTGGTTTACGCAAGTTTG 44-21 In house 
NS1-26 CCAAAGGAGTTGAATTTAAGTGG 92-70 In house 
NS1-103 CAATGCTACTTCATCATTGTCAAA 170-147 In house 
NS1-134 TCAATTTGTCAGTATAGCAGGTTA 201-178 In house 
NS1end CTGCCTTAGCCAAAGCATTA 231-212 In house 
NS1-206 GCACAAATACAATGCCATTCA 270-250 In house 
NS1-442 TCTGAATTACTTGGATTTGATCTTAA 486-511 In house 
NS2-358 AGCCTACAAAGCATACTCCCATAA 953-976 In house 
NS2-468 TACTATAATTTTCAGGCTCCATCTGGAC 1,090-1,063 In house 
NP1674 CTTACAGCCGTGATTAGGAGAGC 1,674-1,696 In house 
N713 CTTCAACTCTACTGCCACCTCTGG 1,860-1,837 In house 
P2128 GCCTAGGCATAATGGGAGAGTA 2,128-2,149 In house 
P162 TATAGGGCTTTCTTTGGTTACTTC 2,513-2,490 In house 
PS3 CAGACAAACGATAATATAACAGCAAGAT 2,720-2,748 In house 
PS4 TCTTTTGCCATCTTTTCACTTTCCTCAT 2,971-2,944 In house 
P3459 CCTTGGGTGTGGATATTTGTTTC 3,459-3,437 In house 
M1 GCCAA[A/C]AAAACAAC[C/T]AGCCAATCC 3,174-3,197 (Gias, 2006) 
M2 GTGTAAAGTAAGGCCAGAATTTGCTTGAG 4,360-4,332 (Gias, 2006) 
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Name Sequence (5’3’) Nucleotide Source† 
SH+ CAGCTACACG[A/T]TTT[G/T]CAATCAAAC 3,994-4,017 (Marsh, 2002) 
SH- GTTGAGATTATCATTGCC 4,842-4,825 (Marsh, 2002) 
SH292 TGATGGCTCAAAACAGTAACCT  4,510-4,531 In house 
G713 TTTTGGTGGTGTTGATGGTTGGCT 5,408-5,385 In house 
GC1 GCAGCATATGCAGCAACA 5,205-5,222 (Roca et al., 2001) 
G886 TCTCCATCCAACATAACAAACCTG 5,558-5,581 In house 
F164 GTTATGACACTGGTATACCAACC 5,855-5,833 
(Sullender et al., 
1993) 
F400 CTTGTTTGTGGATAGTAGAGC 6,188-6,168 (Marsh, 2002) 
F1000 GCAGAGATTTACTTCACTTGG 6,806-6,786 (Marsh, 2002) 
ALW1 ATAACCATGGAGTTGC[C/T][A/G]ATCC 5,655-5,676 (Connor, 1998) 
A2R2 TAGTGTCTTAACCAGCAAAG 6,215-6,234 (Connor, 1998) 
A2R3 GTGACACAATGAACAGTTTA 6,760-6,779 (Connor, 1998) 
ALW2 TTGCAAGGATTCCTTCGTGAC 7,668-7,628 (Connor, 1998) 
M2F TTACAATGGTTTACTATCTGCTCA 7,411-7,434 In house 
M2R GTTCTATTAATGGATTTTGTCTAC 8,669-8,646 In house 
M2-848 ACACTCACCACATCGTTAC 8,444-8,462 In house 
L589 TGTGTTCGATGCAACATCCT 9,078-9,097 In house 
L662 CCTCATTTGATCGATACTGTGTT 9,173-9,151 In house 
L716 TTGGAATCCATTGAGAGTATGA 9,226-9,205 In house 
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Name Sequence (5’3’) Nucleotide Source† 
L1307 TGGCTTGTCTTTCATCTACC 9,796-9,815 In house 
L1116 AAAGCTCAGAAAAATCTGCTATCAA 9,605-9,629 In house 
L2337 TTTTGACACCACCCTTCGAT 10,845-10,826 In house 
L3-1 CTCAGCAAATTCAATCAAGCA 10,598-10,618 In house 
L3-2 CCTCATCATCTCAGTGGCTCT 12,007-11,987 In house 
L3-3 GAGGTGAAAGTCTATTATGCAGTTTA 11,250-11,275 In house 
L3-4 GGGATCACCACCACCAAATA 11,467-11,448 In house 
L4-1 GCAAAATATAGAACCTACATATCCTCA 11,830-11,856 In house 
L4-2 CCCTCTCCCCAATCTTTTTC 13,059-13,040 In house 
L5-1 CACTCAAATCTGGATCTCATGTTA 12,891-12,914 In house 
L5-2 GGGTTTAAATTTATTCCTCCAAGA 15,153-15,130 In house 
L5-3 ACAGACAATTCGGCATCACA 14,319-14,300 In house 
L5-4 TGAGTTTTTAAGGCTGTACAATGG 14,161-14,184 In house 
L5-5 AGATCTTGTTAGAATGGGATTGAT 13,426-13,449 In house 
L5-6 TTCAGAATTAGCAATCCTTATATGTTT 13,588-13,562 In house 
L5-7 GACCATTCCCGCTACAGATG 14,215-14,234 In house 
L5-8 TGTTAGTGTGTAGATGTGGGAATTT 15,041-15,017 In house 
L5-8R AAATTCCCACATCTACACACTAACA 15,017-15,041 In house 
L5-9 ACGAGAAAAAAAGTGCAAAAACT 15,222-15,199 In house 
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Name Sequence (5’3’) Nucleotide Source† 
Lend CATCTTAAAGTGGTTCAATCATGT 14,812-14,825 In house 
L5-2R TCTAGGAGGTATAAATTTAAATCC 15,130-15,153 In house 
Adaptor 
DT88 
GAAGAGAAGGTGGAAATGGCGTTTTGG 
(Modification: 5’-Phosphate & 2’,3’dideoxyC) 
- (Li et al., 2005) 
DT89 CCAAAACGCCATTTCCACCTTCTCTTC - (Li et al., 2005) 
Modified 
DT89 
CCAAAACGCCATTTCCAC - 
Modified from 
(Li et al., 2005) 
 
Nucleotide numbering is based on hRSV A2 genome, GenBank accession number M74568. 
†Primers were designed according to the guidelines described in Dieffenbach and Dveksler (2003) and  
using the Pimer3 program (Rozen and Skaletsky, 2000).  All primers were manufactured by Sigma-
Aldrich (Poole, UK) or Eurofins MWG Operon (Ebersber, Germany).  Freeze dried primers were re-
suspended in DEPC-treated water to a final concentration of 100 µM and 30 µM of working primer 
solutions was prepared in DEPC-treated water. 
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Table 3.6: Summary of RT- PCR and sequencing primers. 
 
Gene
 
RT primer PCR primer pair PCR product size 
Sequencing 
primer 
NS1 
NS1-NS2 IR
a
 
NS2 
NS1 NS1: NS2-468 1,089nt 
NS1, NS1-134, 
NS2-468 
NS1-NS2 IR 
NS2 
NS2-N IR 
N 
NS1-442 NS1-442: N713 1,375nt 
NS1-442, NS2-358, 
N713 
N 
N-P IR 
NP1674 NP1674: P162 840nt NP1674, P162 
M 
M-SH IR 
M1 M1: M2 1,184nt M1, M2 
M-SH IR 
SH 
SH-G IR 
SH+ SH+: SH- 849nt SH+, SH- 
N-P IR 
P 
P-M IR 
P2128 P2128: P3459 1,332nt 
P2128, P3459, PS3, 
PS4, 
SH-G IR 
G 
G-F IR 
SH292 SH292: F164 1,326nt 
SH292, GC1, 
G713, F164 
G-F IR 
F 
G886 G886: F1000 1,249nt 
G886, F400, 
A2R2,F1000 
F 
F-M2 IR 
G886 A2R3: ALW2 869nt A2R3, ALW2 
F-M2 IR 
M2 
M2F M2F: M2R 1,259nt M2F, M2R 
M2, LF1
b 
M2-848 M2-848 : L1307 1,372nt 
M2-848, L1307, 
L589, L662, L716 
LF2 M2-848 L1116: L2337 1,241nt L1116, L2337 
LF3 M2-848 L3-1: L3-2 1,410nt 
L3-1, L3-2, L3-3, 
L3-4 
LF4 L4 L4-1: L4-2 1,230nt L4-1, L4-2 
LF5.1 L5-1 L5-1: L5-3 1,429nt 
L5-1, L5-3, L5-5, 
L5-6 
LF5.2 L5-1 L5-4: L5-2 993nt L5-4, L5-2 
LF5.2 L5-1 
L5-7: L5-8 
(Nested primers for R5.3, 
R5.14, ) 
827nt L5-7, L5-8 
LF5.2 L5-1 
L5-8R: L5-9 
(Used only with R3) 
206nt L5-8R, L5-9 
 
a
IR: Intergenic regions; 
b
 L gene was separated into 6 fragments as follows; LF1 (nt 8,444 to nt 9,815), 
LF2 (nt 9,605 to nt 10,845), LF3 (nt 10,598 to nt 12,007), LF4 (nt 11,830 to nt 13,059), LF5.1 (nt 12,891 
to nt 14,319) and LF5.2 (nt 14,161 to nt 15,153) including  5’ terminal sequence. 
 102 
 
1
0
2
 
3.5.3  Polymerase Chain Reaction (PCR) 
PCR reactions were carried out in 100 μl volumes containing 4 μl of cDNA, 5 mM of 
MgCl2, 1x ImmoBuffer, 0.25 mM mixture of dATP, dCTP and dGTP, 0.5 mM dUTP, 
0.3 μM of each forward and reverse primer (Table 3.5 and 3.6), 5 units of 
IMMOLASE™ DNA polymerase and DEPC-treated distilled water.  PCR was carried 
out in a PTC-200 Thermal Cycler (MJ Research, now Bio-Rad, Hemel Hempstead, UK) 
with the following conditions: an initial denaturation at 95°C for 10 minutes, followed 
by 35 cycles of reactions consisting of a denaturation step at 95°C for 1 minute, an 
annealing step at 55°C for 30 seconds and an elongation step at 72°C for 2 minutes and 
a final elongation at 72°C for 7 minutes.  The reaction was then cooled at 4°C and either 
used immediately or stored at -20°C.  The PCR amplification of all hRSV genes was 
conducted using the reaction and condition as above, except PCR using N1674:P162 
and NS1-442: N713 primer pair.  The first primer pair was carried out at annealing 
temperature of 50°C.  Reactions with the latter primer pair were performed with 3.75 
mM MgCl2 and an annealing temperature of 60°C.   
3.5.4 Genomic RNA circularization for determination of the 5’and 3’terminal 
sequences of the hRSV genome 
Genomic RNA circularization protocols were modified from Krempl et al. (2005) as 
shown in Figure 3.1.  All primers utilised were presented in Table 3.5 and 3.7.  The 
circularization of RNA genome was performed in a reaction mix containing 1 µg of 
total RNA extracted from virus stock or 10 µl of viral RNA isolated from purified virus 
(section 3.5.1), 1x T4 RNA ligase buffer, 10 units of T4 RNA ligase (Ambion, Life 
Technologies Ltd, Paisley, UK) and DEPC treated water to a final volume of 20 µl.  The 
reaction mixtures were incubated overnight at 4°C for RNA circularization and cDNA 
synthesis was then performed as described in section 3.5.2 using the Lend primer that 
bound to the position near the end of L gene.  This was followed by the first round of a 
nested PCR reaction carried out as described in section 3.5.3 using Lend:NS1end.  
Three alternative sets of primers were used for the second round as follows: L5-8R: 
NS1-134, L5-2R:NS1-26 or L5-2R:NS1.1.  
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Table 3.7: Summary of RT- PCR and sequencing primers for determination of the 5’ and 3’ 
terminal sequences. 
 
Procedure
 
RT primer 
1
st
 round PCR primers 
(PCR product size) 
2
nd
 round PCR and 
sequencing primers 
 (PCR product size) 
Genomic RNA 
circularization 
Lend Lend:NS1end (642nt) 
L5-8R:NS1-134 (383nt) 
L5-2R:NS1-26 (185nt) 
L5-2R:NS1.1 (137nt) 
5’RACE L5-8R L5-8R:DT89 (233nt) L5-2R:DT89 (120nt) 
3’RACE from the 
anti-genome 
NS1-206 
NS1-206:modified DT89 
(297nt) 
NS1-103:modified DT89 
(197nt) 
3’RACE from the 
genome 
DT89 
modified DT89:NS1-206 
(297nt) 
modified DT89:NS1-103 
(197nt) 
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Figure 3.1: Schematic diagram for genomic RNA circularization procedure.  
The viral RNA genome oriented 3’ to 5’ was circularized using T4 RNA ligase, followed by cDNA 
synthesis using the Lend primer.  After cDNA containing 3’-5’-ligated RNA end production, two rounds 
of PCR amplification were conducted using the Lend: NS1end primer pair for the first round PCR and the 
L5-8R: NS1-134 primer pair for the second round.  The RNA genome is indicated by a wavy line; cDNA 
and PCR products are straight lines; 3’end is a black box; 5’end is a grey box and primers are arrows. 
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3.5.5 5’ Rapid amplification of cDNA ends (5’RACE) from the hRSV anti-genome 
5’RACE was performed following Figure 3.2 using procedures based upon those 
described by Tillett et al. (2000) and Li et al. (2005).  All primers used in these methods 
are shown in Table 3.5 and 3.7.  The cDNA was synthesized from 1 µg of total RNA or 
10 µl of viral RNA (section 3.5.1) using the L5-8R primer by reverse transcription 
(section 3.5.2) followed by treatment with 2 units of RNase H (Thermo Scientific 
Fermentas, UK) at 37°C for 20 minutes.  The resulting cDNA was purified using a 
GeneJET
TM
 PCR purification kit (Thermo Scientific Fermentas, UK) according to the 
manufacturer’s instructions and then ligated with the adaptor DT88 overnight at room 
temperature using 10 µl of cDNA, 0.4 µM of adaptor DT88, 1x T4 RNA ligase buffer, 3 
units of T4 RNA ligase (Ambion, Life Technologies Ltd, Paisley, UK) and DEPC 
treated water to a final volume of 13 µl.  Another ligation reaction without T4 RNA 
ligase was carried out as a negative control.  
 
The adaptor-ligated cDNA was then subjected to two hemi-nested rounds of PCR 
amplification.  The first and second round PCRs were performed using the virus-
specific primers (L5-8R and L5-2R primers used for 1
st
 and 2
nd
 round PCR, 
respectively) and the DT89 primer, complementary with the adaptor DT88 for both 
rounds, in a PTC-200 Thermal Cycler (MJ Research, now Bio-Rad, Hemel Hempstead, 
UK) with reaction mixes as described in Table 3.8 and with the following conditions: 
95°C for 10 minutes, followed by 35 cycles of 95°C for 20 seconds, 55°C for 20 
seconds, 72°C for 30 seconds and a final elongation at 72°C for 7 minutes.  
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Figure 3.2: Schematic diagram for 5’RACE procedure from the hRSV anti-genome. 
[Modified from original by Hsieh et al. (1997) and Li et al. (2005)]  
The cDNA synthesis was first synthesized from the virus genome using the L5-8R primer.  The cDNA 
was then treated with RNaseH, followed by ligation to adaptor DT88 using T4 RNA ligase.  Then, a first 
round PCR was carried out using the L5-8R primer and the DT89 primer, complementary to the adaptor 
DT88, followed by a hemi-nested second round PCR using the L5-2R and DT89 primers.  The RNA 
genome is indicated by a wavy line; cDNA and PCR products are straight lines; adaptors are black boxes; 
primers are arrows. 
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Table 3.8: PCR Reaction for 5’RACE procedure. 
 
Procedure  PCR reaction  
 
1
st
 round PCR  
 
0.8 M L5-8R 
0.8 M DT89 
5 mM MgCl2 
250 M dNTPs mix 
1.25 U IMMOLASE™ DNA polymerase 
1x ImmoBuffer 
4 µl cDNA 
 
2
nd
 round  PCR 
 
0.8 M L5-2R  
0.8 M DT89 
5 mM MgCl2  
250 M dNTPs mix 
1.25 U IMMOLASE™ DNA polymerase 
1x ImmoBuffer  
4 µl 1:100 diluted 1
st
 round PCR product 
 
2
nd
 round  PCR 
after optimization 
 
0.3 M L5-2R  
0.3 M DT89 
7.5 mM MgCl2  
250 M dNTPs mix 
1.25U IMMOLASE™ DNA polymerase 
1x ImmoBuffer  
4 µl 1:100 diluted 1
st
 round PCR product 
 
        
DEPC treated water was added in all procedures to a final volume of 100 µl. 
3.5.6 3’Rapid amplification of cDNA ends (3’RACE) from the hRSV anti- genome  
The procedure for 3’RACE (Figure 3.3) was modified from a protocol based on that of 
Li et al. (2005) and all primers used in this method are presented in Table 3.5 and 3.7.  
Antigenome cDNA was synthesized from 1 µg of total RNA or 10 µl of viral RNA 
(section 3.5.1) using the NS206 primer by reverse transcription (section 3.5.2) and the 
cDNA was then treated with RNase H (Thermo Scientific Fermentas, UK) as described 
in section 3.5.5.  The adaptor DT88 was ligated to the cDNA overnight at room 
temperature after purification using the GeneJET
TM
 PCR purification kit (Thermo 
Scientific Fermentas, UK).  Ligation reaction contained 10 µl of cDNA, 0.4 µM of 
adaptor DT88, 1x T4 RNA ligase buffer, 3 units of T4 RNA ligase (Ambion, Life 
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Technologies Ltd, Paisley, UK) and DEPC treated water to a final volume of 13 µl.  As 
a negative control, another set of ligation reaction was performed without T4 RNA 
ligase in the solution.  The adaptor-ligated cDNA was then amplified by hemi-nested 
PCR in a PTC-200 Thermal Cycler (MJ Research, now Bio-Rad, Hemel Hempstead, 
UK) using the NS206 and modified DT89 primers in the first round.  The length of 
modified DT89 primer was shorter than unmodified DT89 primer (Li et al., 2005) in 
order to match the Tm with that of NS206 and NS103.  The second round PCR was then 
conducted using the NS103 and modified DT89 primers.  Both PCR reactions were 
performed as described in section 3.5.5 with conditions as described in Table 3.9, but 
with the primers described above. 
 
 
 
Figure 3.3: Schematic diagram for 3’RACE procedure from the hRSV anti-genome.  
[Modified from original by Hsieh et al. (1997) and Li et al. (2005)]  
cDNA was firstly synthesized from the antigenome using the NS206 primer, followed by RNaseH 
treatment.  Adaptor (DT88) ligation was then performed using T4 RNA ligase and followed by hemi-
nested of PCR.  The first round PCR was carried out using the NS206 and modified DT89 primers.  The 
NS103 and modified DT89 primers were used for the second round of the PCR.  The RNA 
genome/antigenome is indicated by a wavy line; cDNA and PCR products are straight lines; adaptors are 
black boxes; primers are arrows. 
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Table 3.9: PCR condition for 3’RACE procedure from the hRSV anti-genome. 
 
Procedure  PCR Condition 
1
st
 round PCR  
 
 
Initial denaturation:    95°C for 10 mins  
Denaturation:              95°C for 20 secs 
Annealing:                  48°C for 20 secs            35 cycles 
Extension:                   72°C for 30 secs 
Final extension:          72°C for 7 mins. 
Cooled:                       4°C 
2
nd
  round PCR  
 
 
Initial denaturation:    95°C for 10 mins  
Denaturation:              95°C for 20 secs 
Annealing:                  55°C for 20 secs            35 cycles 
Extension:                   72°C for 30 secs 
Final extension:          72°C for 7 mins. 
Cooled:                       4°C 
3.5.7 3’Rapid amplification of cDNA ends (3’RACE) from the hRSV genome  
These methods were performed following Li et al. (2005) as illustrated in Figure 3.4 
and are similar to 3’RACE protocols in section 3.5.6, except that DT88 was ligated 
directly onto the virus RNA genome rather than to genomic sense cDNA.  All primers 
used in this method are presented in Table 3.5 and 3.7.  The adaptor DT88 was firstly 
ligated to the viral RNA overnight at 4°C in a ligation reaction mixed containing 1 µg of 
hRSV clone R11 RNA, 3 µg of hRSV clone R3 RNA or 1 µg of uninfected control 
HeLa cell RNA plus 1 µM of adaptor DT88, 1x T4 RNA ligase buffer, 15 units of T4 
RNA ligase (Ambion, Life Technologies Ltd, Paisley, UK) and DEPC treated water to a 
final volume of 20 µl.  Another ligation reaction without T4 RNA ligase was carried out 
as a negative control.  After ligation, cDNA synthesis was conducted using the DT89 
primer (section 3.5.2) and treatment of RNase H was then performed as described in 
section 3.5.5.  The adaptor-ligated RNA was then amplified by hemi-nested PCR in a 
PTC-200 Thermal Cycler (MJ Research, now Bio-Rad, Hemel Hempstead, UK) using 
the NS206: modified DT89 in the first round and the NS103: modified DT89 primer 
pair in the second round.  The reaction and conditions of both PCRs were described in 
section 3.5.6. 
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Figure 3.4: Schematic diagram for 3’RACE procedure from the hRSV genome. 
[Modified from original by Li et al. (2005) and Hsieh et al. (1997)]  
The adaptor (DT88) was firstly ligated with the genome using T4 RNA ligase, followed by cDNA 
synthesis using the DT89 primer.  The ligated RNA was then treated with RNaseH, followed by, the first 
round PCR using the modified DT89 and NS206 primers.  The hemi-nested PCR was then performed 
using the modified DT89 and NS103 primers.  The RNA genome is indicated by a wavy line; cDNA and 
PCR products are straight lines; adaptors are black box; primers are arrows. 
 
3.5.8 Agarose gel electrophoresis 
Materials 
10x TBE buffer 
108 g of Tris base (Melford, Suffolk, UK) and 55 g of boric acid were dissolved in 800 
ml of distilled water.  40 ml of 0.5 M EDTA were then added and made up to a final 
volume of 1 litre.  The solution was autoclaved and store at room temperature. 
6x Gel loading buffer  
25 mg of bromophenol blue and 25 mg of xylene cyanol FF were dissolved in 5 ml of 
distilled water to which was added 3 ml of glycerol.  The solution was made up to a 
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final volume of 10 ml with distilled water, aliquoted in 1 ml volumes and stored at -
20°C. 
1% (w/v) Agarose 
0.5 g LE agarose (Lonza, Rockland, USA) were melted in 50 ml of 1x TBE buffer in a 
boiling water bath.  After melting, gel was mixed with 10 µl of 5 mg/ml ethidium 
bromide, poured into a horizontal submarine agarose slab gel mould (Northumbria 
Biological, UK) and allowed to solidify at room temperature. 
Methods 
PCR products were analysed by agarose gel electrophoresis as described by Sambrook J 
(1989).  The PCR products to which were added one fifth volume of 6x loading buffer 
were loaded into wells of the 1% (w/v) agarose gel.  “100bp DNA ladder plus” (Thermo 
Scientific Fermentas, UK) standard DNA molecular weights markers were also loaded 
into a well.  Electrophoresis was carried out in 1x TBE buffer at 100 V using a Bio-Rad 
power pack (Bio-Rad Laboratories Ltd, Hemel Hempstead) until the dye front had 
migrated approximately 80% of the length of the gel.  PCR product bands in the gel 
were viewed using a gel ultraviolet transilluminator (Bio-Rad Fluor-S Multimager). 
3.5.9 Direct nucleotide sequencing 
Extraction of PCR products from agarose gel 
PCR product bands were excised from agarose gel with sterile scalpel blades under a 
UV transilluminator. The products were then purified from agarose gel using the 
QIAquick Gel Extraction Kit (Qiagen, Crawley, W. Sussex, UK) according to the 
manufacturer’s instructions and eluted with Buffer EB (I0mM Tris-Cl, pH 8.5) and 
either stored at -20C or used immediately. 
 Nucleotide sequencing 
The concentration of DNA was determined using a ND-1000 Nanodrop 
spectrophotometer (NanoDrop products, Wilmington).  Sequences were determined by 
GATC biotech AG (Konstanz, Germany) or Genevision (Newcastle Upon Tyne, UK). 
Apart from the ends, all sequences were determined in both directions with appropriate 
sequencing primers (Table 3.5, 3.6 and 3.7).   Discrepancies were resolved by 
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resequencing a both directions from alternative primers.  For the genome ends, 
sequences obtained in one direction by RACE, were confirmed by sequencing from 
terminal primers designed from published sequences of the A2 strain (GenBank 
accession number M74568).  The regions corresponding to the primers were therefore 
determined in only one direction. 
 
The sequence data were assembled into a single gene contiguous gene sequence (contig) 
using the CAP3 sequence assembly program (Huang and Madan, 1999) and aligned 
using ClustalW and ClustalX version 2 (Larkin et al., 2007) compared to the A2 strain 
obtained from the GenBank database (M74568).  The coding region was translated 
using the ExPasy server (Gasteiger et al., 2003) and the percentage of nucleotide 
identity was obtained from ClustalW program. 
3.6 Protein analysis methods 
3.6.1 SDS Polyacrylamide gel electrophoresis (SDS-PAGE) 
Materials 
8x Stacking gel buffer 
6.05 g Tris base (Melford, Suffolk, UK) were dissolved in 40 ml distilled water.  The 
pH was adjusted to 6.8 using concentrated HCl and made up to a final volume of 50 ml 
with distilled water. 
6x Sample buffer 
15 g of glycerol, 3 mg of bromophenol blue, 2.4 g of sodium dodecyl sulphate (SDS), 
7.5 ml of 8x stacking gel buffer and distilled water to a final volume of 20 ml were 
mixed, aliquoted in 500 µl volumes and stored at -20C.  40 µl of β-mercaptoethanol 
were immediately added to 500 µl aliquots prior to use.  
2x Resolving gel buffer 
45.4 g Tris base (Melford, Suffolk, UK) and 0.8 g SDS were dissolved in 400 ml of 
distilled water. The pH was adjusted to 8.8 using concentrated HCl and made up to a 
final volume of 500 ml with distilled water. 
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10% (w/v) Ammonium persulphate (APS) 
1 g of APS was dissolved in 9 ml of distilled water and stored at 4C for only 7 days. 
12% Acrylamide solution 
9 ml of 40% bis-acrylamide, 15 ml of resolving gel buffer and 6 ml of distilled water 
were mixed well and then degassed for 5 minutes using vacuum equipment (Aerosol 
Products Ltd, London, UK).  Immediately before pouring, 240 μl of 10% (w/v) APS and 
15 μl of Tetramethylethylenediamine (TEMED) were added and gently mixed. 
18% Acrylamide solution 
11.7 ml of 40% bis-acrylamide, 13 ml of 2x resolving gel buffer and 3.9 g of sucrose 
were mixed and then degassed for 5 minutes using vacuum equipment (Aerosol 
Products Ltd, London, UK).  Immediately before pouring, 180 μl of 10% (w/v) APS and 
10 μl of TEMED were added and gently mixed.  
SDS Running buffer 
6.05 g Tris base (Melford, Suffolk, UK), 2 g of SDS and 28.8 g glycine were dissolved 
in 2 litres of distilled water.  
Methods 
SDS-PAGE gel preparation  
An 18% to 12% gradient gel was poured in a Protean II xi gel mould (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK) according to the manufacturer’s instructions. 
A 15-well comb was then gently inserted into the mould and the gel was allowed to set 
for 2 hours at room temperature.  The wells were then rinsed three times with distilled 
water and once with 1x stacking gel buffer.  Gels were either used immediately or kept 
for up to 1 week by storing at 4°C with stacking gel buffer in each well.  
SDS-PAGE gel electrophoresis  
Gel wells were rinsed twice with running buffer before mounting onto the Protean II xi 
gel chamber (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) which was filled with 
SDS running buffer.  Five microlitres of protease inhibitor (Roche, UK) were added into 
500 µl of frozen sample and then rapidly thawed.  The samples were mixed with 6x 
sample buffer to a final concentration of 1x and heated at 100°C for 3 minutes to break 
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disulphide bonds.  Sixty microlitres of samples were loaded into wells alongside with 
10 µl of PAGE Prestained molecular weight markers (Thermo Scientific Fermentas, 
UK).  A magnetic stirrer was placed into a chamber connected to a Grant cooling 
system (Grant Instruments Ltd, Cambridge, UK) and an electrophoresis power supply 
(EPS) 600 (Pharmacia Biotech, now Amersham Biosciences, Buckinghamshire, UK). 
The cooling system was set at 0.5°C and the current for 1 gel was determined by the 
following formula:  
Current (mA) = 16,000 mins/ (expected running time (hr.) x 60)  
3.6.2 Western blotting 
Materials 
Tris-glycine protein transfer buffer 
3.03 g of Tris base (Melford, Suffolk, UK), 14.4 g of glycine and 200 ml of methanol 
were dissolved in 650 ml of distilled water, made up to a final volume of 1 litre and 
stored at 4
o
C. 
10x phosphate buffered saline (PBS) 
160 g of NaCl, 4 g of KH2PO4, 23 g of anhydrous Na2HPO4 and 4 g of KCl were 
dissolved in 2 litres of distilled water and adjusted to pH 6.8. 
Blocking buffer 1 
200 ml of PBS containing 0.1% (v/v) Tween 20 (PBS/T), 20 g of Marvel Milk powder 
(Boots, Newcastle upon Tyne) and 2 g of bovine serum albumin (BSA) were mixed and 
filtered through a glass microfiber filter (Whatman plc, Middlesex, UK) before storage 
at 4
o
C. 
Blocking buffer 3 
360 ml of PBS/T, 40 ml of heat inactivated foetal calf serum and 4 g of bovine serum 
albumin Cohn fraction V powder pH 7.0 (VWR International, Leicestershire, UK) were 
combined, filtered through a 0.2 µM vacuum filter and store at -20
 o
C. 
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Methods 
Protein transfer from SDS-PAGE gels 
After completion of electrophoresis, the gel orientation was marked and it was washed 
three times in the tris-glycine protein transfer buffer at 20 minute intervals.  A sheet of 
polyvinylidenefluoride (PVDF) membrane (Hybond-P, Amersham Biosciences 
Buckinghamshire, UK) and 8 sheets of 3 mm Whatman filter paper (Whatman plc, 
Middlesex, UK) were cut to the same size as the gel.  The membrane was initially 
soaked in methanol for 5 minutes.  Whatman papers and sponges were then soaked in 
the tris-glycine protein transfer buffer for 20 minutes.  The gel and membrane were 
sandwiched together in a holder cassette (Bio-Rad, UK) with 4 sheets of 3 mm 
Whatman filter paper and one sponge either side of them.  The cassette was submerged 
entirely under the protein transfer buffer in Bio-Rad transfer apparatus connected to the 
Grant cooling system and a BIO-Rad 200 power pack.  The cooling system was set at 
0.5C and the power supply was adjusted to 120 V and run for 5 hours.  After transfer, 
the PDVF membrane was washed 3 times in distilled water and blocked overnight in the 
blocking buffer 1 at room temperature. 
 Immunostaining of blot membranes with Enhanced Chemiluminescence (ECL) kit 
The PVDF membrane was washed twice for 5 minutes each in PBS/T and incubated in 
50 ml of primary antibody 1E3 diluted 1/10,000 in blocking buffer 3 with moderate 
shaking for 90 minutes.  The membrane was then washed in PBS/T three times, 15 
minute each wash, and once for 30 minutes followed by 5 minutes in blocking buffer 3.  
Polyclonal goat anti-mouse peroxidase conjugated immunoglobulin (NCL-GAMP) was 
diluted to 1/1000 in blocking solution 3 and incubated on the membrane for 90 minutes 
with moderate shaking.  The membrane was then washed for 15 minutes three times in 
PBS/T and blotted on Whatman filter paper before incubation in ECL detection reagent 
(Amersham Biosciences, Buckinghamshire, UK) for 5 minute.  The membrane was then 
blotted again, wrapped in clingfilm and placed in an X-ray cassette.  Under the safe-
light conditions, the membrane was exposed to photographic film (Hyperfilm ECL, 
Amersham Biosciences, Buckinghamshire, UK) for between 10 seconds and 1 minutes, 
depending on the intensity of the protein bands.  The films were developed in the 
automatic developer (Konica Minolta, Tokyo, Japan) using X-ray developing and fixing 
solutions (Tetenal, Leicester, UK). 
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Chapter 4: Neutralization of susceptible and resistant clones of 
R17532 with palivizumab
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4.1  Preparation of virus stocks 
In previous studies, the anti-F MAb neutralization resistant hRSV strain R17532 was 
isolated from the nasopharyngeal secretions (NPS) of an infected infant.  After repeated 
passaging in HeLa cells, the virus became susceptible to neutralization (Gias, 2006; 
Marsh et al., 2007).  To facilitate study of the resistance mechanism of this virus, an 
attempt was made to produce stable stocks of both resistant and susceptible virus 
variants by plaque purification (Gias et al., 2008).  Whilst clones of the high passage, 
susceptible variant maintained a stable phenotype on further passage, clones of the low 
passage resistant virus remained unstable usually losing resistance after four passages 
unless recloned.   
 
The low passage resistant clone R3.7.8 and high passage susceptible clone R11.1.1 
stocks were prepared in the previous study (Gias et al., 2008).  Clones R3.7.8 and 
R11.1.1 were produced by the 2-fold purification of plaque from a stock of R17532 at 
passage level 3 and 11, respectively.  In the production of clone R3.7.8, clone 7 was 
chosen from the first purification (R3.7) and then clone 8 was selected from the second 
purification (R3.7.8).  For clone R11.1.1, clone 1 was chosen from both the first (R11.1) 
and second purification (R11.1.1).  In this study, the low passage resistant clone was 
produced by the plaque purification once from clone R3.7.8 (section 3.4.1 and 3.4.4).  
Clone 3 was selected (R3.7.8.3) and passaged 3 times further in HeLa NCL cells 
(R3.7.8.3 P3).  The high passage susceptible clone R11.1.1 was passaged 8 times further 
in HeLa NCL cells (R11.1.1 P8).  
4.2 Neutralization of R17532 clones with palivizumab using different methods 
To ensure that the observed difference in phenotype were robust using methodologies 
for neutralization, both clones and A2, the type species of hRSV, were tested for their 
susceptibility to neutralization by palivizumab (PZ) using three neutralization 
techniques – the dilution endpoint neutralization assay, the immunofluorescent focus 
reduction neutralization assay and the immunoperoxidase focus reduction neutralization 
assay.   
4.2.1 Dilution endpoint neutralization 
Viral infectivity of the R17532 clone R11.1.1 P8, clone R3.7.8.3 P3 and A2 were 
quantitated in HeLa NCL cell culture tubes and read 15 days after inoculation (section 
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3.4.8).  The concentration of all three viruses was adjusted to 100 TCID50 /ml and used 
in the neutralization test against PZ as in section 3.4.9.  The infectivity and 
neutralization titres are shown in Table 4.1.   
  
Table 4.1: Neutralization titres of PZ against RSV viruses using the dilution endpoint 
neutralization test.   
 
Type 
Infectivity titres 
(TCID50/ml) 
Neutralization titres† 
(µg/ml) 
Neutralization 
phenotype 
A2 1.58 x 10
6 
0.79 Susceptible 
R11.1.1 P8 3.16 x 10
4 0.39 Susceptible 
R3.7.8.3 P3 7.41 x 10
3 9.52 Resistant 
 
†PZ concentration that neutralized virus in 50% of the inoculated tubes obtained from triplicate 
determinations. 
 
The high passage clone R11.1.1 P8 and A2 exhibited a susceptible phenotype with 
neutralization titres of 0.39 and 0.79 µg/ml, respectively.  The low passage resistant 
clone R3.7.8.3 P3 had a higher neutralization titre than A2 and clone R11.1.1 P8 with 
the titre of 9.52 µg/ml, confirming the difference in susceptibility of these viruses 
reported by Gias (2006) and Welsh (2010).  The dilution endpoint neutralization assay 
is a time-consuming test (4 weeks per determination) and requires large volumes of 
antibody and reagents and is thus cumbersome for the routine quantitation of virus 
stocks.  
4.2.2 Focus reduction neutralization assay using immunofluorescence staining 
i)  Assay optimization 
This assay was firstly optimized using Vero and HeLa NCL cells infected with A2 
(susceptible strain) and clone R3.7.8.3 P3 (resistant strain).  The infected plates were 
incubated for 1, 24, 48 or 72 hours before fixing and staining as in section 3.4.10.  The 
A2 foci could be easily counted in both HeLa NCL (Figure 4.1) and Vero cells (Figure 
4.2) for all incubation times.  For clone R3.7.8.3 P3 foci were only clearly discernible 
on Vero cells at 72 hours (Figure 4.2).  At earlier time points in Vero and throughout the 
experiment in Hela NCL, the putative infectious foci remained small and could not be 
reliably distinguished from debris which was observed at 1 hour after incubation.   
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Figure 4.1: Immunofluorescent foci of A2 and R17532 clone R3.7.8.3 P3 in HeLa NCL cells at 1, 24, 
48 and 72 hours at 100 x magnifications. 
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Figure 4.2: Immunofluorescent foci of A2 and R17532 clone R3.7.8.3 P3 in Vero cells at 1, 24, 48 
and 72 hours at 100 x magnifications. 
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ii)  Determination of EC50 for three viruses 
Three viruses, A2, R17532 clone R3.7.8.3 P3 and clone R11.1.1 P10, were titrated in 
the immunofluorescence focus reduction neutralization test on Vero cells and read at 72 
hours.  Clone R11.1.1 P10 was used to be representative for a high passage susceptible 
strain instead of clone R11.1.1 P8 which was of low volume.  The results are presented 
in Figure 4.3.  The EC50 values of PZ on A2 and clone R11.1.1 P10 were 6.23 and 1.08 
µg/ml, respectively.  The EC50 of PZ for clone R3.7.8.3 P3 (> 125 µg/ml) was higher 
than those of both susceptible virus strains (Figure 4.3).  Clone R3.7.8.3 P3 was 
significantly different from clone R11.1.1 P10 and A2 (P<0.0001) after statistical 
analysis by two-way ANOVA.   
 
 
Figure 4.3: The percentage virus survival of R17532 clone R11.1.1 P10, clone R3.7.8.3 P3 and A2 
after neutralization with PZ using the immunofluorescent focus reduction neutralization assay in 
Vero cells.   
Plots were prepared from duplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
4.2.3 Focus reduction neutralization assay using immunoperoxidase staining 
i)  Comparison of immunofluorescent and immunoperoxidase methods of the high 
passage susceptible clone of R17532 
As the secondary antibody labelled with FITC was expensive and immunofluorescent 
foci must be read immediately.  A further modification of the assay using a secondary 
antibody labelled with peroxidase was evaluated. 
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In order to compare the efficiency of the two methods in titration of hRSV, clone 
R11.1.1 P10 were quantitated 4 times using the immunofluorescent and the 
immunoperoxidase focus assay on Vero cells and read at 72 hours as described in 
section 3.4.5 and 3.4.6.  The mean of infectivity titres was 3.45 x 10
5 
± 1.19 x 10
5
 in the 
immunofluorescent method and 4.32 x 10
5 
± 1.10 x 10
5
 in the immunoperoxidase 
methods.  Statistical analysis by student t-test shows that titres from both methods were 
not significantly different with p-value of 0.34.   
 
The focus reduction neutralization assays using the two methods (section 3.4.10) were 
also compared on Vero cells against the same stock of clone R11.1.1 P10.  The results 
are presented in Figure 4.4.  The EC50 of PZ for clone R11.1.1 P10 in the 
immunofluorescent assay (1.08 µg/ml) was not significantly different from that of the 
immunoperoxidase assay (0.82 µg/ml) with a p-value of 0.25 (Two-way ANOVA).  
This suggests that the two methods have the same effectiveness for the determination of 
neutralization titres of PZ. 
 
However, the focus reduction neutralization assay stained using the immunoperoxidase 
method was chosen to determine the neutralization of further virus clones because the 
secondary antibody labelled with peroxidase (NCL-GAMP) could be used at a dilution 
of 1:1000 compared to the FITC conjugated antibody which worked only at a dilution 
of 1:20.  Also, the immunoperoxidase stained foci were easier to count under the 
stereomicroscope and stained infectious foci remained countable for more than 6 
months. 
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Immunofluorescent method 
 
 
 
Immunoperoxidase method 
 
Figure 4.4: The percentage virus survival of R17532 clones R11.1.1 P10 after neutralization with 
PZ using the immunofluorescent and the immunopereoxidase focus reduction neutralization assay 
in Vero cells.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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ii)  Re-determination of EC50 for the high and low passage clones of R17532 on 
Vero and HeLa NCL79 cells 
Clone R11.1.1 P10 was passaged once in HeLa NCL cells generating clone R11.1.1 
P11.  Clones R11.1.1 P11 and R3.7.8.3 P3 were tested for neutralization by PZ in the 
focus reduction assay in Vero incubated for 72 hours and stained by the 
immunoperoxidase method (section 3.4.6).  In parallel both clones were tested against 
PZ in HeLa NCL79 cells which were used for the original isolation of hRSV R17532 
and which were resuscitated from stocks stored in liquid nitrogen in 1979.   
 
On Vero cells, the EC50 values of PZ for clone R11.1.1 P11 and clone R3.7.8.3 P3 were 
4.19 and 67.34 µg/ml, respectively (P<0.0001) (Figure 4.5).  On HeLa NCL79 the PZ 
EC50 values were 4.84 and 48.46 µg/ml, respectively (P<0.0001) (Figure 4.6).  For 
clone R11.1.1 P11, the EC50 values in Vero were not significantly different from those 
in HeLa NCL79 (P=0.45).  In contrast, the EC50 values for clone R3.7.8.3 P3 in Vero 
was significantly higher than those in HeLa NCL79 (P<0.0001).  In addition, low 
concentrations of antibody enhanced the infectivity of the resistant clone in Vero cells 
but not HeLa NCL79 cells. 
 
Nonetheless, R3.7.8.3 P3 remained an order of magnitude more resistant than R11.1.1 
P11 using HeLa NCL79.  As foci of both clones in HeLa NCL79 cells were larger and 
more clearly defined compared to those in Vero cells (Figure 4.7), the 
immunoperoxidase focus reduction neutralization assay on HeLa NCL79 was selected 
for determination of the neutralization for other virus clones.   
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Figure 4.5: The percentage virus survival of R17532 clones R11.1.1 P11 and R3.7.8.3 P3 after 
neutralization with PZ using the immunoperoxidase focus reduction neutralization assay in Vero 
cells.   
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
 
        
Figure 4.6: The percentage virus survival of R17532 clones R11.1.1 P11 and R3.7.8.3 P3 after 
neutralization with PZ using the immunoperoxidase focus reduction neutralization assay in HeLa 
NCL79 cells.   
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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(A)                   (B)    
 
 
(C)                   (D)     
 
Figure 4.7 : Immunoperoxidase foci of R17532 clone R11.1.1 P11 in Vero (A) and HeLa NCL79 
cells (B) and clone R3.7.8.3 P3 in Vero (C) and HeLa NCL79 cells (D) at 10x magnifications. 
4.3 Variability of the assay 
In order to determine the variability of the immunoperoxidase focus reduction 
neutralization test.  PZ was titrated 9 times against the same stock of clone R11.1.1 P11 
and 3 times against the same stock of clone R3.7.8.3 P3.  The mean of EC50 of the 
antibody for clones R11.1.1 P11 and R3.7.8.3 P3 was 5.88 ± 3.51 and 32.87 ± 10.16, 
respectively (student t test, t = 1.046, P<0.0001).   
4.4 Stability of neutralization phenotype in susceptible and resistant clones of 
R17532 
hRSV R17532 clone R11.1.1 was passaged in HeLa NCL cells from passage 3 to 11.  
The PZ EC50 values of clone R11.1.1 passage 3, 10 and 11 were determined by focus 
reduction titration in HeLa NCL79 cells with immunoperoxidase staining and were 
found to be 2.38, 1.62 and 7.45 µg/ml, respectively (Figure 4.8 and Table 4.2).  These 
values indicated that they all were susceptible to PZ and relatively stable even though 
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they were passaged several times.  Clone R11.1.1 at passage 3 was not significantly 
different from clone R11.1.1 at passage 10 or 11 (Table 4.2). 
 
 
Figure 4.8: The percentage virus survival of R17532 clones R11.1.1 P3, P10 and P11 after 
neutralized by PZ.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
 
Table 4.2: The EC50 values of R17532 clones R11.1.1 P3, P10 and P11 and their p-values. 
 
Virus EC50 (µg/ml) 
Two way ANOVA 
P-value 
vs. Clone R11.1.1 P3 
Clone R11.1.1 P3 2.38   
Clone R11.1.1 P10 1.62 0.32 
Clone R11.1.1 P11 7.45 0.10 
 
 
R17532 clone R3.7.8.3 was passaged in HeLa NCL cells from passage 3 to passage 10 
and the PZ EC50 values determined as above of each passage levels.  In addition, the 
parental clone R3.7.8 (section 3.4.1) from which R3.7.8.3 was derived and was titrated 
in parallel.  The parental R3.7.8 clone was over three fold more resistant than clone 
R3.7.8.3 at passage 3 although this was not significantly different (Table 4.3).  
Furthermore, the phenotype of clone 3.7.8.3 was not stable after further passaged in 
HeLa NCL cells.  From passage 3 to 10, there was a shift of resistant to susceptible 
phenotype (Figure 4.9 and Table 4.3).  Subsequent to a major fall in resistance between 
passage 3 and 4, there was a fluctuation of neutralization phenotype trending downward 
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to passage 10.  Between passage 8 and 10, the level and variability of resistance of 
R3.7.8.3 paralleled that of clone R11.1.1. 
 
Figure 4.9: The percentage virus survival of R17532 parental clone R3.7.8 and clones R3.7.8.3 
passage 3 to passage 10 after neutralized by PZ in HeLa NCL79 cells.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…).  
 
Table 4.3:  The EC50 values of R17532 parental clone R3.7.8 and clones R3.7.8.3 passage 3 to 
passage 10 in HeLa NCL79 cells and their p-values.  
 
Virus EC50 (µg/ml) 
Two way ANOVA 
P-value 
Clone R3.7.8.3 P3 
Parental clone R3.7.8 >125 0.0742 
Clone R3.7.8.3 P3 48.46 
 
Clone R3.7.8.3 P4 13.32 0.0036 
Clone R3.7.8.3 P5 27.48 0.0085 
Clone R3.7.8.3 P6 3.38 <0.0001 
Clone R3.7.8.3 P7 18.48 0.0112 
Clone R3.7.8.3 P8 7.34 0.0033 
Clone R3.7.8.3 P9 2.78 <0.0001 
Clone R3.7.8.3 P10 8.05 0.0006 
4.5 Neutralization of susceptible and resistant clones of R17532 in different 
HeLa cells  
In previous studies, all hRSV isolates have been found to be susceptible to 
neutralization by PZ (Johnson et al., 1997; DeVincenzo et al., 2004).  Resistant hRSV 
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have only rarely been isolated from patients treated with PZ (Boivin et al., 2008; Adams 
et al., 2010; Zhu et al., 2011).  However, our laboratory was able to isolate 
neutralization resistant viruses to anti-F antibodies, including PZ from untreated 
patients.  Thus, Welsh (2010) demonstrated that 74.2% of isolates made in Newcastle 
were resistant to neutralization by PZ.  The HeLa NCL79 cell lines used for isolation in 
this study has been highly selected over twenty year for sensitivity to hRSV in the 
Newcastle diagnostic laboratories.  We proposed the hypothesis that this HeLa NCL79 
cell line may be exceptionally suitable for the replication of resistant strains of hRSV.   
To test this hypothesis, different HeLa cells with no history of selection for hRSV 
isolation (kindly provided from University of Leeds) were used to titrate both 
neutralization resistant parental clone R3.7.8 and susceptible clone R11.1.1 P11 and 
their neutralization by PZ was also compared. 
 
The infectivity titres of the two clones in different HeLa cells are presented in Table 4.4.  
Titres of both clones using HeLa NCL79 were similar to those on HeLa CPV, whereas 
they were significantly higher on HeLa JSF and HeLa Lucy.  However, plaque sizes of 
clone R11.1.1 P11 and parental clone R3.7.8 on HeLa NCL79 were larger than on other 
HeLa cells (Figure 4.10).  
 
Table 4.4:  Infectivity titres of R17532 clone R11.1.1 P11 and parental clone R3.7.8 in different 
HeLa cells and their p-values.  
 
Virus Cells Infectivity titres (FFU/ml) 
Student t-test 
P-value 
vs. HeLa NCL79 
Parental clone 
R3.7.8 
HeLa NCL79 8.78 x 10
5 
± 2.75 x 10
5
  
HeLa JSF 2.01 x 10
6 
± 4.79 x 10
5
 0.0004 
HeLa Lucy 1.38 x 10
6 
± 1.41 x 10
5
 0.0065 
HeLa CPV 1.14 x 10
6 
± 9.40 x 10
4
 0.1043 
    
R11.1.1 P11 
HeLa NCL79 5.09 x 10
5 
± 1.59 x 10
5
  
HeLa JSF 1.38 x 10
6 
± 3.62 x 10
5
 <0.0001 
HeLa Lucy 1.16 x 10
6 
± 3.27 x 10
5
 <0.0001 
HeLa CPV 6.51 x 10
5 
± 7.68 x 10
4
 0.1051 
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Figure 4.10: Immunoperoxidase foci of R17532 clones R11.1.1 P11 and parental clone R3.7.8 in 
different HeLa cells at 10x magnifications. 
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In neutralization assay, clone R11.1.1 P11 was shown to be susceptible to neutralization 
by PZ in all cells (Figure 4.11).  In contrast, the resistant clone R3.7.8 in HeLa NCL79 
was poorly neutralized by PZ as demonstrated previously.  However, PZ EC50 values in 
other HeLa lines, although always significantly higher than those for R11.1.1 were 
lower than in HeLa NCL79 (Table 4.5 and 4.6).     
 
These results revealed a marked variation in the ability of PZ to neutralize infectivity of 
low passage R17532 in different lines of HeLa cells.  It is possible that routine 
screening of cell lines for sensitivity in virus isolation operating in Newcastle in the 
1970s selected for a HeLa cell line capable of supporting the replication of viruses in 
clinical specimens containing antiviral antibodies. 
 
                          HeLa NCL79                                                      HeLa JSF 
     
                              HeLa CPV                                                       HeLa Lucy 
            
Figure 4.11: The percentage virus survival of R17532 clones R11.1.1 P11 and R3.7.8 after 
neutralization with PZ in HeLa NCL79, JSF, CPV and Lucy cells. 
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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Table 4.5:  The PZ EC50 values of R17532 clones R11.1.1 P11 and R3.7.8 in different HeLa cells and 
their p-values compared between the two clones in the same cell lines. 
 
Cells 
EC50 (µg/ml) 
Two way ANOVA 
P-value 
R11.1.1 P11 R3.7.8  R11.1.1 P11 vs. R3.7.8 
HeLa NCL79 5.06  >125 <0.0001 
HeLa JSF 3.57  76.06  <0.0001 
HeLa Lucy 4.37  18.83  <0.0001 
HeLa CPV 4.27 9.47  0.003 
 
Table 4.6:  The PZ EC50 values of R17532 clones R11.1.1 P11 and R3.7.8 in different HeLa cells and 
their p-values compared each clone to EC50 values from HeLa NCL79. 
 
Virus Cells EC50 (µg/ml) 
Two way ANOVA 
P-value 
vs. HeLa NCL79 
Parental clone 
R3.7.8 
HeLa NCL79 >125  
HeLa JSF 76.06  <0.0001 
HeLa Lucy 18.83 <0.0001 
HeLa CPV 9.47 <0.0001 
    
R11.1.1 P11 
HeLa NCL79 5.06   
HeLa JSF 3.57  0.22 
HeLa Lucy 4.27  0.89  
HeLa CPV 4.37 0.49 
 
4.6 Neutralization of susceptible and resistant clones of R17532 in a human 
bronchial epithelial cell line. 
The ability of hRSV isolates to evade neutralization by anti-F antibodies in some cell 
types may be relevant to the pathogenesis of virus infection in vivo.  Epithelial cells of 
the respiratory tract may resemble HeLa NCL79 in being permissive of infection with 
anti-F antibody treated virus.  To test the permissivity of human bronchial epithelial 
cells, PZ was titrated against the parental clone R3.7.8 and clone R11.1.1 in a focus 
reduction assay on 16HBE140, a line of human bronchial epithelial cells (Figure 4.12).  
Foci for both virus clones in 16HBE140 cells were small when compared to those in 
HeLa NCL79 (Figure 4.10 and 4.13).  Although the PZ EC50 for parental clone R3.7.8 
was significantly higher than that for R11.1.1 P11 (P<0.0001), it was low compared to 
that obtained on HeLa NCL79 (P<0.0001). 
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Figure 4.12: The percentage virus survival of R17532 clones R11.1.1 P11 and R3.7.8.3 P3 after 
neutralization with PZ using the immunoperoxidase focus reduction neutralization assay in 
16HBE140 cells.   
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
 
 
 
(A)               (B)    
Figure 4.13: Immunoperoxidase foci of R17532 clone R11.1.1 P11 (A) and parental clone R3.7.8 (B) 
in 16HBE140 cells at 10x magnifications. 
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Chapter 5: Investigation of the entry mechanism of palivizumab 
neutralization susceptible and resistant clones of R17532
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5.1 Introduction 
Previous studies have demonstrated that PZ binds equally well to both neutralization 
resistant and susceptible forms of R17532 (Marsh et al., 2007; Welsh, 2010).  The 
difference between the two viruses exhibited in HeLa NCL79 cells must therefore lie in 
the ability of bound anti-fusion glycoprotein antibody to block the infections process.  
This argues for a fundamental difference in the entry mechanism of the two viruses.  
Our present model of the entry mechanism of hRSV, based largely on studies of the 
sub-type A type stain A2 infection of HeLa and HEp2 cells, is incomplete.  However, it 
is likely that the virus initially binds to glycosaminoglycans on the target cell membrane 
via the G and F glycoproteins (Feldman et al., 2000).  The virion is taken up into 
endocytic vacuoles via clathrin mediated endocytosis (Kolokoltsov et al., 2007). 
 
At some as yet undetermined point in this process the fusion glycoprotein is activated to 
its fusogenic form, by an, as yet, undefined trigger, and mediates fusion of the virus and 
vacuole membrane with release of the nucleocapsid into the cytoplasm (Melero, 2007).  
Previous studies have already demonstrated marked difference in the kinetics of 
attachment between resistant and susceptible clones of R17532 in HeLa NCL cells 
(Welsh, 2010).  However, as PZ has been shown not to block virus binding, but to 
inhibit subsequent steps in the infections process, it is unclear how rapid binding per se 
would induce neutralization resistance. 
 
Therefore, the first aim of this study was to evaluate whether resistant and susceptible 
clones of the virus also differ in their entry into target cells by clathrin-mediated 
endocytosis using two clathrin endocytosis inhibitors - monodansylcadaverine (MDC) 
and chlorpromazine (CP).  The second aim was to compare the two clones with regard 
to factors involved in the activation of the fusion protein to the fusogenic form.  These 
include the extent of post-translational processing, the amounts of the fusion proteins, 
and their response to compounds which inhibit the formation of six helix bundle in the F 
molecule - Heptad repeat 2 (HR2) peptide and small molecular weight inhibitors 
BTA9881 and BMS-433771.  Resistant parental clone 3.7.8 with PZ EC50 in HeLa 
NCL79 > 125 µg/ml and neutralization susceptible clone R11.1.1 P3 with PZ EC50 in 
HeLa NCL79 = 2.38 µg/ml were used throughout these studies. 
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5.2 Viral entry of neutralization susceptible and resistant clones of R17532 in 
HeLa NCL79 cells 
5.2.1 Toxicity studies of clathrin endocytosis inhibitors on HeLa NCL79 cells 
Two clathrin endocytosis inhibitors, monodansylcadaverine (MDC) and chlorpromazine 
(CP), were diluted to different concentrations and tested on HeLa NCL79 cells to screen 
for their cytotoxicities using a trypan blue exclusion test (section 3.4.11).  The 50% 
cytotoxic concentration (CC50) of each inhibitor was evaluated to find the concentration 
that was non-toxic for the cells.  The CC50 values of MDC and CP were 130.8 µM and 
49.20 µg/ml, respectively (Figure 5.1). 
.   
 
             
                    
 
Figure 5.1: The percentage of cell viability and CC50 of MDC (A) and CP (B).  
Plots were prepared from triplicate values and error bars show the standard error.  The CC50 values of PZ 
are indicated in each graph. 
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5.2.2 Effect of clathrin endocytosis inhibitors on neutralization susceptible and 
resistant clones of R17532 
Parental clone 3.7.8 and clone R11.1.1 P3 were treated with MDC at concentrations 
between 25 and 100 µM and with CP at concentrations between 2.5 and 20 µg/ml.  The 
EC50 values of each inhibitor were evaluated in both viruses (section 3.4.11).  The EC50 
values of MDC in clone R11.1.1 P3 and parental clone R3.7.8 were 72.81 and 64.26 
µM, respectively (Figure 5.2).  For CP, clone R11.1.1 P3 and parental clone R3.7.8 had 
the EC50 values of 16.56 and 14.96 µg/ml, respectively (Figure 5.3).  The EC50 values of 
MDC and CP were approximately 50 - 70% less than CC50.  The susceptibility of clones 
R11.1.1 P3 and parental clone R3.7.8 to MDC and CP were not significantly different 
(P=0.09 and P=0.95, respectively), indicating that both viruses required clathrin 
dependent endocytosis in their entry into the host cells. 
 
 
Figure 5.2: The percentage virus survival of clones R11.1.1 P3 and parental clone R3.7.8 after 
treatment with MDC.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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Figure 5.3: The percentage virus survival of clone R11.1.1 P3 and parental clone R3.7.8 after 
treatment with CP.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
5.3 Analysis of F glycoprotein post-translational processing in neutralization 
susceptible and resistant clones of R17532 
The F glycoprotein is post-translationally processed by proteolytic cleavage and 
glycosylation.  To investigate whether F glycoprotein processing might underly the 
differences between susceptible and resistant clones.  The viruses were analysed by 
SDS-PAGE to seek differences in migration of the F glycoprotein corresponding to 
differences in proteolytic cleavage or glycosylation.  
 
Infected HeLa NCL79 cell lysates of susceptible clone R11.1.1 P3 and resistant parental 
clone R3.7.8 were run on SDS-PAGE and their proteins were transferred onto PVDF 
membrane.  The F glycoproteins on the membrane were Western blotted with anti-F 
MAb 1E3 (section 3.6).  The same pattern of two bands with the molecular weight of 52 
and 20kDa occurred in both clones (Figure 5.4).  The 20kDa band has previously been 
reported to be a protease resistant cleavage product of the F1 molecule (Lopez et al., 
1990).  This band in parental clone R3.7.8 was of greater intensity than that in clone 
R11.1.1 P3 which may reflect the slower replication rate of the resistant clone which 
affords greater time for proteolytic degradation of virus proteins accumulating in the 
culture.  The similar band pattern between the two clones indicates that there were no 
observable differences in post-translational processing. 
0.5 1.0 1.5
0
50
100
150
Clone R11.1.1 P3
(EC50= 16.56 g/ml)
Parental clone 3.7.8
(EC50= 14.96 g/ml)
V
ir
u
s
 s
u
rv
iv
a
l 
(%
)
Log10 CP concentration (g/ml)
 139 
 
1
3
9
 
 
 
Figure 5.4: Western blot of the F glycoprotein in parental clone R3.7.8 P2 and clone R11.1.1 P3 
infected cell lysates stained by the anti-F Mab 1E3.  
The lanes were loaded as follows; Lane 1: parental clone R3.7.8; Lane 2: R11.1.1 P3; Lane 3: HeLa cell 
(Negative control). 
5.4 Comparison of the amounts of the fusion protein in neutralization susceptible 
and resistant clones of R17532 
In previous studies, a high density of envelope glycoprotein expression was found on 
the virion surface of neutralization resistant primary HIV-1 isolates compared to 
laboratory adapted HIV-1 which was susceptible to neutralization by soluble CD4 
(O'Brien et al., 1994; Sullivan et al., 1995).  It is possible that high amount of the F 
glycoprotein on resistant hRSV virions is similarly responsible for resistance to 
neutralization by PZ.  Gias (2006) have demonstrated that the level of F expression on 
purified R17532 resistant clone R3 virions was significantly higher than that on 
susceptible clone R11.  However, in a resistant clone N1 of a separate isolate N5843, F 
glycoprotein expression was similar to that of susceptible clone N10a.   
 
In an attempt to investigate this further by a different method, the F glycoprotein present 
on the surface of cells infected with the resistant parental clone R3.7.8 or susceptible 
clone R11.1.1 P3 were measured by anti-F MAb 1E3 using an ELISA whole cell 
method (section 3.4.7).  The results are shown in Figure 5.5.  1E3 antibody equally 
bound to both parental clone R3.7.8 and clone R11.1.1 P3, the binding curves for both 
cell types being superimposable.  This indicates that the same amounts of the F 
glycoprotein were present on both cell types. 
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Figure 5.5: Amounts of the F glycoprotein on the surface of cells infected with parental clone R3.7.8 
and clone R11.1.1 P3. 
Plots were prepared from triplicate values and error bars show the standard deviation.   
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5.5 Effect of antiviral agents directed against the F glycoprotein on 
neutralization susceptible and resistant clones of R17532 
The formation of the six helix bundle (6HB) in the F molecule occurs in the fusion 
process drawing the viral membrane and the host cell membrane into close apposition 
(Zhao et al., 2000).  Anti-F monoclonal antibodies appear to neutralize infectivity by 
blocking this process (Huang et al., 2010).  It was hypothesized that the 6HB formation 
in resistant virions may be different from that in susceptible virion. 
 
To test this hypothesis, antiviral agents directed against the formation of 6HB in the F 
glycoproteins were tested in focus inhibition assays against both resistant and 
susceptible clones (section 3.4.12).  These antiviral agents consisted of two small 
molecular weight inhibitors, BTA9881 and BMS-433771, and a peptide corresponding 
to heptad repeat 2 (HR2) of the R17532 F glycoprotein.  This sequence is conserved in 
all PZ resistant and susceptible clones of virus sequence (see below chapter 6).  The 
results are presented in Figure 5.6.  No cellular toxicity was observed with any of these 
compounds (data not shown). 
 
Clone R11.1.1 P3 was susceptible to R17532-HR2 peptide, BMS-433771 and BTA9881 
with the EC50 values of 13.04, 0.21 and 5.23 µM, respectively.  In contrast, none of 
these anti-fusion inhibitor compounds inhibited parental clone R3.7.8.  These findings 
paralleled the neutralization of the two clones by PZ.   
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                       R17532-HR2 peptide                                                   BMS-433771                                                        
          
                            BTA9881                                                              PZ 
        
 
Figure 5.6: The percentage virus survival of clone R11.1.1 P3 and parental clone R3.7.8 after 
treatment with R17532-HR2 peptide, BMS-433771,  BTA9881 and PZ.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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Chapter 6: Comparison of the membrane associated glycoprotein 
genes of resistant and susceptible clones of R17532 
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6.1 Introduction 
Previous studies indicated that genetic changes in the membrane associated protein 
genes (M, SH, G, F, and their intergenic regions) were not associated with the 
conversion of slow growing - neutralization resistant variants to fast growing - 
neutralization susceptible variants (Gias, 2006; Marsh et al., 2007).  However, although 
sequences of the F, G and F-G intergenic regions were derived for uncloned virus stocks 
and confirmed on virus clones of established neutralization phenotype, the sequence 
analysis of the M, SH and the intergenic regions of both genes were determined only for 
uncloned virus stocks that probably contained a mixture of neutralization resistant and 
susceptible variants.  Although the gene sequences obtained might represent those of the 
predominant variant, minor variants might be preferentially amplified resulting in a 
misleading interpretation.  To further test the conclusions of Marsh et al. (2007), the M, 
SH genes and their intergenic regions for clone R11.1.1 P8 and R3.7.8.3 P3 were 
analysed in the first part of this study.  The EC50 of PZ against clone R3.7.8.3 P3 in the 
focus reduction assay was 48.46 µg/ml (Figure 4.6) and the 50% inhibitory dose in the 
tube neutralization assay was 9.52 µg/ml (Table 4.1).  R11.1.1 P8 was titrated only in 
the tube neutralization assay where the 50% inhibitory dose was 0.39 µg/ml (Table 4.1). 
6.2 Amplification of the M gene and associated intergenic regions of palivizumab 
resistant and susceptible clones of R17532 
For this experiment, clone R11.1.1 P8 and R3.7.8.3 P3 were compared.  In the hRSV 
strain A2 genome, the M gene stretches from nt 3,252 to nt 4,209 (GenBank accession 
number M74568).  For each clone, total RNAs isolated as described in section 3.5.1 
were reverse transcribed using the forward primer M1 and PCR reactions were 
performed using the M1: M2 primer pair (Table 3.5 and 3.6 for all primers).  Negative 
controls using RNA extracted from uninfected HeLa NCL cells and DEPC treated water 
were included in the RT-PCR.  The size of the target band was expected to be 1,184nt 
with autonomous sequence between nt 3,174 to nt 4,360.  Strong bands of this size were 
observed in both clones as shown in Figure 6.1.  No target band was detected in any 
negative control.  Target bands were purified for direct sequencing as described in 
section 3.5.9. 
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Figure 6.1: RT-PCR amplification of the M gene and P-M intergenic region of clones R11.1.1 P8 
and R3.7.8.3 P3 using the M1: M2 primer pair. 
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control) 
6.3 Amplification of the SH gene and associated intergenic regions of 
neutralization susceptible and resistant clones of R17532 
For the hRSV strain A2 genome, the SH gene is encoded by nt 4,219 to nt 4,628 
(GenBank accession number M74568).  The M-SH intergenic region and the SH genes 
of clones R11.1.1 P8 and R3.7.8.3 P3 were reverse transcribed using the forward primer 
SH+ and amplified using the SH+: SH- primer pair (Table 3.5 and 3.6) to yield 
autonomous sequence between nt 3,994 to nt 4,842.  Uninfected HeLa NCL cells and 
DEPC treated water were used as negative controls and amplified in parallel.  The 
expected band of 849nt was found in both clones, but not in negative controls (Figure 
6.2).  This band was isolated and purified for direct sequencing as described in section 
3.5.9. 
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Figure 6.2: RT-PCR amplification of the SH gene and M-SH intergenic region of clones R11.1.1 P8 
and R3.7.8.3 P3 using the SH+: SH- primer pair.   
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control) 
6.4 Sequence comparison of the M and associated intergenic regions of 
neutralization susceptible and resistant clones of R17532 and A2 strain 
The strategy for sequencing the M gene is depicted in Figure 6.3.  The sequences of the 
P-M intergenic region (nt 3,243 to 3251), the 5’UTR (nt 3,252 to 3260) and the M 
coding region (nt 3,261 to 4,031) of clones R11.1.1 P8 and R3.7.8.3 P3 were analysed  
in the 5’ to 3’ direction (antigenome) using the forward primer M1 from the 1,184nt 
amplicand in section 6.2.  The coding region and 3’UTR (nt 4,032 to 4,209) of the M 
gene was sequenced in the 3’ to 5’direction using the reverse primer M2 from the 
1,184nt amplicand in section 6.2 and in the 5’ to 3’ direction using the forward primer 
SH+ from the 849nt amplicand generated in section 6.3.  The P-M intergenic region, 
5’UTR and coding regions of the M gene were subsequently confirmed by sequencing 
in the 3’ to 5’ direction using the reverse primer P3459 from the 1,332nt amplicand 
generated for sequencing the P gene in section 7.8 below.  All primers are presented in 
Figure 6.3, Table 3.5 and 3.6.  This provided readable sequence from nt 3,140 to 4,695 
based on the hRSV A2 genome (GenBank accession number M74568).  Sequence from 
nt 3,763 to 4,014 was obtained from sequencing in only 3’ to 5’ direction using M2 
primer; however, this sequence was in agreement with  the study of Gias (2006).  
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Figure 6.3: Schematic diagram of primers for amplification and sequencing of the M gene and 
associated intergenic regions on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale).  Primers used in sections 6.2 and 6.4 are black 
arrows; sections 6.3 and 6.5 are grey arrows.  Sequencing primer used in sections 7.8 is white arrow.  
Primers M1 (nt 3,174-3,197); P3459 (nt 3,459-3,437); SH+ (nt 3,994-4,017); M2 (nt 4,360-4,332); SH- 
(nt 4,842-4,825) [Nucleotide numbering is based on the A2 genome, GenBank accession number 
M74568]. 
 
Comparison of the M gene and associated intergenic region revealed no nucleotide or 
amino acid changes between clones R11.1.1 P8 and clone R3.7.8.3 P3 (Appendix  
Figure  10.1, 10.2 and 10.3).  Thus, this gene was totally conserved in susceptible and 
resistant variants.  However, several nucleotide differences between R17532 and the A2 
strain were observed across these regions.  In the P-M intergenic region, a deletion of 
six nucleotides and one nucleotide substitution were detected in the A2 strain compared 
to R17532 giving a low percentage of nucleotide identity of 22 (Table 6.1 and Appendix 
Figure 10.1).  The nucleotide differences in the coding regions did not cause amino acid 
changes and the percentage of amino acid identity was 100 as shown in Table 6.1 and 
Appendix Figure 10.2. 
 
Table 6.1: Percentage of nucleotide identity in the P-M intergenic region and the M gene of clone 
R17532 compared to the A2 strain.   
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
P-M IR
c 
1-3 22 N/A 
M 5’UTR 4-13 100 N/A 
M CDS
d 
1-771 97 100 
M 3’UTR 1-176 90 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
IR: Intergenic region;
 d
CDS: Coding sequence. 
 
M2 M1 
P SH M
  G 
G 
P3459 
 
SH+ SH- 
5’
  G 
3’
  G 
 3,242 bp 2,329  4,209  3,252  4,219  4,628  4,673  5,595 
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6.5 Sequence comparison of the SH genes and associated intergenic regions of 
neutralization susceptible and resistant clones of R17532 and A2 strain 
The sequences of the 849nt band for clone R11.1.1 P8 and R3.7.8.3 P3 were determined 
using the forward primer SH+ and the reverse primer SH- in the 5’ to 3’ and 3’ to 5’ 
directions (antigenome), respectively.  Sequence readable in both direction was obtained 
from nt 4,093 to 4,695 based on the hRSV A2 genome (GenBank accession number 
M74568).  No nucleotide changes in the M-SH intergenic region, 5’UTR and the coding 
sequence of the SH gene were observed between the two clones (Appendix Figure 10.4 
and 10.5).  In the 3’UTR region, a deletion of an A residue occurred at the SH gene end 
(GE) sequence of clone R11.1.1, which had 7As in the A-tract region (antigenome 
sense), compared to clone R3.7.8.3 P3 in which these were 8As (Appendix Figure 10.6).  
In this region, A2 had only 5As in the A-tract region.  In addition, there were several 
nucleotide differences in the SH gene between A2 and R17532 strains and the 
percentage of nucleotide and amino acid identity in each region is shown in Table 6.2.  
In the coding region, two amino acid changes were observed between the two viruses 
giving the percentage of amino acid identity of 96 (Table 6.2 and Appendix Figure 
10.5). 
 
Table 6.2: Percentage of nucleotide identity in the M-SH intergenic region and the SH gene of clone 
R17532 compared to the A2 strain.   
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
M-SH IR
c 1-9 77 N/A 
SH 5’UTR 10-93 92 N/A 
SH CDS
d 
1-195 97 96
e 
SH 3’UTR 1-134 82 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
IR: Intergenic region; 
d
CDS: Coding sequence; 
e
F29S and A62V. 
 
6.6 Sequence comparison of the G gene, F gene and associated intergenic regions 
in neutralization resistant and susceptible clones of strain R17532  
Although the sequences of the F and G genes have previously been determined from 
both virus stocks and clones, a limited number of virus clones were sequenced from two 
virus isolates, a resistant and a susceptible clone of isolate R17532 and two resistant and 
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one susceptible clones of isolate N5843 (Gias, 2006).  Variability was observed in both 
the F and the G genes, but none of the mutations correlated with resistance when 
compared across all five clones.  As multiple mutations might confer the same 
phenotypic change, it was of interest to further study both genes in additional 
susceptible and resistant clones from different passage levels. 
 
Clone R3.7.8.3 was serially passaged from passage 3 until passage 10 and the 
neutralization phenotypes at each passage level determined as shown in section 4.4.  
Clone 3.7.8.3 at passage level 3 (PZ EC50 in HeLa NCL79 = 48.46 µg/ml), 6 (PZ EC50 
in HeLa NCL79 = 3.38 µg/ml) and 9 (PZ EC50 in HeLa NCL79 = 2.78 µg/ml) were 
selected to isolate total RNA for sequence analysis of the G and F genes as described in 
section 3.5.1.     
6.6.1 Amplification of the G gene in neutralization resistant and susceptible clones 
of strain R17532 
In the hRSV strain A2 genome, the G gene stretches from nt 4,673 to nt 5,595 
(GenBank accession number M74568).  Total RNA extracted from clones 3.7.8.3 P3, 
P6 and P9 were reverse transcribed using the forward primer SH292 (section 3.5.2) and 
amplified using the SH292: F164 primer pair (Figure 6.5, Table 3.5 and 3.6 for all 
primers) and the standard conditions (section 3.5.3) to yield autonomous sequence 
between nt 4,510 and nt 5,855.  RNAs extracted from uninfected HeLa NCL cells and 
DEPC treated water were included in the RT-PCR as negative controls.  The size of the 
expected band was 1,326nt.  Target bands of this size were detected in all clones, but 
not in negative controls (Figure 6.4).  PCR products were isolated and purified for direct 
sequencing as described in section 3.5.9. 
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Figure 6.4: RT-PCR amplification of the G gene and associated intergenic regions in the susceptible 
and resistant clones of R17532 using the SH292: F164 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R3.7.8.3 P3; Lane 3: R3.7.8.3 P6; 
Lane 4: R3.7.8.3 P9; Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC treated water 
(Negative control). 
6.6.2 Amplification of the F gene in neutralization resistant and susceptible clones 
of strain R17532 
For the hRSV strain A2 genome, the F gene is encoded by nucleotides nt 5,648 to nt 
7,550 (GenBank accession number M74568).   The F gene and associated intergenic 
regions were reverse transcribed from the RNA of clones 3.7.8.3 P3, P6 and P9 using 
the forward primer G886 and amplified in two overlapping fragments using the G886: 
F1000 and the A2R3: ALW2 primer pairs (Figure 6.5) and the standard conditions 
(section 3.5.3).  The target band of the first fragment was 1,249nt with autonomous 
sequence between nt 5,558 and nt 6,806 and the second fragment was 869nt with 
autonomous sequence between nt 6,760 and nt 7,668 (Figure 6.7).  Negative controls 
(HeLa NCL cell RNA and DEPC treated water) were amplified in parallel.  Expected 
bands of 1,249nt and 869nt were observed in all clones of R17532 (Figure 6.6 and 6.7).  
They were isolated and purified for sequencing as previously described in section 3.5.9.  
No target bands or non-specific bands were present in negative controls. 
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Figure 6.5: Schematic diagram of primers for amplification and sequencing of the F gene, G gene 
and associated intergenic regions on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale).  Primers for the G gene are white arrows and primer 
for the first and second fragments of the F genes are black and grey arrows, respectively.  Primers SH292 
(nt 4,510-4,531); GC1 (nt 5,205-5,222); G713 (nt 5,408-5,385); G886 (nt 5,558-5,581); F164 (nt 5,855-
5,833); F400 (nt 6,188-6,168); A2R2 (nt 6,125-6,234); A2R3 (nt 6,760-6,779); F1000 (nt 6,806-6,786); 
ALW2 (nt 7,668-7,628) [Nucleotide numbering is based on the A2 genome, GenBank accession number 
M74568]. 
 
 
 
 
Figure 6.6: RT-PCR amplification of the first fragments of the F gene in the susceptible and 
resistant clones of R17532 using the G886: F1000 primer pairs.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R3.7.8.3 P3; Lane 3: R3.7.8.3 P6; 
Lane 4: R3.7.8.3 P9; Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC treated water 
(Negative control). 
 
 
SH292 
SH
  G 
F164 
A2R2 
F G
  G 
M2
  G 
GC1 G713 
F1000 G886 F400 
A2R3 ALW2 
5’
  G 
3’
  G 
 4,628 bp 4,219  5,595  4,673  5,648 7,550  7,597  8,557 
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Figure 6.7: RT-PCR amplification of the second fragments of the F gene in the susceptible and 
resistant clones of R17532 using the A2R3: ALW2 primer pairs.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R3.7.8.3 P3; Lane 3: R3.7.8.3 P6; 
Lane 4: R3.7.8.3 P9; Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC treated water 
(Negative control). 
6.6.3 Sequence comparison of the G gene, F gene and associated intergenic regions 
of neutralization resistant clones of R17532 and A2 strain 
The sequence of the G gene was analysed using the forward primers SH292 and GC1 in 
the 5’ to 3’ direction and the reverse primers G713 and F164 in the 3’ to 5’ direction 
(antigenome).  In the F gene, the first fragment was sequenced using the forward 
primers G886 and A2R2 in the 5’ to 3’ direction and the reverse primers F400 and 
F1000 in the 3’ to 5’ direction.  The sequence of the second fragment for the F gene was 
determined both 5’ to 3’and 3’ to 5’ directions using the forward primer A2R3 and the 
reverse primer ALW2, respectively.  The comparison of the G, F genes and their 
intergenic regions revealed no nucleotide changes among the resistant (R3.7.8.3 P3) and 
susceptible clones (R3.7.8.3 P6 and P9). 
6.7 Sequence comparison of the G gene, F gene and associated intergenic regions 
in different neutralization resistant and susceptible clones of R17532 
In this study, several clones of R17532 from different passages were plaque purified 
and their neutralization phenotypes were determined.  The sequence analysis of the G 
and F genes in both previously produced clones and newly generated clones were 
determined. 
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6.7.1 Neutralization of resistant and susceptible clones of R17532 at different 
passage levels 
The lineage of all passage levels of R17532 is shown in Figure 6.8.  Previously, anti-F 
monoclonal antibody neutralization resistant virus R17532 was isolated from the 
nasopharyngeal secretions of an infected infant on two separate occasions by Prof. G.L. 
Toms (P1-GLT) and Dr. A. Connor (P1-AC).  The P1-GLT and P1-AC viruses were 
passaged in HeLa cells to level 10 in 1996 and in 1998, respectively.  Their phenotypes 
remained resistant throughout, whereas, the P10-FF virus passaged from the P9-GLT 
virus in 2000 shifted to susceptible and retained its susceptible phenotype after passaged 
to level 11 (P11-RM).  In addition, the P5-RM stock was passaged from the P2-GLT in 
2001 and its phenotype also changed to susceptible during passage. 
 
Several clones have been produced previously from different virus stocks at different 
passage levels.  The clone R3.2-ELG and R3.7.8-ELG were resistant to neutralization 
by anti-F monoclonal antibody, whilst the clone R11.1.1-ELG and R11.2-ELG were 
susceptible.  In this study, new clones were prepared as described in section 3.4.4 from 
the available virus stocks at different passage levels as detailed in Figure 6.8.  New 
clones were designated with the suffix –WH.  The PZ EC50 values of clones in red 
colour in Figure 6.8 were determined as shown in Figure 6.9 and found to vary in 
susceptibility with PZ EC50 values of 3 to 90 µg/ml.  For each clone, total RNAs were 
reverse transcribed using the forward primer SH292 for the G gene and the forward 
primer G886 for the F gene (Figure 6.5, Table 3.5 and 3.6 for all primers).  
Amplification of the entire G gene was performed using the SH292: F164 primer pair, 
whereas two fragments of the F gene was amplified using the G886: F1000 and the 
A2R3: ALW2 primer pairs (data not shown).  
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Figure 6.8: Lineage of different passage levels of hRSV strain R17532.  Clones shown in red colour 
were used in this study.  
GLT- grown by Prof.G.L.Toms; 1996. AC- grown by Dr. A. Connor; 1998 FF- grown by F. Fenwick; 
2000.  RM- grown by Dr. R. Marsh; 2001 ELG - cloned by Dr. E. Gias; 2006. WH- cloned by W. Hiriote; 
2009  
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Figure 6.9: The percentage virus survival of R17532 (A) clone R2, (B) clone R3, (C) clone R5 and 
(D) clone R11  after neutralization with PZ in HeLa NCL79 cells.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
6.7.2 Sequence comparison of the G gene and associated intergenic regions of 
resistant and susceptible clones of R17532 and A2 strain 
The 1,326nt target band for both neutralization resistant and susceptible clones from 
R17532 clones with different passages histories (10 clones, Figure 6.8) were directly 
sequenced in both directions (section 3.5.9).  The forward primers SH292 and GC1 
were used for sequencing in the 5’ to 3’ direction (antigenome) and the reverse primers 
G713 and F164 in the 3’ to 5’ direction (Figure 6.5).  The sequences of all clones were 
compared with the A2 strain (GenBank accession number M74568) and percentage 
comparisons are presented in Table 6.3. 
 
The PZ EC50 values for each clone and a summary of the variability in the SH gene end, 
G gene and G-F intergenic region are shown in Table 6.4 and 6.5.  The sequences of the 
SH GE sequence and the SH-G intergenic region are presented in Appendix Figure 
10.7.  There was a deletion of an A residue from the SH GE sequence in four of five 
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susceptible clones (R2.44, R3.2.4, R11.1.1 and R11.2), resulting in only 7As in the A-
tract as described in section 6.5 and Table 6.4.  However, the susceptible clone R5.14 
did not have this deletion and retained 8As.  Four of the five resistant clones retained 
eight As, but one clone (R5.1) had only seven.  Therefore, this mutation does not appear 
to be responsible for the phenotype switch, being both present and absent in different 
clones of both phenotypes.  This apart, the percentage of nucleotide identity over the SH 
GE sequence and SH-G intergenic region was 100 between all clones.  In this region, 
A2 lacked all three adenines having only 5As in the A-tract.  Furthermore, there were 
four additional differences compared to the R17532 clones with 90% nucleotide identity 
(Table 6.3 and Appendix Figure 10.7).  The sequence of the 5’untranslated region 
(5’UTR) of the G gene for all viruses is also presented in Appendix Figure 10.7.  All 
R17532 clones and the A2 strain were identical in this region.   
 
The full G coding region for all 10 clones and A2 are presented in Appendix Figure 
10.8.  In the G coding region, variation in the R17532 clones occurred at only one 
position, residue 884, (Table 6.4 and Appendix Figure 10.8) where a transition from T 
to C corresponded to an amino acid change at residue 295 (I  T) (Table 6.5).  This 
mutation was in the region of the ectodomain in the mucin like variable region 2.  T was 
present in four of the resistant, but also in two of the susceptible clones, R2.44 and 
R5.14.  C was present in three of the susceptible clones and in the resistant clone R5.1.  
A similar switch at this position from T in the resistant stock to C in the susceptible 
stock of R17532 was reported by Marsh et al. (2007) who also found a mixture of both 
C and T in the chromatogram of a high passage resistant virus stock (P10 GLT).  This 
mutation appeared to be present in both resistant and susceptible clones of virus and 
was therefore not correlated with neutralization phenotype.   
 
The sequences of the 3’UTR of the G gene and the G-F intergenic region are presented 
in Appendix Figure 10.9.  The 3’UTR regions were identical in all clones of R17532, 
although a nucleotide substitution and a deletion were observed in the G GE sequence 
of A2 giving only 84% nucleotide identity to R17532.  In the G-F intergenic region, one 
clone, the resistant clone R5.1, differed from all the tests with a single T  C change at 
position 36.  Again the A2 and R17532 strains showed considerably variation over this 
region with 84% nucleotide identity (Table 6.3). 
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Table 6.3: Percentage of nucleotide identity in the G gene of clone R17532 compared to the A2 
strain.  
 
Region NT
 
#   
% NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity 
R17532 vs. A2 
SH-G IR
c 
1-44 90 N/A 
G 5’UTR 45-59 100 N/A 
G CDS
d 
1-897 92 85
 
G 3’UTR 1-12 84 N/A 
G-F IR 12-64 84 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid; 
c
IR: Intergenic region; 
d
CDS: Coding sequence. 
 
 
Table 6.4: Summary of nucleotides changes of R17532 in the G gene. 
 
Gene 
Nucleotide sequence 
N
u
cl
eo
ti
d
e 
n
u
m
b
er
 
R
5
.3
 
 R
5
.1
 
R
3
.7
.8
.3
 
R
5
.2
 
R
3
.7
.8
.1
7
 
R
3
.2
.4
 
R
2
.4
4
 
R
1
1
.1
.1
 
R
5
.1
4
 
R
1
1
.2
 
PZ EC50  90 70 48 42 21 12 7 5 3 2.7 
SH GE
a 
- 8A 7A 8A 8A 8A 7A 7A 7A 8A 7A 
G CDS
b
  884 T C T T T C T C T C 
G-F IR
c 
36 T C T T T T T T T T 
 
 
a
GE: Gene end sequence; 
b
CDS: Coding sequence;
 c
IR: Intergenic region 
 
 
Table 6.5: Summary of amino acid changes of R17532 in the G glycoprotein. 
 
Protein 
Amino acid sequence 
A
m
in
o
 a
ci
d
 
n
u
m
b
er
 
R
5
.3
 
 R
5
.1
 
R
3
.7
.8
.3
 
R
5
.2
 
R
3
.7
.8
.1
7
 
R
3
.2
.4
 
R
2
.4
4
 
R
1
1
.1
.1
 
R
5
.1
4
 
R
1
1
.2
 
PZ EC50  90 70 48 42 21 12 7 5 3 2.7 
G CDS
a
 295 I T I I I T I T I T 
 
a
CDS: Coding sequence 
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6.7.3 Sequence comparison of the F genes and associated intergenic regions of 
resistant and susceptible clones of R17532 and A2 strain 
The entire F genes of the 10 R17532 clones, amplified in two overlapping fragments, 
were sequenced in both directions as described in section 6.6.3.  The 5’UTR, coding 
sequences and the 3’UTR of the F gene of all clones are compared with the A2 strain 
(GenBank accession number M74568) in Appendix Figure 10.10, 10.11 and 10.12, 
respectively and percentage comparisons are presented in Table 6.6.    
 
A summary of the variability among the R17532 clones is presented in Table 6.7 and 
6.8.  There were no nucleotide differences among the clones of the R17532 in 5’UTR or 
3’UTR of the F gene (Appendix Figure 10.10 and 10.12).  However, several nucleotides 
in the A2 3’UTR were different from those in R17532 with percentage of nucleotide 
identity of 93 (Table 6.6).  In the F coding region, one nucleotide change occurred from 
T in most of clones to G in susceptible clones R11.1.1 and R11.2 and resistant clone 
R5.1 in the position 456 (Table 6.7).  This mutation caused an amino acid change in the 
residue 152 (I  M) located in the HR1 region of the F1 subunit (Table 6.8 and 
Appendix Figure 10.11).  As clones with both resistant and susceptible phenotype 
occurred with both alternatives, this change does not appear to be directly related to the 
phenotype shift. 
 
There were also two silent nucleotide changes in clone R3.2.4 at 946 (C  A) and 1082 
(A  G) and a coding mutation observed in only resistant clone R3.7.8.17 at the residue 
101.  Most clones encoded proline (P), whereas clone R3.7.8.17 encoded serine (S), the 
change resulting from a nucleotide change from C to T at position 301 (Table 6.7 and 
6.8).  This mutation was also found in a previous study where a serine was found at this 
point in the F sequence of susceptible clone N10a of the isolate N5843 (Gias, 2006).  
Accordingly, this mutation is not apparently associated with the shift of resistance to 
susceptibility.  The percentage of amino acid identity for the entire F gene of the 
R17532 and A2 was 96 as shown in Table 6.6.   
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Table 6.6: Percentage of nucleotide identity in the F gene of clone R17532 compared to the A2 
strain.  
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
F 5’UTR 46-58 100 N/A 
F CDS
c 
1-1725 96 96
 
F 3’UTR 1-171 93 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence. 
 
Table 6.7: Summary of nucleotides changes of R17532 in the F gene.  
 
Gene 
Nucleotide sequence 
N
u
cl
eo
ti
d
e 
n
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m
b
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PZ EC50  90 70 48 42 21 12 7 5 3 2.7 
F CDS
a 
301 C C C C T C C C C C 
456 T G T T T T T G T G 
946 C C C C C A C C C C 
1082 A A A A A G A A A A 
 
a
CDS: Coding sequence 
 
 
Table 6.8: Summary of amino acid changes of R17532 in the F glycoprotein.  
 
Protein 
Amino acid sequence 
A
m
in
o
 a
ci
d
 
n
u
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er
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5
.1
 
R
3
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.8
.3
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5
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3
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.8
.1
7
 
R
3
.2
.4
 
R
2
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R
1
1
.1
.1
 
R
5
.1
4
 
R
1
1
.2
 
PZ EC50  90 70 48 42 21 12 7 5 3 2.7 
F CDS
a 
101 P P P P S P P P P P 
152 I M I I I I I M I M 
 
a
CDS: Coding sequence 
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6.7.4 Summary of nucleotide changes of resistant and susceptible clones of R17532 
in the membrane associated protein genes 
Among the 10 virus clones analysed, variability between the SH GE sequence, the G 
and F genes occurred at seven sites (Table 6.9).  The predominant resistant phenotype 
appears to be 8A/T/T/C/T/C/A with susceptible clones acquiring one or more mutations.  
However, clone R5.14 preserves this phenotype and is susceptible and clone R5.1 
differs at 4 of the 7 variable regions yet preserves the resistant phenotypes.  These 
results suggest that none of mutations in the membrane associated glycoprotein genes 
were correlated with the phenotypic shift.  Changes elsewhere in the genome may be 
more important in determining the neutralization phenotype.   
 
Table 6.9: Summary of nucleotide changes of R17532 in the SH GE sequence, G and F genes.  
 
Gene 
Nucleotide sequence 
N
u
cl
eo
ti
d
e 
n
u
m
b
er
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5
.3
 
 R
5
.1
 
R
3
.7
.8
.3
 
R
5
.2
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3
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.1
7
 
R
3
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.4
 
R
2
.4
4
 
R
1
1
.1
.1
 
R
5
.1
4
 
R
1
1
.2
 
PZ EC50  90 70 48 42 21 12 7 5 3 2.7 
SH GE
a 
1-3 8A 7A 8A 8A 8A 7A 7A 7A 8A 7A 
G CDS
b 
884 T C T T T C T C T C 
G-F IR
c 
36 T C T T T T T T T T 
F CDS 
301 C C C C T C C C C C 
456 T G T T T T T G T G 
946 C C C C C A C C C C 
1082 A A A A A G A A A A 
 
a
GE: Gene end sequence, 
b
CDS: Coding sequence;
 c
IR: Intergenic region 
 
In this section the sequences of the region of the hRSV R17532 genome encoding the 
membrane associated genes of the virus from M to F have been compared for resistant 
and susceptible clones R3.7.8.3 and R11.1.1  Changes were found in the R11.1.1 
genome at 3 loci, in the SH GE sequence, in the G and F coding regions  Further 
analysis of multiple clones of differing susceptibility derived from two independent 
isolations of the virus from the original clinical sample revealed no clear cut correlation 
of any mutation with acquisition of resistance and in one clone (clone R5.41) 
acquisition of susceptibility was associated with no mutations in SH gene end the G or 
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the F genes.  It can be concluded therefore that phenotype switching must be associated 
at least for this clone, with changes in other genes.  The sequences of the rest of the 
genome of resistant and susceptible clones were analysed and the results are reported in 
the next chapter. 
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Chapter 7: Comparison of the non-membrane protein genes of 
resistant and susceptible clones of R17532
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7.1 Introduction 
The results from chapter 6 confirmed the conclusion of Gias (2006) and Marsh et al. 
(2007) that mutations in the membrane associated protein genes (M, SH, G, F, and their 
intergenic regions) do not explain the neutralization phenotype shift.  To investigate 
whether changes in the rest of the genome correlated with phenotypic change, 
nucleotide and deduced amino acid sequences of six non-membrane protein genes 
located both upstream (NS1, NS2, N and P) and downstream (M2 and L) of the 
membrane proteins including their intergenic regions were analysed and compared 
between neutralization R17532 susceptible clone R11.1.1 P8 and resistant clone 
R3.7.8.3 P3.  To complete the full sequence of each clone, the 3’leader and 5’trailer 
sequences from both were also determined using genomic RNA circularization, 5’rapid 
amplification of cDNA ends (5’RACE) and 3’rapid amplification of cDNA ends 
(3’RACE) techniques.   
7.2 Preparation of total RNA from infected cell lysates. 
Total RNAs of clone R11.1.1 P8 (PZ 50% inhibitory dose = 0.39 µg/ml; see section 
6.1 ) and clone R3.7.8.3 P3 (PZ EC50 = 48.46 µg/ml) infected cell lysates were isolated 
(section 3.5.1) and this material was used as a template for the RT-PCR amplification of 
all the non-membrane protein genes of the two clones unless stated otherwise.  All 
primers used in amplification and sequence analysis of these genes are presented in 
Table 3.5, 3.6 and 3.7. 
7.3 Amplification of the NS1, NS2, N genes and associated intergenic regions of 
resistant and susceptible clones of R17532  
In the hRSV strain A2 genome, the NS1, NS2 and N genes are encoded by nucleotides  
45 to 576, nucleotides 596 to 1,098 and nucleotides 1,125 to 2,327, respectively 
(GenBank accession number M74568).  The three genes and associated intergenic 
regions were amplified in two overlapping fragments.  For the first fragment, total RNA 
templates were reverse transcribed using the forward NS1 primer (section 3.5.2) and 
amplified using the NS1: NS2-468 primer pair (Figure 7.1) to yield autonomous 
sequence between nt 2 to nt 1,090 and the standard condition described in section 3.5.3.  
Negative controls using RNA extracted from uninfected HeLa NCL cells and DEPC 
treated water were included in the RT-PCR.   
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Figure 7.1: Schematic diagram of primers for amplification and sequencing of the NS1, NS2, N 
genes and associated intergenic regions on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale).  Primers for the first and second fragments are white 
and black arrows, respectively.  Primers NS1 (nt 2-20); NS1-134 (nt 201-178); NS1-442 (nt 486-511); 
NS2-358 (nt 953-976); NS2-468 (nt 1,090-1,063); N713 (nt 1,860-1,837) [Nucleotide numbering is based 
on the A2 genome, GenBank accession number M74568]. 
 
The expected size of the first fragment PCR product was 1,089nt.   Both clones R11.1.1 
P8 and R3.7.8.3 P3 showed two heavy bands and one weak band with the larger heavy 
band being approximately 1,089nt (Figure 7.2).  No bands were present in DEPC 
negative controls.  However, a number of bands of less than 1,000nt were present in the 
HeLa control.  PCR products of the expected size for each primer pair were isolated and 
purified from agarose gels for direct nucleotide sequencing as described in section 3.5.9.  
 
 
Figure 7.2: RT-PCR amplification of the first fragment of the NS1, NS2 genes and associated 
intergenic regions of clones R11.1.1 P8 and R3.7.8.3 P3 using the NS1: NS2-468 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control) 
 
For the second fragment, the forward NS1_442 primer was used in the reverse 
transcription reaction of a fragment of 1,375nt comprising the NS1-NS2 intergenic 
region, the NS2 gene, the NS2-N intergenic region and some part of the N gene.  
Attempts to amplify this fragment using the NS1_442: N713 primer pair to yield 
autonomous sequence between nt 486 to nt 1,860 were initially unsuccessful using 
NS2 NS1
  G 
N 
NS1 NS1-134 
5’
  G 
3’
  G 
NS1-442 N713 NS2-358 
NS2-468 
bp 45 596 576 1,098 1,125 2,327 
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standard conditions (section 3.5.3).  The PCR reaction was therefore optimized for 
magnesium concentration and annealing temperature on the cDNA of clone R11.1.1 P8 
(Figure 7.3 and 7.4).   
 
Figure 7.3 shows the optimization of magnesium concentration at annealing temperature 
55°C.  The expected band of 1,375nt with the least numbers of non-specific bands was 
detected in reaction performed with 7.5 mM MgCl2.  However, when the annealing 
temperature was increased to 60°C, the numbers of non-specific bands in the PCR 
reaction containing 3.75 mM MgCl2 were less than the reaction performed with 7.5 mM 
MgCl2 (Figure 7.4).  Therefore, PCR reaction for both clone R11.1.1 P8 and R3.7.8.3 P3 
were carried out with 3.75 mM MgCl2 and an annealing temperature of 60°C and 
included HeLa NCL and DEPC negative controls.  No band was detected in either 
negative control (Figure 7.5).  The target bands of 1,375nt for both clones were isolated 
and purified from agarose gels for direct nucleotide sequencing (section 3.5.9) 
 
 
Figure 7.3: Optimization of magnesium concentration for the amplification of the second fragment 
included the NS1 gene, NS2 gene, N gene and associated intergenic regions of R11.1.1 P8 using the 
NS1_442: N713 primer pair at annealing temperature 55°C.   
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3, 4 and 5: PCR reaction 
performed with 2.5 mM, 3.75 mM, 5 mM, and 7.5 mM MgCl2, respectively.   
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Figure 7.4: Optimization of magnesium concentration for the amplification of the second fragment 
included the NS1 gene, NS2 gene, N gene and associated intergenic regions of R11.1.1 P8 using the 
NS1_442: N713 primer pair at annealing temperature 60 °C.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2 and 3: PCR reaction performed 
with 3.75 mM and 7.5 mM MgCl2, respectively.   
 
 
Figure 7.5: RT-PCR amplification of the second fragment included the NS1, NS2, N genes and 
associated intergenic regions of R11.1.1 P8 and R3.7.8.3 P3 using the NS1_442: N713 primer pair.   
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2 and 3: R11.1.1 P8; Lane 4 and 5: 
R3.7.8.3 P3; Lane 6: HeLa NCL cells (Negative control) and Lane 7: DEPC treated water (Negative 
control) 
7.4 Sequence comparison of the NS1, NS2, N genes and associated intergenic 
regions of resistant and susceptible clones of R17532 and A2 strain 
The sequence analysis of the NS1 coding region, the NS1 3’UTR, the entire NS2 gene 
and associated intergenic regions were derived from the two fragments of clone R11.1.1 
P11 and clone R3.7.8.3 P3 with the size of 1,089nt (nt 2-1090) and 1,375nt (nt 486-
1860).  The nucleotide numbering was based on the hRSV A2 genome (GenBank 
accession number M74568).    
 
The first fragment was sequenced with the forward NS1 primer in the 5’ to 3’ direction 
(antigenome) and the reverse primers NS1-134 and NS2-468 in the 3’ to 5’ direction as 
described in section 3.5.9 and Figure 7.1.  This provided readable sequence from nt 21 
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to 1,010.  The second fragment was sequenced from forward primers NS1-442 and 
NS2-358 in the 5’ to 3’ direction and the reverse primers N713 in the 3’ to 5’ direction 
provided readable sequence from nt 535 to 1,788.   
 
Comparison of the sequence data between the two clones revealed no nucleotide 
changes in the NS1 coding region (Appendix Figure 10.13), the NS1 3’UTR (Appendix 
Figure 10.14), the entire NS2 gene (Appendix Figure 10.15, 10.16 and 10.17) and 
associated intergenic regions (Appendix Figure 10.15 and 10.18).  These regions were 
fully conserved in the neutralization resistant and susceptible clones of R17532.    
 
There were several nucleotide differences between the R17532 strain and the A2 strain, 
leading to one amino acid change in the NS1 protein and three amino acid changes in 
the NS2 protein with the percentage of amino acid identity of 99 and 97, respectively 
(Table 7.1, Appendix Figure 10.13 and 10.16).  The percentage of nucleotide identity in 
each region between the A2 and R17532 are shown in Table 7.1. 
 
Table 7.1: Percentage of nucleotide identity in the NS1 gene, NS2 gene and associated intergenic 
regions of clone R17532 compared to the A2 strain.  
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity 
R17532 vs. A2 
NS1 CDS
c
 1-420 95 99
d 
NS1-3’UTR 1-57 96 N/A 
NS1-NS2 IR 1-19 89 N/A 
NS2 5’UTR 20-51 90 N/A 
NS2 CDS
 
1-375 96 97
e 
NS2 3’UTR 1-96 91 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence; 
d
I105L; 
e
T8N, R38K and R55K. 
 
7.5 Amplification of the N gene and associated intergenic regions of resistant and 
susceptible clones of R17532  
cDNA comprising the N gene and N-P intergenic region of clone R11.1.1 P8 and clone 
R3.7.8.3 P3 was produced by reverse transcription using the forward NP1674 primer 
(section 3.5.2) and amplified using the NP1674: P162 primer pair (Figure 7.6) and the 
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standard conditions (section 3.5.3).  Negative controls of HeLa NCL cells and DEPC 
treated water were included in the reaction.  Intense bands of the expected size of 840nt 
with autonomous sequence between nt 1,674 to nt 2,513 were present for both clones, 
but not in either negative control (Figure 7.7).  The target bands were isolated and 
purified for direct sequencing as described in section 3.5.9.   
 
 
 
 
 
 
 
Figure 7.6: Schematic diagram of primers for amplification and sequencing of the NS2, N genes 
and associated intergenic regions on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale).  Primers for the NS2, N genes and associated 
intergenic regions used in section 7.3 and 7.4 are white arrows and primers for the N gene and N-P 
intergenic region are black arrows.  Primers NS2-358 (nt 953-976); NP1674 (nt 1,674-1,696); N713 (nt 
1,860-1,837); P162 (nt 2,513-2,490) [Nucleotide numbering is based on the A2 genome, GenBank 
accession number M74568]. 
 
 
 
Figure 7.7: RT-PCR amplification of the N gene and associated intergenic regions of R11.1.1 P8 
and R3.7.8.3 P3 using the NP1674: P162 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2 and 3: R11.1.1 P8; Lane 4 and 5: 
R3.7.8.3 P3; Lane 6: HeLa NCL cells (Negative control) and Lane 7: DEPC treated water (Negative 
control) 
7.6 Sequence comparison of the N gene and associated intergenic regions of 
resistant and susceptible clones of R17532 and A2 strain 
The NS2-N intergenic region and the N coding sequence for clones R11.1.1 P8 and 
R3.7.8.3 P3 were sequenced from the 1,375nt amplicand generated in section 7.3 in 
both directions using the forward primer NS2-358 in the 5’ to 3’ direction (antigenome) 
N NS2
  G 
P 5’
  G 
3’
  G 
P162 NP1674 
N713 NS2-358 
1,098 bp 596  1,125 2,327 2,329  3,242 
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and the reverse primer N713 in the 3’ to 5’ direction (Figure 7.6).  This provided 
readable sequence from nt 535 to 1,788.  The nucleotide numbering was based on the 
hRSV A2 genome (GenBank accession number M74568).  The nucleotide sequence of 
the 840nt target band generated in section 7.5 was analysed using the forward primer 
NP1674 in the 5’ to 3’ direction and the reverse primer P162 in the 3’ to 5’ direction.  
This provided readable sequence from nt 1,725 to 2,457. 
  
The nucleotide and amino acid sequence of the NS2-N intergenic region, the N gene 
and the N-P intergenic region in clone R11.1.1 P8 were the same as those in clone 
R3.7.8.3 P3, suggesting that the N gene was conserved during passage in HeLa cells 
(Appendix Figure 10.18, 10.19 and 10.20).  There were, however, several nucleotide 
differences between the R17532 strain and the A2 strain.  The NS2-N intergenic region, 
varied at 5 nucleotides giving a percentage of nucleotide identity of 80 (Table 7.2 and 
Appendix Figure 10.18).  Three amino acid changes between the two viruses were 
observed and the percentage of amino acid identity was 99 (Table 7.2 and Appendix 
Figure 10.19).  In the N-P intergenic region (2 nucleotides long), a deletion at the 
position 1 of the A2 was observed with only 50% nucleotide identity (Table 7.2 and 
Appendix Figure 10.20).   
 
Table 7.2: Percentage of nucleotide identity in the N gene and associated intergenic regions of clone 
R17532 compared to the A2 strain.   
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
NS2-N IR 1-26 80 N/A 
N 5’UTR 27-41 92 N/A 
N CDS
c 
1-1176 97 99
d 
N 3’UTR 1-13 100 N/A 
N-P IR 14-15 50 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence; 
d
V64L, V160I and Y216H. 
7.7 Amplification of the P gene and associated intergenic regions of resistant and 
susceptible clones of R17532 
In the hRSV strain A2 genome, the P gene stretches from nt 2,329 to nt 3,242 (GenBank 
accession number M74568).  The cDNA synthesis of a fragment consisting of the N-P 
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intergenic region, the P gene, and the P-M intergenic region was performed for both 
clone R11.1.1 P8 and clone R3.7.8.3 P3 using the forward P2128 primer and amplified 
in PCR reactions using the P2128: P3459 primer pair (Figure 7.8) to yield autonomous 
sequence between nt 2,128 to nt 3,459 and the standard conditions (section 3.5.3).  
Uninfected HeLa NCL cells and DEPC controls were included.  An intense target band 
of expected size 1,332nt was detected in reactions for both viruses, whilst there were no 
bands in either negative control (Figure 7.9).  These target bands were purified for direct 
sequencing as described in section 3.5.9. 
 
 
 
 
 
 
Figure 7.8: Schematic diagram of primers for amplification and sequencing of the P gene and 
associated intergenic regions on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale). Primers are black arrows. Primers P2128 (nt 2128-
2149); PS3 (nt 2,720-2,748); PS4 (nt 2,971-2,944); P3459 (nt 3,459-3,437) [Nucleotide numbering is 
based on the A2 genome, GenBank accession number M74568]. 
 
 
 
Figure 7.9: RT-PCR amplification of the P gene and associated intergenic regions of clones R11.1.1 
P8 and R3.7.8.3 P3 using the P2128: P3459 primer pair. 
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
7.8 Sequence comparison of the P gene of resistant and susceptible clones of 
R17532 and A2 strain 
The 1,332nt target for clones R11.1.1 P8 and R3.7.8.3 P3 was sequenced in the 5’ to 3’ 
direction (antigenome) using the forward primer P2128 and PS3.  In the 3’ to 5’ 
direction, the reverse primers P3459 and PS4 were used in direct sequencing (Figure 
P N M 
P2128 
5’
  G 
3’
  G 
PS3 P3459 PS4 
bp 1,125 2,329 2,327 3,242 3,252 4,209 
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7.8).  Readable sequence both directions was obtained from nt 2,139 to 3,449 based on 
the hRSV A2 genome (GenBank accession number M74568).  Sequence of the N-P and 
P-M intergenic regions between the R17532 and A2 were analysed above in section 7.6 
and 6.4, respectively.  The sequence of the P gene revealed no nucleotide changes  
between clones R11.1.1 P8 and R3.7.8.3 P3, suggesting this region was fully conserved 
(Appendix Figure 10.21, 10.22 and 10.23).  
 
However, several nucleotide of A2 were different from those of the R17532.  There 
were only two coding changes between the two viruses and the percentage of amino 
acid identity was 99 (Table 7.3 and Appendix Figure 10.22).  In the P gene 3’UTR, a 
high level of sequence differences between the A2 and R17532 was observed with 87% 
identity percentage  (Table 7.3 and Appendix Figure 10.23).  
 
Table 7.3: Percentage of nucleotide identity in the N-P intergenic region and the P gene of clone 
R17532 compared to the A2 strain.   
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
P 5’UTR 4-17 100 N/A 
P CDS
c 
1-726 97 99
d 
P 3’UTR 1-171 87 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence; 
d
V73A and V171I. 
 
7.9 Amplification of the M2 gene and associated intergenic regions of resistant 
and susceptible clones of R17532 
For the hRSV strain A2 genome, the M2 gene is encoded by nucleotides nt 7,597 to nt 
8,557 (GenBank accession number M74568).  The F-M2 intergenic region and the M2 
gene of clone R11.1.1 P8 and clone R3.7.8.3 P3 were reverse transcribed using the 
forward M2F primer and amplified using the M2F: M2R primer pair (Figure 7.10) and 
the standard conditions (section 3.5.3).  Uninfected HeLa NCL cells and DEPC treated 
water were included as negative controls.   
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Figure 7.10: Schematic diagram of primers for amplification and sequencing of the F-M2 intergenic 
region and the M2 gene on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale). Primers are black arrows. Primers M2F (nt 7,411-
7,434); M2R (nt 8,669-8,646) [Nucleotide numbering is based on the A2 genome, GenBank accession 
number M74568]. 
 
Heavy bands of the expected size of 1,259nt with autonomous sequence between nt 
7,411 to nt 8,646 were produced in reactions for both virus clones.  There was no target 
band in either negative control (Figure 7.11).  The PCR products were extracted and 
purified for direct nucleotide sequencing as described in section 3.5.9. 
 
 
Figure 7.11: RT-PCR amplification of the F-M2 intergenic region and the M2 gene of clones 
R11.1.1 P8 and R3.7.8.3 P3 using the M2F: M2R primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5:  DEPC treated water (Negative control). 
7.10 Sequence comparison of the F-M2 intergenic region and the M2 gene of 
resistant and susceptible clones of R17532 and A2 strain 
The sequence of the 1,259nt band for clone R11.1.1 P8 and R3.7.8.3 P3 was analysed 
using the forward primer M2F and the reverse primer M2R in the 5’ to 3’ and 3’ to 5’ 
directions (antigenome), respectively.  Sequence readable in both direction was obtained 
from nt 7,457 to 8,616 based on the hRSV A2 genome (GenBank accession number 
M74568).  No nucleotide changes in this region were observed between both clones 
(Appendix Figure 10.24, 10.25 and 10.26). 
 
M2 F L 
M2F 
5’
  G 
3’
  G 
M2R 
bp 5,648 7,597 7,550 
8,490 8,557 15,067 
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The M2 sequence of the A2 (GenBank accession number M74568) differed from that of 
the R17532 at several positions.  The percentages of nucleotide identity in each region 
are presented in Table 7.4.  Two coding changes in the residue 120 and 182 were 
detected in the A2 compared to the R17532 and the percentage of amino acid identity 
was 98 (Table 7.4 and Figure 10.25).    
 
Table 7.4: Percentage of nucleotide identity in the F-M2 intergenic region and the M2 gene of clone 
R17532 compared to the A2 strain.   
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
F-M2 IR 1-46 76 N/A 
M2 5’UTR 47-55 100 N/A 
M2 CDS
c 
1-585 97 98
d 
M2 3’UTR 1-367 92 N/A 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence; 
d
P120L and N182S. 
7.11 Amplification of the L gene of resistant and susceptible clones of R17532 
In the hRSV strain A2 genome, the L gene stretches from nt 8,490 to nt 15,067, an 
approximate size of 7 kilo nucleotides (GenBank accession number M74568).  Thus, it 
was amplified in 6 fragments which were LF1 (nt 8,444 to nt 9,815), LF2 (nt 9,605 to nt 
10,845), LF3 (nt 10,598 to nt 12,007), LF4 (nt 11,830 to nt 13,059), LF5.1 (nt 12,891 to 
nt 14,319) and LF5.2 (nt 14,161 to nt 15,153).  The reverse transcriptions of the LF1, 
LF2 and LF3 fragments were performed using the forward M2-848 primer (Figure 
7.12).   
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Figure 7.12: Schematic diagram of primers for amplification and sequencing of the M2 and L genes on hRSV antigenome.   
hRSV genes are depicted as rectangles (not to scale). Primers for the fragments LF1, LF2, LF3, LF4, LF5.1 and LF5.2 are black, red, green, violet, pink and blue arrows, 
respectively. Primers for the second round amplification of the fragment LF5.2 are orange arrows. Primers for amplification of the base between 15,109 and 15,175 of clone 
R3.7.8.3 P3 are grey arrows.  Primers M2-848 (nt 8,444-8,462); L589 (nt 9,078-9,097); L662 (nt 9,173-9,151); L716 (nt 9,226-9,205); L1116 (nt 9,605-9,629); L1307 (nt 
9,815-9,796); L3-1 (nt 10,598-10,618); L2337 (nt 10,845-10,826); L3-3 (nt 11,250-11,275); L3-4 (nt 11,467-11,448); L4-1 (nt 11,830-11,856); L3-2 (nt 12,007-11,987); L5-
1 (nt 12,891-12,914); L4-2 (nt 1,3059-13,040); L5-5 (nt 13,426-13,449); L5-6 (nt 13,588-13,562); L5-4 (nt 14,161-14,184); L5-7 (nt 14,215-14,234); L5-3 (nt 14,319-
14,300); L5-8R (nt 15,017-15,041);  L5-8 (nt 15,041-15,017); L5-2 (nt 15,153-15,130); L5-9 (nt 15,222-15,199) [Nucleotide numbering is based on the A2 genome, 
GenBank accession number M74568]. 
M2 L 
M2-848 
5’
  G 
3’
  G 
L1307 L589 L662 L716 
L1116 L2337 
L3-1 L3-2 
L4-2 
L5-3 
L5-2 
L5-9 L3-4 L3-3 
L4-1 
L5-1 L5-6 L5-5 
L5-4 
L5-7 
L5-8R 
L5-8 
bp 7,597 
8,490 8,557 15,067 
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The PCR reaction of the LF1 fragment was carried out using the M2-848: L1307 primer 
pair and uninfected HeLa NCL cells and DEPC controls were included.  The expected 
size of this PCR product was 1,372nt.  A band of this size was detected in both clone 
R11.1.1 P8 (faint band) and clone R3.7.8.3 P3 (strong band).  Although no target band 
was observed in either negative control, there were some mis-priming products and non-
specific bands in the reactions for both viruses (Figure 7.13).  Nevertheless, the target 
bands were isolated and purified for direct nucleotide sequencing as described in section 
3.5.9.   
 
 
Figure 7.13: RT-PCR amplification of the LF1 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the M2_848: L1307 primer pair. 
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
 
For the LF2 and LF3 fragments, the PCR reactions for clones R11.1.1 P8, R3.7.8.3 P3 
and negative controls (uninfected HeLa NCL cells and DEPC treated water) were 
performed using the L1116: L2337 and L3-1: L3-2 primer pairs, respectively.  The 
expected sizes of amplicons were 1,241nt for the LF2 fragment (Figure 7.14) and 
1,410nt for the LF3 fragment (Figure 7.15).  Bands of the correct size were obtained 
from the two clones, but not from the negative controls.  Both target bands were isolated 
and purified for direct nucleotide sequenced as described in section 3.5.9. 
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Figure 7.14: RT-PCR amplification of the LF2 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the L1116: L2337 primer pair.   
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
 
 
 
 
Figure 7.15: RT-PCR amplification of the LF3 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the L3-1: L3-2 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
 
The forward L4-1 primer was used in reverse transcription of the LF4 fragment in clone 
R11.1.1 P8, clone R3.7.8.3 P3, uninfected HeLa NCL cells and a DEPC treated water 
negative control.  Amplicons of the expected size (1,230nt) for this fragment were 
produced from both clones using the L4-1: L4-2 primer pair.  There was no amplicon of 
this size in either negative control (Figure 7.16).  These target bands were isolated and 
purified for direct nucleotide sequencing as described in section 3.5.9.   
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Figure 7.16: RT-PCR amplification of the LF4 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the L4-1: L4-2 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
 
Figure 7.17 and 7.18 show the amplification of the L5.1 and L5.2 fragments, 
respectively.  Both fragments of clones R11.1.1 P8 and R3.7.8.3 P3 were reverse 
transcribed using the forward L5-1 primer and amplified using the L5-1: L5-3 primer 
pair for the L5.1 fragment and the L5-4: L5-2 primer pair for the L5.2 fragment.  
Negative controls of uninfected HeLa NCL cells and DEPC treated water were 
included.  The target bands of the expected size, 1,429nt for the L5.1 and 993nt for the 
L5.2, were detected in both clones R11.1.1 P8 and R3.7.8.3 P3, but not in the negative 
controls.  Direct nucleotide sequencing of the target bands was performed after isolation 
and purification as described in section 3.5.9.  
 
 
Figure 7.17: RT-PCR amplification of the LF5.1 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the L5-1: L5-3 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
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Figure 7.18: RT-PCR amplification of the LF5.2 fragments of clones R11.1.1 P8 and R3.7.8.3 P3 
using the L5-2: L5-4 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: R3.7.8.3 P3; 
Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated water (Negative control). 
7.12 Sequence comparison of the L gene of resistant and susceptible clones of 
R17532 and A2 strain 
The entire L gene of clone R11.1.1 P8 and R3.7.8.3 P3 was amplified in six overlapping 
fragments and sequenced in the 5’ to 3’direction (antigenome) using the forward 
primers M2-848, L589, L1116, L3-1, L3-3, L4-1, L5-1, L5-4 and L5-5.   In the 3’ to 5’ 
direction, the same PCR products were sequenced using the reverse primers L1307, 
L662, L716, L2337, L3-2, L3-4, L4-2, L5-2, L5-3 and L5-6.  These reactions yielded 
readable sequence in both directions between nt 8,528 and nt 15,108. 
 
In the L coding region, two nucleotide changes were detected between clone R11 and 
R3 as shown in Appendix Figure 10.27.  The first nucleotide change occurred at the 
nucleotide position 916 that was A in clone R3.7.8.3 P3 and G in clone R11.1.1 P8, 
leading to an amino acid change from asparagine to aspartic acid at residue 306.  The 
second nucleotide change, T in clone R3.7.8.3 P3 changed to G in clone R11.1.1 P8 
occurred at position 6162, resulting in an amino acid change from phenylalanine to 
leucine at residue 2054.  The percentage of amino acid identity between clone R11 and 
R3 was 99.   
 
A2 has an asparagine at residue 306 and a leucine at residue 2054 and the percentage of 
amino acid identity between R17532 and A2 was 98 (Table 7.5).  There were 28 
additional amino acid differences between A2 and R17532.  In 3’UTR of the L gene, 
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there were no nucleotide changes between clone R11.1.1 P8 and R3.7.8.3 P3; but the 
percentage of nucleotide identity between A2 and R17532 was 91.  
 
Table 7.5: Percentage of nucleotide identity in the L coding sequence and 3’UTR of the L gene of 
clone R17532 compared to the A2 strain. 
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
L 5’UTR 1-8 100 N/A 
L CDS
c 
1-6,498 97 98
 
L 3’UTR 1-72 91 N/A 
 
 
a
NT: Nucleotide; 
b
AA: Amino acid;
 c
CDS: Coding sequence 
 
7.13 Amplification of the 3’ leader, the 5’UTR of the NS1 gene and 5’ trailer 
regions of resistant and susceptible clones of R17532 
7.13.1 Genomic RNA circularization 
Amplification of the 3’ leader, the 5’UTR of the NS1 gene and 5’ trailer regions from 
crude virus lysate 
Total RNAs of infected cell lysates of clone R11.1.1 P8 (section 7.2) were circularized 
using T4 RNA ligase and the junction region including sequences of both the 3’ and 
5’ends were amplified by RT-PCR as described in section 3.5.4 and Figure 3.1.  
Negative controls (uninfected HeLa NCL cells and DEPC treated water) were included. 
The forward Lend primer was used for reverse transcription and the Lend: NS1end 
primer pair for 1
st
 round PCR (Figure 7.19).  The expected size of this PCR product was 
642nt, but no band of this size appeared in any sample.  Non-specific bands were 
present possibly resulting from mis-priming of RNA of host cells because they were 
also detected in uninfected HeLa NCL cell controls (Figure 7.20).  
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Figure 7.19: Schematic diagram of primers for amplification and sequencing of the genomic RNA 
ligation.   
hRSV genes on the antigenome are depicted as rectangles (not to scale). Primers for the first round PCR 
amplification are white arrows and for the second round PCR are grey and black arrows.  Lend (nt 14812-
14825); L5-8R (nt 15017-15041); L5-2R (nt 15130-15153); NS1.1 (nt 44-21); NS1-26 (nt 92-70); NS1-
134 (nt 201-178); NS1end (231-212) [Nucleotide numbering is based on the A2 genome, GenBank 
accession number M74568]. Tr: 5’trailer region; Le: 3’leader region. 
 
 
 
Figure 7.20: First round PCR amplification of the genomic RNA ligation of clones R11.1.1 P8 using 
the Lend: NS1end primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8; Lane 3: HeLa NCL 
cells (Negative control) and Lane 4: DEPC treated water (Negative control). 
 
The PCR products from the first round PCR were diluted and used as a template for the 
second round PCR using the L5-8R: NS1-134 primer pair.  The expected size of 
amplicon was 383nt.  However, the size of the visible band in clone R11.1.1 P8 
(approximately 290nt) was less than size of the expected amplicon (Figure 7.21).  The 
sequence of the 290nt band was analysed using the forward primer L5-8R and the 
reverse primer NS1-134 in the 5’ to 3’ and the 3’ to 5’ directions (antigenome), 
respectively.  Sequence analysis of this band revealed it to be a ligation product between 
the 5’trailer region from base 15,068 to 15,209 (GenBank accession number M74568) 
not reaching to the end of genome and the NS1 gene from base 154 to 201, not the 
3’leader region (data not shown).  These finding suggested that circularization of broken 
genomes had occurred.  
 
L NS1 
Lend 
5’
  G 
3’
  G 
L5-8R NS1end NS1-134 
34 
NS1-26 L5-2R NS1.1 
Le Tr 
15,222 bp 15,068 1 44 
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Figure 7.21: Second round PCR amplification of the genomic RNA ligation of clones R11.1.1 P8 
using the L5-8R: NS1-134 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1.1 P8 at dilution 10
-1
, Lane 
3: R11.1.1 P8 at dilution 10
-2
, Lane 4: HeLa NCL cells (Negative control) and Lane 5: DEPC treated 
water (Negative control) 
 
An alternative primer pair for the second round PCR L5-2R: NS1-26 was designed in 
the region close to both 5’ and 3’ends to generate an amplicon with the expected size of 
185nt.  Figure 7.22 shows visible bands were slightly larger than the expected amplicon 
approximately 200nt in all dilutions of PCR products.  The sequence of the 200nt band 
for clone R11.1.1 P8 was analysed using the forward primer L5-2R in the 5’ to 3’ 
direction and the reverse primer NS1-26 in the 3’ to 5’direction (antigenome).  
Sequence analysis of this product revealed mixed sequences of the 5’termini connected 
with the 3’termini which were uninterpretable (Figure 7.23).   
 
 
                                             
Figure 7.22: Second round PCR amplification of the genomic RNA ligation of clones R11.1.1 P8 
using L5-2R: NS1-26 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.1. 1 P8 at dilution 10
-1
, Lane 
3: R11.1.1 P8 at dilution 10
-2
, Lane 4: R11.1.1 P8 at dilution 10
-3
, Lane 5: HeLa NCL cells (Negative 
control) and Lane 6: DEPC treated water (Negative control) 
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Figure 7.23: Sequence data of 5’and 3’ termini of the R11.1.1 P8 genome.  
 
Amplification of the 3’ leader, the 5’UTR of the NS1 gene and 5’ trailer regions from 
purified viruses  
The above results failed to resolve the sequences of the 3’ leader, the 5’UTR of the NS1 
gene and 5’ trailer regions.  Consequently, an attempt was made to improve the quality 
of the sequences by using purified virus as a source for RNA.  Clone R11.1.1 P12 and 
clone R3.7.8.3 P3 virions were purified by PEG precipitation followed by 
ultracentrifugation on discontinuous then continuous iodixanol density gradients as 
described in section 3.4.13.  Two continuous gradients were prepared for each clone, 
fractionated and each fraction assayed for virus infectivity by infection focus assay 
(section 3.4.6).  
 
In both clones, the density of 1.17 g/ml was the peak of infectivity.  However, the 
infectivity of clone R11.1.1 P12 in gradient 1 and gradient 2 was distributed across 
fraction 6 – 11 with a density range of 1.14 – 1.23 g/ml and fraction 5 – 7 with a density 
range of 1.11 – 1.17 g/ml, respectively (Figure 7.24 and Table 7.6).  Fraction 6 and 7 of 
gradient 1 and fraction 6 and 7 of gradient 2 were pooled and the infectivity titre of the 
pool was 3.4 x 10
6
.  In clone R3.7.8.3 P3, the infectivity was distributed across fraction 
6 – 9 in both gradient 1 and gradient 2 with a density range between 1.13 – 1.18 for 
gradient 1 and 1.14 – 1.18 for gradient 2 (Figure 7.25 and Table 7.6).  Fraction 7 and 8 
of gradient 1 and fraction 7 of gradient 2 were pooled to give a pool of infectivity 3.0 x 
10
6
.   
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Figure 7.24: The recovery rate and distribution of clone R11.1.1 P12 infectivity across continuous 
iodixanol density gradient 1 and 2. 
Bars were prepared from triplicate values and error bars represent the standard deviation. 
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Figure 7.25: The recovery rate and distribution of clone R3.7.8.3 P3 infectivity across continuous 
iodixanol density gradient 1 and 2. 
Bars were prepared from triplicate values and error bars represent the standard deviation. 
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Table 7.6:  Summary of densities and viral titres of purified clones R11.1.1 P12 and R3.7.8.3 P3 in 
continuous iodixanol gradient 1 and 2. 
 
Virus Fraction 
Gradient 1 Gradient 2 
Density 
(g/ml) 
Titre 
(FFU/ml) 
Standard 
deviation 
Density 
(g/ml) 
Titre 
(FFU/ml) 
Standard 
deviation 
R11.1.1 
P12 
5 N/A - - 1.11 2.27 x 10
4 1.07 x 104 
6 1.14 2.93 x 10
5 1.97 x 105 1.15 2.13 x 105 2.31 x 104 
7 1.17 3.20 x 10
5 1.83 x 105 1.17 1.07 x 105 1.67 x 104 
8 1.18 1.33 x 10
4 8.33 x 103 N/A - - 
9 1.20 4.00 x 10
3 6.93 x 103 N/A - - 
10 1.20 6.67 x 10
3 6.11 x 103 N/A - - 
11 1.23 8.00 x 10
3 0 N/A - - 
R3.7.8.3 
P3 
6 1.13 5.33 x 10
3 4.62 x 103 1.14 5.87 x 104 1.89 x 104 
7 1.17 5.73 x 10
5 8.34 x 104 1.17 2.25 x 105 1.29 x 104 
8 1.17 1.47 x 10
5 4.62 x 104 1.18 4.00 x 104 6.93 x 103 
9 1.18 8.00 x 10
3 4.00 x 103 1.18 8.00 x 103 4.00 x 103 
 
The neutralization phenotype of each pool was determined by immunoperoxidase focus 
reduction neutralization assay against PZ.  The purified clone R11.1.1 P12 was found 
susceptible to neutralization by PZ with an EC50 of 10.23.  Purified clone R3.7.8.3 P3 
was relatively resistant with an EC50 >125 µg/ml (Figure 7.26).  Two-way ANOVA 
analysis showed the two clones to be significantly different (P<0.0001). 
 
Figure 7.26: The percentage virus survival of purified R11.1.1 P12 and R3.7.8.3 P3 after 
neutralization with PZ.  
Plots were prepared from triplicate values and error bars show the standard error.  The 50% reduction 
level is indicated by (…). 
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RNA was extracted from purified clones R11.1.1 P12 and R3.7.8.3 P3 as described in 
section 3.5.1.  The RNA genomes of both clones were circularized by T4 RNA ligase 
(section 3.5.4).  First and second round PCR were carried out using the Lend: NS1end 
and L5-2R: NS1-26 primer pairs (Figure 7.19), respectively.  The expected size of the 
product from the first round was 642nt.  Non-specific bands were detected in the first 
round PCR of both purified clones R11.1.1 P12 and R3.7.8.3 P3 (Figure 7.27 and 7.28, 
respectively).  In the second round, there were no non-specific bands, but the size of the 
visible bands for the two clones (approximately 210nt) was somewhat larger than the 
185nt band expected (Figure 7.29 and 7.30). 
.   
 
 
Figure 7.27: First round PCR amplification of the genomic RNA ligation of purified R11.1.1 P12 
using the Lend: NS1end primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: purified R11.1.1 P12; Lane 3: 
HeLa NCL cells (Negative control) and Lane 4: DEPC treated water (Negative control). 
 
 
 
Figure 7.28: First round PCR amplification of the genomic RNA ligation of purified R3.7.8.3 P3 
using the Lend: NS1end primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: purified R3.7.8.3 P3; Lane 3: 
HeLa NCL cells (Negative control) and Lane 4: DEPC treated water (Negative control) 
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Figure 7.29: Second round PCR amplification of the genomic RNA ligation of purified R11.1.1 P12 
using the L5-2R: NS1-26 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: purified R11.1.1 P12 at 
dilution 10
-1
, 10
-3
 and 10
-5
. Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC treated water 
(Negative control). 
 
 
 
Figure 7.30: Second round PCR amplification of the genomic RNA ligation of purified R3.7.8.3 P3 
using the L5-2R: NS1-26 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3, 4 and 5: purified R3.7.8.3 P3 at 
neat, dilution 10
-1
, 10
-2
 and 10
-3
.  Lane 6: HeLa NCL cells (Negative control) and Lane 7: DEPC treated 
water (Negative control) 
 
The 210nt target for purified clone R11.1.1 P12 was sequenced in the 5’ to 3’ direction 
(antigenome) using the forward primer L5-2R and in the 3’ to 5’ direction using the 
reverse primer NS1-26.  The sequence analysis for this region yielded clear sequences 
of the 5’ and 3’ ends, from nt 15,171 to nt 15,222 and from nt 1 to nt 92 respectively, 
when compared to the published genome end sequence for the A2 strain (GenBank 
accession number M74568); however, two base insertions of thymine were present at 
the junction of the two ends (Figure 7.31A).  To confirm these insertions, the genomic 
RNA circularization and RT-PCR were repeated using the same RNA of purified 
R11.1.1 P12 and the same primer pairs.  No insertions were detected in the sequence 
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analysis of the repeated PCR product, but the first position of 3’end showed multiple 
peaks of A, C and G bases, with G the largest chromatogram (Figure 7.31B).  
 
Alternative reverse primer (NS1.1 primer) was chosen to replace the NS1-26 primer in 
the second round PCR.  The expected size of amplicon of this reaction was 137nt.  
Dilution of the first round product from above (Figure 7.27) was reamplified with these 
primers and a band of this size was observed in undiluted PCR products (Figure 7.32).  
The 137nt band of purified clone R11.1.1 P12 was sequenced using the forward primer 
L5-2R and the reverse primer NS1.1 in the 5’ to 3’ and 3’ to 5’ directions, respectively.  
The sequence analysis of this band still gave multiple peaks at the beginning of 3’end 
(Figure 7.33) 
 
 
 
 
        
 
Figure 7.31: Sequence data of 5’and 3’ termini of purified R11.1.1 P12 genome.  
Panel A: chromatogram showing two nucleotides insertion between 5’ and 3’ end of genome. Panel B: 
chromatogram of repeated sequencing showing multiple peaks (red circle) in the beginning of 3’end 
genome and no insertion. 
 
 
 
 
 
 
 
 
A. 
B. 
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Figure 7.32: Second round PCR amplification of the genomic RNA ligation of purified R11.1.1 P12 
using the L5-2R: NS1.1 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: purified R11.1.1 P12 at 
neat, dilution 10
-1
 and dilution 10
-2
.  Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC 
treated water (Negative control) 
 
 
 
 
 
Figure 7.33: Sequence data of 5’and 3’ termini of purified R11.1.1 P12 genome using the L5-2R: 
NS1.1 primer pair.  The red circle shows multiple peaks at the beginning of 3’end genome. 
 
For purified clone R3.7.8.3 P3, the sequence analysis of the 210nt product from Figure 
7.30 using the forward primer L5-2R in the 5’ to 3’ direction and the reverse primer 
NS1-26 in the 3’ to 5’ direction revealed the L gene sequence directly connected to the 
N gene, not to the NS1 gene (data not shown).  The sequence of the L gene also did not 
reach to the expected end of 5’trailer region.  This suggests that RNA generated from 
purified clone R3.7.8.3 P3 may have insufficient or poor quality.  It was concluded that 
circularization of genomic RNA was unlikely to yield interpretable sequences for the 
ends of the genomic. 
7.13.2 Rapid amplification of cDNA ends (RACE) 
5’RACE 
  
190 
 
1
9
0
 
A circularization of the genome proved unsuccessful, the sequence of the 5’end of 
susceptible and resistant clones was sought using 5’RACE as described in section 3.5.5 
and Figure 3.2.  RNA isolated from purified clone R11.1.1 P12 (PZ EC50 = 10.23 µg/ml) 
was used to optimization the technique.  After reverse transcription using the L5-8R 
primer, cDNA was ligated with the adaptor DT88 and amplified using the L5-8R: DT89 
primer pair for a first round PCR and the L5-2R: DT89 primer pair for a hemi-nested 
second round PCR.  Adaptor-ligated uninfected HeLa NCL cells cDNA, unligated 
purified clone R11.1.1 P12 cDNA, unligated HeLa NCL cells cDNA and DEPC treated 
water were amplified with the same primers as negative controls.  The expected sizes of 
amplicons for the first and second round PCR were 233nt and 120nt, respectively. 
 
Target bands were not visible in any sample after the first round PCR Figure 7.34.    
Hemi-nested second round PCR was carried out with several dilutions of PCR products 
from the first round.  In the adaptor-ligated clone R11.1.1 P12 reactions only, there 
were visible bands with the expected size of 120nt.  No band of this size was detected in 
negative control lanes, although multiple bands of non-specific products were observed 
in all samples (Figure 7.35).   
 
 
Figure 7.34: First round PCR amplification of adaptor-ligated cDNA of purified R11.1.1 P12 using 
the L5-8R: DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: adaptor-ligated and purified 
R11.1.1 P12; Lane 3: adaptor-ligated HeLa NCL cells (Negative control), Lane 4: unligated and purified 
R11.1.1 P12 (Negative control for ligation), Lane 5: unligated HeLa NCL cells (Negative control for 
ligation), Lane 6: DEPC treated water (Negative control for PCR) 
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Figure 7.35: Hemi-nested second round PCR amplification of purified R11.1.1 P12 using the L5-
2R: DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: adaptor-ligated and 
purified R11.1.1 P12 at neat, dilution 10
-1
 and dilution 10
-2
, respectively.  Lane 5, 6 and 7: adaptor-ligated 
HeLa NCL cells (Negative control) at neat, dilution 10
-1
 and dilution 10
-2
, respectively. Lane 8: unligated 
purified R11.1.1 P12 (Negative control for ligation), Lane 9: unligated HeLa NCL cells (Negative control 
for ligation). 
 
The magnesium concentration in the second round was optimized and 7.5 mM MgCl2 
resulted in the most intense band of 120nt (Figure 7.36); however, the target band 
produced was inadequate for sequencing following purification.  Therefore, the hemi-
nested second round PCR product isolated from an agarose gel was reamplified with the 
same primers producing sufficient cDNA for direct sequencing (Figure 7.37). 
  
 
Figure 7.36: Optimization of magnesium concentration for the hemi-nested second round PCR 
amplification of purified R11.1.1 P12 using the L5-2R: DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 4, 6 and 8: adaptor-ligated and 
purified R11.1.1 P12 in PCR reaction with 2.5, 3.5, 5.0 and 7.5 mM MgCl2, respectively.  Lane 3, 5, 7 
and 9: adaptor-ligated HeLa in PCR reaction with 2.5, 3.5, 5.0 and 7.5 mM MgCl2, respectively.   
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Figure 7.37: Re-amplification of the hemi-nested second round PCR products of purified R11.1.1 
P12 using the L5-2R: DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: adaptor-ligated and purified 
R11.1.1 P12; Lane 3: unligated HeLa NCL cells (Negative control) and Lane 4: DEPC treated water 
(Negative control) 
 
For the resistant clone 3.7.8.3 P3 (PZ EC50 = 48.46 µg/ml), 5’RACE was performed 
using the same condition as for purified R11.1.1 P12, but using RNA from unpurified 
virus infected cell lysate due to insufficient or poor quality of RNA from purified virus 
(section 7.13.1).  Bands corresponding to the expected size of 233nt and 120nt were 
detected in the first round and second round PCR, respectively (Figure 7.38 and 7.39).  
Moreover, the PCR product of clone R3.7.8.3 P3 in the hemi-nested second round PCR 
was adequate for direct sequencing, thus the re-amplification of this product was not 
required.   
 
 
Figure 7.38: First round PCR amplification of adaptor-ligated cDNA of clone R3.7.8.3 P3 using the 
L5-8R: DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: adaptor-ligated R3.7.8.3 P3; Lane 
3: unligated R3.7.8.3 P3 (Negative control for ligation), Lane 4: unligated HeLa NCL cells (Negative 
control), Lane 5: DEPC treated water (Negative control). 
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Figure 7.39: Hemi-nested second round PCR amplification of clone R3.7.8.3 P3 using the L5-2R: 
DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2 and 3: adaptor-ligated R3.7.8.3 P3 
at dilution 10
-1
 and dilution 10
-2
, respectively.  Lane 4: unligated R3.7.8.3 P3 (Negative control for 
ligation), Lane 5: unligated HeLa NCL cells (Negative control), Lane 6: DEPC treated water (Negative 
control). 
 
The 120nt target band for purified clone R11.1.1 P12 and clone R3.7.8.3 P3 was 
sequenced using the forward primer L5-2R in the 5’ to 3’ direction (antigenome).  The 
sequence analysis of the two clones showed the clear sequence of 5’termini from nt 
15,176 to nt 15,222 linked with the adaptor DT88 sequence.  The sequence 
chromatogram for clone R3.7.8.3 P3 is only present on Figure 7.40. 
 
 
 
Figure 7.40: Sequence data of 5’trailer region of clone R3.7.8.3 P3 genome ligated with the adaptor 
DT88. 
 
For clone R11.1.1 P8, the sequence of the L gene to base 15,108 was determined in 
section 7.12 and from base 15,109 to 15,209 in section 7.13.1 (genome circularization 
of unpurified virus using the sequencing primers L5-8R and NS1-134).  The remaining 
sequence to base 15,222 was obtained from purified clone R11.1.1 P12 using genome 
circularization (section 7.13.1), albeit with an apparent insertion of two bases between 
the 5’ and 3’ends of the genome.  Following the current experiment, sequence for bases 
15,176 and 15,222 has been determined confirming the terminal sequence obtained by 
  
194 
 
1
9
4
 
genome circularization, but demonstrating the absence of additional thymine residues 
on the 5’end.  For clone R3.7.8.3 P3 only the sequence to base 15,108 had previously 
been determined (section 7.12).  The current experiment provides sequence from base 
15,176 to the end of the genome.  Thus, the bases between 15,109 and 15,175 remain 
unknown.  In order to sequence this region, RNA from unpurified virus infected cell 
lysate of clone R3.7.8.3 P3 was reverse transcribed using the L5-1 primer and PCR 
reactions were performed using the L5-8R: L5-9 primer pair (Figure 7.12).  The 
expected size of 206nt was detected in clone R3.7.8.3 P3 (Figure 7.41).  It was isolated, 
purified as described in section 3.5.9 and sequenced using the forward primer L5-8R 
and the reverse primer L5-9 in the 5’ to 3’ and 3’ to 5’ directions, respectively. 
Sequence readable in both directions was obtained from nt 15,018 to 15,221.   
 
 
 
Figure 7.41: RT-PCR amplification of the L gene of R3.7.8.3 P3 using the L5-8R: L5-9 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R3.7.8.3P3; Lane 3: HeLa NCL 
cells (Negative control) and Lane 4: DEPC treated water (Negative control). 
 
 
Comparison of the sequence between clones R11.1.1 and R3.7.8.3 revealed no 
nucleotide change in the 5’trailer region (Appendix Figure 10.29).  However, the 
nucleotide sequence of the A2 for this region differed from those of the R17532 and the 
percentage of nucleotide identity in each region are presented in Table 7.7.  The length 
of the 5’trailer region in the A2 was shorter than in the R17532 by five bases.  
3’RACE from the hRSV anti-genome 
The sequence of 3’leader region (nt 1 to nt 44) and the 5’UTR of the NS1 gene (nt 45 to 
nt 98) in susceptible and resistant clones was determined using 3’RACE from the hRSV 
anti-genome (section 3.5.6 and Figure 3.3).  The anti-genomic RNA from lysates of 
cells infected with parental clone R3.7.8 (PZ EC50 > 125µg/ml) and clone R11.1.1 P11 
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(PZ EC50 = 7.45µg/ml) was reverse transcribed using the NS206 primer, ligated with the 
adaptor DT88 by T4 RNA ligase and amplified using the NS1-206: modified DT89 
primer pair for a first round PCR and the NS1-103: modified DT89 primer pair for a 
hemi-nested second round PCR.  The expected sizes of target bands for the first and 
second round PCR were 297nt and 197nt, respectively.  Adaptor-ligated uninfected 
HeLa NCL cells cDNA, unligated parental clone R3.7.8 cDNA, unligated clone R11.1.1 
P11 cDNA, unligated HeLa NCL cells cDNA and DEPC treated water were amplified 
as negative controls. 
 
In the first round PCR, bands of the expected size were not observed in any sample 
(Figure 7.42).  Visible bands of approximately 150nt were detected in adaptor-ligated 
parental clone R3.7.8 and clone R11.1.1 P11 PCR products from the hemi-nested 
second round reaction (Figure 7.43), whereas the expected size for this reaction was 
197nt. The sequence of the 150nt band for the two clones was analysed using the 
reverse primer NS1-103 in the 3’to 5’direction (antigenome).  Sequence analysis of this 
band revealed a sequence from the NS1 gene start signal linked directly with the adaptor 
DT88 sequences in which 44nt of the 3’leader region was missing and a single A 
residue was inserted between the adaptor DT88 and the NS1 gene (Figure 7.44).  
 
 
Figure 7.42: First round PCR amplification of adaptor-ligated cDNA of parental clone R3.7.8 and 
clone R11.1.1 P11 using the NS1-206: modified DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: adaptor-ligated R3.7.8, 
R11.1.1 P11 and HeLa NCL cells, respectively. Lane 5, 6 and 7: unligated R3.7.8, R11.1.1 P11 and HeLa 
NCL cells (Negative control for ligation), respectively. Lane 8: DEPC treated water (Negative control). 
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Figure 7.43: Hemi-nested second round PCR amplification of parental clone R3.7.8 and clone 
R11.1.1 P11 using the NS1-103: modified DT89 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: adaptor-ligated R3.7.8 at 
neat, dilution 10
-1
 and 10
-2
, respectively.  Lane 5, 6 and 7: adaptor-ligated R11.1.1 P11 at neat, dilution 
10
-1
 and 10
-2
, respectively. Lane 8: adaptor-ligated HeLa NCL cells (Negative control for ligation). Lane 
9, 10 and 11: unligated R3.7.8, R11.1.1 P11 and HeLa NCL cells (Negative control for ligation), 
respectively. Lane 12: DEPC treated water (Negative control). 
 
 
 
Figure 7.44: Sequence data of the NS1 gene start of clone R11.1.1 P11 ligated with the adaptor 
DT88. 
 
3’RACE from the hRSV genome 
In the previous experiment, sequencing in the 3’leader region and the 5’UTR of the NS1 
gene from cDNA generated from the antigenome was unsuccessful.  An alternative was 
to apply the 3’RACE method directly to the RNA genome (section 3.5.7 and Figure 
3.4).  Adaptor DT88 was ligated to the 3’ end of RNA extracted from parental clone 
R3.7.8 (PZ EC50 > 125µg/ml) and clone R11.1.1 P11 (PZ EC50 = 7.45µg/ml).  After 
cDNA synthesis using the DT89 primer, first round and hemi-nested second round PCR 
were performed using the modified DT89: NS1-206 and the modified DT89: NS1-103 
primer pairs, respectively.  The target band of the first round PCR had the expected size 
of 297nt, whilst the expected size of the target band of the hemi-nested second round 
PCR was 197nt.  Adaptor-ligated uninfected HeLa NCL cells RNA, unligated clone 
R11.1.1 P11 RNA, unligated HeLa NCL cells RNA and DEPC treated water were used 
as negative controls. 
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The product of the first round PCR product of the adaptor-ligated R11.1.1 P11 was 
approximately 240nt which was smaller than expected (Figure 7.45).  Nevertheless, 
target bands of 197nt were observed as expected in the second round PCR of this 
sample.  No bands of this size were present any of the negative controls (Figure 7.46).  
Re-amplification of the hemi-nested second round PCR was required to increase the 
intensity of the target band (197nt band) for direct nucleotide sequencing (Figure 7.47). 
  
 
 
Figure 7.45: First round PCR amplification of adaptor-ligated genomic RNA of clone R11.1.1 P11 
using the modified DT89: NS1-206 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: adaptor-ligated R11.1.1 P11; Lane 
3: HeLa NCL cells (Negative control); Lane 4 and 5: unligated R11.1.1 P11 and HeLa NCL cells 
(Negative control for ligation); Lane 6: DEPC treated water  (Negative control). 
 
 
 
Figure 7.46: Hemi-nested second round PCR amplification of clone R11.1.1 P11 using the modified 
DT89: NS1-103 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2 and 3: adaptor-ligated R11.1.1 P11 
at dilution 10
-1
 and 10
-2
, respectively.  Lane 4: HeLa NCL cells (Negative control); Lane 5 and 6: 
unligated R11.1.1 P11 and HeLa NCL cells (Negative control for ligation), respectively. Lane 7: DEPC 
treated water (Negative control). 
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Figure 7.47: Re-amplification of the hemi-nested second round PCR of clone R11.1.1 P11 using the 
modified DT89: NS1-103 primer pair.  
The lanes were loaded as follows; Lane 1: 100nt DNA ladder; Lane 2 and 3: adaptor-ligated R11.1.1 P11 
at neat and dilution 10
-2
, respectively.   
 
The 3’ end genome of parental clone R3.7.8 was amplified by the same method and the 
expected sizes of 297nt and 197nt were detected in the first and second round PCR, 
respectively (Figure 7.48 and 7.49).  The second round PCR products of both clone 
R11.1.1 P11 and parental clone R3.7.8 were isolated, purified as described in section 
3.5.9 and sequenced using the reverse primer NS103 in the 3’ to 5’ direction 
(antigenome).  For both clones of sequence analysis, these target bands showed the 
3’end sequence directly connected with the adaptor DT88.  The sequence chromatogram 
for parental clone R3.7.8 is only present in Figure 7.50.  Readable sequence was 
obtained from nt 1 to 113 which was numbered according to the hRSV A2 genome 
(GenBank accession number M74568).  There were no thymidine additions to the 3’end 
of the either genome suggesting that the presence of two additional thymidines present 
in the circularization R11.1.1 P12 amplicand were artefactual.   
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Figure 7.48: First round PCR amplification of adaptor-ligated genomic RNA of parental clone 
R3.7.8 using the modified DT89: NS1-206 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: adaptor-ligated R3.7.8; Lane 3: 
unligated HeLa NCL cells (Negative control); Lane 4: DEPC treated water (Negative control). 
 
 
 
Figure 7.49: Reamplification by hemi-nested second round PCR of parental clone R3.7.8 using the 
modified DT89: NS1-103 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: adaptor-ligated R3.7.8 at 
neat, dilution 10
-1
 and 10
-2
, respectively.  Lane 5: unligated HeLa NCL cells (Negative control); Lane 12: 
DEPC treated water (Negative control). 
 
 
 
 
Figure 7.50: Sequence data of 3’leader region of parental clone R3.7.8  genome ligated with the 
adaptor DT88. 
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Comparison of the 3’leader region and the 5’UTR of the NS1 gene between the two 
clones, R11.1.1 P11 and parental clone R3.7.8, revealed no nucleotide differences.  The 
R17532 genome differed somewhat from the A2 in their region (Table 7.7). 
 
Table 7.7: Percentage of nucleotide identity in the 3’ leader region, 5’UTR of the NS1 gene and 5’ 
trailer region of clone R17532 compared to the A2 strain.  
 
Region NT#
 % NT
a
 identity  
R17532 vs. A2 
3’leader region 1-44 97 
NS1 5’UTR 45-98 96 
5’trailer region 1-160 88 
 
                                           a
NT: Nucleotide 
 
The whole genome of R3.7.8.3 P3 (PZ EC50 = 48.46 µg/ml) has been sequenced in both 
direction apart from the ends, bases 1 to 44 at the 3’end obtained from parental clone 
R3.7.8 (PZ EC50 > 125µg/ml) and bases 15,068 to 15,222 at the 5’end from clone 
R3.7.8.3 P3 for which only one direction was achieved.  For clone R11 base 1 to 113 
has been sequenced from clone R11.1.1 P11 (PZ EC50 = 7.45µg/ml), base 114 - 4,695 
from R11.1.1 P8 (PZ EC50 = 0.39 µg/ml), base 4,696 - 15,175 from R11.1.1 P8 and base 
15,176 - 15,222 from purified clone R11.1.1 P12 (PZ EC50 = 10.23 µg/ml).  Again only 
the ends (nt 1 – 113 of 3’end and 15,176 – 15,222 of 5’end) have not been sequenced in 
both directions.  In the regions of the genome encoding non-membrane protein genes – 
from the 3’end to the SH GS sequence and from the F GE sequence to the 5’end – only 
two differences between R3 and R11 were apparent at positions 916 and 6162 in the L 
gene. 
7.14 Identification of the L gene mutation on the resistant and susceptible clones 
of different high- and low-passage of R17532 clones 
Comparison of the non-membrane protein genes between neutralization resistant and 
susceptible clone of R17532 revealed two mutations at position 916 and 6162 in the L 
gene.  To confirm whether those mutations were correlated with the conversion of 
neutralization resistant phenotype to susceptible phenotypes, ten clones of R17532 
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previously determined the neutralization phenotype as described in section 6.7.1 
analysed for these changes in the L gene. 
7.14.1 Sequence analysis of the L gene at position 916 in clone R11.2 
In susceptible clone R11.1.1 P8, the base G was observed at position 916 in the L gene, 
whereas it was A in resistant clone R3.7.8.3 P3 (Appendix Figure 10.27).  However, the 
base A was also found in the A2 which is susceptible to neutralization by PZ.  To 
investigate whether the base G was characteristic of susceptible strains of R17532, the L 
gene of another susceptible clone (R11.2) generated from the same stock as clone 
R11.1.1 was amplified and sequenced at position 916 located in the LF1 fragment.  
 
The PCR reaction of this fragment was performed using the M2-848: L1307 primer pair 
and a band of the expected PCR product, 1,372nt, was detected (Figure 7.51).  The 
target band was isolated, purified and direct sequenced as described in section 3.5.9.  
The sequence of the L gene at position 916 in clone R11.2 was the same as the sequence 
of R3.7.8.3 and A2 strain.  Hence, the nucleotide change at this position was not 
associated with the shift from susceptible to resistant phenotype. 
 
 
 
Figure 7.51: RT-PCR amplification of the L gene of clones R11.2 using the M2_848: L1307 primer 
pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R11.2; Lane 3: HeLa NCL cells 
(Negative control) and Lane 4: DEPC treated water (Negative control). 
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7.14.2 Sequence analysis of the L gene at position 6162 in different clones of R17532 
Sequence of L gene position 6162 in neutralization resistant clones of strain R17532 
serial passaged until susceptible to neutralization 
After passaging from level 3 until level 10, neutralization phenotypes of clone R3.7.8.3 
at different passages were determined as shown in section 4.4.  Clone 3.7.8.3 at passage 
level 3 (resistant clone), 6 (susceptible clone) and 9 (susceptible clone) were selected for 
total RNA isolation.  
 
The L gene at position 6162 was located in the fragment 5.1; therefore, the cDNAs of 
all clones were synthesized using the forward primer L5-1.  Amplification of this 
fragment was carried out using the L5-4: L5-2 primer pair and the expected bands with 
the size of 993nt were detected in all three clones as shown in Figure 7.52.  RNA 
extracted from uninfected HeLa NCL cells and DEPC treated water were also tested as 
negative controls.  The target bands were isolated and purified for direct sequencing 
(section 3.5.9) using the forward primer L5-4 and the reverse primer L5-2 in the 5’ to 3’ 
direction and in the 3’ to 5’ direction (antigenome), respectively.  The sequence analysis 
revealed no variation at position 6162 in the L gene among the passage levels 3, 6 and 
9.  In all a T at position 6162 corresponded to a phenylalanine at position 2054 in the 
amino acid sequence.   
 
Passage of clone R3.7.8.3 although producing a phenotypic change did not result in a 
change on any of variable sites in G, F or L genes identified in this study.  It is surmised 
that the phenotypic change on passage occurred elsewhere in the genome.  
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Figure 7.52: RT-PCR amplification of the L gene in the susceptible and resistant clones of R17532 
using the L5-4: L5-2 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R3.7.8.3 P3; Lane 3: R3.7.8.3 P6; 
Lane 4: R3.7.8.3 P9; Lane 5: HeLa NCL cells (Negative control) and Lane 6: DEPC treated water 
(Negative control). 
 
Sequence of L gene position 6162 in neutralization resistant and susceptible clones of 
strain R17532 
The L gene at position 6162 of ten clones of R17532 described in Figure 6.8 was 
reverse transcribed using the forward primer L5-1 and amplified using the L5-4: L5-2 
primer pair.  The expected size of the target band was 993nt.  The target bands were 
directly sequenced using the forward primer L5-4 in the 5’ to 3’ direction and the 
reverse primer L5-2 in the 3’ to 5’ direction (antigenome).  Negative controls were 
performed in parallel, including uninfected HeLa NCL cells and DEPC treated water. 
 
Figure 7.53 shows the target bands of 993nt in clone R2.44, R3.7.8.17, R3.2.4, R5.1, 
R5.2 and R11.2.  No expected band was observed in clone R5.3, R5.14 and negative 
controls.  Therefore, an alternative primer pair for the second round PCR, the L5-7: L5-
8 primer pair (Figure 7.12), was used to re-amplify this region for those two clones.   
The expected size of 827nt was detected in all dilutions of PCR products from the first 
round PCR of both clone R5.3 and R5.14 (Figure 7.54). 
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Figure 7.53: RT-PCR amplification of the L gene in the susceptible and resistant clones of R17532 
using the L5-4: L5-2 primer pair.  
The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2: R2.44; Lane 3: R3.7.8.17; Lane 4: 
R3.2.4; Lane 5: R5.1; Lane 6: R5.2; Lane 7: R5.3; Lane 8: R5.14; Lane 9: R11.2, Lane 10: HeLa NCL 
cells (Negative control) and Lane 11: DEPC treated water (Negative control) 
 
 
 
Figure 7.54: Reamplification by nested PCR of R5.3 and R5.14 using the L5-7: L5-8 primer pair. 
 The lanes were loaded as follows; Lane 1: 100bp DNA ladder; Lane 2, 3 and 4: R5.3 at dilution 10
-1
, 10
-2
 
and 10
-3
, respectively.  Lane 5, 6 and 7: R5.14 at dilution 10
-1
, 10
-2
 and 10
-3
, respectively. Lane 8: DEPC 
treated water (Negative control). 
 
The nucleotides at position 6162 for all ten clones are shown in Table 7.8, together with 
the corresponding amino acid sequence at residue 2054.  The clones were divisible into 
2 groups following the lineage diagram in Figure 6.8.  Clones in group 1 including 
clone R2.44, R3.2.4, R3.7.8.3, R3.7.8.17, R5.14, R11.1.1 and R11.2 were all produced 
from the P1-GLT virus stock.  Those in group 2, comprising clone R5.1, R5.2 and R5.3, 
were generated from the P1-AC virus stock.   
 
In group 1, there was a T at position 6162 in the two clones with an EC50 > 20 (R3.7.8.3 
and R3.7.8.17), whilst the remaining clones with an EC50 < 20 derived from virus at 
passage level 2, 3, 5 and 11 had a G (R2.44, R3.2.4, R5.14, R11.1.1 and R11.2).  This 
single nucleotide change corresponded to an amino acid change at residue 2054 from 
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phenylalanine in resistant clones to leucine in susceptible clones and is the only amino 
acid change correlated with the switch from resistance to susceptibility of R17532 in 
group 1.  In group 2 of the clones had EC50 > 20, but had a G at position 6162 or leucine 
at position 2054.  It is suggested that there may be another mutation holding these 
viruses in the resistant phenotype for this group.  
 
Table 7.8:  Summary of nucleotide and amino acid changes in the L gene at position 6162 of 
different clones of R17532 in the GLT lineage (A) and the AC lineage (B).  
 
(A)   
Type EC50 (µg/ml) 
L6162 L2054 
Nucleotide Amino acid 
R3.7.8.3 48.46 T F 
R3.7.8.17 21.41 T F 
R3.2.4 12.26 G L 
R2.44 6.89 G L 
R11.1.1 5.06 G L 
R5.14 2.97 G L 
R11.2 2.72 G L 
 
(B)   
Type EC50 (µg/ml) 
L6162 L2054 
Nucleotide Amino acid 
R5.3 89.52 G L 
R5.1 69.82 G L 
R5.2 42.29 G L 
 
7.15 Summary of nucleotide changes of resistant and susceptible clones of R17532 
in the non-membrane gene regions of the genome 
In this section the non-membrane associated protein genes and the 3’ and 5’ ends of the 
genome were amplified and sequenced for resistant and susceptible virus clones.  
Variability was observed at two residues only, both in the L gene.  Changes at residue 
916 were found only between two equally susceptible clones of the susceptible R11 
virus stock and were derived irrelevant to phenotype shift.  Resistant R3.7.8.3 and both 
clones of susceptible R11.1.1 however differed at residue 6162.  Further analysis of 
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variability at this locus in additional clones with differing susceptibility revealed a 
correlation of increased susceptibility with switch from T to G (amino acid F to L) at 
this site in the GLT lineage.  In the second lineage of virus all three clones analysed 
carried a G at position L6162 despite releasing a high level of resistance.  This suggests 
the existence of another mutation, already present in the resistant clones of the GLT 
lineage but absent from the AC lineage which is necessary for the switch to 
susceptibility. 
     Variable sites 
 
 1             2 
    (?)*        (L6162) 
GLT lineage Resistant “s”  r (T) 
  Susceptible “s”  s (G) 
 
AC lineage Resistant “r”  s (G) 
  Susceptible “s”  s (G) 
 
*Hypothetical second site of variability contributing to increased susceptibility 
r = base contributing to resistance 
s = base contributing to susceptibility 
Mutation at both sites is necessary for the acquisition of full susceptibility. 
7.16 Overall conclusion from sequencing data 
There were only four genomic changes identified between resistant R17532 clone 
R3.7.8.3 and susceptible clone R11.1.1, are in each of the SH, G, F and L genes.  It 
must be conclude that these encode the observed phenotypic differences.  For the clones 
derived from the GLT isolate, only the mutation at 6162 in the L gene correlates with 
increasing susceptibility to neutralization (Table 7.9) and may account for the difference 
in replication rate between the slow – growing resistant clone R3 and fast - growing 
susceptible clone R11 reported by Gias (2006).  The three other sequence changes 
between R11.1.1 and R3.7.8.3 (section 6.7.4) may also contribute, however, it appears 
that none of the identified mutations alone is sufficient to confer susceptibility and they 
are all present in clone R5.1 derived from the AC isolate which remains resistant (Table 
7.10).  This argues for the presence of at least one other mutation necessary for the 
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acquisition of susceptibility, already present in R3.7.8.3 but not in the AC isolate 
derived clones.  Sequencing of the whole genome of clones originated from the AC 
lineage should be determined in the future work.  The role of individual mutations 
identified both clones and in concert, might be further investigated in a reverse genetics 
system. 
 
Table 7.9: Summary of nucleotide and amino acid changes in the G, F and L genes of R17532 clones 
considering only the GLT passage arm of Figure 6.8 
 
Gene 
Nucleotide sequence 
NT
a
#
 
R
3
.7
.8
.3
 
R
3
.7
.8
.1
7
 
R
3
.2
.4
 
R
2
.4
4
 
R
1
1
.1
.1
 
R
5
.1
4
 
R
1
1
.2
 
PZ EC50  48 21 12 7 5 3 2.7 
SH GE 1-3 8A 8A 7A 7A 7A 8A 7A 
G CDS
b 
884 T T C T C T C 
G-F IR
c 
36 T T T T T T T 
F CDS 
301 C T C C C C C 
456 T T T T G T G 
946 C C A C C C C 
1082 A A G A A A A 
L 6162 T T G G G G G 
 
a
NT: nucleotide; 
b
CDS: Coding sequence;
 c
IR: Intergenic region 
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Table 7.10: Summary of nucleotide and amino acid changes in the G, F and L genes of R17532 
clones considering only the AC passage arm of Figure 6.8 
 
Gene 
Nucleotide sequence 
NT
a
#
 R5.3 R5.1 R5.2 
PZ EC50  90 70 42 
SH GE
 
1-3 8A 7A 8A 
G CDS
b 
884 T C T 
G-F IR
c 
36 T C T 
F CDS 
301 C C C 
456 T G T 
946 C C C 
1082 A A A 
L 6162 G G G 
 
a
NT: nucleotide; 
b
CDS: Coding sequence;
 c
IR: Intergenic region 
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8.1 Neutralization of low passage resistant and high passage susceptible viruses 
in different cell lines  
The first aim of this study was to produce stable stocks of both low passage resistant 
clones derived from hRSV R17532 clone R3.7.8.3 (clone R3) and high passage 
susceptible clone derived from R11.1.1 (clone R11).  Virus infectivity and antibody 
neutralization may be assayed by either quantal or quantitative means.  Here the 
neutralization phenotypes for each clone were evaluated by both a quantal method – the 
tube dilution endpoint assay (Reed and Muench, 1938) – and a quantitative assay, the 
focus reduction neutralization assay (modified from Dulbecco and Vogt (1954) and 
Welsh (2010)).  For the latter, the effect of both cell types and focus visualization 
technique, immunofluorescence or immunoperoxidase staining, was also assessed.  The 
immunoperoxidase focus reduction assay in HeLa NCL79 cells was selected to use 
throughout this project as in these cells both clones R3 and R11 produced well-defined 
foci which were easy to read with a low-power microscope.  Foci in Vero cells were 
smaller less well defined and difficult to count (Figure 4.7).  McKimm-Breschkin 
(2004) has also found hRSV pinpoint plaques were formed in Vero cells, whereas large 
plaques were detected in HEp-2 cells.  hRSV plaques stained with neutral red in HEp-2 
cells were clearly visible at 7 days postinfection, whilst in Vero cells at 9 days.   
 
Neither the infectivity titre nor the neutralization results for clones R11 were 
significantly different between the immunofluorescent and immunoperoxidase methods 
(Figure 4.4).  Similarly, immunoperoxidase and immunofluorescence assays, when used 
previously for the detection of hRSV in nasopharyngeal secretions, detected an identical 
number of positive specimens (Cevenini et al., 1983).   
 
Neutralization results determined by the three methods tested here showed that the low 
passage clone R3 was resistant and the high passage clone R11 was susceptible to 
neutralization by palivizumab (PZ), confirming the difference in susceptibility of these 
viruses reported by Gias (2006) and Marsh et al. (2007).  Clone R3 appeared to be more 
sensitive to antibody in the dilution endpoint neutralization (Table 4.1) than in the focus 
reduction assay (Figure 4.3, 4.5 and 4.6), perhaps because in the former virus and 
antibody remain in contact with the cells for a longer period. 
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To test the hypothesis that HeLa NCL79 cells may be exceptionally suitable for the 
growth of resistant virus, different HeLa cells were used for titration and neutralization 
tests for both clones R3 and R11.  hRSV foci for both clones in HeLa NCL79 cells were 
clearer than those in other HeLa cells, although infectivity titres of the two clones in 
HeLa JSF and Lucy were significantly higher than those in HeLa NCL79 (Table 4.4 and 
Figure 4.10).  This suggests that whilst a lower number of virions in these virus 
populations may be capable of infecting HeLa NCL79, those that do infect produce 
larger foci, i.e. are capable of propagating more efficiently. 
 
The PZ EC50 values for the high passage clone R11 were not significantly different 
among all the different cell types studied.  However, the EC50 values for the low passage 
clone R3 using HeLa NCL79 cells was higher than those in other cells and in one HeLa 
line, HeLa CPV,  PZ titres were similar for both R3 and R11 (Figure 4.11, Table 4.5 
and 4.6). 
 
Similar differences of neutralization results using various cell lines has been also shown 
in dengue virus (DENV).  The plaque reduction neutralization test (PRNT) titres of 
different DENV strains against anti-DENV neutralizing antibody were different among 
three cell lines.  The PRNT titres of DENV-1, -2 and -4 in BHK-21 cells were 
significantly less than those in Vero cells.  In LLC-MK2 cells, titres of DENV-3 were 
increased, whereas those of DENV-4 were reduced (Thomas et al., 2009).  The 
mechanism caused the differences of PRNT titres in different cell lines is unresolved. 
 
The particular resistance of the early passage R3 R17532 clone in HeLa NCL79 may 
explain the failure of other laboratories, using other cell lines, to report resistance of 
hRSV isolates to PZ.  The origins of HeLa NCL79 cells are obscure.  The line was 
selected for routine isolation of hRSV in the Newcastle virus diagnostic laboratory 
during the 1970s.  Cell lines capable of isolating hRSV from clinical specimens were 
shared among the European virus diagnostic community and in Newcastle the available 
lines were selected for their susceptibility to hRSV in clinical material and subjected to 
regular screening to maintain sensitivity (R McGuckin personal communication).   
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Continuous selection of available cell lines for sensitivity to isolation of hRSV from cell 
culture might be expected to favour retention of any cells with increased capacity to 
replicate virus in the presence of neutralizing antibody which can be found in the 
secretions of infected infants from day 1 (Scott and Gardner, 1974).   
 
In contrast, the other HeLa and Vero cells tested here are of unknown history, but are 
not known to have been selected for susceptibility to hRSV.  Heterogeneity among 
different HeLa cell line is well established.  Herrnstadt et al. (2002) has reported that 
mitochondrial DNA (mtDNA) polymorphisms differ among various HeLa cell sublines.  
Three HeLa sublines (CCL2, 229 and S3-ATCC) obtained from the American Type 
Culture Collection (ATCC), one subline from the Los Alamos National Laboratory (S3-
Los Alamos CalTech) and a Newcastle subline from this laboratory frozen in 1985 were 
analysed.  HeLa CCL2 and HeLa 229 had no any mtDNA differences compared to the 
revised Cambridge reference sequence (CRS) for human mtDNA, whilst the other three 
HeLa sublines including the Newcastle line had a high rate of mtDNA polymorphism.  
These findings demonstrate that HeLa from different sublines may have distinct 
characteristics.   
 
Whether the resistance of low passage virus isolation in HeLa NCL79 cells has any 
relevance to the pathogenesis of human hRSV infection is uncertain.  The resistance of 
parental clone R3 on a more relevant cell line, 16HBE140, was significantly greater 
than that of R11 in the same cell line, but was low compared to that obtained on HeLa 
NCL79 cells (Figure 4.12).  However, it remains uncertain to what extent 16HBE140 
cells retain the authentic properties of human epithelial cells in vivo.  It is noteworthy 
that 16HBE160 appeared less susceptible than HeLa NCL79 when plaque sizes were 
compared (Figure 4.10 and 4.13).  Even if differences in sensitivity to neutralization are 
artefactual, the failure of PZ to neutralize low passage R17532 in HeLa NCL79 remains 
of interest as it indicates that the mechanism of hRSV neutralization is incompletely 
understood. 
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8.2 Neutralization susceptibility of low passage viruses after serial passage in cell 
cultures 
From the lineage of R17532 in Figure 6.8, viruses passaged by Prof. G.L. Toms in 1996 
(GLT) and Dr A. Connor in 1998 (AC) retained the resistant phenotype until passage 
level 10.  In contrast, clone R3 in this study shifted from resistant to susceptible at 
passage level 4 similar results to those of Marsh (2002) and Gias (2006) who reported 
phenotype conversion at passage level 5 (Figure 4.9 and Table 4.3).  Why the resistant 
phenotype has proved less stable in recent studies remains unknown. 
 
Gias (2006) demonstrated that susceptible viruses were present even in apparently 
resistant virus stocks and that their proportion increased on passage.  The number of 
susceptible clones of R17532 retrieved by plaque purification increased from 5% at 
passage level 3 to 44.4% at passage level 5.  Welsh (2010) also reported the percentage 
of susceptible clones picked from R17532 passage 3 as 41.7% compared to 58.3% 
resistant clones.  These results indicate that the predominant quasispecies in the virus 
population changes on passage.   
 
A change in susceptibility to neutralization on serial passaged in cell culture has also 
been shown for other viruses.  Two resistant variants of foot-and-mouth disease virus 
(FMDV), 1-OG2 and 1-HA6, became neutralization susceptible after repeated passage 
to level 20 and 30, respectively.  The sequence of resistant variants 1-OG2 and 1-HA6 
differed from the susceptible parental virus in the capsid proteins VP2 and VP1 at 
residue 72 (D72N) and residue 198 (D198G), respectively.  However, in high passage 
susceptible viruses sequences reversed to those of the parental virus (D at both residue 
72 and 198) (Gonzalez et al., 1991).  Anti-gp120 resistant variants of HIV-1 have also 
been found to be susceptible to neutralization by anti-gp 120 MAbs on further passage.  
Three amino acid changes in gp120 were detected in susceptible variants compared to 
those in resistant variants. One of them (G318R) was located in the V3 region which 
was a major target for neutralizing MAbs.  The effects of the other two changes in the 
V2 (I166R) and C2 (I282N) regions remain unexplained (Wrin et al., 1995).  Thus, 
whilst here are precedents for increasing susceptibility to neutralization on adaptation to 
cell culture, hitherto these changes have been explicable by demonstration of mutations 
in the surface proteins of the virus.  The phenotypic changes reported here and by Marsh 
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et al. (2007) have not been correlated with obvious changes to the viral surface 
glycoproteins.    
8.3 Mechanism of resistance 
8.3.1 Binding of neutralizating antibody to resistant and susceptible clones 
In HIV-1, anti-gp 120 MAbs have been reported to bind equally to gp120 proteins 
expressed on the surface of either neutralization resistant or susceptible variants (Wrin 
et al., 1995).  In hRSV, Marsh (2002) also demonstrated no differences between binding 
of anti-F MAbs to isolated F glycoproteins of neutralization resistant and susceptible 
viruses.  These finding are in agreement with Welsh (2010) who found that PZ bound 
equally to the F glycoprotein of either purified resistant or susceptible hRSV clones.  
These results suggest that the levels of F glycoprotein expression on the surface of cells 
infected with resistant virus are similar to those for susceptible clones.  It has similarly 
been found that neutralization resistance of HIV-1 is not dependent on high amounts of 
envelope glycoprotein expression (Karlsson et al., 1996). 
 
However, in separate studies, neutralization resistant primary HIV-1 isolates have been 
reported to express higher levels of gp120 envelope glycoprotein compared to a 
neutralization susceptible laboratory - adapted strain (O'Brien et al., 1994; Sullivan et 
al., 1995).  These findings suggest that resistance may arise as a result of quantitative 
increase of the envelope glycoprotein on the virus surface, increasing the amount of 
antibody necessary to block activation of the critical number of molecules.  
 
Hence, it was interesting to study whether the amount of the F glycoprotein expressed 
was different between resistant and susceptible clones.  Marsh (2002) could find no 
differences in the level of F glycoprotein expression between resistant and susceptible 
stocks of hRSV R17532 determined by Western blotting.  However, Gias (2006) 
demonstrated that both crude virus infected cell lysates and purified virions of 
neutralization resistant clones of R17532 and a second strain N5843 had higher amounts 
of the F glycoprotein per unit infectivity than resistant clones as measured by F-capture 
ELISA assay.  However, the F glycoprotein per genome copy measured by real-time 
PCR, whilst higher for the resistant clone of R17532, was the same for both clones of 
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N5843.  The relevance of elevated F glycoprotein expression in resistance thus remains 
equivocal. 
 
R17532 clone R3 is resistant to PZ not only in the neutralization assay but also in the 
fusion inhibition assay (Gias, 2006).  If higher levels of F expression are the cause of 
this resistance the concentration of the F glycoprotein on the surface of infected cells 
would be expected to be higher for resistant clones and this can be measured by cell 
surface ELISA.  This was carried out on cell cultures infected with equivalent titres of 
the two clones of virus using MAb 1E3 as the detection antibody.  1E3 was chosen as it 
has previously been shown (GL Toms personal communication) that the affinity of 
binding of 1E3 is the same for the F glycoprotein from both clones R3 and R11 of 
R17532 as determined by the half-saturation ELISA method (West et al., 1994).  
Amounts of the F glycoprotein measured by the ELISA whole cell method with anti-F 
MAb 1E3 determination were identical for resistant clone R3 and susceptible clone R11 
(Figure 5.5).  These results agree with the semi-quantitative Western blot results of 
Marsh (2002) and indicate that higher F glycoprotein expression levels on the cell 
surface are not necessary for resistance of R17532 at least to fusion inhibition.  In 
relating F glycoprotein expression to infectivity or genome number Gias (2006) 
introduced further undefined variables into the determination, those affecting the 
fragility of the virions.  The differences she detected could represent differences in the 
survival of infectivity and integrity of the genome equally as well as those of F 
glycoprotein concentration. 
8.3.2 Post-attachment stages of neutralization resistant and susceptible viruses 
Huang et al. (2010) have reported that the pre-treatment of hRSV with PZ did not block 
viral attachment, whereas this step was inhibited by heparin, an attachment inhibitor.  
This suggests that neutralization by PZ occurs after the attachment step.  In line with 
this Welsh (2010) demonstrated that PZ failed to block viral attachment of either 
neutralization resistant or susceptible R17532 virus clones, but there did appear to be 
differences in the attachment of resistant and susceptible viruses with the resistant 
attaching much more quickly.  Binding of the resistant clone could not be blocked with 
heparinase or free heparin both of which inhibited binding of the susceptible clone 
suggesting that receptor usage differed between the two viruses.  As PZ appears to act 
  
216 
 
2
1
6
 
post-attachment it is not clear how these differences relate to differences in 
susceptibility to PZ neutralization. 
Clathrin-mediated endocytosis of neutralization resistant and susceptible viruses 
Previous studies have shown that clathrin-mediated endocytosis is involved in the entry 
of cell culture adapted hRSV into target cells.  Inhibition of clathrin coat construction in 
endocytosis by blocking the expression of clathrin associated protein or treatment with 
clathrin inhibitors resulted in inhibition of hRSV infection (Kolokoltsov et al., 2007; 
Gutierrez-Ortega et al., 2008).  It was hypothesised that the requirement for clathrin-
mediated endocytosis might differ between resistant and susceptible clones. 
 
To test this hypothesis, PZ neutralization resistant and susceptible clones were treated 
with two clathrin inhibitors, monodansylcadaverine (MDC) and chlorpromazine (CP), 
and their susceptibility to these inhibitors were determined.  Both clones were equally 
inhibited by MDC and CP suggesting that clathrin-mediated endocytosis is equally 
necessary for entry of both viruses into target cells (Figure 5.3).  These results suggest 
that differences downstream of pinocytosis are involved in determining the 
susceptibility to neutralization by PZ. 
Activation of the F glycoprotein in neutralization resistant and susceptible viruses 
Activation of the fusion protein depends upon prior post-translational modification of 
the fusion protein precursor F0 and is fundamental to the post-pinocytotic stages of the 
infectious process, allowing fusion of virion and host cell membrane and penetration of 
the virus core.  Factors involved in this process were therefore compared between the 
two variants including F glycoprotein post-translational processing and activation. 
 
In order to evaluate post-translational processing involving proteolytic cleavage and 
glycosylation, the migration of the F glycoprotein in lysates of cells infected with low 
passage clone R3 and high passage clone R11 were analysed by SDS-PAGE and 
Western blotting using anti-F MAb 1E3.  Two protein bands of the F1 subunit, 52 and 
20kDa, were detected in both viruses (Figure 5.4).  These results although differing in 
detail point to the same conclusion as those of Welsh (2010) who demonstrated three 
additional minor bands of 70, 48 and 44kDa in crude virus lysate of clones R3 and one 
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more band (70kDa) in clone R11.  The 70kDa band corresponds in size to the uncleaved 
F0 precursor and its absence in the present study suggests that all the F glycoprotein has 
undergone cleavage at least one of the two potential cleavage sites (see section 1.4.10).  
Cleavage at the second site should release a 27 amino acid peptide (Gonzalez-Reyes et 
al., 2001).  Differences in the extent of second site cleavage between the two viruses 
should, therefore, be visible as differences in the size of the major F1 band.  No such 
differences were apparent in either study.  The minor 48 and 44kDa bands observed by 
Welsh (2010) in R17532 clone R3 were not present in crude lysates of another resistant 
clone N1 or in purified virions of either clones R3 or N1 and may be proteolytic 
breakdown products of the 52kDa F1 generated during the prolonged replication of this  
slow growing virus.  However, Western blot analysis is a relatively insensitive means of 
investigating modification.  Unfortunately more sensitive techniques, such as mass 
spectrometry, require purification of the F glycoprotein in quantities as yet unachievable 
with unstable antibody resistant virus clones studied here.  
  
During the transition of the F glycoprotein from the pre-fusion to the post-fusion form 
in the fusion process, a 6HB is formed drawing viral and host cell membranes into close 
apposition.  This complex occurs from interaction of the HR1 and HR2 domains of the 
F1 subunit (Zhao et al., 2000).  McLellan et al. (2011) have shown that motavizumab 
(MZ), a potent derivative of PZ, can tightly bind to the post-fusion conformation of the 
F glycoprotein.  However, its epitope has been found on a domain which is not involved 
in the conformation changes.  MZ may be capable of binding to multiple conformations 
of the F glycoprotein and may neutralize virus by interfering with the activation of the F 
molecule.  Neither MZ nor PZ have been found to block the transition from a pre-fusion 
to a pre-hairpin conformation (Huang et al., 2010).  In the lipid-mixing assay, treatment 
with MZ and PZ was not able to inhibit the transfer of lipids from hRSV to target cells, 
but virus transcription and cell-to-cell fusion were inhibited by these antibodies.  This 
suggests that PZ and MZ block the transition from either a pre-hairpin to a hairpin 
conformation or a hairpin to post-fusion conformation (Figure 8.1).   
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Figure 8.1: Model of the proposed actions of fusion inhibitors and anti-F MAbs in the process of 
rearrangement in the F glycoprotein. 
[Modified from original by Huang et al. (2010)]  
HR1: Hepatad repeat 1; HR2: Heptad repeat 2; PZ: palivizumab; MZ: motavizumaab. 
 
To investigate the fusion activation, susceptibility of both resistant and susceptible 
clones to inhibition by anti-fusion inhibitor compounds directed against 6HB formation, 
two small molecular inhibitors (BTA9881 and BMS-433771) and an HR2 peptide 
(residues 488 – 522), were analysed.  BMS-43771 has been reported to interact with 
HR1 in a hydrophobic cavity at pre-hairpin intermediate stage of the F glycoprotein, 
interfering with the formation of 6HB as shown in Figure 8.1 (Cianci et al., 2005). 
Similarly, HR2 peptide is thought to bind to the HR1 peptide coiled coil interrupting the 
conformational change (Zhao et al., 2000; Russell et al., 2001).  The mechanism of 
inhibition by BTA9881 is still unknown, but it is known that it inhibits F glycoprotein-
mediated membrane fusion (Luttick et al., 2007). 
 
In focus inhibition assays, all compounds failed to inhibit resistant parental clone R3, 
but efficiently blocked infection by clone R11 (Figure 5.6).  The EC50 values of 
R17532-HR2 peptide, BMS-433771 and BTA9881 for clone R11 were 13.04, 0.21 and 
5.23 µM.  Lambert et al. (1996) reported that T-118 peptide, similar to R17532-HR2 
peptide, inhibited infection with hRSV Long strain at EC50 values of 0.05 µM which 
was 260 times lower than those in inhibition of susceptible clone R11 in this study.  
However, the two studies are not directly comparable in the absence of accurate 
information on the purity of the two peptide preparations. 
 
Cianci et al. (2004c) found that the EC50 value of BMS-433771 for a variety of hRSV 
strains and isolates varied between 0.012 and 0.05 µM some 4-fold or higher than that 
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for clone R11 determined here.  However, in the study of Cianci et al. (2004c) EC50 
values were determined in assays measuring either cell protection or inhibition of virus 
specific proteins, whereas here the percentage of virus survival was measured.  Hence, 
these values cannot be compared directly.  For BTA9881, there are no previous reports 
of EC50 value. 
 
Resistance of HIV-1 to fusion inhibitors has been reported to be associated with an 
increase in either gp120/ coreceptor affinity or coreceptor density on the surface of 
target cells, leading to an increase rate of membrane fusion (Reeves et al., 2002).  A 
similar mechanism may also render early passage hRSV resistant to anti-fusion agents.  
Welsh (2010) found that for PZ resistant clones attachment was independent on cell 
surface heparan sulphate (HS) binding, whereas susceptible clones required HS.  It is 
suggested that the neutralization susceptibility to PZ of low and high passage viruses 
may be affected by differences in receptor usage for cell binding, possibly resulting in 
differences in the kinetics of the F glycoprotein mediated fusion.   
8.4 Comparison of nucleotide and deduced amino acid sequences of M and SH 
genes between neutralization resistant and susceptible virus clones 
As previously demonstrated, genetic changes in the antibody binding sites of the F 
glycoprotein have been shown to be associated with resistance to neutralization in cell 
cultures and animal models among both laboratory virus strains and clinical isolates 
(Zhao et al., 2004a; Boivin et al., 2008; Adams et al., 2010; Zhu et al., 2011).  The F 
glycoprotein associates with other membrane proteins including the G, SH and M 
proteins (Feldman et al., 2001; Collins and Crowe, 2007).  Therefore, it is postulated 
that genetic changes in their genes might also indirectly affect the interaction of the F 
glycoprotein with antibody leading to resistance to neutralization.   
 
Marsh (2002) and Gias (2006) have reported that none of the mutations detected in 
either the F glycoprotein genes or other membrane associated protein gene of variants of 
R17532 and N5843 isolates were correlated with susceptibility to neutralization by anti-
F MAbs.  However, the sequence analysis of the M and SH genes were derived not 
from well characterized virus clones but from virus stocks subsequently shown to be a 
mixture of neutralization resistant and susceptible viruses.  To confirm these results, the 
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sequences of both of these genes for resistant clone R3 and susceptible clone R11 were 
analysed.   
 
The results showed no nucleotide changes in the coding region of the M gene between 
the two clones of R17532 (Appendix Figure 10.1, 10.2 and 10.3), suggesting that this 
gene was completely conserved and was not involved in neutralization phenotype shift 
confirming the conclusion of Gias (2006).  The nucleotide sequence of R17532 was 
slightly different from A2 and the percentage of identity was 97.  However, no amino 
acid changes were found between R17532 and A2, suggesting that the M protein was 
fully conserved among hRSV strains.  These findings were in agreement with the report 
of Kumaria et al. (2011) who found no amino acid variability in the M gene among 14 
hRSV strains which were isolated from nasophayngeal washings of infected infants in 
Colorado, USA.  Whole genomes of all these isolates were directly sequenced from 
patient specimens without passage in tissue culture (Kumaria et al., 2011).  The 
presence of highly conserved sequence in the M gene may be because the M protein is 
important in regulating viral transcription and viral assembly (Kaptur et al., 1991; 
Lenard, 1996; Coronel et al., 2001).    
 
Analysis of the coding sequence in the SH gene showed no variations occurring 
between resistant clone R3 and susceptible clone R11.  However, there were five 
nucleotide changes in this region of R17532 compared to A2 giving a percentage of 
nucleotide conservation of 97%.  Two of five mutations caused amino acid changes at 
residue 29 and 62 resulting in 96% amino acid identity (Appendix Figure 10.5 and 
Table 6.2).  This low level of nucleotide variability is consistent with the study of Cane 
and Pringle (1991) who reported nucleotide identity of the SH gene within the 
subgroups to be in the range 93% to 99%.  A similar level of amino acid variation was 
observed by Lima et al. (2012) who analysed the SH gene from 424 isolates collected 
from 965 patients in Brazil and found very low variability of this gene.  93.5% of strains 
exhibited no amino acid substitution, but 6.5% had one or two altered amino acids.   
 
The identity of the SH gene in resistant and susceptible R17532 clones indicates that the 
origin of the phenotype differences between the clones does not lie here.   
  
221 
 
2
2
1
 
8.5 Comparison of nucleotide and deduced amino acid sequences of G and F 
genes between neutralization resistant and susceptible virus clones  
In previous studies, the sequences of F and G genes were analysed from both virus 
stocks and clones. Whilst a number of genetic changes were identified, none were 
unambiguously associated with the shift from a slow growing-neutralization resistant to 
a fast growing-neutralization susceptible phenotype (Gias, 2006; Marsh et al., 2007).  
However, these studies were carried out on a limited number of virus clones.  Hence, to 
test this conclusion further, both G and F genes were sequenced from additional 
susceptible and resistant clones at different passage levels and degrees of resistance to 
neutralization. 
 
Initially, resistant clone R3 was passaged from level 3 to 10 during the course of which 
susceptibility to neutralization increased by approximately ten fold (Figure 4.9), and the 
sequences of the G gene, F gene and associated intergenic regions at passage 3, 6 and 9 
were analysed.  There were no nucleotide changes observed among them, despite the 
increase in susceptibility to neutralization.  Furthermore, comparison of the sequence 
from the end of the SH gene to the end of the F gene of 10 R17532 clones comprising 
resistant and susceptible clones derived from two separate isolations of the virus at 
different passage levels, although identifying variations at 7 sites found no clear cut 
correlation with phenotype (Table 6.9).  This confirms the observation of Marsh et al. 
(2007) who reported that in one instance passage of a resistant stock of virus resulted in 
acquisition of susceptibility to neutralization without sequence change in the F or G 
genes.  
8.5.1 Variability of the G gene in different clones  
Among 10 clones of R17532 analysed, only one variable residue was found in the G 
coding sequence at nucleotide position 884 which varies between T and C (Table 6.4).  
This change caused an amino acid change from isoleucine to threonine at residue 295 
(Appendix Figure 10.8).  Both forms were found in susceptible and resistant clones.  
Marsh et al. (2007) have previously reported T or a mixture of T and C at this position 
in resistant R17532 stocks and C in a susceptible stock.  However, the result presented 
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here indicates that this mutation is not involved in neutralization phenotype shift being 
present in both resistant and susceptible variants.  
 
This change is located in the carboxy-terminal third of the G protein which is highly 
variable (Melero, 2007).  Frameshift mutations have been found in this region in escape 
mutant viruses resistant to neutralization by anti-G MAbs.  Frameshifts were caused by 
single adenosine insertions and/or deletions and resulted in truncated G proteins 
(Garcia-Barreno et al., 1990; Rueda et al., 1991).  Variation in this part of the G protein 
did not affect to hRSV infectivity.  Heterogeneity at position 884 has been reported 
previously.  Sequence analysis of 14 isolates collected from patients in Colorado 
revealed nucleotide variation of T and C at position 884 (Kumaria et al., 2011).  Nine 
isolates had T, whilst five isolates had C at this position.  In contrast in a Milwaukee 
population (Rebuffo-Scheer et al., 2011), the predominant quasispecies variants were C 
at this position which were detected in 21 specimens, whilst T was present only in 3 
specimens.  These findings demonstrate that heterogeneity at this residue is widespread 
in clinical isolates, but its significance, if any, remains unclear. 
8.5.2 Variability of the F gene in different clones  
Sequence comparison of the F coding gene among 10 clones of R17532 with various 
neutralization phenotypes revealed four variable nucleotides, two of which resulted in 
amino acid changes (Table 6.7 and 6.8).  In addition, one variable site occurred in the 
G-F intergenic region.  Variability in residue 152, lying in the region encoding the HR1, 
was previously identified as variable in R17532 by Marsh et al. (2007) and Gias (2006).  
Whilst most clones carried a T at this site, a G was present in susceptible clones R11.1.1 
and R11.2 and in resistant clone R5.1 corresponding to an amino acid change from 
isoleucine to methionine at residue 152 (Appendix Figure 10.11).  Similarly, this 
variation was found in both resistant (P10-GLT) and susceptible (P10-FF) virus stocks 
(Marsh et al., 2007).  At this residue, a valine was present in A2, whereas 37 of 39 
hRSV sequences published in GenBank have an isoleucine similar to the majority of 
R17532 clones and the other two have a valine like A2 (Kumaria et al., 2011; Rebuffo-
Scheer et al., 2011). 
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The second coding mutation was found only in resistant clone R3.7.8.17 encoding 
serine at residue 101 dictated by a T at nucleotide 301, whilst most clones had a C 
encoding proline at this point.  This variation was also reported by Gias (2006) who 
found a serine at this residue in susceptible clone N10a of isolate N5843.   
 
In addition to the coding mutations, two silent mutations were observed in clone 3.2.4 at 
position 946 (C  A) and 1082 (A  G).  Theses changes were not found in previous 
studies from either virus stocks or clones of R17532 (Gias, 2006; Marsh et al., 2007). 
However, one isolate from a Milwaukee population had an A at position 946, whilst the 
majority of isolates carried a C at this point (Rebuffo-Scheer et al., 2011).   
 
One coding mutation of leucine in clone R3 to isoleucine in clone R11 at residue 386 
reported in a previous study (Gias, 2006) was not found in R3 clone, R3.7.8.3, tested 
here which had an isoleucine at this point, although both R3 clones were derived from 
the same parent stock.    
 
It is noteworthy that none of the coding mutations detected in previous studies or in this 
study were located within the known binding sites of PZ (around residue 272 – 275) or 
the two anti-F MAbs used in the study of Gias (2006) and Marsh et al. (2007), MAb19 
(residues 422 – 438) and RS348 (residues 200 – 225 and 253 - 289).   
8.6 Comparison of nucleotide sequences of all intergenic regions between 
neutralization resistant and susceptible virus clones 
The intergenic regions of hRSV gene have been revealed to vary in length from 1 to 58 
nucleotides among hRSV strains reported to date.  They are not conserved in either 
nucleotide sequences or obvious features of secondary structures, except there is an A 
residue (genome sense) at the end of all genes (Collins et al., 1986; Collins and Crowe, 
2007).  These regions have not been found in monocistronic mRNAs, indicating that the 
polymerase does not transcribe them, but moves across this region to reinitiate 
transcription at the downstream gene start region (Collins et al., 1986; Rassa et al., 
2000).   
 
  
224 
 
2
2
4
 
In the present study, sequences of all intergenic regions were compared between 
resistant and susceptible variants of R17532 and also between R17532 and A2.  The 
results showed no nucleotide changes between the two fully sequenced R17532 clones 
in any of the intergenic regions, suggesting that these regions are conserved and not 
involved in differences in neutralization phenotype.  However, among the sequences of 
R17532 10 clones varying in neutralization susceptibility and passage levels a single 
nucleotide change (T  C) was observed in one clone, R5.1, at position 36 in the G-F 
intergenic region (Appendix Figure 10.9).  These results are broadly in agreement with 
those of Marsh et al. (2007) who demonstrated identical sequences of the M-SH, SH-G 
and G-F intergenic regions in resistant and susceptible virus stocks and also with Gias 
(2006) who showed that the sequences of the G-F intergenic regions in resistant clones 
of isolates R17532 and N5843 did not differ from those of the susceptible clones.  
However, several variations were observed between R17532 and A2 as shown in Table 
8.1.  The percentage of nucleotide identity ranged from 22 to 100.  The sequences of 
R17532 in all these regions were between 3 and 53 nucleotides in length and contained 
A at the end of each sequence confirming to the observations of Collins et al. (1986) 
and Collins and Crowe (2007).    
 
In the N-P intergenic region, the percentage of nucleotide identity between R17532 and 
A2 was only 50% (Table 8.1).  This was because this region in A2 contained a single 
nucleotide (3’…A…5’, genome sense), whereas an insertion of C was observed in 
R17532 (3’...CA…5’) (Appendix Figure 10.20).  This variation was also found in 4 of 
14 isolates in a Colorado population and 14 of 25 isolates in Milwaukee (Kumaria et al., 
2011; Rebuffo-Scheer et al., 2011).  Another  study has also reported this change from 4 
of 14 strains obtained from infected patients in USA (Alabama) and UK (Birmingham, 
Glasgow and Newcastle) and described the effect of this variation on transcription at the 
N/P gene junction (Moudy et al., 2004).  Replicons containing CA in the N-P intergenic 
region had a 2.5-fold increase in the synthesis of readthrough RNAs compared to 
replicons comprising A as in the A2 sequence, suggesting that this variation reduces the 
efficient of termination of the upstream gene.  However, the change did not affect the 
initiation of downstream gene transcription as demonstrated by identical initiation levels 
for the P gene of both CA and A variants.  Hence, it can be inferred that termination at 
N/P gene junction in R17532 is likely to be less efficient than that in A2. 
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Table 8.1: Summary of percent nucleotide identity in all intergenic regions of R17532 and A2 
strains.   
 
Intergenic 
Region 
Length 
(nt)
 
% NT
a
 identity  
R17532 vs. A2 
NS1-NS2 19 89 
NS2-N 26 80 
N-P 2 50 
P-M 3 22 
M-SH 9 77 
SH-G 44 90 
G-F 53 84 
F-M2 46 76 
M2-L 45 100 
 
                    a
NT: Nucleotide. 
 
 
The sequence of the P-M intergenic region in R17532 (5’…GAT…3’) was also 
substantially different from A2 (5’…GGAAAGGGT…3’) giving a very low percentage 
of identity of 22 (Table 8.1).  A deletion of six nucleotides (5’…GGAAAG…3’) and 
one nucleotide change (G  A) at position 8 in A2 were observed in R17532 
(Appendix    Figure 10.1).  This variation has also been reported previously, being 
present in 6 of 14, hRSV strains isolated from infected infants in Colorado, USA 
(Kumaria et al., 2011).  Moreover, 14 of 25 hRSV specimens collected from patients in 
Milwaukee (Rebuffo-Scheer et al., 2011) and 8 of 14 hRSV strains isolated from USA 
and UK (Moudy et al., 2004) also had this change.  Moudy et al. (2004) have shown 
that alteration of the sequence and the length in the P-M intergenic region did not affect 
either efficient termination of the upstream gene or initiation of the downstream gene.  
Therefore, the different sequence and nucleotide length of the P-M intergenic region 
between R17532 and A2 would not be expected to affect either termination of the P 
gene or initiation of the M gene transcription. 
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8.7 Comparison of nucleotide sequences of the 5’ untranslated regions (UTR) of 
all genes between neutralization resistant and susceptible virus clones  
The 5’UTR of all genes was analysed in resistant and susceptible clones of R17532 and 
A2.  The results showed identical sequences in these regions between the two R17532 
clones, suggesting that they were fully conserved as previously reported by Marsh 
(2002) and Gias (2006) for the 5’UTR of the M, SH, G and F genes.   The sequences of 
R17532 slightly differed from those of A2 in the range 92% to 100% as shown in Table 
8.2.  For six genes the homology between the two viruses in this region was 100%.   
This may be because these are the shorter intergenic regions and contain a gene start 
(GS) sequence which is highly conserved.  The 5’UTR of the M, M2 and L genes 
consists only of the GS.  The GS consensus sequence for hRSV is 3′-CCCCGUUUA-5’, 
except in the L gene (3′-CCCUGUUU-5’).  The GS sequence is important in regulating 
the initiation of mRNA synthesis (Collins and Crowe, 2007).  Kuo et al. (1997) has 
reported that most of the positions in the GS sequence appear to affect its activity.  
Substitution with any nucleotide at position 1, 3, 6, 7 and 9 has shown to decrease 
transcription levels.  
 
Table 8.2: Summary of percent nucleotide identity in the 5’ untranslated regions (UTR) of all genes 
of R17532 and A2 strains.   
 
5’UTR Length (nt) 
% NT
a
 identity  
R17532 vs. A2 
NS1 54 96 
NS2 32 90 
N 15 92 
P 17 100 
M 9 100 
SH 84 92 
G 15 100 
F 13 100 
M2 9 100 
L 8 100 
 
a
NT: Nucleotide. 
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8.8 Comparison of nucleotide sequences of the 3’ untranslated regions (UTR) of 
all genes between neutralization resistant and susceptible virus clones 
The 3’UTR containing the gene end (GE) sequence is present in all hRSV genes and is 
an important region involved in viral transcription.  The GE sequence is semiconserved 
and consists of three regions (presented in genome sense): an upstream conserved 
pentanucleotide region (3’-UCAAU-5’), a non-conserved central region (N1-4) and a 
downstream conserved U-tract (U4-7).  It directs polyadenylation of mRNA by slippage 
on the U-tract template and termination of transcription by mRNA release (Barr and 
Wertz, 2001; Harmon et al., 2001).  Efficient termination depends on the specific 
sequence of the GE sequence.  Positions 2 to 6 are necessary for termination and highly 
sensitive to base changes and position 8 is allowed to be only A or U due to the 
requirement for weak nucleotide pairing between the template and mRNA during 
reiterative transcription or termination (Harmon et al., 2001).   
 
The position of the U-tract is also important in transcriptional termination and its proper 
location has been shown to be at position 8 to 13.  In addition, the length of the U-tract 
is critical and the minimum number of the U residue allowing efficient activity is 5 
residues (Harmon et al., 2001).  A U4-tract combined with an intergenic region 
containing A at the beginning has been reported to reduce transcriptional termination at 
the M-SH and F-M2 intergenic region (Sutherland et al., 2001; Harmon and Wertz, 
2002).  Increasing the length of the U-tract in the F GE sequence from 5 to 8 U residues 
has also been shown to decrease efficient termination (Sutherland et al., 2001).  
 
The sequence analysis of the 3’UTR in the SH gene between resistant clone R3 and 
susceptible clone R11 revealed one nucleotide difference occurring in the U-tract of the 
GE sequence or the A-tract in the antigenome sense as presented here (Appendix Figure 
10.6).  There were 8 adenosines in the A-tract (8As) in clone R3, but only 7 in clone 
R11.  This contrasts to results of Marsh (2002) who found 7As in both resistant and 
susceptible virus stocks of R17532.  This region was also sequenced in additional 
susceptible and resistant clones.  7As was detected in four of five susceptible clones 
(R3.2.4, R2.44, R11.1.1 and R11.2) and one of the resistant clone (R5.1), whereas 8As 
was found in four of five resistant clones (R5.3, R3.7.8.3, R5.2 and R3.7.8.17), and one 
of the susceptible clone (R5.14) (Appendix Figure 10.7).  This suggested that this 
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mutation may play some role in the neutralization phenotype conversion.  From 39 
sequences of hRSV isolates published in GenBank (accession number JF920046 – 
JF920070 and GU591758 – GU591771) only 5As (the same as A2) and 6As were 
reported in the SH GE sequence.  That the A-tract of R17532 is longer than that of A2 
suggests that termination in R17532 may be less efficient than in A2 (Sutherland et al., 
2001).   
 
Apart from the SH gene, there were no nucleotide changes observed in the 3’UTRs in 
the rest of the genome between clones R3 and R11.  However, several changes were 
found between R17532 and A2 as shown in Table 8.3.  In the 3’UTR of the M gene, 
there were 5As in the GE sequence in R17532 which is shorter than that in A2 which 
contains 6As (Appendix Figure 10.3).  This suggests that the M GE sequence of 
R17532 terminates more efficiency than A2. 
 
Table 8.3: Summary of percent nucleotide identity in the 3’ untranslated regions (UTR) of all genes 
of R17532 and A2 strains.   
 
3’UTR Length (nt) 
% NT
a
 identity  
R17532 vs. A2 
NS1 57 96 
NS2 96 91 
N 13 100 
P 171 87 
M 176 90 
SH 134 83 
G 12 84 
F 165 93 
M2 99 92 
L 72 91 
 
a
NT: Nucleotide. 
 
In the 3’UTR of the G gene (Appendix Figure 10.9), there was a Nucleotide substitution 
at position 4 from C in R17532 to T in A2 (A4G) and a deletion of C at position 6 (-6G) 
giving percent nucleotide identity of 84 (Table 8.3).  These variations were also found 
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in the virus stock of R17532 reported by Marsh (2002) and in 33 of 39 hRSV specimens 
published in GenBank (Kumaria et al., 2011; Rebuffo-Scheer et al., 2011).  
 
Moudy et al. (2003) have shown that replicons containing either the A4G variation 
alone or the combination between A4G and -6G variations in the G GE sequence 
reduced the termination efficiency and the initiation of the upstream gene.  The A4G 
variation alone produced a readthrough 10-fold higher than A2, whilst only a 4-fold 
higher readthrough occurred with the combination of A4G and -6G compared to A2.  In 
contrast, the -6G variation alone only slightly affected termination, suggesting that a 
partial compensation for A4G may occur in the presence of the two variations.  From 
these finding, it appears likely that the termination efficiency at the G-F junction in 
R17532 may be less than that in A2, resulting in a reduction in F gene expression.  
8.9 Comparison of nucleotide sequences of the 3’ leader and 5’ trailer regions 
between neutralization resistant and susceptible virus clones  
The 3’leader and 5’trailer regions contain promoters which are necessary for the 
synthesis of mRNA and the antigenome, respectively (Collins and Crowe, 2007).  It has 
been reported that the first 11-nt of the genome are required for both transcription and 
replication (Fearns et al., 2002).  To investigate whether these regions were related to a 
difference in susceptibility to neutralization by PZ.  Sequences of these regions were 
compared between resistant and susceptible clones.   
 
The genomic RNA circularization method was initially adopted to sequence both the 
3’leader and 5’trailer regions.  This method has previously been used for determination 
of complete consensus sequences of two hMPV isolates, CAN97-83 and CAN98-75 
(Biacchesi et al., 2003).  However, in this study, incomplete sequence of 5’trailer region 
for clone R11 and none of sequence for clone R3 were obtained using this method.  The 
RNA templates used were extracted from gradient purified viruses to avoid interference 
from mRNA.  One possibility for failure was that the templates were insufficient or of 
poor quality, especially for clone R3, where virus titres in cultures prior to purification 
were lower.   
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5’rapid amplification of cDNA ends (5’RACE) and 3’RACE were subsequently 
developed.  In these assays, RNA for clone R3 was isolated from cell lysates which was 
higher quality than that from purified samples.  The 5’end and 3’end of the genome for 
both resistant clone R3 and susceptible clone R11 was successfully sequenced by 
5’RACE from the antigenome and 3’RACE from the genome (Figure 7.40 and 7.50), 
respectively.  The method of 3’RACE from the antigenome failed to sequence the 3’end 
possibly due to interference from mRNA.  Whilst all sequences for clone R3 were 
derived from a parental clone R3.7.8 and a single passage 3 preparation of clone 
R3.7.8.3, for clone R11 three preparations were used.  The 5’end sequence was derived 
from R11.1.1 passage 8 and 12 and the 3’end sequence from R11.1.1 passage 11 and 
12.  All preparations of this clone preserved the susceptible phenotype . 
 
Analysis of the 3’leader (44 nucleotides) and 5’trailer (160 nucleotides) regions 
revealed no nucleotide changes between resistant and susceptible clones (Appendix 
Figure 10.29 and 10.30), suggesting that these regions were completely conserved.  
However, R17532 sequences in these regions were slightly different from A2 with 97% 
and 91% nucleotide identity in 3’ and 5’end of the genome, respectively.  The length of 
the 5’trailer region of R17532 was longer than that of A2 by five bases.  However, the 
26 nucleotides at the terminal of the 3’leader in R17532 and the complementary 
sequence in the terminal of the 5’trailer region thought to be important element in the 
promoter of genome and antigenome respectively (Mink et al., 1991), were fully 
conserved.   
8.10 Comparison of nucleotide and deduced amino acid sequences of non- 
membrane protein genes between neutralization resistant and susceptible 
virus clones 
As sequence comparison of membrane protein genes, the genome ends or intergenic 
regions of neutralization resistant and susceptible clones revealed no mutations which 
unequivocally correlated with the neutralization phenotype alteration attention turned to 
the non-membrane protein genes.  Sequences of the NS1, NS2, N, P, M2 and L coding 
regions were compared between clones R3 and R11.  The results showed that nucleotide 
sequences for the two clones were identical in the NS1, NS2, N, P and M2 genes.   
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The sequences of the coding region of these genes in R17532 differed a little from A2 
in a range from 95 – 97% for nucleotide identity and 97 – 99% for amino acid level 
(Table 8.4).  All of these proteins are necessary for hRSV infection and have previously 
been found to be highly conserved (Kumaria et al., 2011; Rebuffo-Scheer et al., 2011).  
The NS1 protein had only one amino acid substitution (Table 7.1), two substitutions 
occurred in the P and M2 genes (Table 7.3 and 7.4) and three substitutions in the NS2 
and N protein (Table 7.1 and 7.2).  One and two amino acid changes respectively 
observed in the NS1 and NS2 protein were also reported in two isolates by Kumaria et 
al. (2011). 
 
The L gene was less well conserved.  There were 28 nucleotide changes between 
R17532 and A2 (Appendix Figure 10.27), giving a percentage of nucleotide identity of 
97% (Table 8.4) and two changes between the two clones of R17532 at positions 912 
and 6162.   
 
Table 8.4: Summary of percent nucleotide identity in the coding region of the NS1, NS2, N, P, M2 
and L gene of R17532 and A2 strains.   
 
Coding region % NT
a
 identity  
R17532 vs. A2 
% AA
b
 identity  
R17532 vs. A2 
NS1 95 99 
NS2 96 97 
N 97 99 
P 97 99 
M2 97 98 
L 97 98 
 
a
NT: Nucleotide; 
b
AA: Amino acid. 
 
In the first variation of the L gene between the R17532 clones, an A in resistant clone 
R3.7.8.3 was changed to a G in susceptible clone R11.1.1 at position 916 resulting in a 
shift of amino acid from asparagine to aspartic acid at residue 306 (Appendix Figure 
10.27).  However, another susceptible clone R11.2 had an A at this position, the same as 
R3 and A2.  This change is not correlated with phenotype shift.  The second variation 
occurred at position 6162 (T  G) causing an amino acid change from phenylalanine in 
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clone R3 to leucine in clone R11 at residue 2054.  The prevalence of this change in the 
virus clones derived from various passage levels of R17532 isolated from a clinical 
specimen in 1996 (the GLT lineage) was investigated (Table 7.8).  This isolate lost 
resistance on passage at passage 5 on one occasion and at passage 10 on another and 
both resistant and susceptible clones were derived from it.  Whilst both resistant clones, 
derived from passage 3 of this isolate, had a T at this position, all of the susceptible 
clones carried a G.  Thus, for this lineage of the virus change at L6162 correlates with 
phenotype shift.  However, a separate isolation of virus from the same stored specimen 
was made two years later.  This isolate preserved the resistant phenotype to passage 10 
and only resistant clones were recovered from it (the AC lineage).  All three of these 
carried a G at L6162 demonstrating that this mutation alone is insufficient to confer 
susceptibility.  It is necessary to postulate that at least on additional mutation is 
necessary and that this has already occurred by passage 2 in the GLT lineage.  
 
The L protein is a major component of the viral RNA dependent RNA polymerase 
complex which also includes P, N and M2 proteins.  It plays a major role in all 
enzymatic activities during viral replication and transcription, including capping, 
methylation and polyadenylation (Collins and Crowe, 2007).  It has been shown that 
omission of this protein abrogates RNA synthesis (Yu et al., 1995).  Therefore, the 
mutation occurring in this gene at L6162 may influence hRSV infection and underly 
differences in replication ability between the slow-growing resistant clone R3 and fast-
growing susceptible clone R11 reported by Gias (2006) as both of these clones  
originated from the P1-GLT virus stock. 
 
This study has confirmed the relative resistance of low passage isolates of hRSV to 
neutralization by PZ and their F glycoprotein inhibitors.  In culture, this resistance is 
transient.  The switch to antibody susceptibility was not associated with changes in PZ 
epitopes on the F glycoprotein but may be associated with mutations in the L gene and 
increased rates of virus replication.  Whether the resistance to neutralization of clinical 
isolates is an artefact of replication in cell culture or a property of the virus experienced 
in the infant respiratory tract remains uncertain.  The results of the IMPACT study (The 
IMpact-RSV Study Group, 1998) indicate that prophylactic PZ ameliorates the clinical 
effects of hRSV infection.  Antibody epitope escape mutants have been recovered from 
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treated patients suggesting that PZ is effective in limiting virus infection in vivo.  
However, this cannot be construed an evidence that virus in vivo is sensitive to 
neutralization as the mode of action of PZ is not known and mechanisms other than 
neutralization may limit virus infection.  Thus, non-neutralizing anti-hRSV G 
glycoprotein antibodies provide in vivo protection, in mice acting at least partially via 
complement mediated pathways (Mekseepralard et al., 2006).  Further studies of early 
passage isolates possibly in authentic primary human bronchiolar cell cultures, may 
serve to resolve this issue. 
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The aim of this study was to investigate the mechanism of neutralization phenotype 
change by a comparison of resistant and susceptible clones of the R17532 virus isolate. 
This and previous studies have shown anti-F antibodies bind equally to both resistant 
and susceptible virus clones, but that there are striking differences in the interaction of 
the two viruses with the host cell.  Resistant viruses bind more rapidly to HeLa cells, are 
less GAG dependent and are resistant, not only, to anti-F antibody but also to 
compounds which block activation of the fusion protein.  This suggests that there are 
major differences in the mechanism of entry of the two clones into the cells.  This 
however is cell-line dependent with cell lines varying in their permissiveness to 
antibody treated virus.    
 
In future work it will be of interest to compare fusion kinetics between resistant and 
susceptible clones which may give rise to differences in susceptibility to anti-fusion 
inhibitors.  The surface proteins of host cells involved in entry of resistant virus should 
also be investigated among different cell lines.  It will be important also to seek 
confirmation of the conclusions, concerning post-translational modification of F in 
clones of both phenotypes by a more defined technique e.g. mass spectrometry. 
 
The genetic basis for differences between resistant and susceptible phenotypes has 
proved complex.  Although, on passage of the virus, genetic changes are most prevalent 
in the surface protein genes, none correlates simply with the phenotypic change.  
Sequencing of the whole genome of a susceptible and a resistant clone revealed only 4 
changes, one or all of which must be responsible for the phenotypic differences.  
However, none of these changes correlate individually with susceptibility in other 
clones. 
 
The best correlation exists between the L6162 mutation and the acquisition of 
susceptibility in the GLT lineage of R17532.  How a change in the L gene may result in 
alterations in susceptibility to antibody neutralization is obscure.  Mutations in the L 
gene have previously been associated with changes in transcription and replication rates 
and it is conceivable that L6162 may account for the change in replication rate in HeLa 
cells and that increased transcription and replication rates may affect changes in the 
interaction between the infected cell and virus with consequent changes in the 
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composition of the virion membrane.  Confirmation of this interpretation could be 
sought by appropriate reverse genetics techniques in future work. 
 
Although in the GLT lineage, a G at L6162 was associated with susceptibility, clones in 
the AC lineage with a G at position 6162 retained resistance, suggesting that additional 
mutations already present at passage 2 in the GLT lineage may be necessary for the 
acquisition of susceptibility.  To test this hypothesis future work should analyse the 
whole genome of clones originated from the AC lineage.   
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                  5’UTR 
R3.7.8.3   ------GATGGGGCAAAT  12 
R11.1.1    ................... 
A2         GGAAAG.G...........          
 
Figure 10.1: Nucleotide sequence comparison of the P-M intergenic region (P-M IR) and 5’UTR of 
the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3, dashes indicate alignment gaps and 
underlined bases indicate different nucleotides of clone R3.7.8.3 compared to another strain.  
 
           M Gene Start codon 
R3.7.8.3  ATGGAAACATACGTGAACAAACTTCACGAAGGCTCCACATACACAGCTGCTGTT  54  
     M  E  T  Y  V  N  K  L  H  E  G  S  T  Y  T  A  A  V   18 
R11.1.1   ...................................................... 
A2        ....................G................................. 
R3.7.8.3  CAATACAATGTCCTAGAAAAAGACGATGACCCTGCATCACTTACAATATGGGTG 108 
     Q  Y N  V  L  E  K  D  D  D  P  A  S  L  T  I  W  V    36 
R11.1.1   ...................................................... 
A2        ............T......................................... 
R3.7.8.3  CCCATGTTCCAATCATCCATGCCAGCAGATTTACTTATAAAAGAACTAGCTAAT 162 
           P  M  F  Q  S  S  M  P  A  D  L  L  I  K  E  L  A  N   54 
R11.1.1   ...................................................... 
A2        .................T.................................... 
R3.7.8.3  GTCAACATACTAGTGAAACAAATATCCACACCCAAAGGACCTTCATTAAGAGTA 216  
     V  N  I  L  V  K  Q  I  S  T  P  K  G  P  S  L  R  V   72 
R11.1.1   ...................................................... 
A2        ...................................G.........C.......C 
R3.7.8.3  ATGATAAACTCAAGAAGTGCAGTGCTAGCACAAATGCCCAGCAAATTCACTATA 270 
          M  I  N  S  R  S  A  V  L  A  Q  M  P  S  K  F  T  I   90 
R11.1.1   ...................................................... 
A2        ...............................................T..C... 
R3.7.8.3  TGCGCCAATGTGTCCTTGGATGAAAGAAGCAAGCTGGCATATGATGTAACCACA 324 
           C  A  N  V  S  L  D  E  R  S  K  L  A  Y  D  V  T  T  108 
R11.1.1   ...................................................... 
A2        .....T..........................A..A.................. 
R3.7.8.3  CCCTGCGAAATCAAGGCATGTAGTCTAACATGCCTAAAATCAAAAAATATGTTA 378 
           P  C  E  I  K  A  C  S  L  T  C  L  K  S  K  N  M  L  126 
R11.1.1   ...................................................... 
A2        .....T...............................................G 
M GS sequence 
 
P-M  
IR
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R3.7.8.3  ACTACAGTTAAAGATCTCACTATGAAAACACTCAACCCAACACATGACATCATT 432 
           T  T  V  K  D  L  T  M  K  T  L  N  P  T  H  D  I  I  144 
R11.1.1   ...................................................... 
A2        ..........................G...........T........T..T... 
R3.7.8.3  GCTTTATGTGAATTTGAAAATATAGTAACATCAAAAAAAGTCATAATACCAACA 486 
           A  L  C  E  F  E  N  I  V  T  S  K  K  V  I  I  P  T  162 
R11.1.1   ...................................................... 
A2        ....................C................................. 
R3.7.8.3  TACCTAAGATCCATCAGTGTCAGAAATAAAGATCTGAACACACTTGAAAATATA 540 
           Y  L  R  S  I  S  V  R  N  K  D  L  N  T  L  E  N  I  180 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ACAACCACCGAATTCAAAAATGCCATCACAAATGCAAAAATCATCCCTTACTCA 594 
           T  T  T  E  F  K  N  A  I  T  N  A  K  I  I  P  Y  S  198 
R11.1.1   ...................................................... 
A2        ........T..............T.............................. 
R3.7.8.3  GGATTACTGTTAGTCATCACAGTGACTGACAACAAAGGAGCATTCAAATACATA 648 
           G  L  L  L  V  I  T  V  T  D  N  K  G  A  F  K  Y  I  216 
R11.1.1   ...................................................... 
A2        ........A............................................. 
R3.7.8.3  AAGCCACAAAGTCAATTCATAGTAGATCTTGGAGCTTACCTAGAAAAAGAAAGT 702 
           K  P  Q  S  Q  F  I  V  D  L  G  A  Y  L  E  K  E  S  234 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATATATTATGTTACAACAAATTGGAAGCACACAGCTACACGATTTGCAATCAAA 756 
           I  Y  Y  V  T  T  N  W  K  H  T  A  T  R  F  A  I  K  252 
R11.1.1   ...................................................... 
A2        ..............C....................................... 
R3.7.8.3  CCCATGGAAGATTAA 771 
           P  M  E  D XXX 256 
R11.1.1   ............... 
A2        ............... 
 
Figure 10.2: Comparison of nucleotide and deduced amino acid sequences of the M gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
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           M gene 3’UTR 
R3.7.8.3  CCTTTT-CCTCTACATCAGCTAGTTGATTCATACACACTTTCTACCTACATTCT  53 
R11.1.1   ...................................................... 
A2        ......T............TGT...A.........A.................. 
R3.7.8.3  TCACTTCACAAACATAATCACCAACCCTCTGTGGTTTAACCAATCAAACAAAAC 107 
R11.1.1   ...................................................... 
A2        .........C.T..C......A...A..........C................. 
R3.7.8.3  TTATCTGGAGTCTCAGATCATCCCAAGTCATTATTCATCAGATCTAGTACTCAA 161 
R11.1.1   ...................................................... 
A2        .......A....C...................G..T.................. 
R3.7.8.3  ATAAGTTAATAAAAA-  176 
R11.1.1   ................ 
A2        ...............A 
Figure 10.3: Nucleotide sequence comparison of the 3’UTR of the M gene of neutralization resistant 
and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3, dashes indicate alignment gaps and 
underlined bases indicate different nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
                 5’UTR 
R3.7.8.3  TACCCACATGGGGCAAATAATCATCGGAGGAAATCCAACTAATCACAATATCTG  54 
R11.1.1   ...................................................... 
A2        ..TA....................T............................. 
R3.7.8.3  TCAACATAGACAAGTCAACACGCCAAACAAAATCAACCA 93 
R11.1.1   ....................................... 
A2        .T..............C....A...T...G......... 
 
Figure 10.4: Nucleotide sequence comparison of the M-SH intergenic region (M-SH IR) and 5’UTR 
of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
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           SH Gene Start codon                     
R3.7.8.3  ATGGAAAATACATCCATAACAATAGAATTCTCAAGCAAATTCTGGCCTTACTTT  54 
           M  E  N  T  S  I  T  I  E  F  S  S  K  F  W  P  Y  F   18 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ACACTAATACACATGATCACAACAATAATCTTTTTGCTAATCATAATCTCCATC 108 
           T  L  I  H  M  I  T  T  I  I  F  L  L  I  I  I  S  I   36 
R11.1.1   ...................................................... 
A2        ...............................C...................... 
                                         S 
R3.7.8.3  ATGATTGCAATACTAAACAAACTCTGTGAATATAACGTATTCCATAACAAAACC 162 
           M  I  A  I  L  N  K  L  C  E  Y  N  V  F  H  N  K  T   54 
R11.1.1   ...................................................... 
A2        .......................T..............................     
R3.7.8.3  TTTGAGCTACCAAGAGCTCGAGCCAATACATAG 195 
           F  E  L  P  R  A  R  A  N  T XXX  64 
R11.1.1   ................................. 
A2        ......T...............T...C......   
                                V 
 
Figure 10.5: Comparison of nucleotide and deduced amino acid sequences of the SH gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
  
           SH Gene 3’UTR 
R3.7.8.3  CATTCACCAATCTGATGGCTCAAAACAGTAACCTTGCATTTGTAAGTGAGCAAC  54 
R11.1.1   ...................................................... 
A2        ......T.....CA.CA..C.....................AA..A...A.... 
R3.7.8.3  CTTCACCTTTTTACAAAACCACATCAACATCTCACCATGCAAGCCATCATCCAT 108 
R11.1.1   ...................................................... 
A2        .CCT....C.......C...T...T......C..........A...CT...... 
R3.7.8.3  ACTATAAAGTAGTTAATTAAAAAAAA  134 
R11.1.1   .........................- 
A2        .......................---                     
 
Figure 10.6: Nucleotide sequence comparison of the 3’UTR of the SH gene of neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 Stop codon  
 
 SH GE - sequence 
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R5.3        89   AGTTAATTAAAAAAAATAGTCATAACAATGAACTAAGATATTAAGACT  32 
R5.1        70   ...............-................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ...............-................................ 
R2.44        7   ...............-................................ 
R11.1.1      5   ...............-................................ 
R5.14        3   ................................................ 
R11.2      2.7   ...............-................................ 
A2               .............---...................G.....C...... 
 
R5.3        89   AACAACAACGTTGGGGCAAATGCAAAC  59 
R5.1        70   ........................... 
R3.7.8.3    48   ...........................  
R5.2        42   ........................... 
R3.7.8.17   21   ........................... 
R3.2.4      12   ........................... 
R2.44        7   ........................... 
R11.1.1      5   ........................... 
R5.14        3   ........................... 
R11.2      2.7   ........................... 
    A2           .....T...A................. 
 
 
Figure 10.7: Nucleotide sequence comparison of the SH GE sequence, the SH-G intergenic region 
and 5’UTR of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3, dashes indicate alignment gaps and 
underlined bases indicate different nucleotides of clone R5.3 compared to another strain.  
 
 
 
 
 
 
 
. 
SH GE sequence  SH-G IR 
  
 5’UTR 
 
PZ  
EC50 
  G GS sequence 
  
243 
 
2
4
3
 
                 Cytoplasmic tail  
                 G Gene Start codon                     
R5.3        89   ATGTCCAAAACCAAGGACCAACGCACCGCCAAGACACTAGAAAAGACC  48 
                  M  S  K  T  K  D  Q  R  T  A  K  T  L  E  K  T   16 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........A..................T......T......G.... 
                           N                    R 
R5.3        89   TGGGACACTCTCAATCATCTATTATTCATATCATCGTGCTTATACAAG  96 
                  W  D  T  L  N  H  L  L  F  I  S  S  C  L  Y  K   32 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .........T.........................T............ 
R5.3        89   TTAAATCTTAAATCTATAGCACAAATCACATTATCCATTCTGGCAATG 144 
                  L  N  L  K  S  I  A  Q  I  T  L  S  I  L  A  M   48 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...............G................................ 
                                 V 
PZ
EC50 
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                          Hydrophobic transmembrane domain  
R5.3        89   ATAATCTCAACTTCACTTATAATTGTAGCCATCATATTCATAGCCTCA 192 
                  I  I  S  T  S  L  I  I  V  A  I  I  F  I  A  S   64 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .........................C.....................G 
                                          A 
 
R5.3        89   GCAAACAACAAAGTCACACTAACAACTGCAATCATACAAGATGCAACA 240 
                  A  N  N  K  V  T  L  T  T  A  I  I  Q  D  A  T   80 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ......C............C............................ 
                        H           P 
R5.3        89   AGCCAGATCAAGAACACAACCCCAACATACCTGACCCAGAATCCCCAG 288 
                  S  Q  I  K  N  T  T  P  T  Y  L  T  Q  N  P  Q   96 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................C...........T...                            
             Mucin-like VR1                       Ectodomain
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R5.3        89   CTTGGAATCAGCTTCTTTAATCTGTCTGGAACTACATCACAAACCACC 336 
                  L  G  I  S  F  F  N  L  S  G  T  T  S  Q  T  T  112 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...........TCC..C.....C.....A..T...........T....  
          P  S     P     E  I           I  
R5.3        89   GCCACACTAGCTTTAACAACACCAAGTGTCGAGTCAATCCTGCAATCT 384 
                  A  T  L  A  L  T  T  P  S  V  E  S  I  L  Q  S  128  
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               A...T........C..........G.A...A......C.........C                            
                  T  I        S           G     K     T                
R5.3        89   ACAACAGTCAAGACCAAAAACACAACAACAACCCAAATACAACCCAGC 432 
                  T  T  V  K  T  K  N  T  T  T  T  Q  I  Q  P  S  144 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................T....C..........                            
                                                      T 
                                                                    
PZ  
EC50 
  
246 
 
2
4
6
 
                                   
R5.3        89   AAGCCCACCACAAAACAACGCCAAAACAAACCGCCAAACAAACCCAAT 480 
                  K  P  T  T  K  Q  R  Q  N  K  P  P  N  K  P  N  160 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................A....G..........                            
                                                      S 
                        Central region segment         
R5.3        89   AATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCATATGC 528 
                  N  D  F  H  F  E  V  F  N  F  V  P  C  S  I  C  176 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................................                            
                                                      
R5.3        89   AGCAACAATCCAACTTGCTGGGCCATCTGCAAAAGAATACCAAGCAAA 576 
                  S  N  N  P  T  C  W  A  I  C  K  R  I  P  S  K  192 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..............C........T...................A....   
                                                            N                          
PZ  
EC50
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                          Mucin-like VR2 
R5.3        89   AAACCTGGAAAGAAAACCACCACCAAGCCCACAAAAAAACCAACCATC 624 
                  K  P  G  K  K  T  T  T  K  P  T  K  K  P  T  I  208 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .....A..............T........................C.. 
                                                               L                          
R5.3        89   AAGACAACCAAAAAAGATCTCAAACCTCAAACCACAAAACCAAAGGAA 672 
                  K  T  T  K  K  D  L  K  P  Q  T  T  K  P  K  E  224 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...................C...............T...T........ 
                                    P                    S                                 
R5.3        89   GCACCTACCACCAAGCCCACAGAAAAGCCAACCATCAACATCACCAAA 720 
                  A  P  T  T  K  P  T  E  K  P  T  I  N  I  T  K  240 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .T...C..................G...............C....... 
                  V                       E              T                                     
PZ  
EC50 
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R5.3        89   CCAAACATCAGAACTACACTGCTCACCAACAGTACCACAGGAAATCTA 768 
                  P  N  I  R  T  T  L  L  T  N  S  T  T  G  N  L  256 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               A.........T.........A......TC..AC.............C. 
                  T        I                 S  N              P                                    
R5.3        89   GAACACACAAGTCAAGAGGAAACCCTCCATTCAACCTCCTCCGAAGGC 816 
                  E  H  T  S  Q  E  E  T  L  H  S  T  S  S  E  G  272 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ....T..........AT.......T....C.....T............ 
                     L           M        F                                                       
 
R5.3        89   AATACAAGCCCTTCACAAGTCTATACAACATCCGAGTACCTATCACAA 864 
                  N  T  S  P  S  Q  V  Y  T  T  S  E  Y  L  S  Q  288 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...C..........T.......C.................C....... 
                     P                 S                 P    
PZ  
EC50 
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R5.3        89   CCTCCATCTCCATCCAACATAACAAACCTGTAG 897 
                  P  P  S  P  S  N  I  T  N  L XXX 298 
R5.1        70   ...................C............. 
                                    T 
R3.7.8.3    48   ................................. 
R5.2        42   ................................. 
R3.7.8.17   21   ................................. 
R3.2.4      12   ...................C............. 
                                    T 
R2.44        7   ................................. 
R11.1.1      5   ...................C............. 
                                    T 
R5.14        3   ................................. 
R11.2      2.7   ...................C............. 
                                    T 
A2               ...T........C......C.C..CG..A.... 
                     S        P     T  P  R  Q                                                  
Figure 10.8: Comparison of nucleotide and deduced amino acid sequences of the G gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3 and underlined bases indicate different 
nucleotides of clone R5.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
 
 
 
 
                              
 
R5.3        89   TAGTCA-TTAAAAAGCGTATTATTGCAAAAAACCATGACTAAATCAAAC 46 
       XXX 
R5.1        70   .......................................C......... 
R3.7.8.3    48   ................................................. 
R5.2        42   ................................................. 
R3.7.8.17   21   ................................................. 
R3.2.4      12   ................................................. 
R2.44        7   ................................................. 
R11.1.1      5   ................................................. 
R5.14        3   ................................................. 
R11.2      2.7   ................................................. 
A2               ....T.C.......-.A......CA......G.......C..C.T.... 
 
 
 
 
 
 Stop codon  
 
G GE sequence 
 
PZ  
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 3’UTR  
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R5.3        89   AGAATCAAAATAAGCTCT 64 
R5.1        70   .................. 
R3.7.8.3    48   .................. 
R5.2        42   .................. 
R3.7.8.17   21   .................. 
R3.2.4      12   .................. 
R2.44        7   .................. 
R11.1.1      5   .................. 
R5.14        3   .................. 
R11.2      2.7   .................. 
A2               .............A....                      
Figure 10.9: Nucleotide sequence comparison of the 3’UTR of the G gene and G-F intergenic region 
of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3 and underlined bases indicate different 
nucleotides of clone R5.3 compared to another strain.  
 
 
 
 
R5.3        89   GGGGCAAATAACA 13 
R5.1        70   ............. 
R3.7.8.3    48   ............. 
R5.2        42   ............. 
R3.7.8.17   21   ............. 
R3.2.4      12   ............. 
R2.44        7   ............. 
R11.1.1      5   ............. 
R5.14        3   ............. 
R11.2      2.7   ............. 
A2               .............                      
Figure 10.10: Nucleotide sequence comparison of the SH-G intergenic region and 5’UTR of the 
neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3 and underlined bases indicate different 
nucleotides of clone R5.3 compared to another strain.  
 
 
 
 
 
 
 
 
 
 
  F GS – signal 
 5’UTR 
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                 F Gene Start codon                     
R5.3        89   ATGGAGTTGCCAATCCTCAAAACAAATGCAATTACCACAATCCTTGCT 48 
      M  E  L  P  I  L  K  T  N  A  I  T  T  I  L  A  16 
R5.1        70   ....... ......................................... 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........T....T.....G......................CA.. 
                           L           A                 T  
                                     
R5.3        89   GCAGTCACACTCTGTTTCGCTTCCAGTCAAAACATCACTGAAGAATTT 96 
                  A  V  T  L  C  F  A  S  S  Q  N  I  T  E  E  F  32 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .........T.T.....T.....TG.......................  
                           F        G 
R5.3        89   TATCAATCAACATGCAGTGCAGTTAGCAAAGGCTATCTTAGTGCTTTA 144 
                  Y  Q  S  T  C  S  A  V  S  K  G  Y  L  S  A  L   48  
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .............................................C.G 
PZ  
EC50
NH2-terminal signal peptide 
  
252 
 
2
5
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            Heptad repeat 3 
R5.3        89   AGAACTGGTTGGTATACTAGTGTTATAACTATAGAATTAAGTAATATC 192 
                  R  T  G  W  Y  T  S  V  I  T  I  E  L  S  N  I   64 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .................C..............................  
R5.3        89   AAGGAAAATAAGTGTAATGGAACAGACGCTAAGGTAAAATTGATAAAA 240 
                  K  E  N  K  C  N  G  T  D  A  K  V  K  L  I  K   80 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........................T.....................        
 
R5.3        89   CAAGAATTAGATAAATATAAAAATGCTGTAACAGAATTGCAGTTGCTC 288 
                  Q  E  L  D  K  Y  K  N  A  V  T  E  L  Q  L  L   96 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................ 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........................T..................... 
PZ  
EC50 
  
253 
 
2
5
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R5.3        89   ATGCAAAGCACACCAGCAGCCAACAATCGAGCCAGAAGAGAACTACCA 336 
                  M  Q  S  T  P  A  A  N  N  R  A  R  R  E  L  P  112 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ............T................................... 
                              S 
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...............C..A.A........................... 
                 P  T           
R5.3        89   AAGTTTATGAATTATACACTCAACAACACCAAAAATACCAATGTAACA 384 
                  K  F  M  N  Y  T  L  N  N  T  K  N  T  N  V  T  128 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .G........................TG.......A............ 
   R                          A    K          
 
 
 
R5.3        89   TTAAGCAAGAAAAGGAAAAGAAGATTTCTTGGCTTTTTGTTAGGTGTT 432 
                  L  S  K  K  R  K  R  R  F  L  G  F  L  L  G  V  144 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...............................TT............... 
                                 V       
F2 Subunit  F1 Subunit 
Heptad  
repeat 3                 
 Cleavage site I  
            
 
 Cleavage site II  
 
                 
 
 Fusion peptide 
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254 
 
2
5
4
 
R5.3        89   GGATCTGCAATCGCCAGTGGCATTGCTGTATCTAAAGTCCTGCACCTA 480 
                  G  S  A  I  A  S  G  I  A  V  S  K  V  L  H  L  160 
R5.1        70   .......................G........................ 
         M 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   .......................G........................ 
                    M 
R5.14        3   ................................................ 
R11.2      2.7   .......................G........................ 
         M 
A2               .....................G.G...........G............ 
                        V                                 
R5.3        89   GAAGGGGAAGTGAACAAAATCAAAAGTGCTCTACTATCCACAAACAAG 528 
                  E  G  E  V  N  K  I  K  S  A  L  L  S  T  N  K  176 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .................G.............................. 
                                        
R5.3        89   GCTGTAGTCAGCTTATCAAATGGAGTTAGTGTCTTAACCAGCAAAGTG 576 
                  A  V  V  S  L  S  N  G  V  S  V  L  T  S  K  V  192 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...C............................................ 
             L 
PZ  
EC50 
Fusion           
peptide  Heptad repeat 1                            
0 
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R5.3        89   TTAGACCTCAAAAACTATATAGATAAACAGTTGTTACCTATTGTGAAC 624                    
                  L  D  L  K  N  Y  I  D  K  Q  L  L  P  I  V  N  208   
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .............................A.................. 
R5.3        89   AAGCAAAGCTGCAGCATATCAAACATTGAAACTGTGATAGAATTCCAA 672 
                  K Q  S  C  S  I  S  N  I  E  T  V  I  E  F  Q   224 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .......................T..A..............G......                   
R5.3        89   CAAAAGAACAACAGACTACTAGAGATTACCAGGGAATTTAGTGTTAAT 720 
                  Q  K  N  N  R  L  L  E  I  T  R  E  F  S  V  N  240 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................................ 
 
PZ  
EC50 Heptad repeat 1                          
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R5.3        89   GCAGGTGTAACTACACCTGTAAGCACTTATATGTTAACAAATAGTGAA 768 
                  A  G  V  T  T  P  V  S  T  Y  M  L  T  N  S  E  256 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .............................C........T......... 
                                 
R5.3        89   TTATTATCATTAATCAATGATATGCCTATAACAAATGATCAGAAAAAG 816 
                  L  L  S  L  I  N  D  M  P  I  T  N  D  Q  K  K  272 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .....G.......................................... 
 
                                     
 
R5.3        89   TTAATGTCCAACAATGTTCAAATAGTTAGACAGCAAAGTTACTCTATC 864 
                  L  M  S  N  N  V  Q  I  V  R  Q  Q  S  Y  S  I  288 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .....G.......................................... 
PZ  
EC50 
binding site 
Palivizumab  
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R5.3        89   ATGTCCATAATAAAGGAGGAAGTCTTAGCATATGTAGTACAATTACCA 912 
                  M  S  I  I  K  E  E  V  L  A  Y  V  V  Q  L  P  304 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..............G................................. 
                       Cysteine-rich domain 
R5.3        89   CTATATGGTGTAATAGATACACCTTGTTGGAAACTACACACATCCCCT 960 
                  L  Y  G  V  I  D  T  P  C  W  K  L  H  T  S  P  320 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   .................................A.............. 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...........T...........C........................ 
R5.3        89   CTATGTACAACCAACACAAAGGAAGGGTCCAACATCTGTTTAACAAGA 1008 
                  L  C  T  T  N  T  K  E  G  S  N  I  C  L  T  R   336 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ....................A........................... 
 
 
PZ  
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R5.3        89   ACCGACAGAGGATGGTACTGTGACAATGCAGGATCAGTGTCTTTCTTC 1056 
                  T  D  R  G  W  Y  C  D  N  A  G  S  V  S  F  F   352 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..T...................................A......... 
R5.3        89   CCACAAGCTGAAACATGTAAAGTTCAATCGAATCGAGTATTTTGTGAC 1104 
                  P  Q  A  E  T  C  K  V  Q  S  N  R  V  F  C  D   352 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   .........................G...................... 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .............................A.................. 
R5.3        89   ACAATGAACAGTTTAACATTACCAAGTGAAGTAAATCTCTGCAACATT 1152 
                  T  M  N  S  L  T  L  P  S  E  V  N  L  C  N  I   384 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..............................A.............TG.. 
        I              V 
 
PZ  
EC50 
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R5.3        89   GACATATTCAACCCCAAATATGATTGCAAAATTATGACTTCAAAAACA 1200 
                  D  I  F  N  P  K  Y  D  C  K  I  M  T  S  K  T   400 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........................T..................... 
R5.3        89   GATGTAAGCAGCTCTGTTATCACATCTCTAGGAGCCATTGTGTCATGC 1248 
                  D  V  S  S  S  V  I  T  S  L  G  A  I  V  S  C   416 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..............C................................. 
R5.3        89   TATGGCAAAACTAAATGTACAGCATCCAATAAAAATCGTGGAATCATA 1296 
                  Y  G  K  T  K  C  T  A  S  N  K  N  R  G  I  I   432 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..............C.................................      
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                    Cysteine-rich Domain  
R5.3        89   AAGACATTTTCTAACGGGTGTGATTATGTATCAAATAAGGGGGTGGAC 1344 
                  K  T  F  S  N  G  C  D  Y  V  S  N  K  G  V  D   448 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ....................C.................A...A..... 
          M 
R5.3        89   ACTGTATCTGTAGGTAATACATTATATTATGTAAATAAGCAAGAAGGA 1392 
                  T  V  S  V  G  N  T  L  Y  Y  V  N  K  Q  E  G   464 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .....G...........C.............................T 
   Heptad repeat 2 
R5.3        89   AAAAGTCTCTATGTAAAAGGTGAACCAATAATAAATTTCTATGACCCA 1440 
                  K  S  L  Y  V  K  G  E  P  I  I  N  F  Y  D  P   480 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................................................ 
PZ  
EC50
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R5.3        89   TTAGTGTTCCCTTCTGATGAATTTGATGCATCAATATCTCAAGTCAAT 1488 
                  L  V  F  P  S  D  E  F  D  A  S  I  S  Q  V  N   496 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .....A.....C.................................... 
R5.3        89   GAGAAGATTAACCAGAGCCTAGCATTTATTCGTAAATCTGATGAATTA 1536 
                  E  K  I  N  Q  S  L  A  F  I  R  K  S  D  E  L   512 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .......................................C........ 
 
 
R5.3        89   TTACATAATGTAAATGTTGGTAAATCCACCACAAATATCATGATAACT 1584 
                  L  H  N  V  N  V  G  K  S  T  T  N  I  M  I  T   528 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ................C............................... 
PZ  
EC50
          Domain 
Heptad repeat 2  Transmembrane                
0 
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R5.3        89   ACTATAATTATAGTGATTATAGTAATATTGTTATTATTAATTGCAGTT 1632 
                  T  I  I  I  V  I  I  V  I  L  L  L  L  I  A  V   544 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..................................C............. 
           S 
              Transmembrane domain           Cytoplasmic tail 
R5.3        89   GGACTGTTCCTATACTGCAAGGCCAGAAGCACACCAGTCACACTAAGC 1680 
                  G  L  F  L  Y  C  K  A  R  S  T  P  V  T  L  S   560 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ......C..T.......T.............................. 
    L  
   
R5.3        89   AAGGATCAACTGAGTGGTATAAATAATATTGCATTTAGTAACTGA 1725 
                  K  D  Q  L  S  G  I  N  N  I  A  F  S  N XXX  574 
R5.1        70   ............................................. 
R3.7.8.3    48   ............................................. 
R5.2        42   ............................................. 
R3.7.8.17   21   .............................................                              
R3.2.4      12   ............................................. 
R2.44        7   ............................................. 
R11.1.1      5   ............................................. 
R5.14        3   ............................................. 
R11.2      2.7   ............................................. 
A2               ..A........................................A. 
 Stop codon  
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Figure 10.11: Comparison of nucleotide and deduced amino acid sequences of the F gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3 and underlined bases indicate different 
nucleotides of clone R5.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
 
 
 
 
        F Gene 3’UTR 
R5.3        89   ATAAAAATAGTACCTAATCATGTTCTTACAATGGTTCACTATCCGATC 48 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ..........C.........................T......T.C.. 
R5.3        89   ATAGACAACCCATCTATCATTGGATTTTCTTAAAGTCTGAACTTCATT 96 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               ...............G..................A............C 
 
 
 
 
PZ  
EC50
  
264 
 
2
6
4
 
 
R5.3        89   GCAACTCTCATCTATAAACCATCTCACTTACACTATTTAAGTAGATTC 144 
R5.1        70   ................................................ 
R3.7.8.3    48   ................................................ 
R5.2        42   ................................................ 
R3.7.8.17   21   ................................................                              
R3.2.4      12   ................................................ 
R2.44        7   ................................................ 
R11.1.1      5   ................................................ 
R5.14        3   ................................................ 
R11.2      2.7   ................................................ 
A2               .A.............................................. 
 
R5.3        89   CTATTTTATAGTTATATAAAA 165 
R5.1        70   ..................... 
R3.7.8.3    48   ..................... 
R5.2        42   ..................... 
R3.7.8.17   21   .....................                             
R3.2.4      12   ..................... 
R2.44        7   ..................... 
R11.1.1      5   ..................... 
R5.14        3   ..................... 
R11.2      2.7   ..................... 
A2               ..................... 
Figure 10.12: Nucleotide sequence comparison of the 3’UTR of the F gene of the neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R5.3 and underlined bases indicate different 
nucleotides of clone R5.3 compared to another strain.  
 
 
 
           NS1 Gene Start codon 
R3.7.8.3  ATGGGCAGCAATTCATTGAGTATGATAAAAGTTAGATTACAAAATTTATTTGAC  54  
     M  G  S  N  S  L  S  M  I  K  V  R  L  Q  N  L  F  D   18 
R11.1.1   ...................................................... 
A2        ...............................................G......   
R3.7.8.3  AATGATGAAGTAGCATTGTTAAAAATAACCTGCTATACTGACAAATTGATACAT 108  
     N  D  E  V  A  L  L  K  I  T  C  Y  T  D  K  L  I  H   36 
R11.1.1   ...................................................... 
A2        .............................A...........T.....A......   
 F GE sequence 
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R3.7.8.3  TTAACTAATGCTTTGGCTAAGGCAGTGATACATACAATCAAATTGAATGGCATT 162  
     L  T  N  A  L  A  K  A  V  I  H  T  I  K  L  N  G  I   54 
R11.1.1   ...................................................... 
A2        ........C............................................. 
R3.7.8.3  GTATTTGTGCATGTTATTACAAGTAGTGATATTTGCCCTAATAATAATATTGTA 216  
     V  F  V  H  V  I  T  S  S  D  I  C  P  N  N  N  I  V   72 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  GTGAAATCCAACTTCACAACAATGCCAGTGTTACAAAATGGAGGTTATATATGG 270  
     V  K  S  N  F  T  T  M  P  V  L  Q  N  G  G  Y  I  W   90 
R11.1.1   ...................................................... 
A2        ..A........T.................AC....................... 
R3.7.8.3  GAAATGATGGAATTAACACACTGCTCTCAACCCAATGGCCTAATAGATGACAAT 324  
     E  M  M  E  L  T  H  C  S  Q  P  N  G  L  I  D  D  N  108 
R11.1.1   ...................................................... 
A2        ....................T...........T.....T...C........... 
             L 
R3.7.8.3  TGTGAAATCAAATTCTCCAAAAAACTAAGCGATTCAACAATGACCAACTATATG 378  
     C  E  I  K  F  S  K  K  L  S  D  S  T  M  T  N  Y  M  126 
R11.1.1   ...................................................... 
A2        ........T....................T.................T...... 
 
R3.7.8.3  AATCAATTATCTGAATTACTTGGATTTGATCTTAATCCATAA 420  
     N  Q  L  S  E  L  L  G  F  D  L  N  P XXX 140 
R11.1.1   .......................................... 
A2        ..........................................   
        
Figure 10.13: Comparison of nucleotide and deduced amino acid sequences of the NS1 gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence 
    
 
      NS1 Gene 3’UTR 
R11  ATTATAATAAATATCAACTAGAAATCAGTGTCACTAACACCATTAGTTAATATAAAA  57 
R3   .........................................................  
A2   ........T..................A.............................   
 
Figure 10.14: Nucleotide sequence comparison of the 3’UTR of the NS1 gene of neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 NS1 GE sequence  
 
 Stop codon 
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           NS1-NS2 IR      5’UTR 
R3.7.8.3  CTTGACAGAAGATAAAAATGGGGCAAATAAATAAACTCAGCCGACCCAACC 51  
R11.1.1   ................................................... 
A2        ...A........C...................C..T......A........    
Figure 10.15: Nucleotide sequence comparison of the NS1-NS2 intergenic region (NS1-NS2 IR) and 
5’UTR of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
           NS2 Gene Start codon 
R3.7.8.3  ATGGACACAACACACAATGATACCACACCACAAAGACTGATGATCACAGACATG  54  
     M  D  T  T  H  N  D  T  T  P  Q  R  L  M  I  T  D  M   18 
R11.1.1   ...................................................... 
A2        ...........C..........AT..............................                              
                                N   
R3.7.8.3  AGACCATTGTCACTTGAGACTATAATAACATCACTAACCAGAGACATCATAACA 108 
     R  P  L  S  L  E  T  I  I  T  S  L  T  R  D  I  I  T   36 
R11.1.1   ...................................................... 
A2        .....G..............C.................................                                                             
R3.7.8.3  CACAGATTTATATACTTGATAAATCATGAATGTATAGTGAGAAAACTTGATGAA 162 
     H  R  F  I  Y  L  I  N  H  E  C  I  V  R  K  L  D  E   54 
R11.1.1   ...................................................... 
A2        ....A.................................................                              
              K   
R3.7.8.3  AGACAGGCCACATTTACATTCCTGGTCAACTATGAAATGAAACTATTGCACAAA 216 
     R  Q  A  T  F  T  F  L  V  N  Y  E  M  K  L  L  H  K   72 
R11.1.1   ...................................................... 
A2        .A.............................................A......                              
           K 
R3.7.8.3  GTGGGAAGCACTAAATACAAAAAATATACTGAATACAACACAAAATATGGCACT 270 
     V  G  S  T  K  Y  K  K  Y  T  E  Y  N  T  K  Y  G  T   90  
R11.1.1   ...................................................... 
A2        ..A..............T....................................                              
                                
 
R3.7.8.3  TTCCCTATGCCAATATTTATCAATCATGATGGGTTCTTAGAATGCATTGGCATT 324 
     F  P  M  P  I  F  I  N  H  D  G  F  L  E  C  I  G  I  108 
R11.1.1   ...................................................... 
A2        .................C....................................       
                        
NS2 GS signal 
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R3.7.8.3  AAGCCTACAAAGCACACTCCCATAATATACAAGTATGATCTCAATCCATGA 375 
     K  P  T  K  H  T  P  I  I  Y  K  Y  D  L  N  P XXX 124  
R11.1.1   ................................................... 
A2        ..............T..................................A.                              
Figure 10.16: Comparison of nucleotide and deduced amino acid sequences of the NS2 gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
 
           NS2 Gene 3’UTR 
R3.7.8.3  ATTTCAACACAAGATTCACACAATCTGAAATAACAACTTCATGCGTAACTACAC 54     
R11.1.1   ...................................................... 
A2        ............T.............A...C.......CT....A......T..                              
 
R3.7.8.3  TCCATAGTCCAAATGGAGCCTGAAAATTATAGTAATTTAAAA 96 
R11.1.1   .......................................... 
A2        ...........G.............................. 
Figure 10.17: Nucleotide sequence comparison of the 3’UTR of the NS2 gene of neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
           NS2-N IR               5’UTR 
R3.7.8.3  TTAAGGAGAGACATAAGACGAAGGATGGGGCAAATACAAAA 41 
R11.1.1   ......................................... 
A2        ...........T......TAG.A.................G 
Figure 10.18: Nucleotide sequence comparison of the NS2-N intergenic region (NS2-N IR) and 
5’UTR of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
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           N Gene Start codon 
R3.7.8.3  ATGGCTCTTAGCAAAGTCAAGTTGAACGATACACTCAACAAAGATCAACTTCTG 54 
     M  A  L  S  K  V  K  L  N  D  T  L  N  K  D  Q  L  L  18 
R11.1.1   ...................................................... 
A2        ..........................T...........................                              
R3.7.8.3  TCATCCAGCAAATACACCATCCAACGGAGCACAGGAGATAGTATTGATACTCCT 108 
           S  S  S  K  Y  T  I  Q  R  S  T  G  D  S  I  D  T  P   36  
R11.1.1   ...................................................... 
A2        ......................................................                              
R3.7.8.3  AATTATGATGTACAGAAACACATCAACAAGTTATGTGGCATGTTATTAATCACA 162 
           N  Y  D  V  Q  K  H  I  N  K  L  C  G  M  L  L  I  T   54 
R11.1.1   ...................................................... 
A2        ...........G..............T...........................                              
R3.7.8.3  GAAGATGCTAATCATAAATTCACTGGGGTAATAGGTATGTTATATGCTATGTCT 216 
           E  D  A  N  H  K  F  T  G  V  I  G  M  L  Y  A  M  S   72  
R11.1.1   ...................................................... 
A2        ...........................T...................G......  
                                      L 
R3.7.8.3  AGATTAGGAAGAGAAGACACCATAAAAATACTCAGAGATGCGGGATATCATGTA 270 
           R  L  G  R  E  D  T  I  K  I  L  R  D  A  G  Y  H  V   90   
R11.1.1   ...................................................... 
A2        ..G...................................................                              
R3.7.8.3  AAAGCAAATGGAGTGGATGTAACAACACATCGTCAAGACATTAATGGGAAAGAA 324 
           K  A  N  G  V  D  V  T  T  H  R  Q  D  I  N  G  K  E  108    
R11.1.1   ...................................................... 
A2        ..............A................................A......                              
R3.7.8.3  ATGAAATTTGAAGTGTTAACATTGGCAAGCTTAACAACTGAAATTCAAATCAAC 378 
           M  K  F  E  V  L  T  L  A  S  L  T  T  E  I  Q  I  N  126    
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATTGAGATAGAATCTAGAAAATCCTACAAAAAAATGCTAAAAGAAATGGGAGAG 432 
           I  E  I  E  S  R  K  S  Y  K  K  M  L  K  E  M  G  E  144    
R11.1.1   ...................................................... 
A2        ......................................................                                                          
R3.7.8.3  GTAGCTCCAGAATACAGGCATGACTCTCCTGATTGTGGGATGATAGTATTATGT 486 
           V  A  P  E  Y  R  H  D  S  P  D  C  G  M  I  V  L  C  162    
R11.1.1   ...................................................... 
A2        .............................................A........  
           I      
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R3.7.8.3  ATAGCAGCATTAGTAATAACCAAATTAGCAGCAGGGGATAGATCTGGTCTCACA 540 
           I  A  A  L  V  I  T  K  L  A  A  G  D  R  S  G  L  T  180    
R11.1.1   ...................................................... 
A2        ....................T.................C...........T....  
R3.7.8.3  GCTGTAATTAGGAGAGCTAATAATGTTCTAAAAAATGAAATGAAACGTTATAAA 594 
           A  V  I  R  R  A  N  N  V  L  K  N  E  M  K  R  Y  K  198    
R11.1.1   ...................................................... 
A2        ..C..G....................C.......................C...  
R3.7.8.3  GGCTTACTACCAAAGGATATAGCCAACAGCTTCTATGAAGTGTTTGAAAAATAT 648 
           G  L  L  P  K  D  I  A  N  S  F  Y  E  V  F  E  K  Y  216    
R11.1.1   ...................................................... 
A2        ...........C.....C..................................C. 
             H  
R3.7.8.3  CCTCACTTTATAGATGTTTTTGTTCATTTTGGTATAGCACAATCTTCTACCAGA 702 
           P  H  F  I  D  V  F  V  H  F  G  I  A  Q  S  S  T  R  234 
R11.1.1   ...................................................... 
A2        ..C...................................................  
R3.7.8.3  GGTGGCAGTAGAGTTGAAGGGATTTTTGCAGGATTGTTTATGAATGCCTATGGT 756 
           G  G  S  R  V  E  G  I  F  A  G  L  F  M  N  A  Y  G  252 
R11.1.1   ...................................................... 
A2        ......................................................  
R3.7.8.3  GCAGGGCAAGTGATGTTACGGTGGGGGGTCTTAGCAAAATCAGTTAAAAATATT 810 
           A  G  Q  V  M  L  R  W  G  V  L  A  K  S  V  K  N  I  270 
R11.1.1   ...................................................... 
A2        ..........................A...........................  
R3.7.8.3  ATGCTAGGACACGCTAGTGTGCAAGCAGAAATGGAACAAGTTGTGGAGGTTTAT 864 
           M  L  G  H  A  S  V  Q  A  E  M  E  Q  V  V  E  V  Y  288 
R11.1.1   ...................................................... 
A2        ...T.......T................................T.........  
R3.7.8.3  GAATATGCCCAAAAATTGGGTGGAGAAGCAGGATTCTACCATATATTGAACAAC 918 
           E  Y  A  Q  K  L  G  G  E  A  G  F  Y  H  I  L  N  N  306 
R11.1.1   ...................................................... 
A2        .......................T..............................  
R3.7.8.3  CCAAAAGCATCATTATTATCTTTGACTCAATTCCCCCACTTTTCCAGTGTAGTA 972 
           P  K  A  S  L  L  S  L  T  Q  F  P  H  F  S  S  V  V  324 
R11.1.1   ...................................................... 
A2        ................................T..T.....C............  
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R3.7.8.3  TTAGGCAATGCTGCTGGCCTAGGCATAATGGGAGAATACAGAGGTACACCAAGG 1026 
           L  G  N  A  A  G  L  G  I  M  G  E  Y  R  G  T  P  R   342 
R11.1.1   ...................................................... 
A2        ...................................G..............G...  
R3.7.8.3  AATCAAGATCTATATGATGCTGCAAAGGCATATGCTGAACAACTCAAAGAAAAT 1080 
           N  Q  D  L  Y  D  A  A  K  A  Y  A  E  Q  L  K  E  N   360 
R11.1.1   ...................................................... 
A2        ....................A.................................  
R3.7.8.3  GGTGTGATTAACTACAGTGTATTAGACTTGACAGCAGAAGAACTAGAGGCTATC 1134 
           G  V  I  N  Y  S  V  L  D  L  T  A  E  E  L  E  A  I   378 
R11.1.1   ...................................................... 
A2        .....................C................................  
 
R3.7.8.3  AAACATCAGCTTAATCCAAAAGATAATGATGTAGAGCTTTGA 1176 
           K  H  Q  L  N  P  K  D  N  D  V  E  L XXX  391 
R11.1.1   .......................................... 
A2        ..........................................  
Figure 10.19: Comparison of nucleotide and deduced amino acid sequences of the N gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
 
 
 
 
      
 
R3.7.8.3  TGAGTTAATAAAAAAGT  15 
          XXX 
R11.1.1   ................. 
A2        ...............-. 
Figure 10.20: Nucleotide sequence comparison of the 3’UTR of the N gene and the N-P intergenic 
region (N-P IR) of neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3, dashes indicate alignment gaps and 
underlined bases indicate different nucleotides of clone R3.7.8.3 compared to another strain.  
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R3.7.8.3  GGGGCAAATAAATCATC  17 
R11.1.1   ................. 
A2        ................. 
 
Figure 10.21: Nucleotide sequence comparison of 5’UTR of the neutralization resistant and 
susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
           P Gene Start codon 
R3.7.8.3  ATGGAAAAGTTTGCTCCTGAATTCCATGGAGAAGACGCAAACAACAGAGCTACT 54 
           M  E  K  F  A  P  E  F  H  G  E  D  A  N  N  R  A  T  18 
R11.1.1   ...................................................... 
A2        ...................................T...........G......  
R3.7.8.3  AAATTCCTAGAATCAATAAAGGGCAAATTCACATCACCTAAAGATCCCAAGAAA 108 
           K  F  L  E  S  I  K  G  K  F  T  S  P  K  D  P  K  K   36  
R11.1.1   ...................................................... 
A2        ......................................C...............  
R3.7.8.3  AAAGATAGTATCATATCTGTCAACTCAATAGATATAGAAGTAACCAAAGAAAGC 162 
           K  D  S  I  I  S  V  N  S  I  D  I  E  V  T  K  E  S   54  
R11.1.1   ...................................................... 
A2        ......................................................  
R3.7.8.3  CCTATAACATCAAATTCAACCATTATAAACCCTACAAATGAGACAGATGATACT 216 
           P  I  T  S  N  S  T  I  I  N  P  T  N  E  T  D  D  T   72  
R11.1.1   ...................................................... 
A2        ....................T.....C.....A.....................  
R3.7.8.3  GTAGGGAACAAGCCCAATTATCAAAGGAAACCTCTAGTAAGTTTCAAAGAAGAC 270 
           V  G  N  K  P  N  Y  Q  R  K  P  L  V  S  F  K  E  D   90  
R11.1.1   ...................................................... 
A2        .C........................A........................... 
     A 
R3.7.8.3  CCTACACCAAGTGATAATCCCTTTTCAAAACTATACAAAGAAACCATAGAAACA 324 
           P  T  P  S  D  N  P  F  S  K  L  Y  K  E  T  I  E  T  108  
R11.1.1   ...................................................... 
A2        ..........................T...........................  
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R3.7.8.3  TTTGATAACAATGAAGAAGAATCTAGCTATTCATATGAAGAAATAAATGATCAG 378 
           F  D  N  N  E  E  E  S  S  Y  S  Y  E  E  I  N  D  Q  126  
R11.1.1   ...................................................... 
A2        .......................C..........C...................  
R3.7.8.3  ACAAACGATAATATAACAGCAAGATTAGATAGGATTGATGAAAAATTAAGTGAA 432 
           T  N  D  N  I  T  A  R  L  D  R  I  D  E  K  L  S  E  144  
R11.1.1   ...................................................... 
A2        ......................................................  
R3.7.8.3  ATACTAGGAATGCTTCACACACTAGTAGTAGCGAGTGCGGGACCTACATCTGCT 486 
           I  L  G  M  L  H  T  L  V  V  A  S  A  G  P  T  S  A  162  
R11.1.1   ...................................................... 
A2        .....................T.......G..A.....A...............  
R3.7.8.3  CGGGATGGTATAAGAGATGCCATGGTTGGTTTAAGAGAAGAAATGATAGAAAAA 540 
           R  D  G  I  R  D  A  M  V  G  L  R  E  E  M  I  E  K  180  
R11.1.1   ...................................................... 
A2        ........................A............................. 
     I 
R3.7.8.3  ATCAGAACTGAAGCATTAATGACCAATGATAGATTAGAAGCTATGGCAAGACTC 594 
           I  R  T  E  A  L  M  T  N  D  R  L  E  A  M  A  R  L  198  
R11.1.1   ...................................................... 
A2        .............................C........................  
R3.7.8.3  AGGAATGAGGAAAGTGAAAAGATGGCAAAAGATACATCAGATGAAGTGTCTCTC 648 
           R  N  E  E  S  E  K  M  A  K  D  T  S  D  E  V  S  L  216  
R11.1.1   ...................................................... 
A2        ................................C.....................  
R3.7.8.3  AATCCAACATCAGAAAAATTGAACAACCTGTTGGAAGGGAATGATAGTGACAAT 702 
           N  P  T  S  E  K  L  N  N  L  L  E  G  N  D  S  D  N  234  
R11.1.1   ...................................................... 
A2        ..............G..............A........................  
 
R3.7.8.3  GATCTATCACTTGAAGATTTCTGA 726 
           D  L  S  L  E  D  F XXX 241  
R11.1.1   ........................ 
A2        ........................  
Figure 10.22: Comparison of nucleotide and deduced amino acid sequences of the P gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
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           P Gene 3’UTR 
R3.7.8.3  TCAGTTACCAATCTGCACATCAACACACAACACCAACAGAAGACCGACAAACAA 54 
R11.1.1   ...................................................... 
A2        .T........C...T...............T..............A......T. 
 
R3.7.8.3  AACAACTCACCTATCCAACCAAACATCTATCTGCCAATCATCCAACCAGCCAAA 108 
R11.1.1   ...................................................... 
A2        .C....C..ATC......T........C...C........G....A.......C 
R3.7.8.3  AAAACACCCAGCCAATCCAAAACTAGTCACCCGGAAAAAATCGATACTATAGTT 162 
R11.1.1   ...................................................... 
A2        ......A..................AC...............T...A....... 
R3.7.8.3  ACAAAAAAA 171 
R11.1.1   .......... 
A2        .......... 
Figure 10.23: Nucleotide sequence comparison of the 3’UTR of the P gene of neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
 
           F-M2 IR  
R3.7.8.3  AACTACTGAGTACCAGATTAACTCACTATTTGTAAAAATTAGAAATGGGGCAAAT 55 
R11.1.1   ....................................................... 
A2        C..A.T...A.G...........T..C..C.........G.A..C.......... 
Figure 10.24: Nucleotide sequence comparison of the F-M2 intergenic region (F-M2 IR) and 5’UTR 
of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
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R3.7.8.3  ATGTCACGAAGGAATCCTTGCAAATTTGAAATTCGAGGTCATTGCTTGAATGGT 54 
           M  S  R  R  N  P  C  K  F  E  I  R  G  H  C  L  N  G  18  
R11.1.1   ...................................................... 
A2        ...............................................A......  
R3.7.8.3  AAGAGGTGTCATTTTAGTCATAATTATTTTGAATGGCCACCCCATGCACTGCTT 108 
           K  R  C  H  F  S  H  N  Y  F  E  W  P  P  H  A  L  L   36  
R11.1.1   ...................................................... 
A2        ......................................................  
R3.7.8.3  GTAAGACAAAACTTTATGTTAAACAGAATACTTAAGTCTATGGATAAAAGCATA 162 
           V  R  Q  N  F  M  L  N  R  I  L  K  S  M  D  K  S  I   54 
R11.1.1   ...................................................... 
A2        ..................................................T...  
R3.7.8.3  GATACTTTATCAGAAATAAGTGGAGCTGCAGAGTTGGACAGAACTGAAGAGTAT 216 
           D  T  L  S  E  I  S  G  A  A  E  L  D  R  T  E  E  Y   72 
R11.1.1   ...................................................... 
A2        .....C......................................A.........  
R3.7.8.3  GCCCTCGGTGTAGTTGGAGTGCTAGAGAGTTATATAGGATCAATAAATAATATA 270 
           A  L  G  V  V  G  V  L  E  S  Y  I  G  S  I  N  N  I   90 
R11.1.1   ...................................................... 
A2        ..T..T.........................................C......  
R3.7.8.3  ACTAAACAATCAGCATGTGTTGCCATGAGCAAACTCCTCACTGAACTCAACAGT 324 
           T  K  Q  S  A  C  V  A  M  S  K  L  L  T  E  L  N  S  108 
R11.1.1   ...................................................... 
A2        .............................................T........  
R3.7.8.3  GATGACATCAAAAAACTAAGGGACAATGAAGAGCCAAATTCACCCAAGATAAGA 378 
           D  D  I  K  K  L  R  D  N  E  E  P  N  S  P  K  I  R  126 
R11.1.1   ...................................................... 
A2        ..................................T................... 
          L  
R3.7.8.3  GTGTACAATACTGTCATATCATATATTGAAAGCAACAGGAAAAACAATAAACAA 432 
           V  Y  N  T  V  I  S  Y  I  E  S  N  R  K  N  N  K  Q  144 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ACTATCCATCTGTTAAAAAGATTGCCAGCAGACGTATTGAAGAAAACCATCAAA 486 
           T  I  H  L  L  K  R  L  P  A  D  V  L  K  K  T  I  K  162 
R11.1.1   ...................................................... 
A2        ...................................................... 
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R3.7.8.3  AACACATTGGATATCCACAAGAGCATAACCATCAATAACCCAAAAGAATCAACT 540 
           N  T  L  D  I  H  K  S  I  T  I  N  N  P  K  E  S  T  180 
R11.1.1   ...................................................... 
A2        .................T.................C.................. 
 
R3.7.8.3  GTTAATGATACAAACGACCATGCCAAAAATAATGATACTACCTGA 585 
       V  N  D  T  N  D  H  A  K  N  N  D  T  T XXX 194 
R11.1.1   ............................................. 
A2        ....G.........T.............................. 
                            S 
Figure 10.25: Comparison of nucleotide and deduced amino acid sequences of the M2 gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
 
 
           M2 Gene 3’UTR 
R3.7.8.3  CAAATATCCTTGTAGTATAAATTCCATACTAATAACAAGTAGTTGTAGAGTTAC 54 
R11.1.1   ...................................................... 
A2        ....................C.....................A........... 
R3.7.8.3  TATGTATAATCAAAAGAACACACTATATTTCAATCAAAACAACCAAAATAACCA 108 
R11.1.1   ...................................................... 
A2        ............................................C......... 
R3.7.8.3  TATATACTCACCAAATCAACCATTCAATGAAATCCATTGGACCTCTCAAGACTT 162 
R11.1.1   ...................................................... 
A2        ...G........G......A...............................A.. 
R3.7.8.3  GATTGATGCAATTCAAAATTTTCTACAACATCTAGGTGTTACTGATGATATATA 216 
R11.1.1   ...................................................... 
A2        ......CA.........T...................A...T...G........ 
R3.7.8.3  CACAATATATATATTAGTGTCATAACACTCAATACCAATACTTACCACATCATC 270 
R11.1.1   ...................................................... 
A2        T................................T.T..C...C........G.T 
 
R3.7.8.3  AAACTATTAACTCAAACAATTCAAACCATGGGACAAAATGGATCCCATTATTAAT 325 
                                                M  D  P  I  I  N   6 
R11.1.1   ...................................................... 
A2        .C.T......T.............GTTG.......................... 
 Stop codon  
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R3.7.8.3  GGAAATTCTGCTAATGTTTATCTAACCGATAGTTATTTAAAA 367 
           G  N  S  A  N  V  Y  L  T  D  S  Y  L  K   20 
R11.1.1   .......................................... 
A2        ..........................................  
Figure 10.26: Nucleotide sequence comparison of the 3’UTR of the M2 gene and 5’UTR of the L 
gene of neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
 
     L Gene Start codon                     
R3.7.8.3  ATGGATCCCATTATTAATGGAAATTCTGCTAATGTTTATCTAACCGATAGTTAT 54 
           M  D  P  I  I  N  G  N  S  A  N  V  Y  L  T  D  S  Y  18 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTAAAAGGTGTTATTTCTTTCTCAGAATGTAATGCTTTAGGAAGTTACATATTC 108 
           L  K  G  V  I  S  F  S  E  C  N  A  L  G  S  Y  I  F   36 
R11.1.1   ...................................................... 
A2        ..............C...........G........................... 
R3.7.8.3  AATGGTCCTTATCTCAAAAATGATTACACCAACTTAATTAGTAGACAAAATCCA 162 
           N  G  P  Y  L  K  N  D  Y  T  N  L  I  S  R  Q  N  P   54 
R11.1.1   ...................................................... 
A2        ..........................T........................... 
R3.7.8.3  TTAATAGAACACATAAATCTAAAGAAATTAAATATAACACAGTCCTTAATATCT 216 
           L  I  E  H  I  N  L  K  K  L  N  I  T  Q  S  L  I  S   72 
R11.1.1   ...................................................... 
A2        ..............G............C.......................... 
     M 
R3.7.8.3  AAGTATCATAAAGGTGAAATAAAAATAGAAGAACCTACTTATTTTCAGTCATTA 270 
           K  Y  H  K  G  E  I  K  I  E  E  P  T  Y  F  Q  S  L   90 
R11.1.1   ...................................................... 
A2        ........................T............................. 
          L 
R3.7.8.3  CTTATGACATACAAGAGTATGACCTCGTCAGAACAGATTACTACCACTAATTTA 324 
           L  M  T  Y  K  S  M  T  S  S  E  Q  I  T  T  T  N  L  108 
R11.1.1   ...................................................... 
A2        .......................................G.............. 
              A 
R3.7.8.3  CTTAAAAAGATAATAAGAAGAGCTATAGAAATTAGTGATGTCAAAGTCTATGCT 378 
           L  K  K  I  I  R  R  A  I  E  I  S  D  V  K  V  Y  A  126 
R11.1.1   ...................................................... 
A2        ................................A..................... 
 M2 GE sequence 
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R3.7.8.3  ATATTGAATAAACTGGGGCTTAAAGAAAAAGACAAGATTAAATCCAACAATGGA 432 
           I  L  N  K  L  G  L  K  E  K  D  K  I  K  S  N  N  G  144 
R11.1.1   ...................................................... 
A2        ..............A..............G........................ 
R3.7.8.3  CAAGATGAAGACAACTCAGTTATTACAACCATAATCAAAGATGATATACTTTTA 486 
           Q  D  E  D  N  S  V  I  T  T  I  I  K  D  D  I  L  L  162 
R11.1.1   ...................................................... 
A2        ..........................G.........................C. 
  S 
R3.7.8.3  GCTGTTAAGGATAATCAATCTCATCTTAAAGCAGGCAAAAATCACTCTACAAAA 540 
           A  V  K  D  N  Q  S  H  L  K  A  G  K  N  H  S  T  K  180 
R11.1.1   ...................................................... 
A2        ........A.........................A................... 
                D 
R3.7.8.3  CAAAAAGATACTATCAAAACAACACTCTTGAAAAAATTAATGTGTTCGATGCAA 594 
           Q  K  D  T  I  K  T  T  L  L  K  K  L  M  C  S  M  Q  198 
R11.1.1   ...................................................... 
A2        ........C..A....................G.....G........A...... 
R3.7.8.3  CATCCTCCATCATGGTTAATACATTGGTTTAATTTATACACAAAATTAAACAAC 648 
           H  P  P  S  W  L  I  H  W  F  N  L  Y  T  K  L  N  N  216 
R11.1.1   ...................................................... 
A2        ................................C..................... 
R3.7.8.3  ATATTAACACAGTATCGATCAAATGAGGTAAAAAACCATGGTTTTATATTGATA 702 
           I  L  T  Q  Y  R  S  N  E  V  K  N  H  G  F  I  L  I  234 
R11.1.1   ...................................................... 
A2        .........................................G....C....... 
   T 
R3.7.8.3  GATAATCATACTCTCAATGGATTCCAATTTATTTTGAATCAATATGGTTGTATA 756 
           D  N  H  T  L  N  G  F  Q  F  I  L  N  Q  Y  G  C  I  252 
R11.1.1   ...................................................... 
A2        ........A.....T.G......T..............C............... 
       Q        S   
R3.7.8.3  GTTTATCATAAGGAACTCAAAAGAATTACTGTGACAACCTATAATCAATTCTTG 810 
           V  Y  H  K  E  L  K  R  I  T  V  T  T  Y  N  Q  F  L  270 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ACATGGAAAGATATTAGCCTTAGTAGATTAAATGTTTGTTTAATTACATGGATT 864 
           T  W  K  D  I  S  L  S  R  L  N  V  C  L  I  T  W  I  288 
R11.1.1   ...................................................... 
A2        ...................................................... 
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R3.7.8.3  AGTAACTGTTTGAACACATTAAACAAAAGCTTAGGCTTAAGATGTGGATTCAAT 918 
           S  N  C  L  N  T  L  N  K  S  L  G  L  R  C  G  F  N  306  
R11.1.1   ...................................................G.. 
            D 
A2        ........C..............T....................C......... 
             
R3.7.8.3  AATGTTATCTTGACACAACTATTCCTTTATGGAGATTGTATATTAAAACTATTC 972 
           N  V  I  L  T  Q  L  F  L  Y  G  D  C  I  L  K  L  F  324 
R11.1.1   ...................................................... 
A2        ..........................................C....G.....T 
R3.7.8.3  CACAATGAAGGGTTCTACATAATAAAAGAGGTAGAGGGATTTATTATGTCTCTA 1026 
           H  N  E  G  F  Y  I  I  K  E  V  E  G  F  I  M  S  L   342 
R11.1.1   ...................................................... 
A2        ........G............................................. 
R3.7.8.3  ATTTTAAATATAACAGAAGAAGATCAATTCAGAAAACGGTTTTATAATAGTATG 1080 
           I  L  N  I  T  E  E  D  Q  F  R  K  R  F  Y  N  S  M   360 
R11.1.1   ...................................................... 
A2        ......................................A................ 
R3.7.8.3  CTCAACAACATCACAGATGCTGCTAATAAAGCTCAGAAAAATCTGCTATCAAGA 1134 
           L  N  N  I  T  D  A  A  N  K  A  Q  K  N  L  L  S  R   378 
R11.1.1   ...................................................... 
A2        ....................................................... 
R3.7.8.3  GTATGTCATACATTATTAGATAAGACAGTATCCGATAATATAATAAATGGCAGA 1188 
           V  C  H  T  L  L  D  K  T  V  S  D  N  I  I  N  G  R   396 
R11.1.1   ...................................................... 
A2        .............................G........................ 
R3.7.8.3  TGGATAATTCTATTAAGTAAGTTCCTTAAATTAATTAAGCTTGCAGGTGACAAT 1242 
           W  I  I  L  L  S  K  F  L  K  L  I  K  L  A  G  D  N   414 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  AACCTTAACAATCTGAGTGAATTATATTTTTTATTCAGAATATTTGGACACCCA 1296 
           N  L  N  N  L  S  E  L  Y  F  L  F  R  I  F  G  H  P   432 
R11.1.1   ...................................................... 
A2        .....................C..........G..................... 
R3.7.8.3  ATGGTAGATGAAAGACAAGCCATGGATGCTGTTAAAGTTAATTGCAACGAGACC 1350 
           M  V  D  E  R  Q  A  M  D  A  V  K  V  N  C  N  E  T   450 
R11.1.1   ...................................................... 
A2        ....................................A..........T...... 
     I 
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R3.7.8.3  AAATTTTACTTGTTAAGCAGTTTGAGTATGTTAAGAGGTGCCTTTATATATAGA 1404 
           K  F  Y  L  L  S  S  L  S  M  L  R  G  A  F  I  Y  R   468 
R11.1.1   ...................................................... 
A2        .....................C................................ 
R3.7.8.3  ATTATAAAAGGGTTTGTAAATAATTACAACAGATGGCCTACTTTAAGGAATGCT 1458 
           I  I  K  G  F  V  N  N  Y  N  R  W  P  T  L  R  N  A   486 
R11.1.1   ...................................................... 
A2        ...............................................A...... 
R3.7.8.3  ATTGTTTTACCCTTAAGATGGTTAACTTACTATAAACTAAACACTTATCCTTCC 1512 
           I  V  L  P  L  R  W  L  T  Y  Y  K  L  N  T  Y  P  S   504 
R11.1.1   ...................................................... 
A2        .....................................................T 
R3.7.8.3  TTGTTGGAACTTACAGAAAGAGATTTGATTGTTTTATCAGGACTACGTTTCTAT 1566 
           L  L  E  L  T  E  R  D  L  I  V  L  S  G  L  R  F  Y   522 
R11.1.1   ...................................................... 
A2        ................................G..................... 
R3.7.8.3  CGTGAGTTTCGGTTGCCTAAAAAAGTGGATCTTGAAATGATCATAAATGATAAG 1620 
           R  E  F  R  L  P  K  K  V  D  L  E  M  I  I  N  D  K   540 
R11.1.1   ...................................................... 
A2        .........................................T...........A 
R3.7.8.3  GCTATATCACCTCCTAAAAATTTGATATGGACTAGTTTCCCTAGAAATTATATG 1674 
           A  I  S  P  P  K  N  L  I  W  T  S  F  P  R  N  Y  M   558 
R11.1.1   ...................................................... 
A2        ..................................................C...  
R3.7.8.3  CCGTCACACATACAAAATTATATAGAACATGAAAAATTAAAATTTTCCGAGAGT 1728 
           P  S  H  I  Q  N  Y  I  E  H  E  K  L  K  F  S  E  S   576 
R11.1.1   ...................................................... 
A2        ..A..............C.................................... 
R3.7.8.3  GATAAATCAAGAAGAGTATTAGAGTACTATTTAAGAGATAACAAATTCAATGAA 1782 
           D  K  S  R  R  V  L  E  Y  Y  L  R  D  N  K  F  N  E   594 
R11.1.1   ...................................................... 
A2        ..........................T...........................  
R3.7.8.3  TGTGATTTATATAACTGTGTAGTTAATCAAAGCTACCTTAACAACCCTAATCAT 1836 
           C  D  L  Y  N  C  V  V  N  Q  S  Y  L  N  N  P  N  H   612 
R11.1.1   ...................................................... 
A2        ...........C....................T..T..C...............  
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R3.7.8.3  GTGGTATCATTGACTGGCAAAGAAAGAGAACTCAGTGTAGGTAGAATGTTTGCA 1890 
           V  V  S  L  T  G  K  E  R  E  L  S  V  G  R  M  F  A   630 
R11.1.1   ...................................................... 
A2        ..............A.......................................  
R3.7.8.3  ATGCAACCAGGAATGTTCAGACAAGTTCAAATATTAGCAGAGAAAATGATAGCT 1944 
           M  Q  P  G  M  F  R  Q  V  Q  I  L  A  E  K  M  I  A   648 
R11.1.1   ...................................................... 
A2        ........G..............G...........G..................  
R3.7.8.3  GAAAACATTTTACAATTCTTTCCTGAAAGTCTTACAAGATATGGTGATCTAGAA 1998 
           E  N  I  L  Q  F  F  P  E  S  L  T  R  Y  G  D  L  E   666 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTACAGAAAATATTAGAATTGAAAGCGGGAATAAGTAACAAATCAAATCGTTAC 2052 
           L  Q  K  I  L  E  L  K  A  G  I  S  N  K  S  N  R  Y   684 
R11.1.1   ...................................................... 
A2        C....A....................A.......................C... 
R3.7.8.3  AATGACAGTTACAACAATTACATCAGTAAGTGCTCTATCATCACAGATCTCAGC 2106 
           N  D  S  Y  N  N  Y  I  S  K  C  S  I  I  T  D  L  S   702 
R11.1.1   ...................................................... 
A2        .....T.A...............T.............................. 
       N 
R3.7.8.3  AAATTCAATCAAGCATTTCGGTATGAAACATCATGTATTTGTAGTGATGTTCTG 2160 
           K  F  N  Q  A  F  R  Y  E  T  S  C  I  C  S  D  V  L   720 
R11.1.1   ...................................................... 
A2        ....................A........G....................G... 
R3.7.8.3  GATGAACTGCATGGAGTACAATCTCTATTTTCCTGGTTACATTTAACTATTCCT 2214 
           D  E  L  H  G  V  Q  S  L  F  S  W  L  H  L  T  I  P   738 
R11.1.1   ...................................................... 
A2        ..............T....................................... 
R3.7.8.3  CATGTCACAATAATATGCACATATAGGCATGCACCCCCCTATATAAGAGATCAC 2268 
           H  V  T  I  I  C  T  Y  R  H  A  P  P  Y  I  R  D  H   756 
R11.1.1   ...................................................... 
A2        .............................................G.......T 
        G 
R3.7.8.3  ATTGTGGATCTTAACAATGTAGATGAACAAAGTGGATTATATAGATATCATATG 2322 
           I  V  D  L  N  N  V  D  E  Q  S  G  L  Y  R  Y  H  M   774 
R11.1.1   ...................................................... 
A2        .....A............................................C... 
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R3.7.8.3  GGTGGTATCGAAGGGTGGTGTCAAAAACTATGGACCATAGAAGCTATATCACTA 2376 
           G  G  I  E  G  W  C  Q  K  L  W  T  I  E  A  I  S  L   792 
R11.1.1   ...................................................... 
A2        .....C.......................G........................ 
R3.7.8.3  TTGGATCTAATATCTCTCAAAGGGAAATTCTCAATTACTGCCTTAATTAATGGT 2430 
           L  D  L  I  S  L  K  G  K  F  S  I  T  A  L  I  N  G   810 
R11.1.1   ...................................................... 
A2        .........................................T............ 
R3.7.8.3  GACAATCAATCAATAGATATAAGCAAACCAGTCAGACTCATGGAAGGTCAAACT 2484 
           D  N  Q  S  I  D  I  S  K  P  V  R  L  M  E  G  Q  T   828 
R11.1.1   ...................................................... 
A2        ..............................A....................... 
           I 
R3.7.8.3  CATGCTCAAGCAGATTATTTGCTAGCATTAAATAGTCTTAAATTGCTGTATAAA 2538 
           H  A  Q  A  D  Y  L  L  A  L  N  S  L  K  L  L  Y  K   846 
R11.1.1   ...................................................... 
A2        ...................................C........A......... 
R3.7.8.3  GAGTATGCAGGCATAGGCCACAAATTAAAAGGAACTGAGACTTATATATCAAGA 2592 
           E  Y  A  G  I  G  H  K  L  K  G  T  E  T  Y  I  S  R   864 
R11.1.1   ...................................................... 
A2        ...................................................C.. 
R3.7.8.3  GATATGCAATTTATGAGTAAAACAATTCAACATAACGGTGTATATTACCCAGCT 2646 
           D  M  Q  F  M  S  K  T  I  Q  H  N  G  V  Y  Y  P  A   882 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  AGTATAAAGAAAGTCCTAAGAGTGGGACCGTGGATAAACACTATACTTGATGAT 2700 
           S  I  K  K  V  L  R  V  G  P  W  I  N  T  I  L  D  D   900 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTCAAAGTGAGTCTAGAATCTATAGGTAGTTTGACACAAGAATTAGAATATAGA 2754 
           F  K  V  S  L  E  S  I  G  S  L  T  Q  E  L  E  Y  R   918 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  GGTGAAAGTCTATTATGCAGTTTAATATTTAGAAATGTGTGGTTATATAATCAA 2808 
           G  E  S  L  L  C  S  L  I  F  R  N  V  W  L  Y  N  Q   936 
R11.1.1   ...................................................... 
A2        ......................................A..............G 
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R3.7.8.3  ATTGCTTTACAACTAAAAAATCATGCATTATGTAACAATAAATTATATTTGGAC 2862 
           I  A  L  Q  L  K  N  H  A  L  C  N  N  K  L  Y  L  D   954 
R11.1.1   ...................................................... 
A2        ......C.....T.............................C........... 
R3.7.8.3  ATATTAAAGGTTCTGAAACACTTAAAAACCTTTTTTAATCTTGATAATATTGAT 2916 
           I  L  K  V  L  K  H  L  K  T  F  F  N  L  D  N  I  D   972 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ACAGCATTAACATTGTATATGAATTTGCCTATGTTATTTGGTGGTGGTGATCCC 2970 
           T  A  L  T  L  Y  M  N  L  P  M  L  F  G  G  G  D  P   990 
R11.1.1   ...................................................... 
A2        ..........................A..C........................ 
R3.7.8.3  AACCTGTTATATCGAAGTTTCTATAGAAGAACTCCTGATTTCCTCACAGAGGCT 3024 
           N  L  L  Y  R  S  F  Y  R  R  T  P  D  F  L  T  E  A  1008 
R11.1.1   ...................................................... 
A2        ...T..................................C............... 
R3.7.8.3  ATAGTTCACTCTGTGTTCATACTTAGTTATTATACAAACCATGATTTAAAAGAT 3078 
           I  V  H  S  V  F  I  L  S  Y  Y  T  N  H  D  L  K  D  1026 
R11.1.1   ...................................................... 
A2        ............................................C......... 
R3.7.8.3  AAACTTCAAGATCTGTCAGACGATAGATTGAATAAGTTCTTAACATGCATAATC 3132 
           K  L  Q  D  L  S  D  D  R  L  N  K  F  L  T  C  I  I  1044 
R11.1.1   ...................................................... 
A2        ....................T................................. 
R3.7.8.3  ACGTTTGACAAAAACCCTAATGCTGAATTCGTAACATTGATGAGAGATCCTCAA 3186 
           T  F  D  K  N  P  N  A  E  F  V  T  L  M  R  D  P  Q  1062 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  GCCTTAGGGTCTGAGAGGCAAGCTAAAATTACTAGCGAAATCAATAGACTGGCA 3240 
           A  L  G  S  E  R  Q  A  K  I  T  S  E  I  N  R  L  A  1080 
R11.1.1   ...................................................... 
A2        ..T..............A.................................... 
R3.7.8.3  GTTACTGAGGTTTTGAGCACAGCTCCAAACAAAATATTCTCCAAAAGTGCACAA 3294 
           V  T  E  V  L  S  T  A  P  N  K  I  F  S  K  S  A  Q  1098 
R11.1.1   ...................................................... 
A2        .....A...........T.................................... 
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R3.7.8.3  CACTATACCACTACAGAGATAGATCTAAATGATATTATGCAAAATATAGAACCT 3348 
           H  Y  T  T  T  E  I  D  L  N  D  I  M  Q  N  I  E  P  1116 
R11.1.1   ...................................................... 
A2        ..T.....T............................................. 
R3.7.8.3  ACATATCCTCATGGGCTAAGAGTTGTTTATGAAAGTTTACCCTTTTACAAAGCA 3402 
           T  Y  P  H  G  L  R  V  V  Y  E  S  L  P  F  Y  K  A  1134 
R11.1.1   ...................................................... 
A2        ...............................................T...... 
R3.7.8.3  GAGAAAATAGTAAATCTTATATCCGGTACAAAATCTATAACTAACATACTGGAA 3456 
           E  K  I  V  N  L  I  S  G  T  K  S  I  T  N  I  L  E  1152 
R11.1.1   ...................................................... 
A2        .......................A.............................. 
R3.7.8.3  AAGACTTCTGCCATAGACTTAACAGATATTGATAGAGCCACTGAGATGATGAGG 3510 
           K  T  S  A  I  D  L  T  D  I  D  R  A  T  E  M  M  R  1170 
R11.1.1   ...................................................... 
A2        ..A................................................... 
R3.7.8.3  AAAAACATAACTTTGCTTATAAGGATATTTCCATTAGATTGTAACAGAGATAAA 3564 
           K  N  I  T  L  L  I  R  I  F  P  L  D  C  N  R  D  K  1188 
R11.1.1   ...................................................... 
A2        ...........................C.......................... 
        L 
R3.7.8.3  AGAGAAATATTGAGTATGGAAAACCTAAGTATTACTGAATTAAGCAAATATGTT 3618 
           R  E  I  L  S  M  E  N  L  S  I  T  E  L  S  K  Y  V  1206 
R11.1.1   ...................................................... 
A2        .....G................................................ 
R3.7.8.3  AGAGAAAGATCTTGGTCTTTATCCAATATAGTTGGTGTTACATCACCCAGTATC 3672 
           R  E  R  S  W  S  L  S  N  I  V  G  V  T  S  P  S  I  1224 
R11.1.1   ...................................................... 
A2        ..G................................................... 
R3.7.8.3  ATGTATACAATGGACATCAAATATACAACAAGCACTATAGCTAGTGGCATAATC 3726 
           M  Y  T  M  D  I  K  Y  T  T  S  T  I  A  S  G  I  I  1242 
R11.1.1   ...................................................... 
A2        ..........................T............T.............. 
          S 
R3.7.8.3  ATAGAGAAATATAATGTCAACAGTTTAACACGTGGTGAGAGAGGACCCACTAAA 3780 
           I  E  K  Y  N  V  N  S  L  T  R  G  E  R  G  P  T  K  1260 
R11.1.1   ...................................................... 
A2        .................T.................................... 
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R3.7.8.3  CCATGGGTTGGTTCATCTACACAAGAGAAAAAAACAATGCCAGTTTATAATAGA 3834 
           P  W  V  G  S  S  T  Q  E  K  K  T  M  P  V  Y  N  R  1278 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  CAAGTTTTAACCAAAAAACAGAGAGATCAAATTGATCTATTAGCAAAATTGGAT 3888 
           Q  V  L  T  K  K  Q  R  D  Q  I  D  L  L  A  K  L  D  1296 
R11.1.1   ...................................................... 
A2        .....C..........................A..................... 
R3.7.8.3  TGGGTGTATGCATCTATAGATAACAAGGATGAATTCATGGAAGAACTTAGCATA 3942 
           W  V  Y  A  S  I  D  N  K  D  E  F  M  E  E  L  S  I  1314 
R11.1.1   ...................................................... 
A2        ...............................................C....... 
R3.7.8.3  GGAACTCTTGGGTTAACATATGAGAAAGCCAAAAAATTATTTCCACAATATTTA 3996 
           G  T  L  G  L  T  Y  E  K  A  K  K  L  F  P  Q  Y  L  1332 
R11.1.1   ...................................................... 
A2        .......................A..G.....G..................... 
R3.7.8.3  AGTGTTAACTATTTGCATCGCCTTACAGTCAGTAGTAGACCATGTGAATTCCCT 4050 
           S  V  N  Y  L  H  R  L  T  V  S  S  R  P  C  E  F  P  1350 
R11.1.1   ...................................................... 
A2        .....C..T............................................. 
R3.7.8.3  GCATCAATACCAGCTTATAGAACTACAAATTATCACTTTGATACTAGCCCTATT 4104 
           A  S  I  P  A  Y  R  T  T  N  Y  H  F  D  T  S  P  I  1368 
R11.1.1   ...................................................... 
A2        .......................A.................C............ 
R3.7.8.3  AATCGCATATTAACAGAAAAGTATGGTGATGAAGATATTGATATAGTATTCCAA 4158 
           N  R  I  L  T  E  K  Y  G  D  E  D  I  D  I  V  F  Q  1386 
R11.1.1   ...................................................... 
A2        .........................................C............ 
R3.7.8.3  AACTGTATAAGCTTTGGCCTTAGCTTAATGTCAGTAGTAGAGCAATTTACCAAT 4212 
           N  C  I  S  F  G  L  S  L  M  S  V  V  E  Q  F  T  N  1404 
R11.1.1   ...................................................... 
A2        .......................T.................A........T... 
R3.7.8.3  GTATGTCCTAATAGAATTATTCTCATACCCAAGCTTAACGAGATACACTTGATG 4266 
           V  C  P  N  R  I  I  L  I  P  K  L  N  E  I  H  L  M  1422 
R11.1.1   ...................................................... 
A2        ...........C.................T........T........T...... 
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R3.7.8.3  AAACCTCCCATATTCACAGGTGATGTTGATATTCACAAGTTAAAACAAGTGATC 4320 
           K  P  P  I  F  T  G  D  V  D  I  H  K  L  K  Q  V  I  1440 
R11.1.1   ...................................................... 
A2        .....................................................A 
R3.7.8.3  CAAAAACAGCATATGTTTTTACCAGACAAAATAAGTTTGACTCAATATGTGGAA 4374 
           Q  K  Q  H  M  F  L  P  D  K  I  S  L  T  Q  Y  V  E  1458 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTATTCTTAAGTAATAAAACACTCAAATCTGGATCTCATGTTAATTCTAATTTA 4428 
           L  F  L  S  N  K  T  L  K  S  G  S  H  V  N  S  N  L  1476 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATATTGGCACATAAGATATCTGACTATTTTCATAATACTTACATTTTAAGTACT 4482 
           I  L  A  H  K  I  S  D  Y  F  H  N  T  Y  I  L  S  T  1494 
R11.1.1   ...................................................... 
A2        ..............A....................................... 
R3.7.8.3  AATTTAGCTGGACATTGGATTCTGATTATACAACTTATGAAAGATTCTAAAGGT 4536 
           N  L  A  G  H  W  I  L  I  I  Q  L  M  K  D  S  K  G  1512 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATTTTTGAAAAAGATTGGGGAGAGGGATATATAACTGATCATATGTTCATTAAT 4590 
           I  F  E  K  D  W  G  E  G  Y  I  T  D  H  M  F  I  N  1530 
R11.1.1   ...................................................... 
A2        ...............................................T...... 
R3.7.8.3  TTGAAAGTTTTCTTCAATGCTTATAAGACCTATCTCTTGTGTTTTCATAAAGGT 4644 
           L  K  V  F  F  N  A  Y  K  T  Y  L  L  C  F  H  K  G  1548 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TACGGCAGAGCAAAGCTGGAGTGTGATATGAATACTTCAGATCTCCTATGTGTA 4698 
           Y  G  R  A  K  L  E  C  D  M  N  T  S  D  L  L  C  V  1566 
R11.1.1   ...................................................... 
A2        ..T....A................................................ 
       K 
R3.7.8.3  TTGGAATTAATAGACAGTAGTTATTGGAAGTCTATGTCTAAGGTATTTTTAGAA 4752 
           L  E  L  I  D  S  S  Y  W  K  S  M  S  K  V  F  L  E  1584 
R11.1.1   ...................................................... 
A2        ...................................................... 
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R3.7.8.3  CAAAAAGTTATCAAATACATTCTCAGCCAGGATGCAAGTTTACATAGAGTAAAA 4806 
           Q  K  V  I  K  Y  I  L  S  Q  D  A  S  L  H  R  V  K  1602 
R11.1.1   ...................................................... 
A2        .......................T.....A........................ 
R3.7.8.3  GGATGTCATAGCTTCAAACTATGGTTTCTTAAACGTCTTAATGTAGCAGAATTC 4860 
           G  C  H  S  F  K  L  W  F  L  K  R  L  N  V  A  E  F  1620 
R11.1.1   ...................................................... 
A2        ..................T................................... 
R3.7.8.3  ACAGTTTGCCCTTGGGTTGTTAACATAGATTATCATCCAACACATATGAAAGCA 4914 
           T  V  C  P  W  V  V  N  I  D  Y  H  P  T  H  M  K  A  1638 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATATTAACTTATATAGATCTTGTTAGAATGGGATTGATAAATATAGATAGAATA 4968 
           I  L  T  Y  I  D  L  V  R  M  G  L  I  N  I  D  R  I  1656 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TACATTAAAAATAAACACAAATTCAATGATGAATTTTATACTTCTAATCTCTTT 5022 
           Y  I  K  N  K  H  K  F  N  D  E  F  Y  T  S  N  L  F  1674 
R11.1.1   ...................................................... 
A2        C..................................................... 
      H 
R3.7.8.3  TACATTAATTATAACTTCTCAGATAATACTCATCTATTAACTAAACATATAAGG 5076 
           Y  I  N  Y  N  F  S  D  N  T  H  L  L  T  K  H  I  R  1692 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  ATTGCTAATTCTGAATTAGAAAATAATTACAACAAATTATATCATCCTACACCT 5130 
           I  A  N  S  E  L  E  N  N  Y  N  K  L  Y  H  P  T  P  1710 
R11.1.1   ...................................................... 
A2        .....................................................A 
R3.7.8.3  GAAACTCTAGAAAATATACTAACCAATCCGGTTAAATGCGATGACAAAAAGATA 5184 
           E  T  L  E  N  I  L  T  N  P  V  K  C  D  D  K  K  I  1728 
R11.1.1   ...................................................... 
A2        .....C.....G.........G........A.....A.TA............C. 
                                A        I     S  N           T 
R3.7.8.3  CTGAATGACTATTGTATAGGTAAAAATGTTGACTCAATAATGTTACCATTGTTA 5238 
           L  N  D  Y  C  I  G  K  N  V  D  S  I  M  L  P  L  L  1746 
R11.1.1   ...................................................... 
A2        ...................................................... 
 
  
287 
 
2
8
7
 
R3.7.8.3  TCTAATAAGAAGCTTATTAAATCGTCTACAATGATTAGAACCAATTACAGCAAA 5292 
           S  N  K  K  L  I  K  S  S  T  M  I  R  T  N  Y  S  K  1764 
R11.1.1   ...................................................... 
A2        ...........................G.......................... 
             A 
R3.7.8.3  CAAGATTTGTATAATTTATTTCCTACGGTTGTGATTGATAAAATTATAGATCAT 5346 
           Q  D  L  Y  N  L  F  P  T  V  V  I  D  K  I  I  D  H  1782 
R11.1.1   ...................................................... 
A2        .........................T..............G............. 
          M              R 
R3.7.8.3  TCAGGTAATACAGCCAAATCTAACCAACTTTACACTACTACTTCTCATCAAATA 5400 
           S  G  N  T  A  K  S  N  Q  L  Y  T  T  T  S  H  Q  I  1800 
R11.1.1   ...................................................... 
A2        .....C..............C.......................C..C...... 
R3.7.8.3  TCTTTAGTACACAATAGCACATCACTTTATTGCATGCTTCCTTGGCATCATATT 5454 
           S  L  V  H  N  S  T  S  L  Y  C  M  L  P  W  H  H  I  1818 
R11.1.1   ...................................................... 
A2        ........G....................C........................ 
R3.7.8.3  AATAGATTCAATTTTGTGTTTAGTTCTACAGGTTGTAAAATTAGTATAGAGTAT 5508 
           N  R  F  N  F  V  F  S  S  T  G  C  K  I  S  I  E  Y  1836 
R11.1.1   ...................................................... 
A2        .................A.................................... 
R3.7.8.3  ATTTTAAAAGACCTTAAAATTAAAGATCCTAATTGTATAGCATTCATAGGTGAA 5562 
           I  L  K  D  L  K  I  K  D  P  N  C  I  A  F  I  G  E  1854 
R11.1.1   ...................................................... 
A2        ...........T.................C........................ 
R3.7.8.3  GGAGCAGGGAATTTATTGTTGCGTACAGTAGTGGAACTTCATCCTGATATAAGA 5616 
           G  A  G  N  L  L  L  R  T  V  V  E  L  H  P  D  I  R  1872 
R11.1.1   ...................................................... 
A2        .................A.............................C...... 
R3.7.8.3  TATATTTACAGAAGTCTGAAAGATTGCAATGATCATAGTTTACCTATTGAGTTT 5670 
           Y  I  Y  R  S  L  K  D  C  N  D  H  S  L  P  I  E  F  1890 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTAAGGCTGTACAATGGACATATCAACATTGATTATGGTGAAAATTTGACCATT 5724 
           L  R  L  Y  N  G  H  I  N  I  D  Y  G  E  N  L  T  I  1908 
R11.1.1   ...................................................... 
A2        ...................................................... 
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R3.7.8.3  CCCGCTACAGATGCAACCAACAACATTCATTGGTCTTATTTGCATATAAAGTTT 5778 
           P  A  T  D  A  T  N  N  I  H  W  S  Y  L  H  I  K  F  1926 
R11.1.1   ...................................................... 
A2        ..T......................................A............ 
R3.7.8.3  GCTGAACCTATCAGTCTTTTTGTTTGTGATGCTGAATTGCCTGTAACAGTCAAC 5832 
           A  E  P  I  S  L  F  V  C  D  A  E  L  P  V  T  V  N  1944 
R11.1.1   ...................................................... 
A2        .......................C........C......T.............. 
               S    
R3.7.8.3  TGGAGTAAAATCATAATAGAGTGGAGCAAGCATGTAAGAAAATGCAAGTACTGT 5886 
           W  S  K  I  I  I  E  W  S  K  H  V  R  K  C  K  Y  C  1962 
R11.1.1   ...................................................... 
A2        ...........T........A....................G............ 
R3.7.8.3  TCCTCAGTTAATAAATGTACGTTAATAGTAAAATATCATGCTCAAGATGATATC 5940 
           S  S  V  N  K  C  T  L  I  V  K  Y  H  A  Q  D  D  I  1980 
R11.1.1   ...................................................... 
A2        ...................T.................................T 
         M 
R3.7.8.3  GATTTCAAATTAGACAACATAACTATATTAAAAACTTATGTATGCTTAGGCAGT 5994 
           D  F  K  L  D  N  I  T  I  L  K  T  Y  V  C  L  G  S  1998 
R11.1.1   ...................................................... 
A2        .................T.................................... 
R3.7.8.3  AAGTTAAAGGGGTCTGAAGTTTACTTAGTCCTTACAATAGGCCCTGCAAATGTG 6048 
           K  L  K  G  S  E  V  Y  L  V  L  T  I  G  P  A  N  V  2016 
R11.1.1   ...................................................... 
A2        ...........A..G..G.......................T.....G...A.A 
            I 
R3.7.8.3  TTCCCAGTATTTAATGTAGTACAAAATGCTAAATTGATACTATCAAGAACCAAA 6102 
           F  P  V  F  N  V  V  Q  N  A  K  L  I  L  S  R  T  K  2034 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  AATTTCATCATGCCTAAGAAGGCTGATAAAGAGTCTATTGATGCAAATATTAAA 6156 
           N  F  I  M  P  K  K  A  D  K  E  S  I  D  A  N  I  K  2052 
R11.1.1   ...................................................... 
A2        ....................A................................. 
R3.7.8.3  AGTTTTATACCCTTTCTTTGTTACCCTATAACAAAAAAAGGAATTAATACTGCA 6210 
           S  F  I  P  F  L  C  Y  P  I  T  K  K  G  I  N  T  A  2070 
R11.1.1   .....G................................................ 
    L 
A2        .....G................................................ 
    L 
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R3.7.8.3  TTGTCAAAACTAAAGAGTGTTGTTAGTGGAGATATACTATCATATTCTATAGCT 6264 
           L  S  K  L  K  S  V  V  S  G  D  I  L  S  Y  S  I  A  2088 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  GGACGTAATGAAGTTTTCAGCAATAAACTTATAAATCATAAGCATATGAACATC 6318 
           G  R  N  E  V  F  S  N  K  L  I  N  H  K  H  M  N  I  2106 
R11.1.1   ...................................................... 
A2        ...................................................... 
R3.7.8.3  TTAAAGTGGTTCAATCATGTTTTAAATTTCAGATCAACAGAACTCAACTATAAT 6372 
           L  K  W  F  N  H  V  L  N  F  R  S  T  E  L  N  Y  N  2124 
R11.1.1   ...................................................... 
A2        .....A......................................A........C 
R3.7.8.3  CATTTATATATGGTAGAATCTACATATCCTTATCTAAGTGAATTGTTAAACAGC 6426 
           H  L  Y  M  V  E  S  T  Y  P  Y  L  S  E  L  L  N  S  2142 
R11.1.1   ...................................................... 
A2        ................................C..................... 
R3.7.8.3  TTGACAACTAATGAACTTAAAAAACTGATTAAAATCACAGGTAGTTTGTTATAC 6480 
           L  T  T  N  E  L  K  K  L  I  K  I  T  G  S  L  L  Y  2160 
R11.1.1   ...................................................... 
A2        ........C....................................C........ 
R3.7.8.3  AACTTTCATAATGAATAA 6498 
           N  F  H  N  E XXX 2165 
R11.1.1   .................. 
A2        .................. 
 
Figure 10.27: Comparison of nucleotide and deduced amino acid sequences of the L gene coding 
region of the neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain. Deduced amino acid sequences are under the 
nucleotide sequence.   
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           L Gene 3’UTR 
R3.7.8.3  TGAATAAAAATCTTATATTAAAAATTCCCACATCTACACACTAACACTGTATTC 54 
R11.1.1   ...................................................... 
A2        ........G........A............T.G...T................. 
 
R3.7.8.3  AATTATAGTTATTTAAAA 72 
R11.1.1   ................... 
A2        .............A..... 
Figure 10.28: Nucleotide sequence comparison of the 3’UTR of the L gene of neutralization 
resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
 
           5’trailer region 
R3.7.8.3  TTAAAAATTATAAATTATATAATTTTT--AATAACTTTTAGTGGACTAATCCTA 52 
R11.1.1   ...................................................... 
A2        ........C-------...........TA..............A.......... 
R3.7.8.3  AAATTATCATTTTGATCTAGGAGGTATAAATTTAAATCCAAATCTAATTGGTTT 106 
R11.1.1   ...................................................... 
A2        ..G..........A....T.....A...........C..T.............. 
R3.7.8.3  ATATGTATATTAACTAAACTACGAGATATTAGTTTTTGACACTTTTTTTCTCGT 160 
R11.1.1   ...................................................... 
A2        .....G...........T.................................... 
Figure 10.29: Nucleotide sequence comparison of the 5’trailer region of neutralization resistant and 
susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3, dashes indicate alignment gaps and 
underlined bases indicate different nucleotides of clone R3.7.8.3 compared to another strain.  
 
 
 
 
 
 
 
   L GE sequence  
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       3’Leader region                          5’UTR  
R3.7.8.3   ACGCGAAAAAATGCGTACAACAAACTTGCGTAAACCAAAAAAATGGGGCAAATA 54 
R11.1.1    ......................................................    
A2         .............................A........................ 
R3.7.8.3   AGAATTTGATAAGTACCACTTAAATTCAACTCCTTTGGTTAGAG 98 
R11.1.1    ............................................    
A2         ..........................T......C.......... 
Figure 10.30: Nucleotide sequence comparison of the 3’leader region and 3’UTR of the NS1 gene of 
neutralization resistant and susceptible clones of R17532 and A2 strain. 
Dots indicate identical nucleotides compared to clone R.3.7.8.3 and underlined bases indicate different 
nucleotides of clone R3.7.8.3 compared to another strain.  
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